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Abstract 
The furanocembranes are a family of marine diterpenoids isolated from octocoral 
invertebrates. These macrocyclic natural products possess interesting molecular structures 
including a furan ring at C3-C6 and a butenolide moiety encompassing C10-C12.  As well as 
their unique structures, family members have shown promising biological activities, and thus 
they represent attractive synthetic targets. 
This thesis describes the synthetic efforts towards two of these family members: pukalide 
and 7-acetylsinumaxmol B. In particular, focus has been directed towards the investigation 
of different synthetic strategies and the synthesis of key fragments; culminating in the total 
synthesis of 7-epi-pukalide and 7-acetylsinumaximol B. The key synthetic approach 
undertaken was designed to take advantage of new methodology developed by our group 
for the synthesis of highly functionalised furans, including epoxy-furans, in which 
tetrahydrothiophene (THT) was used as an organocatalyst. The reaction promotes the 
formation of both a furan and an epoxide in one step from a Knoevenagel condensation 
product. 
 
 
 
 
 
In the first approach described herein, an intramolecular Knoevenagel condensation strategy 
for macrocycle formation was explored. The C12-C14/C1-C4 and C5-C11 were initially 
coupled through esterification; however, after further functionalisation, macrocyclisation 
could not be effected under Knovenagel conditions. The second approach focused on the 
use of an intermolecular Knoevenagel condensation reaction for fragment coupling. Although 
fragment coupling was successful further functionalisation proved to be difficult because of 
the reactive nature of the ynenone intermediates. The third and final approach investigated 
the development of a one-pot condensation and furan formation; combining the 
Knoevenagel condensation with organocatalytic tetrahydrothiophene to produce the furan 
directly from two separate fragments. This approach was successful, allowing completion of 
the full skeleton to be effected through macrolactonisation and ring-closing metathesis. 
Following this strategy both 7-epi-pukalide and 7-acetylsinumaximol B were accessed in 16 
steps from the chiral pool starting material (R)-perillyl alcohol.  
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Abbreviations 
Ac  Acetyl 
ACDC  asymmetric counterion directed catalysis 
ADD   1,1'-(azodicarbonyl)dipiperidine 
aq  aqueous 
Ar  aryl 
Bn  benzyl 
BQ  1,4-benzoquinone 
brsm  based on recovered starting material 
Bu  butyl 
Bz  benzoyl 
CI  chemical ionisation 
COX-2  cyclooxygenase-2 
CSA  camphorsulfonic acid  
Cy  cyclohexyl 
dba  dibenzylideneacetone 
DBU  1,8-Diazabicyclo[5.4.0]undec-7-ene 
DCC  dicyclohexylcarbodiimide 
DCE  dichloroethane 
DDQ  2,3-Dichloro-5,6-dicyano-1,4-benzoquinone 
DEAD  diethyl azodicarboxylate 
DIPA  diisopropylamine 
DIPEA  diisopropylethylamine 
DMAP  4-(dimethylamino)pyridine 
DMDO  dimethyldioxirane 
DMF  N,N-dimethylformamide 
DMP  Dess-Martin periodinane 
dppf  1,1'-bis(diphenylphosphino)ferrocene 
dr  diastereomeric ratio 
E  electrophile 
EDDA  ethylene diammonium diacetate 
ee  enantiomeric excess 
EMA  European Medicines Agency 
equiv  equivalents 
ERK1/2 extracellular signal–regulated kinases 1/2 
ESI  electrospray ionisation 
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Et  ethyl 
EWG  electron withdrawing group 
FDA  U.S. Food and Drug Administration 
Grubbs II Grubbs second generation catalyst 
HG II  Hoveyda-Grubbs second generation catalyst 
HMDS  hexamethyldisilazane 
HOMO  highest occupied molecular orbital 
HRMS  high resolution mass spectometry 
HWE  Horner-Wadsworth Emmons   
i  iso 
IBX  2-iodoxybenzoic acid 
IC50  half maximal inhibitory concentration 
iNOS   inducible nitric oxide synthetase  
IR  infrared 
L  ligand 
LA  Lewis acid 
LDA  lithium diisopropyl amide 
LRMS  low resolution mass spectometry 
LUMO  lowest unoccupied molecular orbital  
mCPBA p-chloroperbenzoic acid 
Me  methyl 
MEM  2-methoxyethoxymethyl ether 
Mes  mesityl (2,4,6-trimethyllphenyl) 
MMTr  4-methoxytrityl (4-methoxytriphenylmethyl) 
MNBA  2-methyl-6-nitrobenzoic anhydride 
MOM  methoxymethyl 
Ms  mesyl (methanesulfonyl) 
MTBD   7-methyl-1,5,7-triazabicyclo[4.4.0]dec-5-ene 
n  normal 
NBS  N-bromosuccinimide 
NHC  N-heterocyclic carbene 
NHK  Nozaki-Hiyama-Kishi 
NMO  N-methylmorpholine-N-oxide 
Nu  nucleophile 
OPP  diphosphate 
pet  petroleum 
Ph  phenyl 
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Piv  pivaloyl 
PMB  p-methoxybenzyl 
PPTS  pyridinium p-toluenesulfonate 
Pr  propyl 
Pr  propyl 
pTSA  p-toluenesulfonic acid 
pyr  pyridine 
quant.  quantitative 
R  generalised group 
RCM  ring-closing metathesis 
rt  room temperature 
SAR  structure-activity relationship 
SM  starting material 
SN  nucleophilic substitution 
T  temperature 
t  tert 
TBAF  tetra-n-butylammonium fluoride 
TBAI  tetra-n-butylammonium iodide 
TBDPS t-butyldiphenylsilyl 
TBS  t-butyldimethylsilyl 
TES  triethylsilyl 
Tf  trifluoromethanesulfonyl 
TFA  trifluoroacetic acid 
THF  tetrahydrofuran 
THP  tetrahydropyranyl 
THT  tetrahydrothiophene 
TIPP  triisopropylphenyl 
TIPS  triisopropylsilyl 
TLC  thin layer chromatography 
TMEDA tetramethylethylenediamine 
TMP  2,2,6,6-tetramethylpiperidine 
TMS  trimethylsilyl 
TMSE  trimethylsilylethyl 
TRIP-H 3,3’-bis(2,4,6-triisopropylphenyl)-1,1’-binaphthyl-2,2’-diyl hydrogenphosphate 
Ts  tosyl (toluenesulfonyl) 
TsOH  toluenesulfonic acid 
UV  ultraviolet  
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1 Introduction 
1.1 Furan Containing Natural Products and Bioactivity 
1.1.1 Drug Discovery from Natural Products 
Natural products can be defined as structurally diverse substances which are created by 
living organisms. Their varying structural nature means that they cover a wide area of 
chemical space relevant to biology.[1] This inherent diversity allows molecules to spatially 
complement biological targets, often resulting in greater substrate selectivity. As a result, 
many natural products have acted as a source of inspiration for drug discovery and, to date, 
they remain one of the best sources of drug leads, with some of the biggest selling 
pharmaceuticals being natural product derivatives. 
Natural products represent a rich source of novel molecular scaffolds. Subsequently, the 
discovery of new natural products holds significant promise for advances in chemistry, 
biochemistry and medicine.[2–4] Most currently available medicines derived from nature come 
from terrestrial species; however, the marine world has also proven to be a rich source of 
biological and chemical diversity.[5] Marine organisms produce a range of structurally 
interesting secondary metabolites as protection against predation and the extreme 
conditions of their surroundings. These secondary metabolites often have interesting 
biological properties and unusual modes of action.[6] Ziconotide (1) was the first marine 
natural product approved for use by the FDA in 2004.[7] Isolated from a marine cone snail, 
this peptide was approved for the treatment of chronic pain resulting from spinal chord injury. 
A second natural product, trabectedin (2), originally isolated from a sea squirt, was the first 
anti-cancer agent of marine origin to be approved.[8] In 2007, it was approved by the EMA for 
the treatment of soft tissue sarcoma.  
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Figure 1 Structures of ziconotide and trabectedin 
The enormous structural and chemical diversity associated with natural products is 
unsurpassed by any synthetic library. However, despite this, there are many challenges 
associated with the transition from drug discovery to pharmaceutical product; limited supply, 
low yield and limited possibility for structural modification all detract from the appeal of 
natural products as drug candidates. For this reason, total synthesis is often required to 
provide sufficient quantities for biological testing and to allow modifications for SAR 
studies.[9] 
1.1.2 Furans in Biologically Active Molecules 
The furan system is a common motif in natural products, biologically active molecules and 
pharmaceuticals. Members of many natural product families, including acetogenins, 
terpenes and complex alkaloids, contain a furan within their structure.[10] Bioactive marine 
natural products such as lophotoxin (3) and nakadomarin A (4) possess a tri-substituted 
furan as part of their macrocyclic core (Figure 2) and exhibit potent biological activity.[11,12] 
Lophotoxin, acts as a neurotoxin by inhibiting nicotinic acetylcholine receptors, and 
nakadomarin A displays cytotoxicity against specific lymphoma cell lines, as well as some 
anti-microbial activity.[13,14] Furano epothilone C (5) is a biologically active natural product 
analogue, shown to be an inhibitor of cancer cell growth in vitro.[15] 
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Figure 2 Examples of furan-containing natural products and analogues 
Many marketed drugs also contain a furan moiety. The anti-ulcer drug ranitidine (6), which 
acts as an H2-receptor antagonist, as well as the common urinary-tract infection antibiotic 
nitrofurantoin (7), both contain a di-substituted furan (Figure 3). 
 
 
 
 
Figure 3 Examples of furan-containing drug molecules 
The prevalence of the furan motif within biologically active molecules and natural products 
has meant that the development of new, mild and efficient protocols for the synthesis of 
highly substituted furans has become an important goal for synthetic chemists. Thus, in 
recent years many metal-mediated as well as a few organocatalytic methods for the 
synthesis of substituted furans have been developed, in addition to classical protocols.  
1.1.3 The Furanocembranoid Natural Product Family 
1.1.3.1 Isolation, Structure and Biological Activity of the Furanocembranes 
The furanocembrane natural products are a family of diterpenoids isolated from octocorals; a 
group of marine invertebrates which include species of sea fans, sea whips and soft 
corals.[11,16–18] From within this group the vast majority of compounds have been isolated 
from gorgonian corals. As a result of their interesting molecular structures and promising 
biological activities, the furanocembranes have received the attention of many synthetic 
chemists. Studies concerning these natural products have led to many discoveries regarding 
their pharmacological activities as well as some advances in synthetic methodology.[16–18] 
The furanocembranoids feature a 14-membered carbocyclic skeleton which includes a furan 
ring at C3-C6 and a butenolide moiety encompassing C10-C12 (Figure 4). Pseudopterane 
and gersolane natural products have similar structures but the carbocyclic skeletons are 
comprised of only 12 and 13 carbons respectively and they have different substitution at the 
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C7 and C8 positions. They are thought to be biosynthetically derived from furanocembrane 
type compounds through photochemical and enzymatic transformations.[19,20] 
 
 
 
 
 
 
 
Figure 4 Skeletons of the furanocembrane, pseudopterane and gersolane natural products 
Oxidation patterns and saturation levels vary greatly amongst the natural products within the 
furanocembranolide family, whilst the basic backbone always remains the same. Oxidation 
typically occurs at C2, C13 and C18 and across the double bonds at C7-C8 and C11-C12. In 
most furanocembranes, the stereocentre at C1 has the R configuration; however, some 
furanocembranoids have been found to exhibit the opposite.[21] Lophotoxin (3), pukalide (8) 
and bipinnatin G (9), along with their various oxygenated and deoxygenated congeners, are 
representative of the family (Figure 5). 
 
 
 
 
 
Figure 5 Representative members of the furanocembrane family 
The biosynthesis of the cembrane skeleton begins with the cyclisation of geranyl-geranyl 
diphosphate (10) to give a 14-membered macrocycle 11 as a carbocationic species 
(Scheme 1). Loss of a proton from the isopropyl side chain subsequently affords the natural 
product neo-cembrene (12). A series of oxidation and reduction reactions, and the closure of 
the furan ring, occur subsequently to afford the furanocembrane products. Despite a 
significant number of family members having been isolated, the full enzymatic pathway from 
neo-cembrene has yet to be elucidated.[22] 
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Scheme 1 Biosynthetic pathway to the furanocembranoids 
Many of the natural products within the furanocembrane family have been found to be 
biologically active. Several studies have delivered promising results, with new compounds 
still being recently isolated.[23] Lophotoxin (3) is the most recognized biologically active family 
member and is found in multiple species of Lophogorgia. It is a potent irreversible inhibitor of 
the nicotinic acetylcholine receptor, making it an effective neurotoxin.[13] Other compounds 
isolated alongside lophotoxin from the gorgorian coral Lophorgorgia peruana have also 
exhibited some cytotoxic activity against breast, lung and colon tumor cell lines.[24] 
1.1.3.2 Pukalide and 7-Acetylsinumaximol B 
In 1975, pukalide (8), was the first furanocembranoid to be isolated and identified, after 
extraction from the alcynacean octocoral Sinularia abrupta. Subsequently, this natural 
product has been isolated from several other coral species. Scheuer and Missakian 
published the original structure; of which the stereochemistry has now been revised.[25] 
Pukalide, along with its derivatives (13-15) and other structurally related compounds are 
found in a variety of octocorals in the orders Gorgonacea and Alcyonacea.[26] Reportedly it is 
most abundant in the egg-bearing colonies and recently released eggs of Sinularia 
species.[27] 
 
 
 
 
 
 
Figure 6 Structure of the natural product pukalide and its biological derivatives 
Studies based around the ecological activity of pukalide within Leptogorgia virgulata, a sea 
whip of the order Gorgonocea found on North-western Atlantic coastlines,  have shown that 
ingestion of pukalide by fish induces vomiting episodes.[28] Therefore, the terpenoid is 
partially or completely responsible for the emetic properties of the Leptogorgia species 
skeletal tissues. 
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Although little is known about the pharmacological activity of pukalide, studies have shown 
promising results for closely related family members. Cozar-Castellano et al. reported that 
epoxypukalide activates the ERK1/2 pathway to induce β-cell proliferation, making it a 
potential treatment for diabetes.[29] The epoxide at C11-C12, along with the ester group, was 
found to be essential for activity. SAR studies focusing on the activity of the analagous 
molecule lophotoxin also revealed the importance of the epoxide.[30] The results suggested 
that the pharmacophore necessary for irreversible inhibition of the nicotinic acetylcholine 
receptor retains the γ-lactone and the trisubstituted epoxide, which are also present in 
pukalide, and which are thought to mimic the acetate oxygens and cationic ammonium group 
in acetylcholine. 
7-acetylsinumaximol B (16) was recently isolated in 2015 by Su et al. from the cultured soft 
coral Sinularia sandensis.[23] It was found alongside another new cembranoid, 4-
carbomethoxyl-10-epigyrosanoldie E (17), and several other related known metabolites; 
including pukalide and sinumaximol B. The absolute configurations of carbomethoxyl-10-
epigyrosanoldie E (17) and pukalide (8) were determined by single crystal X-ray 
crystallography. The determined absolute configurations, and comparison with known 
analogues, showed the hypothesis that cembrane diterpenes obtained from Alcyonacean 
soft corals and Gorgonacean corals belong to different series with respect to their C1 
stereochemistry does not apply to some cembranoids.[31,32] All compounds isolated were 
tested for anti-inflammatory activity resulting from inhibition of protein expression of inducible 
nitric oxide synthetase (iNOS) and cyclooxygenase-2 (COX-2). Several metabolites were 
found to be active; however, pukalide (8), sinumaximol B (18) and 7-acetylsinumaximol B 
(16)  were shown to be inactive. 
 
Figure 7 Metabolites isolated from Sinularia sandensis. 
 
16 
 
1.2 Total Syntheses of Furanocembranoids 
To date numerous syntheses of octocoral diterpene natural products have been reported. 
One of the earliest publications by Paquette et al. in 1992 reported the total synthesis of the 
pseudopterane derivative gorgiacerone.[33] The Paquette group also completed the first total 
synthesis of the furanocembranoid acerosolide in 1993.[34] Since then, numerous groups, 
including those of Pattenden, Trauner and Marshall, have reported total syntheses of and 
synthetic studies directed toward the furanocembranoid family of natural products.[35–37] The 
majority of completed total syntheses pertain to deoxygenated members or enantiomers of 
the natural compounds. 
1.2.1 Total Synthesis of Natural Furanocembranoids 
1.2.1.1 The Total Synthesis of Acerosolide 
In 1993, Paquette et al. reported the first total synthesis of a 14-membered 
furanocembranolide, acerosolide (19).[34] Acerosolide contains 2-stereogenic centres at C1 
and C10 and a double bond at C7-C8; total synthesis allowed the relative and absolute 
configuration of the two stereogenic centres to be determined.  
Following previous work reported by the group, for the synthesis of the pseudopterane 
gorgiacerone, key disconnections were made alpha to the butenolide, ketone and isoprene 
groups of acerosolide to give three fragments (20, 21 and 22) (Scheme 2); the synthesis of 
which had been reported previously. The two stereocentres could therefore be installed by a 
Lewis acid promoted addition reaction between the allylic stannane (21) and aldehyde (22) 
and an intramolecular Cr(II) promoted reductive coupling reaction, following previous 
methodology. 
 
 
 
 
 
 
Scheme 2 Retrosynthetic analysis of acerosolide 
The forward synthesis began with the SnCl4 promoted reaction of aldehyde 22 with allylic 
stannane 20, to give homoallylic alcohol 23. Acid-catalysed lactone formation, followed by an 
oxidative sequence via the bis-selenide afforded the butenolide 24 in four steps. The 
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aldehyde 24 was then converted to the bromide 25 and this compound coupled with 
vinylstannane 21 to afford seco-cembrane 26. A further three steps afforded aldehyde 27. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 3 Forward synthesis of acerosolide 
Following the elaboration of seco-cembrane 26 into bromo aldehyde 27, in a three-step 
sequence, cyclisation was effected using CrCl2 to afford a single homoallylic alcohol 28. 
Finally, oxidation of the hydroxyl group gave (±)-acerosolide (19), as confirmed by 
comparison with the natural product spectra. 
 
 
 
 
 
Scheme 4 Final steps in the total synthesis of acerosolide  
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1.2.1.2 The Total Synthesis of (−)-Rubifolide 
Marshall et al. reported the first total synthesis of (−)-rubifolide ((−)-29), the non-natural 
enantiomer of the natural product, in 1997.[38] The group earlier reported the synthesis of 2-
vinylfurans through base mediated rearrangement of 2-hexen-4-yn-1-ols possessing a 
leaving group (OR) at the 6-position.[39] With this methodology in mind they proposed to use 
the reaction for the synthesis of the rubifolide skeleton. Model studies showed that formation 
of furan 31 could be effected from a mixture of four diastereoisomers 30.[40] 
 
 
 
 
 
 
Scheme 5 Model studies for the formation of the rubifolide skeleton 
At the onset of the synthesis the absolute stereochemistry of rubifolide was unknown. (S)-
Perillyl alcohol (32) was therefore utilised due to its economic viability; however, this 
ultimately resulted in the formation of the natural product enantiomer. The key building 
blocks were formed in 6 and 4 steps respectively from simple building blocks; alkyne 33 was 
formed in 6 steps from (S)-perillyl alcohol (32) and aldehyde 36 was formed in 4 steps from 
epoxide 34 and alkyne 35. Fragment coupling was accomplished by attack of the alkyne 
anion of 33 onto aldehyde 36. Subsequent carbonate formation afforded diyne intermediate 
37 in high yield.  
 
 
 
 
 
 
 
 
Scheme 6 Initial steps in the synthesis of (−)-rubifolide 
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Deprotection of the propargylic alcohol 37 using DDQ, followed by mesylate formation and 
addition of the cuprate of lithiated tributyltin afforded allenylstannane 38 in 84% yield over 
the 3 steps. Deprotection of the primary alcohol followed by oxidation, as the magnesium 
alkoxide, with ADD (1,1'-(azodicarbonyl)dipiperidine) furnished aldehyde 39, which 
underwent ring closure upon treatment with boron trifluoride etherate to form the 
corresponding homopropargylic alcohol. Oxidation with Dess-Martin periodinane and in situ 
isomerisation of the resulting ketone gave allenone 40 as a mixture of eight 
diastereoisomers.  
 
 
 
 
 
 
 
 
 
 
 
Scheme 7 Formation of a cyclised intermediate in the synthesis of rubifolide 
Furan formation was effected in 84% yield by treatment of allenone 40 with silver nitrate 
impregnated silica gel to afford furan 41. Highly Z-selective elimination of the protected 
tertiary hydroxyl group in the presence of tosylic acid, followed by carbonate cleavage 
afforded propargylic alcohol 42 in good yield. Despite the results of earlier model studies, 
attempts to effect elimination using the originally reported base-mediated conditions led to 
decomposition.  
 
 
 
 
 
Scheme 8 Furan formation in the synthesis of rubifolide 
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Following separation of the two hydroxyl isomers 42 and formation of the trifluoracetate 43, a 
one-pot Pd(0)-catalysed hydrocarbonylation and silver nitrate catalysed cyclisation reaction 
furnished (−)-rubifolide ((−)-29), via the allenic acid 44. The reaction proceeds with inversion 
of configuration at the C-O bond. Marshall et al. therefore achieved the synthesis in 19 steps 
(longest linear sequence) from (S)-perillyl alcohol. 
 
Scheme 9 Completion of the total synthesis of rubifolide 
1.2.1.3 The Total Synthesis of Bipinnatin J 
1.2.1.3.1 Trauner's Approach 
In 2006, Trauner et al. described the first total synthesis of bipinnatin J (45) as a racemate.[37] 
Following a similar strategy to Paquette et al. for the synthesis of acerosolide,[34] key 
disconnections were made between C1-C2 and C6-C7 to allow CrCl2 catalysed 
macrocyclisation and Stille coupling as the key synthetic steps from proposed fragments 47 
and 48. 
 
 
 
 
 
Scheme 10 Retrosynthetic analysis of bipinnatin J by Trauner  
Synthesis of the targeted butenolide fragment 48 was achieved in 5 steps starting from 
known vinyl iodide 49. Oxidation of alcohol 49 with DMP gave the corresponding aldehyde 
before addition of lithiated ethyl propiolate to afford propargylic alcohol 50. A ruthenium(II)-
catalysed enyne reaction, initially reported by Trost,[41] gave a 7:1 mixture of butenolide 51 
and its corresponding regioisomer. The key ruthenium catalysed reaction is thought to 
proceed through formation of the equivalent enol intermediate int-51, followed by 
tautomerisation and intramolecular transesterification. A further two step Wittig olefination 
and reduction sequence yielded butenolide 48. 
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Scheme 11 Formation of the butenolide fragment in bipinnatin J 
Following preparation of the vinylic iodide 48, coupling of this compound with furyl stannane 
47 under Stille conditions afforded allylic alcohol 52. Subsequent closure of the macrocycle 
was achieved through formation of the corresponding allylic bromide and cyclisation using 
Nozaki-Hiyama-Kishi conditions to afford (±)-bipinnatin J with a dr of > 9:1 in a total of 8 
steps from the alcohol 49.  
 
Scheme 12 Completion of the racemic synthesis of (±)-bipinnatin J 
Following this success, Trauner et al. went on to report the enantiomeric synthesis of (−)-
bipinnatin J in a slightly longer 16 step sequence from vinyl iodide 49.[42] The initial 
stereochemistry was set through reduction of propargylic ketone 53 using (S)-alpine borane. 
A further 3-step sequence from alcohol 54 gave the common intermediate 50 which was 
transformed into (−)-bipinnatin J in 8 steps using a similar sequence to that described 
previously.  
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Scheme 13 Formation of the butenolide stereocentre for (−)-bipinnatin J 
With (−)-bipnnatin J in hand, the group was able to exploit a biosynthetic approach for the 
synthesis of other family members (Scheme 14). An SN1 deoxygenation reaction of (−)-
bipinnatin J ((−)-45) with triethylsilane and trifluoroacetic acid gave (+)-rubifolide ((+)-29) in 
almost quantitative yield.[42] Oxidation of the furan with mCPBA resulted in the formation of 
(+)-isoepilophodione 55. The group also reported the synthesis of intracarene 58 in 3 steps 
from (−)-bipinnatin J; an initial Achmatowicz rearrangement gave 56 which was acetylated to 
afford 57. Subsequently a one-pot elimination and 1,3-dipolar cycloaddition occurred to 
afford intracarene (58). It was also found that selective addition of singlet oxygen followed by 
reduction also gave 58; giving insight into the potential biosynthesis of this compound. Later, 
in 2014, a photochemical method for the formation of intricarene from (−)-bipinnatin J was 
also reported.[43] In 2010, Trauner et al. reported the further manipulation of (+)-rubifolide in a 
series of oxidation and rearrangement steps to furnish coralloidolides A, B, C and E (59, 61, 
62 and 60 respectively).[44]  
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Scheme 14 Synthesis of multiple family members from (−) bipinnatin J 
1.2.1.3.2 Rawal's Approach 
In 2006, Rawal et al. reported a second synthesis of bipinnatin J in racemic form using 
similar disconnections to those reported by Trauner.[45] Rawal proposed to use the same 
precursor 46 and final macrocyclisation step as Trauner et al. but expected to form the 
precursor through a γ-alkylation reaction of a butenolide fragment and subsequent Negishi 
cross-coupling (Scheme 15). 
 
 
 
 
 
Scheme 15 Retrosynthetic analysis of (±)-bipinnatin J by Rawal et al.  
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In the forward synthesis, the butenolide fragment 65 was formed in 6 steps from 5-bromo-2-
methylpent-2-ene 66 (Scheme 16). Alkylation of the butenolide was achieved through 
formation of siloxyfuran 67 and subsequent treatment with allylic bromide 63 in the presence 
of silver trifluoroacetate. Negishi coupling with organozinc compound 64, prepared in situ, 
furnished the completed carbon scaffold 69. Deprotection of both the primary alcohol and 
aldehyde was carried out under acidic conditions and the corresponding alcohol was 
transformed in to the bromide 70 using the Appel reaction. The Nozaki-Hiyama 
macrocyclisation reaction was then carried out, as described by Trauner, to afford (±)-
bipinnatin J in a total of 12 steps.  
 
Scheme 16 Racemic synthesis of bipinnatin J by Rawal et al. 
1.2.2 Total Synthesis of Deoxygenated Furanocembranoids 
1.2.2.1 Synthesis of Deoxypukalide 
Deoxypukalide is the degradation product of pukalide and exists in nature solely as the Z-
alkene isomer. There have been two enantiomeric syntheses and one synthesis of the 
natural enantiomer of this natural product: Marshall (2001),[46] Donohoe (2008)[47] and 
Pattenden (2010).[35] The original synthesis, completed by Marshall and van Devander was 
published before deoxypukalide had been isolated as a natural product.  The isolation of 
deoxypukalide was first reported by Darias et al. in 2007 from the Pacific octocoral 
Leptogorgia spp.[48] The formation of deoxypukalide by deoxygenation of pukalide has also 
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been established experimentally by treatment of pukalide with zinc in refluxing ethanol 
(Scheme 17).[46] 
 
 
 
 
 
Scheme 17 Experimental formation of deoxypukalide from pukalide 
1.2.2.1.1 Marshall and Van Devander's Approach 
In 2001 Marshall and Van Devander reported the synthesis of the unnatural enantiomer, (−)-
Z-deoxypukalide ((−)-15).[46] Starting from (S)-perillyl alcohol (32) the group described the 
total synthesis in 27 linear steps (Scheme 21). Based on their earlier work on the total 
synthesis of rubifolide the group proposed the same key disconnections and a similar late 
stage furan formation from a cyclic precursor. 
The synthesis of iodo-compound 71 was achieved in 16 steps from (S)-perillyl alcohol (32). 
Cyclisation was effected by treatment of β-keto ester 71 with KOtBu under high dilution 
conditions to furnish macrocycle 72 in 83% yield. Selective cleavage of the TBS-silyl ether 
followed by oxidation with Dess-Martin periodinane furnished ynone 73. The furan was 
subsequently installed by a mild acid-catalysed process using silica to afford 74; analogous 
to the method used for the synthesis of rubifolide. Ketone 74 was converted to the 
corresponding Z-alkene 75 in a five step sequence involving enol triflate formation, Pd-
catalysed methylation and deprotection of the propargylic alcohol.  
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Scheme 21 Formation of the furan macrocycle in the synthesis of (−)-Z-deoxypukalide by Marshall 
With alkyne 75 in hand attention was turned to formation of the butenolide 76. A Pd-
catalysed carbohydroxylation from the in situ formed trifluoroacetate of propargylic alcohol 
75 and subsequent cyclisation upon treatment with silver nitrate impregnated silica gel 
afforded butenolide 76. Pyrolysis of the tert-butyl ester followed by methylation of the 
corresponding acid with TMS-diazomethane installed the methyl ester, furnishing (−)-Z-
deoxypukalide.  
 
Scheme 22 Final steps in Marshall's synthesis of (−)-Z-deoxypukalide 
1.2.2.1.2 Donohoe's Approach 
In 2008, Donohoe et al. also reported the total synthesis of the unnatural enantiomer, (−)-Z-
deoxypukalide ((−)-15), from the same chiral pool starting material, (S)-perillyl alcohol 32.[47] 
Donohoe et al. proposed that the furan-alkene bond could be formed by Negishi cross 
coupling as shown by Rawal et al. in the synthesis of bipinnatin J.[45] Disconnections through 
the butenolide ring were also envisioned to allow ring closure through macrolactonisation 
and RCM; leading to two key fragments 77 and 78. It was anticipated that the furan ring 
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could also be formed through RCM and that the resulting fragment 79 could in turn be 
formed from the chiral pool starting material (S)-perillyl alcohol 32. 
 
Scheme 23 Retrosynthetic analysis of (−)-Z-deoxypukalide by Donohoe et al.  
The forward synthesis began with the four-step synthesis of ring-closing metathesis 
precursor 80 from (S)-perillyl alcohol 32 (Scheme 24). Treatment of 80 with Grubbs II in 
refluxing CH2Cl2 furnished the cyclic olefin 81 which was immediately aromatised in situ 
under acidic conditions to afford the furan 82 in 85% yield. This was followed by a three-step 
functional group manipulation to give the furan fragment 83. 
 
Scheme 24 Furan formation in the total synthesis of (−)-Z-deoxypukalide by Donohoe et al. 
The side-chain on the furan ring was installed by a Negishi cross-coupling reaction with the 
vinylic iodide 77, which was synthesised in a four-step sequence previously reported by 
Pattenden.[49] Double deprotonation of 83 with LDA and in situ transmetalation with zinc 
bromide was followed by Pd-catalysed coupling to furnish 84. Following this, deprotection, 
macrolactonisation under Shiina conditions[50] and a second ring-closing metathesis reaction 
afforded (−)-Z-deoxypukalide ((−)-15) (Scheme 25). Following this route, synthesis of (−)-Z-
deoxypukalide was completed in 12 steps (longest linear sequence) with an overall yield of 
15%. 
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Scheme 25 Final steps in the synthesis of (−)-Z-deoxypukalide by Donohoe et al. 
1.2.2.1.3 Pattenden's Approach 
A further total synthesis of (+)-Z-deoxypukalide ((+)-15) was reported by Pattenden et al. in 
2010.[35] Disconnections were made as in Trauner's synthesis of bipinnatin J;[42] between C6-
C7 and C1-C2. The same vinylic iodide fragment 48 was used; although synthesised in an 
alternative manner in 9 steps from diol 86. 
 
Scheme 26 Key disconnections and initial steps in Pattenden's synthesis of  (+)-Z-deoxypukalide 
Having established a route to vinylic iodide fragment 48, Stille coupling with furylstannane 85 
afforded the cyclisation precursor 87. Formation of the corresponding bromide using NBS 
and PPh3, followed by NHK macrocyclisation furnished the macrocycle 88 in good yield. 
Deoxygenation was carried out in high yield using TFA and triethylsilane to afford 89. 
Subsequent deprotection of the primary alcohol, followed by oxidation with manganese 
dioxide, gave the corresponding aldehyde 90, which was further converted into the methyl 
ester in two steps to complete the synthesis of (+)-Z-deoxypukalide.  
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Scheme 27 Pattenden's synthesis of (+)-Z-deoxypukalide 
1.2.2.2 Synthesis of Bis-deoxylophotoxin 
In 2005, Pattenden et al. reported the synthesis of bis-deoxylophotoxin (91); a lophotoxin 
analogue with alkenes in place of the epoxides across C7-C8 and C11-C12.[51] 
Disconnections between C6-C7 and C12-C13 led to the proposal of Stille coupling and an 
aldol-type reaction as the key steps for fragment coupling of the iodide 92 to the stannane 93.  
 
 
 
 
 
 
Scheme 28 Retrosynthetic analysis of bis-deoxylophotoxin (91) 
Formation of lactone fragment 92 was achieved from chiral epoxide 95, which was obtained 
from (R)-epichlorohydrin (94) in four steps and with high ee. Treatment of epoxide 95 with 
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the lithium salt of 1-ethoxyacetylene, followed by reaction with pTSA afforded lactone 96 in 
high yield. α-Phenylselenolactone 92 was subsequently formed through formation of the silyl 
enol ether and trapping with phenylselenium bromide; direct trapping of the lithium enolate 
resulted in formation of the bis-selenated lactone.  
 
Scheme 29 Formation of the lactone fragment for the formation of bis-deoxylophotoxin 
Furan-aldehyde fragment 93 was prepared from oxazolidinone 97 in 10 steps. Deconjugative 
alkylation through deprotonation of oxazolidinone imide 97 and treatment with ethyl-2-
bromomethyl-3-furoate furnished the furan adduct 98. Reduction of the imide to the 
corresponding alcohol using two equivalents of Super Hydride was followed by tosylate 
formation, reduction of the ethyl ester using DIBAL-H and subsequent SN2 nitrile formation to 
afford alcohol 99. A further five-step sequence furnished furan-aldehyde 93 required for the 
coupling reaction. 
 
 
 
 
 
 
 
 
 
Scheme 30 formation of furan fragment 93 in the synthesis of bis-deoxylophotoxin 
Formation of the macrocycle 101 was achieved in three steps from fragments 92 and 93. 
Intermolecular alkylation proceeded in high yield, furnishing alcohol 100 as a mixture of 
diastereoisomers. Oxidative elimination of the phenylselenide using H2O2 delivered the 
butenolide whilst a subsequent intramolecular Stille reaction completed formation of the 
macrocycle to furnish 101 as a ~2:1 mixture of diastereoisomers in low yield. Intermolecular 
Stille coupling followed by an intramolecular aldol reaction was also explored; however, 
macrocycle formation was not observed. A three-step acetylation, deprotection and oxidation 
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sequence furnished both epimers of bis-deoxylophotoxin (91) from the corresponding 
isomeric alcohols 101. 
 
 
 
 
 
 
 
 
 
 
 
Scheme 31 Completion of the synthesis of the bis-deoxylophotoxin (91) 
1.2.2.3 Synthesis of Deoxyprovidencin 
One of the most recent publications by Mulzer et al. detailed the total synthesis of 17-
deoxyprovidencin (102).[52] The synthesis was completed in a longest linear sequence of 17 
steps, from a known compound, in an overall yield of 1.6%. The key furan motif was 
constructed using a base-mediated cyclisation reaction whilst the desired alkene geometry 
was obtained by isomerisation under UV-B light; a method previously unseen in the 
synthesis of these natural products. Retrosynthetic analysis suggested that both epoxides 
could be installed at a late stage in the synthesis after completion of the macrocycle 103 
using RCM of an intermediate generated by intermolecular aldol coupling of the two key 
fragments 104 and 105. 
 
 
 
 
 
 
Scheme 32 Retrosynthetic analysis of deoxyprovidencin by Mulzer et al.  
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Synthesis of furan fragment 104 began from the known cyclobutane 106, which was 
converted into the corresponding diol through ozonolysis and reduction. Differentiation of the 
two primary alcohols was achieved by selective tritylation of the less hindered alcohol to 
afford alcohol 107. A five-step sequence subsequently yielded alkyne 108 which underwent 
base-mediated cyclisation to install the furan functionality, affording vinylfuran 109. The final 
furan fragment 104 was obtained after a two-step hydroxyl deprotection-oxidation sequence.  
 
 
 
 
 
 
 
Scheme 33 Key steps in the synthesis of fragment 104 
Selenolactone fragment 105 was prepared from (R)-glycidyl tosylate (110) in three steps. 
Cuprate mediated addition of isoprenyl magnesium bromide afforded alcohol 111 which was 
converted into selenide 112 through NaH promoted epoxide formation and treatment with 
the dianion of phenylselenyl acetic acid. The seco-acid 112 was subsequently cyclised under 
Steglich conditions too afford selenolactone 105.  
 
 
 
 
Scheme 34 Formation of selenolactone fragment 105 
An intermolecular aldol reaction between fragments 104 and 105 furnished the aldol adduct 
as a mixture of four diastereoisomers. Subsequent treatment with H2O2 promoted oxidative 
elimination of the selenide to afford the butenolide 113 as a mixture of alcohol epimers. 
Ring-closing metathesis using Grubbs second generation catalyst resulted in the formation 
of the readily separable Z-olefin diastereoisomers 114 in a 1.5:1 ratio. Acetylation of the (S)-
alcohol ((S)-114) was followed by treatment with sodium hypochlorite, under conditions 
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reported by Node et al.,[53] to form the C11-C12 epoxide diastereoselectively and afford 115. 
Irradiation of 115 with UV-B light resulted in Z/E isomerisation to give desired E-olefin 116. 
Ketone 117 was generated though TBAF mediated silyl ether cleavage and subsequent 
oxidation with IBX. Stereoselective epoxidation of the C7-C8 olefin was then conducted 
using DMDO before a final Wittig methylenation reaction afforded 17-deoxyprovidencin (102).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 35 Final steps in the synthesis of 17-deoxyprovidencin by Mulzer et al.  
1.2.3 Synthetic Approaches Towards the Furanocembrane Skeleton  
In addition to the total syntheses discussed previously, other studies directed toward 
furanocembranoid natural products have been reported by several groups. These studies 
have either largely focused on the construction of the furanocembrane skeleton or more 
highly oxygenated family members such as lophotoxin, pukalide and providencin.  
1.2.3.1 Paterson's Approach to the Furanocembrane Skeleton 
In 1999, Paterson et al. reported studies towards the synthesis of the skeleton of lophotoxin 
and pukalide; an intermolecular aldol reaction was used to join the key fragments and an 
intramolecular Stille coupling reaction was employed to close the model macrocycle.[36] 
Model fragments 118 and 119 were both formed in three steps from known starting materials 
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and then coupled using an intermolecular aldol reaction with LiHMDS as the base to afford 
the alcohol 120 in high yield. However, this strategy proved to be unsuitable as the 
intramolecular Stille coupling-oxidation sequence afforded the macrocycle 121 in very low 
yield (15%). Despite the limitations of this approach it was later adopted by Pattenden et al. 
for the synthesis of bis-deoxylophotoxin.  
 
 
 
 
 
Scheme 36 Synthesis of the furanocembranoid backbone by Paterson 
1.2.3.2 Wipf's Approach to the Furanocembrane Skeleton 
In 2002, Wipf and Soth reported a synthesis of the C1-C10 fragment of lophotoxin and 
pukalide using Pd catalysis to assemble the furan ring through intramolecular reaction of an 
alkyne with a ketone.[54] They had earlier reported the formation of tri-substituted furans 125 
in this manner from β-keto esters 122 but reported little selectivity with respect to the E/Z 
ratio of the alkene product.[55] They proposed that the E/Z ratio could be tuned depending on 
the facial selectivity of the allene protonation step; if one face was blocked by a bulky group 
then one alkene isomer would predominate because the proton would approach from the 
opposite face. 
 
 
 
 
Scheme 37 Facial selectivity in Wipf and Soth's furan formation 
After a five-step synthesis of furan precursor 126 had been achieved, formation of the C1-
C10 fragment was explored. As proposed, cyclisation proceeded with a high level of 
stereocontrol to give (Z)-alkenylfuran 127 in a ca. 15:1 ratio in high yield. The TMS group 
was converted into the desired methyl substituent using a silane-iodine exchange reaction 
followed by Negishi cross-coupling to give the desired (E)-isomer 128. 
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Scheme 38 Furan formation described by Wipf and Soth 
Preparation of an advanced racemic intermediate 131 was achieved subsequently following 
the same protocol. From intermediate 129 cyclisation, silyl-iodine exchange and Negishi 
coupling proceeded as before, in moderate yield, to give furan 131. Overall the fragment was 
synthesised in a total of 11 steps and with an overall yield of 10% from 1,4-butanediol.  
 
 
 
 
 
 
 
 
 
 
Scheme 39 Synthesis of an advanced intermediate 131 of the furanocembranes 
In 2006, Wipf and Grenon reported further advances in their synthesis of lophotoxin 
fragments.[56] Starting from cyclic meso-anhydride 132 the C13 stereocentre was installed by 
catalytic desymmetrisation to afford carboxylic acid 133. Reduction of the free carboxylic 
acid furnished alcohol 134, which was converted to the [1,3]dioxin-4-one 136 through 
oxidation and a Horner-Wadsworth-Emmons reaction with phosphonate 135. A novel 1,6-
addition of an organocuprate bearing the isoprene functionality ensued to give ester 137 as 
a 1:1 mixture of diastereoisomers.  Attempts to improve the stereoselectivity of the reaction 
using a rhodium catalyst and potassium isoprenyltrifluoroborate were largely unsuccessful, 
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delivering moderate yields and low dr. Thermolysis of the dioxin-4-one ring afforded the 
corresponding β-keto ester which was alkylated with iodide 138 to afford alkyne 139. 
Palladium catalysed furan formation was then effected as described previously, albeit with 
an alternative catalyst and base, to afford furan 140. Despite preparing this late stage 
intermediate, Wipf reported no further progress towards the targets of interest.  
 
Scheme 40 Lophotoxin fragment synthesis reported by Wipf  
 
1.2.3.3 White's Approach to the Furanocembrane Skeleton 
Recently, White et al. published studies concerning the total synthesis of providencin 
(141).[57] They envisioned that the macrocyclic structure could be constructed by use of Stille 
coupling between a vinyl iodide 142 and the furylstannane 143 to construct the C6-C7 bond 
and intermolecular aldol condensation of the enolate of the selenyl lactone to construct the 
C12-C13 bond (Scheme 9). 
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Scheme 41 Retrosynthetic strategy adopted by White et al for the synthesis of providencin
 
The furan moiety 145 was synthesised by a silver nitrate/silica mediated cyclisation of the 
keto-allene 144 under conditions similar to those described by Marshall (Scheme 21).[46] 
Subsequent functionalisation of 145, over five further steps, led to the formation of furan 146 
with the desired exocyclic alkene. Stannylation of the furan and coupling with vinyl iodide 
147 resulted in the formation of the trisubstituted furan 148. However, all attempts 
accomplish cyclisation to form the full natural product were unsuccessful. Oxidation of the 
primary alcohol also resulted in oxidation of the phenylselenyl functionality, which underwent 
thermal elimination to produce butenolide 149. Therefore, the envisioned aldol reaction could 
not be carried out and the macrocyclic skeleton of the natural product could not be 
completed. 
 
Scheme 42 Key steps reported by White et al. towards the synthesis of providencin 
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1.2.3.4 Bach's Approach to the Furanocembrane Skeleton 
In 2005, Bach et al. reported studies towards the furanocembrane skeleton using a 
regioselective bromine-magnesium exchange reaction.[58] Starting from 4,5-dibromofurfural 
(150), dibromofuran 151 was prepared in high yield using a Horner-Wadsworth-Emmons 
reaction. A subsequent three-step deprotection, reduction and protection sequence afforded 
furan 152.  
 
 
 
 
 
Scheme 43 Formation of dibromofuran 152 
Formation of the furfuryl-Grignard reagent from 152 occurred readily and reaction with vinyl 
aldehyde 153 occurred cleanly and regioselectively to give alcohol 154. Attempts to form the 
C2-C3 carbon bond in other ways were unsuccessful; cross-coupling failed and the use of 
lithium-halogen exchange gave yields of less than 30%. A further four steps were required to 
convert furan 154 into aldehyde 155 which underwent subsequent intramolecular Nozaki-
Hiyama coupling in low yield to afford propargylic alcohol 156. The alkyne 156 represents a 
similar intermediate to those described in previous furanocembrane syntheses by 
Marshall;[38,46] however, completion of the synthesis was not reported in this case.  
 
 
 
 
 
 
 
 
 
 
Scheme 44 Synthesis of an advanced furanocembrane skeleton intermediate 156 by Bach 
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1.2.3.5 Honda's Approach to the Furanocembrane Skeleton 
Honda et al. reported the synthesis of two potentially useful intermediates, furfuryl ether 165 
and butenolide 171 in a synthetic approach to bipinnatin J (45).[59] The group postulated that 
the butenolide could be installed stereoselectively at a late stage in the synthesis, giving 157 
as the proposed intermediate. In turn, they proposed that the homoallylic alcohol 157 could 
be formed by [2.3]-Wittig rearrangement of furfuryl ether 158. Disconnections adjacent to the 
alkyne led to the proposal of aldehyde 159 as the key fragment.  
 
 
 
 
 
 
 
 
Scheme 45 Retrosynthetic analysis of bipinnatin J by Honda et al.  
Starting from furfuryl alcohol 160, etherification with allyl chloride 161 gave furfuryl ether 162 
in moderate yield. Stille coupling of furyl bromide 162 and stannane 163 subsequently 
furnished vinylfurfuryl ether 164, which underwent a further six-step sequence to afford the 
alkyne cyclisation precursor 165. However, treatment of 165 with CuI, NaI and Cs2CO3 in 
DMF at 80 °C resulted in SN2' substitution, instead of the expected SN2 substitution, giving 
15-membered macrocycle 166 instead of the desired 17-membered macrocycle.  
 
  
 
 
 
 
 
 
Scheme 46 Studies towards bipinnatin J by Honda et al.  
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The group also examined construction of the butenolide using a model system. Propargylic 
alcohol 169 reaction of the aldehyde 168 with the alkynyl Grignard reagent derived from 
bromide 167. The propargylic alcohol 169 was then converted into allenic alcohol 170 
through a procedure originally reported by Myers et al.[60] utilising Mitsunobu elimination and 
subsequent removal of the MOM protecting group with CBr4 in iPrOH. The butenolide was 
finally installed by ruthenium catalysed cyclocarbonylation to afford γ-butenolide 171 in 66% 
yield.  
 
 
 
 
 
 
 
 
Scheme 46 Synthetic studies towards the butenolide moiety in the furanocembrane skeleton 
1.2.4 Conclusion 
Despite numerous studies and total syntheses there are still many difficulties associated with 
the synthesis of furanocembranes due to their complex structures and reactive functionality. 
Notably, all of the previously reported total syntheses have been of family members 
possessing low oxidation levels. Introduction of the C7–C8 epoxide that is present in 
lophotoxin and pukalide has proven to be particularly challenging, with only Mulzer et al. 
having established a successful strategy for its incorporation.[52] Consequently, a total 
synthesis of pukalide, as well as other oxygenated members, has yet to be achieved. This 
fact, coupled with the interesting associated biological activity, makes furanocembrane 
natural products highly attractive total synthesis targets. 
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1.3 Furan Synthesis 
1.3.1 Furan Formation 
Polysubstituted furans have received a great deal of attention as they are not only common 
motifs in natural products and pharmaceuticals, but are also useful building blocks for the 
construction of highly complex structures. For example, members of the furanocembrane 
natural product family include a trisubstituted furan within their core structure. 
 
 
 
 
 
Figure 8 Structures of lophotoxin and pukalide 
In the past 30 years many new reactions have been discovered for the synthesis of furans; 
these approaches employ a range of both inter- and intramolecular processes 
encompassing many transition metal catalysed reactions as well as some involving 
acid/base catalysed reactions and a small number involving organocatalytic processes.[61–64] 
This section comprises a brief overview of furan synthesis with particular focus on the 
synthesis of tri-substituted furans. 
1.3.2 Classical Synthesis of Furan Molecules 
The two most important traditional methods for the formation of furans are the Paal-Knorr 
and Feist-Benary syntheses, first reported in the late 19th and early 20th centuries.[65–68] In 
1884, C. Paal and L. Knorr independently reported the formation of substituted furans by 
dehydration of 1,4-diketones; this reaction is now known as the Paal-Knorr synthesis 
(Scheme 47). Although the reaction was discovered more than a century ago the 
mechanism was only fully elucidated in 1995 by Amarnath et al.[69] The mechanism of this 
transformation involves protonation of one of the carbonyl groups, which is then attacked by 
the enol of the second carbonyl to generate the dihydrofuran intermediate 174. Subsequent 
dehydration promoted by a strong acid, Lewis acid or dehydrating agent, such as acetic 
anhydride, followed by enolisation, delivers the desired furan 177.  
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Scheme 47 Paal-Knorr synthesis of furans 
The Feist-Benary synthesis, originally reported by Feist in 1902, also proceeds via a 
condensation type reaction.[67,68] The process involves the reaction of a β-dicarbonyl 
compound 178 with an α-haloketone 179 in the presence of a base. The reaction proceeds 
through the formation of the aldol adduct 180 and subsequent intramolecular nucleophilic 
displacement of the chloride by the enolate; upon dehydration, the reaction affords the 
desired furan 182.  
 
Scheme 48 Feist-Benary synthesis of furans 
Although these classical methods are useful, they have two major disadvantages: their 
incompatibility with acid or base sensitive functional groups and the fact that they do not 
allow for the introduction of a great amount of complexity on the furan ring. As a result of 
these limitations, many other furan-forming reactions have since been developed. 
1.3.3 Metal-catalysed Furan Synthesis 
Developments in the field of transition-metal chemistry have led to many new efficient and 
selective synthetic reactions.[70] The construction of furans under mild metal-catalysed 
conditions has been reported using a wide range of metals such as copper, gold, zinc, 
platinum, palladium and silver. Herein, representative examples of metal-mediated 
procedures for the synthesis of tri-substituted furans are discussed. 
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1.3.3.1 Palladium Catalysis 
To date, palladium catalysis, along with gold catalysis, has become one of the most 
commonly used methods for the synthesis of substituted furans.[71] Utimoto reported some of 
the first examples of Pd(II)-catalysed furan formation in 1983.[72] The use of β,γ-acetylenic 
ketones 184 and 2-methoxy-3-alkyn-1-ols 186 for the formation of furans 185 by an 
intramolecular cyclisation process was described, utilising either palladium(II) chloride or 
bis(benzonitrile)palladium(II) chloride (Scheme 49). 
 
 
 
 
Scheme 49 Pd-catalysed furan formation reported by Utimoto 
Since then, numerous groups have reported the use of alkenynols and alkenynones for the 
formation of a variety of tri- and tetra-substituted furans under similar Pd(II)-catalysed 
reaction conditions.[73] Recently, in 2013, Wang and co-workers reported a palladium-
catalysed reaction using conjugated enynones 187 as carbene precursors for the formation 
of furans 189 by a migratory insertion process (Scheme 50).[74]  
 
 
 
 
 
 
Scheme 50 Palladium catalysed furan formation described by Wang 
The reaction proceeds in good yields; however, the nature of the R4 group affects the E/Z 
selectivity. It was found that a bulky substituent at this position gave the Z isomer with high 
selectivity, whereas smaller substituents, such as TMS, resulted in the production of a 
mixture of E and Z isomers.  The catalytic cycle is proposed to begin with oxidative addition 
of Pd(0) into the halo compound, followed by activation of the alkyne 190 and cyclisation of 
the oxygen atom onto it to generate a palladium (2-furyl)carbene intermediate 191. 
Subsequent migratory insertion and β-hydride elimination affords the product; the catalyst is 
regenerated by treatment trapping of HBr with base (Scheme 51). 
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Scheme 51 Catalytic cycle proposed by Wang   
In subsequent work, Wang et al. described the formation of 2-alkenyl substituted furans 194 
and 195 with high (E)-selectivity using a combination of carbene chemistry and palladium 
cross-coupling.[75] Oxidative cross-coupling of enynone 193 with either an aryl or a vinyl 
boronic acid occurs in good yield and with excellent stereoselectivity. 
 
 
 
 
 
 
Scheme 52 Synthesis of 2-alkenyl substituted furans by Wang 
The reaction is proposed to proceed through initial oxidation of Pd(0) to Pd(II) using 
benzoquinone; consequent oxidative addition of the boronic acid generates the intermediate 
palladium species 196. The alkyne 193 is then activated by the newly formed palladium 
species 197 and nucleophilic attack of the carbonyl oxygen onto the alkyne ensues. The 
resulting (2-furyl)carbene species 198 undergoes migratory insertion to give the final 
intermediate 199, before β-hydride elimination occurs to afford the 2-alkenyl furan 194/195. 
The reactive palladium(0) species is then regenerated upon reaction of the palladium 
hydride 200 with base. 
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Scheme 53 Catalytic cycle for formation of 2-alkenyl furans 
 
1.3.3.2 Zinc Catalysis 
In 2012, Vicente and Lopez reported the formation of cyclopropyl-furans as a result of the 
zinc chloride catalysed intermolecular reaction between an enynone and alkene. (Scheme 
54).[76] The method described generates a zinc carbenoid species 205 from enynone 201 
and the zinc salt. Initially, the zinc is proposed to co-ordinate to the carbonyl and alkyne of 
the enynone 201 to give a zinc complex 204. Attack of the carbonyl onto the alkyne results in 
5-exo-dig cyclisation and subsequent tautomerisation. The alkene can then trap the carbene 
intermediate to form the cyclopropane product 203. Using this methodology a wide range of 
highly functionalised cyclopropyl-furans was synthesised with moderate to high 
stereocontrol, depending on the nature of the substituents on the cyclopropane ring.  
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Scheme 54 The zinc chloride catalysed formation of cyclopropyl-furans as described by Vicente and Lopez 
Vicente et al. reported an extension of this work in 2013 wherein they described a zinc-
catalysed cyclisation, followed by C-O or C-N bond formation through reaction with primary 
or secondary alcohols or with an azole, such as a pyrazole, imidazole or triazole (Scheme 
55).[77] Unlike their earlier work, it was found that an electron-rich aryl group was required for 
the reaction to proceed. A higher catalyst loading of 20 mol% zinc chloride was also 
required. 
 
 
    
 
Scheme 55 Representative example of the zinc-catalysed cyclisation reported by Vicente 
Intramolecular Zn-mediated processes, such as that described by Dembinski et al. in 2007, 
have also been employed for the synthesis of substituted furans (Scheme 56).[78] The zinc 
chloride catalysed reaction proceeds via a 5-endo-dig cycloisomerisation of 1,4-di- and 
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1,2,4-trisubstituted but-3-yn-1-ones 208 in CH2Cl2 at room temperature to give 2,5-di- and 
2,3,5-trisubstituted furans 209. 
 
 
 
 
Scheme 56 Zinc catalysed furan formation described by Dembinski 
1.3.3.3 Gold Catalysis 
Gold catalysts have proven to be particularly useful for the synthesis of functionalised furans 
due to the bifunctional properties of the metal. Gold species are adept at activating alkynes 
and allenes through complexation; cationic gold species also possess strong Lewis acidic 
properties.  
Two interesting examples of gold-catalysed furan-formation are denoted in the works 
published by Arcadi et al. and Pale et al. (Scheme 57).[79,80] Arcadi's group described the 
coupling of a 1,3-dicarbonyl compound 211 with a propargylic alcohol 210 in a tandem 
cascade process to form tetra-substituted furans 212. Pale et al. reported the rearrangement 
of alkynyloxiranes 213 upon treatment with triphenylphosphine gold triflate; giving tri-
substituted furans 214 in good yields. In this case an external nucleophile, namely MeOH, is 
required to promote the gold-catalysed isomerisation reaction 
 
 
 
 
 
 
Scheme 57 Examples of gold-catalysed furan formation 
In 2013, Pale et al. went on to report the formation of tri-substituted furans 216 using a 
gold(I) complex from γ-acyloxyalkynyl ketone precursors 215.[81] Furan formation was found 
to proceed with moderate yield when both R1 and R2 were alkyl substituents and R3 was 
either an alkyl substituent or an electron-rich aryl group (Scheme 58).  
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Scheme 58 Gold catalysed furan formation from γ-acyloxyalkynyl ketones 
Pale proposed a mechanism for the reaction based on the ability of the gold catalyst to 
function as both a π and σ Lewis acid. He hypothesised that, when acting as a σ Lewis acid, 
the gold cation would complex to the oxygen of the ketone 217, acting as an oxophilic 
activator. This would be followed by 1,4-addition of the nucleophilic acyloxy group to the 
alkyne to form allene 218, which would in turn be in equilibrium with E and Z vinyl 
intermediates 219 and 221. The π Lewis acidic pathway leads to the same intermediate via 
gold complexation to the alkyne 220 and nucleophilic attack of the acyloxy carbonyl. 
Rearrangement of 221 produces the carbenoid species 222 which undergoes intramolecular 
attack of the carbonyl onto the alkene to generate the cyclic oxocarbenium ion 223.  
Tautomerisation with regeneration of the gold catalyst then furnishes the furan product 216.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 59 Mechanism of Pale's gold-catalysed furan formation 
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In 2014, Hashmi et al. reported a gold-catalysed cyclisation cascade reaction for the 
synthesis of tri-substituted formylfurans 225 and 226 (Scheme 60).[82] These motifs, or 
higher oxidation state analogues thereof, are found in the furanocembrane natural products. 
The group reported that treatment of diynol 224 with IPrAuCl, in combination with silver 
triflate and an oxidant, resulted in the formation of the formylfurans. When substituents R 
and R1 were identical, high yields of desired product were reported. However, reactions of 
diynols that lacked symmetry gave lower yields and produced mixtures of regioisomers, 225 
and 226.  
 
Scheme 60 Gold(I) catalysed cascade reaction for tri-substituted formylfuran formation 
Mechanistic studies, using isotopic 18O and 13C, led to the elucidation of the reaction 
mechanism. Initially, in an established process, α-oxo gold carbenoid 227 is generated from 
the diyne 224 in the presence of gold(I) and the pyridine N-oxide (Scheme 61).[83] A 1,2-
alkyne shift onto the gold carbenoid then occurs instead of a potential 1,2-hydride shift, to 
give intermediate 228, which subsequently isomerised to give aldehyde 229 before 
cycisation to form the desired furan product 225.  
 
Scheme 61 Mechanism of the gold(I) catalysed furan formation 
1.3.3.4 Copper Catalysis 
Copper catalysts have been employed instead of transition metal catalysts for the synthesis 
of substituted furans. In 2008, Barluenga et al. reported regioselective methodology for the 
50 
 
synthesis of tri-substituted furans 232 from bis-propargylic esters 230 using copper(I) 
complexes.[84] The reaction proceeds through the formation of a furyl-copper carbene 
complex 231, which allows functionalisation through the creation of a carbon-heteroatom 
bond; in the absence of a suitable reaction partner, furyl alkene dimers are isolated 
(Scheme 62). The reaction tolerates a wide range of functionality and the reaction proceeds 
in good yield when R1 = alkyl, vinyl, allyl, aryl or silyl and R2 = alkyl or vinyl.  
 
Scheme 62 Furan formation described by Barluenga et al. 
In 2016, a new approach to the synthesis of furan-substituted allenes was reported by Wang 
et al (Scheme 63). In this case, furan formation occurs through a copper-catalysed carbene 
migratory insertion reaction.[75] The reaction between eneynedione 233 and an alkyne 234 in 
the presence of catalytic amounts of copper(I) gives carbene complex 235, which then 
undergoes migratory insertion to furnish the desired allene product 237. A wide range of 
alkynes 234 are tolerated under the reaction conditions; electron-rich, electron-poor, aryl and 
alkyl substituted systems were all found to give moderate yields.  
 
 
 
 
 
 
 
 
 
 
Scheme 63 Synthesis of furan-substituted allenes 
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1.3.4 Organocatalytic and Acid/Base Methods 
Interest in organocatalysis has increased greatly in recent years and many enantioselective 
organocatalytic reactions have been developed. As a result, many synthetic transformations 
can now be carried out organocatalytically.[85,86] Organocatalysed and acid/base catalysed 
reactions have great potential in synthesis and possess particular advantages when 
compared to their metal-catalysed counterparts; namely that small molecules are generally 
stable to air and water and have a low toxicity. In addition, small organic molecules are often 
cheaper than transition metals and more readily available.[87] Despite their growing popularity, 
organocatalysts have been used less frequently than metal catalysis in the field of furan 
synthesis. 
1.3.4.1 Synthesis of 2-Hydroxyalkylfurans and 2-Aminoalkylfurans 
In 2010, Jørgensen et al. reported an organocatalytic and enantioselective method for the 
synthesis of trisubstituted furans, and specifically 2-hydroxyalkyl and 2-aminoalkyl furans, 
based on the Feist-Benary synthesis.[88] The method allows furans to be synthesised in a 
highly enantioselective fashion (ee >90%) under mild conditions and with low catalyst 
loadings (Scheme 64). 
In the Jørgensen protocol, a proline derivative is employed as a catalyst for the epoxidation 
or aziridation of an α,β-unstaurated trans alkenal 238, to afford an enantioenriched 2,3-
epoxyaldehyde or 2,3-aziridinyl aldehyde 239. These compounds were then used in the 
Feist-Benary type reaction to give an electron-poor 2-hydroxyalkyl furan or furfuryl amine 
241. 
 
 
 
 
 
Scheme 64 Synthetic approach towards 2-aminoalkylfurans and 2-hydroxyalkylfurans 
The methodology allows for the use of both γ-branched aliphatic and aromatic α,β-
unsaturated aldehydes as substrates as well as a variety of 1,3-diketones, which provides 
scope to change the functionality of the trisubstituted furan products. Numerous acids and 
bases were screened to promote the furan formation and it was found that using a milder 
base such as K2CO3 or Hünig’s base allowed for the isolation of the hydroxyl/tosylamide 
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intermediate 240. However, use of MTBD (7-methyl-1,5,7-triazabicyclo[4.4.0]dec-5-ene) with 
either CSA or TFA proved to be optimal for preparation of the hydroxy and amino products 
241 in a one-pot procedure.  
1.3.4.2 Acid Catalysed Synthesis of Cyclopropyl-substituted Furans 
Recently, in 2015, the Clark group reported the synthesis of cyclopropyl-substituted furans 
using a Brønsted acid promoted cascade reaction.[89] In the reaction, chloroacetic acid is 
used to promote an efficient and diastereoselective intramolecular cascade reaction of 
electron-deficient enynones 242 to deliver products that feature a 2,3,5-trisubstituted furan 
bearing a fused cyclopropyl substituent at the 5-position 243 (Scheme 65). This method 
allowed for the synthesis of polycyclic building blocks featuring rings of various sizes and 
featuring various heteroatoms.  
 
Scheme 65 Brønsted acid promoted formation of cyclopropyl-substituted furans 
It has been proposed that the acid-catalysed reaction proceeds by an unusual mechanism in 
which a free carbene is generated under acidic conditions. Initially, an allene 246 is formed 
through protonation and isomerisation. The allene is then converted into a carbene 247 by 
attack of the enol onto the allene (Scheme 66). 
 
 
 
 
 
 
 
 
 
Scheme 66 Proposed mechanism for the formation of carbene 247 
53 
 
It was found that in cases where an allylic ether was present, the free carbene underwent 
competitive C-H insertion and intramolecular cyclopropanation to give 248 and 249 
respectively (Scheme 67). Intermolecular cyclopropanation and intramolecular C-H insertion 
reactions of less activated substrates were found to be disfavoured, suggesting that 
cyclisation to give the furan and carbene is reversible in the absence of a reactive group able 
to trap the carbene. It was also suggested that a low concentration of carbene intermediate 
247 is present within the reaction mixture as a result of the equilibrium between the carbene 
and cationic species 246. 
 
 
 
 
 
 
 
 
Scheme 67 Formation of C-H insertion and cyclopropanation products 
1.3.4.3 Phosphine Promoted Synthesis of Furans from Enynes 
In 1999, Kuroda et al. published a phosphine-initiated method for the preparation of furans 
from substituted enynes.[90] The group went on to further investigate the method and in 2004 
published work outlining the formation of tri- and tetra-substituted furans from more highly 
substituted enynes under these conditions (Scheme 68).[91] The reactions were performed in 
the presence of a stoichiometric amount of phosphine. 
 
 
 
 
Scheme 68 Phosphine promoted formation of tetrasubstituted furans 
Investigations in to the reaction mechanism led to the proposal of the formation of an ylide 
as an intermediate as using triethylamine as a catalyst did not deliver the furan product. 
Kuroda suggested that the phosphine acted as a reaction initiator through 1,6-addition to the 
enyne and that this reaction was followed by cyclisation to give the phosphonium 
intermediate 254. A Wittig reaction of an aldehyde with the ylide would therefore give the 
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desired unsaturated furan product (Scheme 69). Kuroda's work showed that organic 
compounds could be used to promote furan formation, moving away from the more 
conventional metal-catalysed approach.  
 
 
 
 
 
 
 
 
 
Scheme 69 Proposed reaction mechanism for phosphine mediated furan formation 
 
1.3.4.4 Condensation of γ-acyloxy Butynoates 
An additional strategy for the construction of substituted furans promoted by a phosphine 
was described by Krische et al. in 2004.[92] γ-Acyloxy butynoates were exposed to an excess 
of triphenylphosphine resulting in the formation of substituted furans by an intramolecular 
reductive condensation. The proposed mechanism for this transformation involves the 
conjugate addition of triphenylphosphine into the butynoate 255 and attack of the resulting 
enolate onto the ester carbonyl group to generate the five-membered oxacycle 256 
(Scheme 70). This is followed by rearrangement to the oxaphosphetane 257 and extrusion 
of triphenylphosphine oxide to produce the allenic ester 258. Nucleophilic attack by a second 
equivalent of triphenylphosphine onto the allenic ester and cyclisation of the resulting 
zwitterionic intermediate 259 results in the formation of phosphonium ylide 260 which 
undergoes enolisation with elimination of triphenylphosphine to generate the furan product 
261. Studies into the efficiency of the method revealed that the reaction is most proficient 
when R2 of the butynoate is electron-deficient; thus, making the carbonyl group more 
reactive towards nucleophilic attack in the initial step.  
55 
 
 
Scheme 70 Proposed mechanism for Krische et al.’s furan synthesis 
 
1.3.4.5 Organosulfur Catalysed Synthesis 
Inspired by the methodology published by Kuroda, Clark et al. proposed that an analogous 
reaction could be promoted by a thioether. In 2012, the Clark group published novel 
methodology for the organocatalytic formation of highly substituted furans from ynenones 
using tetrahydrothiophene (THT) (Scheme 71).[93] Treatment of the enyne 262 with 10 mol% 
of THT in the presence of a suitable nucleophile, such as a carboxylic acid, alcohol or 
sulfonamide, gave the resulting highly functionalised furfuryl product 263. Various electron 
withdrawing groups (EWGs) were found to be well-tolerated (ketones, esters, nitriles, 
sulfones and phosphonates) and it was shown that the R1 group could be alkyl, aryl or silyl.  
 
Scheme 71 THT catalysed furan formation 
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The proposed reaction mechanism begins with conjugate addition of the tetrahydrothiophene 
(268) into the enyne 262 followed by formation of ylide 265 through intramolecular 
cyclisation of the resulting enolate onto the allene. In the presence of a proton donor, the 
sulfonium ylide is protonated to form the sulfonium ion 266 and the corresponding 
nucleophile. The THT is released back into the catalytic cycle through formation of the 
oxonium intermediate 267 which is then trapped by the nucleophile to form the product 
(Scheme 72). It is likely that this transformation proceeds through the described SN1 
pathway rather than through a direct SN2 displacement of THT. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 72 Mechanism for the THT promoted furan formation 
Further investigation of the reaction mechanism revealed that three side products are formed 
when the reaction is performed using an electrophilic ynenone and tert-butyl alcohol. In this 
case, alcohol 271, alkene 272 and dimer 273 were all found to be produced alongside the 
desired product 270. 
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Scheme 73 Formation of side-products in the THT catalysed furan formation 
Formation of the three side-products is proposed to arise at different points in the catalytic 
cycle (Scheme 74). Dimer 273 is thought to arise through nucleophilic attack of the sulfur 
ylide 275 onto a second enynone compound, giving intermediate 278. Cyclisation is then 
thought to arise through an SN2 type mechanism, eliminating THT to furnish the dimer 273. 
Vinyl furan 272 is proposed to result from proton abstraction and elimination of THT from 
cationic intermediate 276. Alcohol by-product 271 arises from competing nucleophilic 
addition of water to the cationic sulfur intermediate 276; this by-product is not observed 
when there is rigorous exclusion of water from the reaction. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 74 Mechanism of formation of furan by-products 
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An example of a tandem one-pot condensation and furan-forming reaction was also reported 
by the Clark group as an extension to this methodology (Scheme 75). One-pot 
transformations have the added advantage that they significantly reduce chemical waste and 
improve synthetic efficiency. The reaction of acetylacetone (279) and the alkynyl aldehyde 
280 in the presence of benzoic acid, THT and piperidine afforded the furan 281 in 57% yield, 
which was comparable to the overall yield obtained when the reactions were performed 
separately.   
 
 
 
 
 
Scheme 75 One-pot condensation furan formation 
Alongside the intermolecular trapping of the sulfonium ion intermediates with a nucleophile, it 
was also demonstrated that nucleophilic attack can occur by an intramolecular process 
(Scheme 76). Treatment of enyne 282 with THT resulted in the formation of the epoxyfuran 
species 283. Epoxyfurans can be unstable and thus the formation of 283 in good yield 
demonstrates the mild nature of the reaction conditions. This result suggested a potential 
application of the reaction in the total synthesis of complex natural products which possess 
an epoxyfuran motif, such as the marine furanocembranoids. 
 
 
 
 
Scheme 76 Organocatalytic formation of an epoxyfuran 283  
More recent work has also shown that tethered tetrahydropyrans and tetrahydrofurans can 
be synthesised in the same manner (Scheme 77).[94] Starting from acyclic enynediones 284 
and 285, which contain a tethered primary alcohol, tetrahydrofuran and pyran products 286 
and 287 were obtained in good yield using 20 mol% of THT as the catalyst. The reaction 
was also extended to systems containing a carboxylic acid nucleophile. Treatment of 
alcohols 284 and 285 with DMP, followed by oxone, afforded the corresponding carboxylic 
acids 288 and 289. Cyclisation of these enynedione substrates bearing ω-carboxylic acids 
afforded bicyclic γ-butyrolactone 290 and δ-valerolactone 291 products.  
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Scheme 77 Synthesis of bicyclic furan species 
Cyclisation reactions of enynediones 292 possessing tethered secondary alcohols and 
branched chains were also found to proceed well in the presence of a higher catalytic 
loading of THT (50 mol%). In this case, phenylphosphonic acid was also required as a co-
catalyst to effect tandem cyclisation. Little to no stereocontrol was observed for the formation 
of the tetrahydrofuran ring when R1 was a small group (Me, Et etc.) (entries 1-3, Table 1). 
However, diastereoselectivity was observed when a branched chain primary alcohol was 
used (entry 4). The use of a tert-butyl group at R1 also resulted in a reasonable level of 
diastereocontrol during tetrahydropyran formation (entry 5). 
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Table 1 Diastereoselective formation of bicyclic furans  
 
 
 
 
Entry n R
1 
R
2 
Ratio (293:294) Yield (%) 
1 1 Me H 1:1.2 79 
2 1 Et H 1:1.1 77 
3 1 iPr H 1.2:1 71 
4 1 H Me 4.3:1 73 
5 2 tBu H 2.7:1 80 
 
Studies were also performed to determine whether cyclisation could be effected in an 
enantioselective manner.[95] Having established that an acidic co-catalyst helps promote 
furan formation, it was hypothesised that the new stereocentre could be introduced using a 
chiral acid through asymmetric counterion directed catalysis (ACDC). However, the best 
cases, in which (S)-(+)-TRIP-H was employed as the catalyst, afforded the product 296 in 
high yield but with just 12% ee.  
 
 
 
 
 
Scheme 78 Attempted enantioselective synthesis of trisubstituted furans 
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2 Results and Discussion 
2.1 Background and Retrosynthetic Strategy 
In 2012 the Clark group reported a novel organocatalytic method for the synthesis of 
trisubstituted furans from ynenones, which are easily obtainable through Knoevenagel 
condensation of propargylic aldehydes.[93] This new methodology has been used to prepare 
a wide range of substrates, including the epoxyfuran 283, through treatment of the ynenone 
282 with a sub-stoichiometric amount of tetrahydrothiophene (THT) (Scheme 79). The 
formation of epoxyfuran 283 in good yield highlights the mild nature of the reaction 
conditions. Moreover, it represents a strategy for the formation of such an epoxide in the 
presence of other reactive alkenes present in the substrate. These observations suggested a 
potential application of the reaction in the total synthesis of complex natural products that 
possess an epoxyfuran unit. 
 
 
 
Scheme 79 Epoxyfuran formation using organocatalytic THT 
With the THT methodology in mind, we became interested in exploring whether the 
transformation could be used as the furan-forming reaction in the total synthesis of members 
of the furanocembrane natural product family. Construction of the epoxyfuran unit that is 
present in many of the family members has so far proven to be very challenging. Mulzer et 
al. addressed this by performing a late stage epoxidation of a conjugated alkene using 
DMDO in their synthesis of deoxyprovidencin;[52] however, in substrates where the 
butenolide is present, selective epoxidation of the C7-C8 bond is not possible. 
Pukalide, an interesting family member which had so far eluded synthesis, was chosen as 
the initial target. Previously, epoxyfuran formation under the THT conditions had only been 
accomplished using the ynenone 282 as the substrate. However, pukalide possesses an 
ester group at C18 and so an ynenone possessing non-equivalent carbonyl groups would be 
required for the synthesis. To examine whether cyclisation of this type of substrate would be 
feasible, a reaction was performed using a mixture of E/Z ynenones 297 under the THT 
catalysed conditions (Scheme 80). Complete conversion of the E-alkene occurred within 19 
hours to give the desired epoxyfuran product 298; however, most of the Z isomer was 
recovered. The difference in reactivity between the two isomers suggested implications for 
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the total synthesis; during the late-stage Knoevenagel condensation the product with the 
desired E geometry would have to be formed in order to complete the target in good yield. 
Slow isomerisation of Z to E was observed; however, after 48 hours 66% of the Z isomer 
was still present. 
 
Scheme 80 Formation of epoxyfuran 298 
The synthesis of pukalide was envisioned to include the THT-mediated reaction as a mild 
and efficient way to install the C7-C8 epoxide and furan, simultaneously, at a late stage. 
Retrosynthetic analysis led to disconnection of the furan and epoxide to give macrolactone 
299 as a late stage intermediate. It was anticipated that this could in turn be formed from two 
key fragments: aldehyde 300 and β-ketoester 301. In a forward sense, it was envisioned that 
the ynenone would be constructed through Knoevenagel condensation of a propargylic 
aldehyde and a β-ketoester. The butenolide would be assembled through esterification and 
ring-closing metathesis. However, a decision as to which order these reactions would be 
utilised was to be made at a later stage. Disconnection of the methyl and alkyne groups in 
fragment 300 led to amide 302 as the key intermediate, whilst for fragment 301 cleavage of 
the β-keto ester by retro-Claisen condensation, removal of the methylene group and 
reconnection of C3 to C12 revealed (R)-perillyl alcohol ((R)-32) as the starting material. 
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Scheme 81 Retrosynthetic analysis of pukalide 
2.2 Synthesis of (R)-Perillyl Alcohol 
Retrosynthetic analysis of pukalide and the subsequently proposed fragments led to the 
proposal of (R)-perillyl alcohol as a starting material. However, (R)-perillyl is not 
commercially available and at the outset of this study, a synthetic protocol for its preparation 
had not been described in the literature; although, bio-catalytic methods were known.[96] For 
this reason, in several previous syntheses of furanocembrane natural products, (S)-perillyl 
alcohol had been utilised as the starting material, resulting in the formation of the natural 
products in antipodal form.[38,47] At the beginning of this project it was therefore necessary to 
establish a synthetic route for the synthesis of (R)-perillyl alcohol. In the course of the 
project, Evans et al. reported the synthesis of (R)-perillyl alcohol in which a palladium-
mediated rearrangement reaction was employed.[97] 
It was thought that the desired (R)-perillyl alcohol ((R)-32) could be prepared from the 
commercially available and relatively cheap starting material (+)-limonene oxide (303) 
(Scheme 82). It was proposed that (R)-perillyl alcohol could be formed by Wharton 
rearrangement of epoxy ketone 307, which could in turn be synthesised through 
rearrangement and oxidation of (+)-limonene oxide. Base-mediated epoxide rearrangement 
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of (+)-limonene oxide (303) afforded allylic alcohol 304 as a 1:1 mixture of diastereoisomers 
in good yield.[98] However, manipulation of the allylic alcohol proved to be problematic. 
Attempts to oxidise the allylic alcohol 304 resulted in dimerisation of the highly unstable 
product 305, and epoxidation with VO(acac)2 led to the formation of a complex mixture which 
could not be separated.  
 
Scheme 82 Attempted synthesis of (R)-perillyl alcohol 
Following these disappointing results, a new strategy was sought. It was found that 
treatment of allylic alcohols 304 with methanesulfonyl chloride in the presence of 
triethylamine resulted in the formation of the corresponding mixture of mesylates 308, which 
underwent SN2
’ rearrangement to afford (R)-perillyl alcohol ((R)-32) in good yield upon 
aqueous work-up. The effect of pH and temperature on the SN2
’ rearrangement was 
investigated. Both acidic and mildly basic work-up conditions afforded the desired product, 
but treatment with saturated aq. NaHCO3 was found to be optimal for product formation. 
However, use of a stronger base, such as sodium acetate caused degradation of the starting 
material.  
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Table 2 Formation of (R)-perillyl alcohol 
 
Aq. solution 
 
Temperature 
 
Scale (mmol) 
 
Yield (%) 
aq. NaHCO3
* 
rt 0.66 47 
aq. NaHCO3 rt 0.66 61 
aq. NaHCO3 rt 170.8 44 
H2O rt 0.17 - 
H2O 40 °C 1.36 48 
1M HCl rt 0.17 - 
1M HCl 40 °C 1.36 43 
NaOAc (2 eq.) rt 0.17 degradation 
NaOAc (2 eq.) 40 °C 0.17 degradation 
* Wet Et3N used 
2.3 Approach 1: An Intramolecular Knoevenagel Condensation Strategy 
for Macrocycle Formation 
In the first synthetic strategy it was anticipated that the epoxy furan and butenolide 
functionality would be introduced in the final steps of the synthesis through THT catalysed 
furan formation and ring-closing metathesis. These ideas led to the proposal of macrocycle 
309 as the key intermediate. Earlier proof of concept studies for the formation of epoxyfuran 
297 from the ynenone 298 had shown that furan formation was only effected from the 
corresponding E isomer. It was therefore envisioned that macrocyclisation through 
Knoevenagel condensation would result in sole formation of the E isomer, due to ring strain, 
and as such would allow for full conversion to the desired furan. Disconnection of the 
macrocycle 309 through the ynenone subsequently gave aldehyde 310 as the precursor. In 
the forward direction it was proposed that this intermediate could be formed by fragment 
coupling of 300 and 301 through esterification. Macrocyclisation by the proposed method 
was unprecedented for rings of this size and consequently, this initial strategy was risky.  
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Scheme 83 Retrosynthetic analysis through intramolecular Knoevenagel condensation 
2.3.1 Synthesis of the C12-C14/C1-C4 Fragment 
After a viable method for the synthesis of (R)-perillyl alcohol had been established, efforts 
were focused on the synthesis of fragment 301, C12-C14/C1-C6. (R)-Perillyl alcohol ((R)-32) 
was protected as its triisopropylsilyl (TIPS) ether 311 and then subjected to selective 
ozonolysis, under conditions reported by Donohoe et al.[47] Chemoselective reduction of the 
aldehyde 312 using sodium triacetoxyborohydride afforded hydroxyketone 313 in 41% yield 
over three steps.[99] Wittig methylenation followed, to furnish alkene 314 in high yield. 
 
Scheme 84 Synthesis of alkene 314 
Following the synthesis of alcohol 314, subsequent steps for the formation of the β-keto 
ester fragment 301 were explored (Scheme 85). Oxidation of alcohol 314 with Dess-Martin 
periodinane afforded aldehyde 315 in quantitative yield. Formation of the β-ketoester 316 
under conditions reported by Roskamp,[100] occurred without full conversion and the desired 
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product 316 was obtained in a moderate 57% yield alongside recovered aldehyde (28%). 
Increasing the number of equivalents of methyl diazoacetate as well as changes to the 
concentration of the reaction mixture were found to have no effect on the yield. However, the 
yield could be improved by increasing the quantity of tin(II) dichloride; use of a stoichiometric 
amount resulted in full conversion and afforded the desired β-keto ester in 86% yield. 
Following this, silyl ether cleavage using TBAF occurred cleanly in high yield to give primary 
alcohol 317. Initially, one-pot oxidation procedures for the conversion of alcohol 317 to 
carboxylic acid 301 were investigated, but in all cases the desired product was not observed. 
Therefore, aldehyde 318 was accessed through oxidation with DMP and it was envisioned 
that acid 301 could be obtained through a second oxidation step. Unfortunately, all 
conditions tested resulted in oxidation of the methylene group of the α,β-dicarbonyl system 
and so desired product 301 was not observed. After these disappointing results it was 
decided that an alternative route would be required and a masked analogue of fragment 301 
was targeted.  
 
 
 
 
 
 
 
 
Scheme 85 Failed synthesis of β-keto ester fragment 301 
Given that synthesis of carboxylic acid 301 with the β-ketoester present was unsuccessful, 
due to over-oxidation, it was decided that the carboxylic acid analogue 321 would be 
synthesised and functionalisation to form the β-ketoester would be carried out after fragment 
coupling. Starting from previously formed primary alcohol 314, the synthesis of the acid 
fragment 321 was completed in four steps; eight steps from (R)-perillyl alcohol (Scheme 86). 
Protection of the primary hydroxyl group of 314 as a PMB ether, followed by silyl ether 
cleavage resulted in the formation of alcohol 320 in 87% yield over the two steps. 
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Subsequent oxidation with Dess-Martin periodinane, followed by Pinnick oxidation, afforded 
the desired carboxylic acid 321 in quantitative yield. 
 
 
 
 
 
 
 
Scheme 86 Synthesis of acid analogue 321 
2.3.2 Synthesis of a Racemic C5-C11 Fragment 
A route for the synthesis of the C5-C11 aldehyde fragment as a racemate was initially 
pursued to allow optimisation of reaction conditions and exploration of the diastereoselective 
methylation reaction. Starting from triisopropylsilyl acetylene (322) and acetaldehyde (323) 
addition of the lithiated acetylene to the aldehyde gave alkynyl alcohol 324. Oxidation of the 
resulting propargylic alcohol in the presence of MnO2 subsequently delivered ynone 325.
[101] 
An aldol reaction with trans-2-heptenal (326) resulted in the formation of the alcohol 327 in 
good yield. Trans-2-heptenal was chosen as a readily available aldehyde to facilitate 
handling and purification. 
 
Scheme 87 Formation of the racemic alcohol intermediate 327 
Following the synthesis of alcohol 327 in three steps, conditions for the diastereoselective 
methylation of the ketone were explored. Initially, methylation was effected by treatment of 
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ketone 327 with MeLi and ZnBr2. Under these conditions a 2.4:1 anti:syn mixture of the diols 
328 was obtained. Assignment of the relative stereochemistry was carried out through 
formation of the six-membered carbonates 329 and 330 and subsequent NOE studies 
(Scheme 88). Relevant NOEs were observed between the axial allylic proton and methyl 
group in the desired syn isomer, whilst a weak NOE was observed between the axial allylic 
proton and the TIPS group in the undesired anti isomer.  
 
Scheme 88 Determination of the configuration of diol methylation products  
After the preliminary methylation result and determination of the relative stereochemistries, 
screening of further methylation conditions was carried out. Several conditions were 
screened with the objective of improving the diastereomeric ratio in favour of the desired syn 
isomer (Table 3). The most favourable diastereomeric ratio (syn:anti 5.9:1) was obtained 
when MeTi(OiPr)3 (formed in the presence of excess TiCl(OiPr)3) was employed as the 
reagent (entry 8). Determination of the dr was conducted on a small scale using 1H NMR 
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analysis and the isolated yield was not obtained. However, degradation with resultant by-
product formation was not observed. With the exception of the initial MeLi, ZnBr2 conditions, 
all of the reaction conditions explored resulted in the formation of the desired syn 
diastereoisomer as the major product. It is also notable that although full conversion was 
observed in most cases, unknown by-product/decomposition peaks were also observed by 
NMR. 
Table 3 Methylation conditions 
 
Entry Methylating Reagents Solvent syn:anti
a 
Conversion
a 
1 ZnBr2, MeLi CH2Cl2 1:2.4 100 % 
2 ZnBr2, MeMgCl Et2O 2.8:1 100 % 
3 MeMgCl Et2O 2:1 10 % 
4 ZnBr2, AlMe3 CH2Cl2 1.8:1 100 % 
5 AlMe3 PhMe 1.5:1 100 % 
6 MeCeCl2
b
 THF 1.5:1 100 % 
7 MeTi(OiPr)3
c,d 
Et2O 1.6:1 100 % 
8 MeTi(OiPr)3
c,e
 Et2O 5.9;1 100 % 
9 Me2TiCl2
f 
CH2Cl2 decomposition 100 % 
10 MeTiCl3
g 
CH2Cl2 decomposition 100 % 
a 
Established through 
1
H NMR, 
b
 formed in situ from CeCl3/MeMgCl 1:1
 c 
formed in situ from TiCl4/Ti(OiPr)4 1:3 and MeLi, 
d
 4 eq. 
MeLi used with respect to TiCl4, 
e
 3 eq. of MeLi used with respect to TiCl4, 
f 
formed in situ from TiCl4/Me2Zn 1:1, 
g 
formed in situ 
from TiCl4/Me2Zn 2:1,  
The opposite diastereoselectivities obtained using MeLi/ZnBr2 and MeTi(OiPr)3 can be 
explained by consideration of the corresponding transition states (Figure 9). In the case of 
the zinc procedure, co-ordination of zinc to the hydroxyl group produces a chair transition 
state including the methyl group. Internal methyl addition therefore occurs on the Re face of 
the carbonyl to produce the anti diol. When MeTi(OiPr)3 is employed as the reagent, co-
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ordination of titanium to both the carbonyl and hydroxyl group occurs, producing a half-chair 
transition state. External methyl addition, from a separate titanium species, occurs 
subsequently from the least hindered face of the ketone to afford the syn diol through a 
chair-like transition state.  
 
 
 
 
Figure 9 Methylation transition states 
With a route to syn-328 having been established, attention was turned to manipulation of the 
protecting groups and introduction of the formyl group (Scheme 89). Deprotection of the 
acetylene to afford 331, followed by protection of both the allylic and tertiary alcohols as silyl 
ethers, resulted in the formation of alkyne 332 in a high yield (97% over 2 steps). 
Subsequent formylation of the alkyne 332 proceeded in quantitative yield to afford aldehyde 
333. 
 
 
 
 
 
 
Scheme 89 Synthesis of aldehyde 333 
Deprotection conditions were investigated for the selective cleavage of the secondary silyl 
ether (Table 4), but in all cases either a mixture of products was observed or degradation 
dominated. In most cases multiple products were observed, indicative of silyl migration 
occurring after initial deprotection. Product mixtures were found to be inseparable and 
characterisation to confirm formation of specific by-products was not possible. Given that 
selective deprotection could not be effected, aldehyde 333 was treated with TBAF to try and 
promote cleavage of both silyl ethers simultaneously; in this case, the desired diol was not 
observed. Instead, the conjugate addition product 336 was obtained in 58% yield. 
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Table 4 Attempted selective deprotection conditions  
 
 
 
 
Following these disappointing results, it was envisioned that a protected version of the 
aldehdye 340 could be used for fragment coupling. Reduction of the aldehyde 333 with 
sodium borohydride occurred in a high yield (88%) to afford alcohol 337 (Scheme 90). 
However, attempts to protect the primary alcohol as its TBDPS ether resulted in the 
formation of two inseparable products with similar 1H NMR shifts. It is proposed that silyl 
migration occurs under the reaction conditions, resulting in a mixture of both the desired 
compound 338 and the migration side product 339 being produced. As a consequence of 
this result, this approach was abandoned. 
 
 
 
 
 
 
Entry Reagent Solvent T (ºC) Time (h) Result 
1 AcOH THF/H2O −20 30 complex mixture 
2 AcOH THF/H2O 0 2.5 complex mixture 
3 PPTS THF 0 - rt 4.5 degradation at rt 
4 PPTS THF/MeOH 0 3 complex mixture 
5 HF•pyridine THF −10 18 complex mixture 
6 (+)-CSA MeOH 0 3 degradation 
7 TBAF THF rt 1.5 336 exclusively formed 
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Scheme 90 Attempted synthesis of protected aldehyde fragment 
2.3.3 Synthesis of an Enantiopure C5-C11 Fragment 
Synthesis of the enantiopure fragment was explored after completion of fragment studies in 
racemic form. Starting from the same aldehyde, trans-2-heptenal (326), a diastereoselective 
Crimmins aldol reaction was used to set the alcohol stereochemistry at C10. Initially, the 
readily available thiazolidine-2-thione auxiliary 343 was employed.[102] However, formation of 
product 341 occurred in only moderate yield with low diastereoselectivity (Scheme 91). In an 
attempt to improve both the yield and diastereomeric ratio, the oxazolidinethione auxiliary 
344 was synthesised in seven steps from ethylene glycol following a procedure reported by 
Crimmins in 2006.[103] The aldol reaction carried out with oxazolidinethione auxiliary 344 
resulted in a significantly higher yield with almost exclusive formation of the desired 
diastereoisomer 342. The bulky mesityl group present in the auxiliary 344 provides a greater 
degree of facial selectivity during the aldol reaction than its benzyl counterpart as a 
consequence of its increased bulk and decreased flexibility. Therefore, the chlorotitanium 
enolate species reacts to primarily give one diastereoisomer. 
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Scheme 91 Crimmins aldol reaction to set the stereochemistry of the C10 hydroxyl group 
The stereochemistry of the allylic alcohol was now established and so attention turned to 
further functionalisation of the molecule (Scheme 92). Conversion of Crimmins aldol adduct 
342 into the Weinreb amide 345 occurred in 91% yield. Subsequent protection of the alcohol 
345 as its silyl ether afforded compound 346 in quantitative yield. Protection of the 
secondary alcohol was essential to prevent a retro-aldol reaction occurring under the basic 
conditions required for the addition of the acetylene group in the next step. 
 
 
 
Scheme 92 Synthesis of Weinreb intermediate 346 
Problems had already been experienced when preparing fragments 335 and 340 in racemic 
form (Section 2.3.2), and so a new strategy was sought for introduction of the acetylene with 
a protected primary alcohol. It was decided that the reactivity difference between the allylic 
and tertiary alcohols could be exploited during fragment coupling and so protection of the 
tertiary alcohol would not be necessary. Consequently, the diol 350 was selected as the 
target (Figure 10). 
 
 
 
Figure 10 Originally targeted western fragments vs. revised strategy 
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Known TBDPS ether 347 was formed in one step from propargyl alcohol.[104] Addition of the 
corresponding lithium acetylide species to the amide 346 afforded a mixture of the desired 
ketone 348 and unreacted protected propargyl alcohol 347. Subsequent cleavage of the 
triethylsilyl ether under acidic conditions afforded allylic alcohol 349 in 77% yield over the 
two steps. Treatment of the ketone 349 under the previously established methylation 
conditions, using MeTiOiPr3, afforded the desired syn diol in 72% yield. The observed dr was 
comparable to that obtained during the synthesis of the racemic TIPS protected ynone 328. 
The similar dr’s observed for both the formation of 327 and 349 confirm that the outcome of 
methyl addition reaction is due to the directing effects of the free alcohol; changing the size 
of the acetylene group has no effect on the diastereomeric ratio of the products. Synthesis of 
the desired syn diol 350 was therefore completed in six steps and 40% overall yield from 
trans-2-heptenal (326). As well as overcoming the protection and deprotection issues 
encountered previously, this new revised route allowed access to the desired coupling 
fragment in fewer steps. 
 
Scheme 93 Synthesis of syn diol 350 
2.3.4 Fragment Coupling and Functionalisation 
A synthetic route to both fragments 321 and 350 had been established and so attention was 
turned to the coupling of the two fragments by ester formation. Multiple conditions for the 
formation of ester 351 were investigated with varying degrees of success (Table 5). In all 
cases at least small amounts of the desired product were observed; in two cases the major 
observed product was the acid anhydride 352. The use of coupling reagents was found to be 
superior to formation of the acyl chloride, which underwent degradation and delivered only 
trace amounts of the desired product. When Steglich and Yamaguchi esterification 
conditions were utilised (entries 1 and 2), the major products were the anhydride 352 and 
acid-reagent coupled intermediates. Attempts to push these reactions to completion by use 
76 
 
of larger quantities of DMAP, longer reaction times and heat were unsuccessful and it was 
found that 352 was highly unreactive. The use of MNBA, under conditions reported by 
Shiina,[50] gave the best results; the product 351 was obtained in 68% yield (Entry 3). The 
diol starting material 350 was also recovered despite complete consumption of the acid, due 
to formation of the anhydride by-product 352. 
Table 5 Coupling conditions for the formation of ester 351 
 
 
 
 
 
 
a
 determined by 
1
H NMR 
Following formation of the ester 351, protection of the tertiary alcohol as a silyl ether 
proceeded in high yield and subsequent benzyl ether cleavage with DDQ afforded the 
primary alcohol 353 in 93% yield. When cerium ammonium nitrate was used for 
debenzylation, complete decomposition was observed. The alcohol 353 was oxidised to the 
corresponding aldehyde 354 in quantitative yield using DMP and then subjected to an aldol 
reaction with methyl acetate to afford the desired β-hydroxy ester intermediate 355 as a 1:1 
Entry Conditions T Ratio 351:352
a 
Isolated yield (%) of 351 
1 
 
DCC, Et3N, DMAP 
 
rt 1:3 - 
2 
, Et3N, DMAP 
 
 
rt 1:3 8 
3 
, Et3N, DMAP 
 
rt 3:1 68 
4 SOCl2, DMF rt degradation - 
77 
 
mixture of inseparable diastereoisomers in excellent yield. The stereochemistry at C3 was 
inconsequential so the mixture of isomers was carried forward to subsequent reactions. 
Global deprotection was then performed to afford triol 356 in 98% yield. The addition of 
AcOH as a buffer was necessary to avoid retro-aldol, but this resulted in a very slow 
deprotection time of five days.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 94 Formation of intermediate 356 
Oxidation of triol 356 was performed using Dess-Martin periodinane to install both the 
aldehyde and β-keto ester in a single step and thereby deliver the Knoevenagel 
condensation precursor 357. Disappointingly, all attempts to effect intramolecular 
Knoevenagel condensation resulted in either polymerisation or degradation and macrocycle 
358 was never obtained.  
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Scheme 95 Failed intramolecular Knoevenagel condensation 
As a last resort, an attempt was made to perform ring-closing metathesis between the 
methylene and trans-substituted alkene to install the butenolide at an earlier stage in the 
synthesis (Scheme 96). However, the desired product 360 was not obtained. Following this 
unsuccessful result a revision of the synthetic strategy was required. 
 
Scheme 96 Attempt to effect ring-closing metathesis at an early stage  
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2.4 Approach 2: An Intermolecular Knoevenagel Condensation Approach 
The discovery that macrocycle formation through Knoevenagel condensation was not viable 
meant that another approach was required. Following the same initial disconnections 
through the epoxyfuran and butenolide rings gave the same retrosynthetic lactone (309) as 
before. However, it was envisioned that this intermediate would now be formed through 
macrolactonisation of seco acid 361. Disconnection through the ynenone gave the same key 
fragments 300 and 301 as before, leading to the proposal that fragment coupling would be 
carried out by intermolecular Knoevenagel condensation. 
 
 
 
 
Scheme 97 New retrosynthetic strategy 
2.4.1 Exploration of Knoevenagel Condensation as the Fragment Coupling 
Step 
Routes to suitable coupling fragments had already been established in the previous strategy 
and so studies were performed to ascertain the yield and E/Z selectivity of the coupling 
reactions, as well as the tolerance of products towards further manipulation. Initially 
aldehyde 333 was utilised in the Knoevenagel condensation reaction with β-keto ester 316. 
This reaction proceeded in high yield to afford ynenone 362 as a 1.5:1 (Z:E) mixture of 
stereoisomers. The stereochemical outcome is hypothesised to result from steric repulsion 
between the large triethylsilyl protecting groups and the carbon skeleton of the β-keto ester 
chain; favouring the less hindered Z isomer. Despite this, the resultant isomeric mixture 362 
was taken forward. Attempts to cleave the triethylsilyl ethers under acidic conditions did not 
result in the expected ynenone product 363; the spiroacetal 364 was formed instead. 
Interestingly, the Z isomer also reacted in this case. Only one spiroacetal diastereoisomer 
was observed. An attempt was made to determine the configuration of the new stereocentre 
through further functionalisation of the primary alcohol and crystallisation. However, 
degradation occurred during this process and so the configuration of the new stereocentre 
remains undetermined. 
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Scheme 98 Formation of a spirocyclic by-product 
A further investigation into the formation of the spirocycle was conducted using racemic 
aldehyde (±)-333. Reaction of (±)-333 with ethyl acetoacetone under Knoevenagel 
conditions afforded the corresponding ynenone 365 as a 1:1 mixture of E:Z isomers. 
Treatment of the ynenone 365 with CSA in this case afforded two products: the furan 366 
and the spirocycle 367. 
 
Scheme 99 Investigation into Spirocycle Formation 
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Formation of both the furan 366 and the spirocycle 367 led to the proposal of a mechanism 
to account for cyclisation. Upon cleavage of the silyl ethers to give the 1,3-diol 368, attack of 
the secondary alcohol onto the alkyne occurs. Protonation occurs to afford furan 366 (blue 
arrows) or conjugate addition occurs to produce the allene 369 (red arrows). The enol 
/enolate can then react with the allene to form the spirocyclic compound 367.  
 
Scheme 100 Mechanism of spirocycle formation 
To prevent formation of the undesired spirocycle, protection of the secondary alcohol was 
necessary. Starting from previously synthesised diol 350, the secondary alcohol was 
protected as its pivalate ester 371 to allow easy differentiation between the hydroxyl groups. 
Silyl ether cleavage with TBAF followed to afford the diol 372 in 75% yield. The propargylic 
aldehyde was installed using DMP to give tertiary alcohol 372, which was subsequently 
converted to its triethylsilyl ether 374 upon treatment with TESOTf. 
 
 
 
 
 
 
Scheme 101 Formation of aldehyde coupling partners 
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Both of the aldehydes 373 and 374 were coupled with the β-keto ester 316 to explore the 
Knoevenagel condensation reaction further. Both reactions gave a more favourable isomeric 
product ratio (1.2:1, Z:E) than the reaction of the di-TES analogue 362 (entry 3), but lower 
yields were obtained in both cases. In the case of the substrate bearing the free tertiary 
hydroxyl group, an inseparable mixture of E:Z isomers was obtained along with unreacted 
aldehyde (entry 2). The E:Z ratios obtained indicate the tertiary alcohol protecting group (R1) 
has no effect on selectivity of the reaction, whilst the bulkiness of the allylic alcohol 
protecting group (R) has a profound effect. It is also interesting to note that in the presence 
of a free tertiary hydroxyl (entry 2), the reaction still proceeds well, albeit with lower 
conversion. This suggested that a second protection step may not be necessary in this 
synthetic route.  
Table 6 Intermolecular Knoevenagel Condensation 
Entry Product R R
1
 E:Z ratio Yield (%) 
1 375 Piv TES 1:1.2 57 
2 376 Piv H 1:1.2 69 (brsm) 
3 362 TES TES 1:1.5 88 
Silyl ether cleavage of ynenone 375 was effected using CSA to give a mixture of compounds 
which was directly subjected to THT-mediated furan formation (Scheme 102). As expected, 
the E isomer was converted into the corresponding epoxyfuran 377 whilst the Z isomer 
remained unreacted. The major by-product, formed under acidic deprotection conditions, 
was found to be cyclopropylfuran 378. Previous work in the Clark group had shown that 
cyclopropyl products of this type could be produced by treatment of ynenones bearing a 
tethered alkene with chloroacetic acid.[89] Other Brønsted acids had been utilised, but CSA 
had not been previously found to promote cyclopropane formation. Cyclopropyl furan 
formation is thought to proceed through reversible formation of a carbene as described in 
Section 1.3.4.2. 
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Scheme 102 Exploration of epoxyfuran formation 
The results obtained during these studies led to two conclusions. Firstly, that Knoevenagel 
condensation needs to be performed with a free tertiary hydroxyl in place to avoid competing 
side reactions resulting from deprotection and secondly, that furan formation needs to be 
effected directly after Knoevenagel condensation due to the highly reactive nature of the 
resultant ynenones. With these considerations in mind a revised strategy was adopted. 
2.4.2 Revision of the Retrosynthetic Strategy 
Results of initial Knoevenagel condensation studies showed that furan formation would need 
to be effected earlier in the synthesis than had been intended. The new strategy was 
therefore devised so that ring-closing metathesis and macrolactonisation would be used to 
install the butenolide and macrolactone from seco acid precursor 379 as the final steps in 
the synthesis. Prior to this sequence, epoxyfuran formation would be effected directly after 
Knoevenagel condensation of the two fragments to form 361. This strategy had not been 
considered previously because epoxyfurans are usually considered to be relatively unstable.  
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Scheme 103 Revised synthetic Strategy 
2.4.3 Epoxyfuran Stability Studies 
To ascertain whether the epoxyfuran motif would tolerate the reaction conditions required for 
further functionalisation of the surrounding molecule, a model epoxyfuran system was 
treated under varying conditions. The synthesis of the model epoxyfuran commenced from 
the tertiary alcohol 380 (Scheme 104). Protection of the tertiary alcohol as its triethylsilyl 
ether occurred in high yield to afford alkyne 381. Formylation of the alkyne to give the 
propargylic aldehyde 382 was then followed by Knoevenagel condensation with ethyl 
acetoacetate to give 383 as a 1:1 mixture of E:Z isomers. Silyl ether cleavage occurred 
under acidic conditions to afford tertiary alcohol 297 which, upon treatment with THT, 
afforded the targeted epoxyfuran 298.  
 
 
 
 
 
 
 
 
 
 
Scheme 104 Formation of a model epoxyfuran system 
Ring-closing metathesis had been proposed as the final synthetic step and so initial studies 
focussed on the stability of the epoxyfuran in the presence of Grubbs catalyst and under 
prolonged heating (Table 7). The epoxyfuran 298 was treated with Grubbs II catalyst in two 
different solvents at varying temperatures. A heated control, without the catalyst, was also 
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studied. Reactions were followed by 1H NMR and in all cases minimal signs of epoxyfuran 
degradation were observed.  
Table 7 Stability of the epoxyfuran motif to metathesis conditions 
 
As well as establishing the stability of the epoxyfuran motif in the presence of Grubbs II 
catalyst, a full RCM reaction was conducted in its presence to ensure that catalyst activity 
was not affected. A model substrate (386) for butenolide synthesis was synthesised in two 
steps from commercially available hydrocinnamaldehyde (384) (Scheme 105). The 
synthesis involved Grignard addition to afford the allylic alcohol 385, followed by 
esterification with methacrylic acid to furnish the RCM precursor 386. 
 
 
 
 
 
 
Scheme 105 Synthesis of a ring closing metathesis precursor 
Butenolide formation in the presence of epoxyfuran 298 proceeded well and the butenolide 
387 was obtained in 97% yield. Although some degradation of the epoxyfuran was observed, 
92% of the epoxyfuran 298 was recovered after column chromatography. These results 
demonstrated the viability of using a ring-closing metathesis reaction at a very late stage in 
the synthetic route. 
 
 
Solvent Temperature (°C) Reagent Time (h) 
 
Toluene 
 
80 
 
- 
 
24 
Toluene rt Grubbs II 24 
Toluene 80 Grubbs II 24 
DCM 45 Grubbs II 24 
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Scheme 106 Butenolide formation in the presence of epoxyfuran 
The stability of the epoxyfuran was also tested under basic conditions as both deprotection 
and macrolactonisation conditions would require the presence of base. Both strongly and 
weakly basic conditions were utilised to determine general stability. When the epoxyfuran 
298 was treated with TBAF at room temperature over a 24 hour period, almost no 
degradation was observed and 98% of the starting material recovered. However, treatment 
of the model substrate with lithium hydroxide led to a lower recovery of only 86% after 24 
hours. Products arising from epoxide opening and ester hydrolysis were identified by high 
resolution mass spectrometry.   
 
Scheme 107 epoxyfuran stability under basic conditions 
All of the reaction conditions explored gave promising results for the retention of the 
epoxyfuran motif and these findings suggested that it would be possible to install it at an 
earlier stage in the synthesis than originally planned. Acidic conditions were not investigated 
because it was not anticipated that they would be required during the final steps of the 
synthesis. 
2.4.3 Installation of the β-Keto Ester in the C12-C14/C1-C4 Fragment 
During the exploration of an intramolecular Knoevenagel condensation route, a viable 
synthetic strategy for the synthesis of protected alcohol 321 had been established. It was 
therefore envisioned that this fragment could be converted to the desired β-keto ester 
fragment 301 following a short synthetic sequence. 
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Starting from the carboxylic acid 321, cleavage of the p-methoxy benzyl ether occurred 
quantitatively in the presence of DDQ. However, due to the polarity of the resulting hydroxy 
acid 388 it could not be separated from reagent residues and the alcohol 388 was carried 
forward crude to the subsequent oxidation step. In this case, a large excess of Dess-Martin 
periodinane was required to promote full conversion of the alcohol 388 into the 
corresponding aldehyde 389 and the product could not be separated from reagent residues. 
Other oxidising reagents, including IBX, were also explored, but clean conversion could not 
be effected.  
 
 
Scheme 108 Formation of crude aldehyde 
Aldehyde 389 was carried forward crude to investigate whether the β-keto ester functionality 
could be installed. Treatment of the aldehyde with freshly prepared methyl diazoacetate in 
the presence of tin (II) dichloride led to incomplete conversion and the product 301 could not 
be separated from oxidation reagent residues. In addition, an aldol approach did not give 
any of the desired product and resulted in degradation of the starting material.  
 
 
 
 
 
 
Scheme 109 Installation of the β-keto ester 
2.4.4 A New Protecting Group Strategy for the C12-C14/C1-C4 Fragment  
Attempts to synthesise the PMB analogue 321 had been unsuccessful and so a new 
protecting group strategy was devised for the synthesis of the β-keto ester fragment. 
Problems with purification had arisen because of the presence of inseparable reagent 
residues and so the use of an acid/base labile protecting group and subsequent purification 
of the hydroxy acid 388 by extraction was explored. MOM and acetate protecting groups 
were selected and the synthetic routes for preparation of the β-keto ester 301 were explored 
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in parallel. Selective conversion of the keto aldehyde 313 into the acetal 390 was explored 
as a protection strategy, but only degradation was observed in this case (Scheme 110). 
 
 
 
Scheme 110 Attempted acetal formation 
The previously synthesised primary alcohol 313 was converted into the MOM ether 392 in 3 
steps (Scheme 111). Protection of the primary alcohol 313 as its MOM ether 391 occurred in 
good yield. This was followed by Wittig methylenation of the ketone and cleavage of the silyl 
ether to form allylic alcohol 392. A similar three-step sequence was used to furnish acetate 
393: Wittig methylenation of the ketone, acetylation of the alcohol 314 and silyl ether 
cleavage. A two-step oxidation sequence, involving Dess-Martin periodinane and Pinnick 
oxidation, afforded the carboxylic acids 394 and 395 in quantitative yield. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 111 Synthesis of the carboxylic acids 394 and 395 
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Treatment of MOM ether 394 with HCl resulted in complete degradation of the starting 
material and none of the desired hydroxy acid 388 was obtained (Scheme 112). However, 
acetate cleavage under basic conditions afforded the desired hydroxy acid 388 in 95% yield 
upon acidic aqueous work-up. Oxidation of the primary alcohol was followed by β-keto ester 
installation under Roskamp conditions to afford β-keto ester 301 in moderate yield.  
 
 
 
 
 
 
 
 
 
Scheme 112 Formation of the β-keto ester fragment 
2.4.5 Synthesis of a Mono-protected C5-C11 Fragment 
Previous studies had shown that protection of the secondary hydroxyl group is necessary for  
effective Knoevenagel condensation to occur. They had also revealed that the tertiary 
hydroxyl did not require protection during the reaction. An aldehyde substrate possessing a 
protected secondary hydroxyl group and unprotected tertiary hydroxyl group was therefore 
targeted. 
Starting from previously discussed Weinreb amide 346, addition of lithiated TIPS acetylene 
followed by triethylsilyl ether cleavage afforded allylic alcohol 327 in high yield (Scheme 
113). Stereoselective methylation under previously described conditions gave diol 328 with a 
high dr and in excellent yield. Deprotection of the acetylene group occurred readily using 
TBAF to afford terminal alkyne 397. Disappointingly, treatment of the alkyne 397 under 
formylation conditions did not afford the corresponding aldehyde but instead gave the 
tetrahydrofuran containing by-product 398.  
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Scheme 113 Towards the synthesis of the C5-C11 fragment 
Selective protection of the secondary hydroxyl group as a silyl ether was performed using 
various silylating reagents and reaction conditions to give substrates that could be tested in 
the coupling reaction (Table 8). Ultimately, a less bulky group was required to minimize 
formation of the undesired Z isomer during Knoevenagel condensation. A mix of both mono- 
and di-protected products was obtained when TESCl/imidazole and TBSOTf/lutidine were 
utilised (entries 1 and 3). However, clean conversion was observed when using sodium 
hydride as a base along with the appropriate silyl chloride (entries 4 and 5). 
Table 8 Selective protection of the secondary hydroxyl 
 
Entry Reagent Base Solvent Temperature Product Ratio (SM:A:B) Isolated Yield A (%) 
 
1 
 
TESCl 
 
imidazole 
 
DCM 
 
rt 
 
0.25:1:0.4 
 
57 
2 TBSCl imidazole DMF rt → Δ 1:0:0 - 
3 TBSOTf lutidine DCM 0 °C 2:1:5 13 
4 TBSCl NaH THF 0 °C → rt 0:1:0 95 
5 TIPSCl NaH THF 0 °C → rt 0:1:0 98 
 
91 
 
Formylation of both the TBS and TIPS analogues 399 and 400 resulted in quantitative 
formation of the corresponding aldehydes 401 and 402 (Scheme 114). However, when the 
TES analogue was treated under the same conditions, multiple products were observed. 
Scrambling of the silyl ether appeared to occur and the previously isolated tetrahydrofuran  
by-product 398 was also observed. 
 
 
 
 
Scheme 114 Synthesis of aldehyde fragments 401 and 402 
2.4.6 Intermolecular Knoevenagel Coupling 
Completion of the aldehyde 401 and β-keto ester 301 meant that attention could be turned to 
the Knoevenagel coupling of the two fragments (Scheme 115). However, all attempts to 
perform Knoevenagel coupling were unsuccessful and ynenone 403 was not isolated. It was 
proposed that salt formation between the carboxylic acid and the piperidine may be 
occurring, hampering the reaction. 
  
 
 
 
 
Scheme 115 Failed Knoevenagel coupling 
To prevent unfavourable interactions and explore the Knoevenagel condensation further, 
masking of the carboxylic acid was necessary. The carboxylic acid 395 was therefore 
protected as its methyl ester through esterification before cleavage of the acetate was 
performed under basic conditions to afford the corresponding alcohol 404 (Scheme 116). 
Primary alcohol 404 was then oxidised to give the aldehyde 405 using Dess-Martin 
periodinane. Installation of the β-keto ester was performed thereafter to give the methyl ester 
406. Interestingly, when acetate cleavage was attempted under acidic conditions, the 
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tetrahydrofuran 408 was formed in good yield instead of the desired primary alcohol 
(Scheme 117).  
 
Scheme 116 Formation of a methyl ester coupling partner 
 
 
 
 
Scheme 117 Formation of a furan by-product 
Knoevenagel coupling of the aldehyde 401 and the methyl ester 406 afforded a mixture of E 
and Z ynenones 409 (1:1.2 ratio) along with some unreacted β-ketoester starting material 
(Scheme 118). This mixture of isomers was subjected directly to THT-mediated furan 
formation, but none of the desired product 410 was obtained and the mixture of ynenones 
409 was not recovered. 
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Scheme 118 Knoevenagel condensation 
In addition, the mixture of ynenones 409 proved to be highly reactive in the presence of 
small quantities of acid. When it was left in CDCl3 for four hours complete consumption of 
the E isomer was observed and a new product was formed (Figure 11). This product is 
proposed to be cyclopropyl furan 411 but isolation was not performed and so full 
characterisation data were not obtained. 
 
 
 
 
 
 
 
 
 
 
 
Figure 11 Consumption of the E ynenone in CDCl3 
Z 
E
Z 
E    Z 
Z 
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It became apparent that a two-step procedure for the formation of the desired epoxyfuran 
was not viable. Attention was therefore turned to a new approach in which one-pot 
Knoevenagel condensation and THT promoted furan formation would be performed. 
2.5 Approach 3: A One-Pot Knoevenagel Condensation and Furan 
Formation Strategy 
2.5.1 Initial One-Pot Furan Formation Studies 
The two-step Knoevenagel condensation furan formation approach was not feasible and so 
attention was turned to a one-pot method. Previously, Clark et al. had described the one-pot 
synthesis of the furan 281 by THT-promoted reaction of acetoacetone (279) with the 
propargylic aldehyde 280 in the presence of benzoic acid as the nucleophile (Scheme 119). 
However, a one-pot procedure with intramolecular trapping of the sulfur ylide had not been 
devised.   
 
 
 
Scheme 119 Previous one-pot synthesis reported by Clark et al 
The conditions reported for the formation of the furan 281 were adapted to include acetic 
acid, as a proton source, and molecular seives. Reaction of the aldehyde 402 with the β-keto 
ester 406 produced the epoxyfuran product 412 in a very low yield (3%) along with the 
acetate addition product 413 in slightly higher yield (Scheme 120). The protected secondary 
alcohol 402 was chosen, despite the bulky TIPS group, as it was thought to be more stable 
to prolonged periods of heating in the presence of acid than its TBS counterpart.  
 
 
 
 
 
 
Scheme 120 Initial strategy for one-pot furan formation 
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Increasing the amount of THT present using dichloromethane as a solvent, had little effect 
on the reaction outcome. However, when THT was used as a solvent, a large increase in 
conversion to both the epoxyfuran product 412 and the acetate 413 was observed by 1H 
NMR. Replacing the acetic acid with phenylphoshonic acid in an attempt to effect sole 
formation of the epoxyfuran resulted in degradation, as did performing the reaction in the 
absence of an acid. 
2.5.2 Introduction of the TMSE Protecting Group 
It had become apparent that a one-pot strategy for the synthesis of the furan was possible 
and so a strategy for the protection of the carboxylic acid functionality was sought. Initially 
the methyl ester derivative 406 was employed for proof of concept studies, but selective 
deprotection would not be possible without affecting the furyl ester. Trimethylsilyl ethyl ester 
was therefore chosen so that deprotection of both the alcohol and acid functionalities could 
be effected in the same step in the presence of fluoride ion. 
Starting from the acid 395, which had been synthesised previously, the TMSE ester 414 was 
prepared by DCC mediated esterification with trimethylsilyl ethanol (Scheme 121). 
Hydrolysis of the acetate group under basic conditions was followed by oxidation with Dess-
Martin periodinane to furnish the aldehyde 415 in high yield. The synthesis of the β-keto 
ester 416 was completed by a tin(II) chloride mediated reaction of the aldehyde 415 with 
methyl diazoacetate.[100] 
 
Scheme 121 Formation of TMSE ester 416 
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2.5.3 One-Pot Furan Formation and Cyclisation Studies 
Now that a viable synthetic route to TMSE ester 416 was established, one-pot furan 
formation was explored again (Scheme 122). Knoevenagel condensation of the aldehyde 
402 with the β-keto ester 416 and in situ cyclisation proceeded in moderate yield to afford 
the epoxyfuran 417 and the corresponding acetate addition product 418. Unreacted β-keto 
ester 416 (46%) was also recovered. As before, both products were obtained as a mixture of 
diastereoisomers. A more favourable ratio of the epoxide 417 to the acetate 418 was 
obtained by decreasing the quantity of acetic acid present in the reaction mixture to 30 
mol%.  
 
 
 
 
 
 
Scheme 122 One-pot furan formation 
The formation of the acetate product 418 suggested that the strategy could also be used for 
the formation of the natural product 7-acetylsinumaximol B (16) which was isolated in 
2015.[23] Therefore, the selectivity of the furan formation reaction was deemed to be less 
important at this point until investigations for the further development of both compounds had 
been conducted.   
 
 
 
 
 
Figure 12 Structure of 7-acetylsinumaximol B 
Both 417 and 418 were now readily available and so methods for their deprotection and 
macrocyclisation were explored. The epoxy furan 417 was treated with a cooled solution of 
TBAF to afford the seco-acid 419 and this compound was subjected to macrolactonisation 
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without further purification (Scheme 123). Macrolactonisation under Yamaguchi conditions 
afforded macrocycle 420 in moderate yield as a single diastereoisomer, with unknown 
stereochemistry at the C7 position. Shiina macrolactonisation conditions, utilising MNBA, 
were also explored but did not deliver the required product. 
 
 
 
 
 
Scheme 123 Macrocycle formation 
Disappointingly, all attempts to effect ring-closing metathesis of the macrolactone 420 were 
unsuccessful. Treatment of 420 with both Grubbs second generation and Hoveyda-Grubbs 
second generation catalysts did not result in reaction of the starting material (Scheme 124). 
Addition of ethylene to the reaction mixture resulted in formation of the terminal alkene 421 
but no further reaction was observed. Degradation occurred after addition of further catalyst 
and prolonged heating.  
 
 
 
 
 
 
Scheme 124 Attempted ring-closing metathesis 
2.5.4 Synthesis of a Terminal Alkene C5-C11 Fragment 
Originally, a C5-C11 propargylic aldehyde fragment 402 containing a trans alkene with an n-
butyl side chain was synthesised from trans-2-heptenal. Despite successful coupling through 
Knoevenagel condensation and furan formation, and subsequent macrolactonisation, ring-
closing metathesis reactions could not be effected to install the butenolide. As a result, the 
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route was redesigned to exclude the n-butyl side chain and a terminal alkene was targeted 
as the RCM substrate. 
Following a procedure reported by Nagaiah et al., the Weinreb amide 424 was synthesised 
from isoprene (422) and thiazolidinethione 343 in a two-step sequence involving an aldol 
reaction and subsequent displacement of the auxiliary (Scheme 125).[105] Nagaiah had 
reported an observed dr of 85:15 for the formation of allylic alcohol 423, but a dr of greater 
than 2:1 could not be obtained in spite of numerous attempts to perform the reaction. 
Following this, protection of the alcohol group as its triethylsilyl ether afforded Weinreb 
amide 425, which was converted to ynone 426 by addition of lithiated TIPS acetylene. Silyl 
ether cleavage was effected under acidic conditions to afford allylic alcohol 427 in 
quantitative yield. Diastereoselective methylation was carried out as previously described 
using methyl titanium isopropoxide to afford a separable 9:1 mixture of syn:anti diols 428. 
Deprotection of the syn diol afforded acetylene 429 in high yield and the corresponding 
mono- or di-triisopropylsilyl ethers 430 and 431 were formed through treatment with sodium 
hydride/triisopropylsilyl chloride and lutidine/triisopropylsilyl triflate respectively. Formylation 
of both acetylenes 430 and 431 subsequently occurred in high yield to afford the desired 
aldehyde coupling fragments 432 and 433. 
 
 
 
 
 
 
 
 
 
 
 
Scheme 125 Synthesis of the C5-C11 aldehyde fragment 
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The relative stereochemistry of the syn and anti diols was confirmed by formation of 
carbonates 434 and 435 and subsequent NOE experiments (Scheme 126). The carbonates 
were prepared by silyl cleavage of syn- and anti-428 to form the terminal alkynes syn- and 
anti-429, followed by reaction with triphosgene to furnish cyclic carbonates 434 and 435. 
Selective NOE experiments confirmed the major isomer as the syn diol, with an NOE 
observed between the allylic proton and the methyl substituent. This NOE was absent in the 
case of the minor isomer, which confirmed this compound as the anti diol.  
 
 
 
 
 
 
 
Scheme 126 Confirmation of the relative stereochemistry of the syn and anti diastereomers of diol 429 
2.5.5 Optimisation of One-Pot Knoevenagel Condensation and Furan 
Formation 
The synthesis of the aldehyde 432 allowed the coupling reaction with the β-keto ester 416 to 
be performed as described previously to afford a ca. 1:1 separable mixture of epoxy furan 
436 and acetate 437 (Scheme 127). It was envisioned that these compounds would be used 
for the synthesis of different natural products, namely pukalide and 7-acetylsinumaximol B, 
and so optimisation for the selective synthesis of each compound was required. 
 
  
 
 
 
 
Scheme 127 One-pot Knoevenagel condensation-furan formation 
100 
 
It was proposed that the selectivity of the reaction could be altered by changing the amount 
and type of carboxylic acid additive or by protecting the tertiary alcohol. Initially, the effect of 
the quantity of acetic acid present was explored (Entries 1-3, Table 9). It was found that 
increasing the quantity of acetic acid favoured formation of the acetate adduct 437 and 
decreasing the quantity reversed that selectivity. However, highly selective formation of 
neither the epoxy furan 436 nor the acetate 437 could be achieved simply by varying the 
amount of acetic acid. The use of ethylenediammonium diacetate (EDDA) also resulted in 
the formation of both compounds but in diminished yield (Entry 4) and the addition of 
thioacetic acid led to the degradation of both starting materials (Entry 5). Changing the acid 
source from acetic acid to a bulkier derivative in order to minimise formation of the addition 
product 437 and allow selective formation of the epoxy adduct 436 was proposed. Several 
acids were screened (Entries 6-8), with pivalic acid affording the highest yield of epoxy furan. 
Interestingly, it was found that increasing bulk too much hampered formation of the epoxy 
furan 436; the reaction involving 1-adamantane carboxylic acid afforded the product in only 
23% yield and that involving triphenylacetic acid afforded only trace amounts of product. 
Epoxide 436 was obtained exclusively in 62% yield when the concentration of pivalic acid 
was increased to 0.6 equivalents (Entry 9); increasing the quantity of acid further resulted in 
a diminished yield (Entry 10). Selective formation of the acetate 438 was accomplished in 
85% yield (3:2 mixture of diastereoisomers) when the bis-protected aldehyde 433 was used 
as a substrate and the reaction was performed in the presence of 1.2 equivalents of acetic 
acid (Entry 11). 
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Table 9 One-pot Knoevenagel condensation and furan formation 
 
Entry Aldehyde Acid Equiv. RCO2H Yield 436 (%)
a 
Yield 437 (%)
a 
Yield 438 (%)
a 
 
1 
 
432 
 
MeCO2H 
 
0.3 
 
36 
 
24 
 
- 
2 432 MeCO2H 0.6 30 32 - 
3 432 MeCO2H 1.0 16 50 - 
4 432 EDDA
b 
0.1 23 10 - 
5 432 MeCOSH 0.1 - - - 
6 432 Ph3CO2H 0.1 -
c 
- - 
7 432 1-adamantane-CO2H 0.1 23 - - 
8 432 tBuCO2H 0.1 39 - - 
9 432 tBuCO2H 0.6 62 - - 
10 432 tBuCO2H 1.2 54 - - 
11 433 MeCO2H 1.2 - - 85 
12 432 -
d 
- - - - 
a
 isolated yield; 
b 
used without piperidine present; 
c 
trace observed in NMR; 
d
 no acid added - control experiment 
2.5.6 Completion of 7-epi-Pukalide 
Conditions for the selective formation of epoxyfuran 436 had now been established and so 
attention was turned to the formation of the macrocycle and installation of the butenolide. 
Simultaneous cleavage of the silyl ether and the ester was accomplished by treatment of the 
epoxyfuran 436 with tetrabutylammonium fluoride (Scheme 128). The crude seco-acid 439 
was used without further purification in the macrolactonisation step. Interestingly, when the 
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reaction was performed at room temperature, tetrahydrofuran by-product 440 was observed. 
Similarly, when the temperature or quantity of TBAF present was decreased TMSE ester 
441 was isolated. 
 
Scheme 128 Silyl deprotection  
The hydroxy-acid 439 was then subjected to Yamaguchi macrolactonisation conditions to 
afford the lactone 421 as a single isomer in 39% yield over two steps; the other 
diastereoisomer failed to undergo cyclisation under the reaction conditions (Scheme 129). 
Cyclisation of the hydroxy-acid using the Corey–Nicolaou method also delivered the lactone 
421 in 46% yield as a single isomer. Other macrolactonisation conditions were explored in 
an attempt to effect cyclisation of the second diastereoisomer; Shiina conditions using 
MNBA and macrolactonisation utilising DCC gave neither the previously observed 
macrolactone 421 nor the corresponding diastereoisomer. At this point the stereochemistry 
of the C7 position was unknown. 
  
 
 
 
 
Scheme 129 Macrolactonisation of seco acid 421 
Attempts to construct the butenolide by ring-closing metathesis (RCM) with either the 
Grubbs second generation catalyst or the Hoveyda–Grubbs second generation catalyst were 
unsuccessful. However, the very reactive modified Hoveyda–Grubbs second generation 
catalyst 442, developed by Matsugi et al.,[106] proved to be highly effective and the butenolide 
was obtained in 90% yield. The aromatic anthracene at the 3-position of the 2-isopropoxy 
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styrene ligand results in an intramolecular steric hindrance between the aromatic ring of the 
ligand and the methyl group of the isopropoxy substituent, which alters the coordination 
environment between the lone electron pair of the ether oxygen and the ruthenium. As the 
rate-determining step is thought to be the release of the bidentate ligand the reaction rate is 
determined by its ligation ability. Due to the steric strain caused by the CH3-π interaction the 
ligand is released more readily, increasing the activity of the catalyst. 
 
 
 
 
 
 
Scheme 130 Installation of the butenolide ring and catalyst conformation 
1H and 13C NMR spectra for the final compound were found to be inconsistent with the 
original data recorded for natural pukalide. NOE analysis of the final compound revealed that 
it was in fact the C7-epimer 443 (Figure 13). Selective NOE analysis of the C7 proton 
showed observed NOEs between it and both the C8 methyl substituent and the C5 furan 
proton. On the basis of this result, it is evident that the epoxide isomer, required for the 
synthesis of natural pukalide, did not undergo macrolactonisation. The trans epoxide is more 
sterically strained than its cis counterpart and as such the finding that the cis epoxide isomer 
of 439 undergoes cyclisation whilst the trans epoxide isomer does not, is not unsurprising.    
 
 
 
 
Figure 13 Observed NOEs for 7-epi-pukalide 
2.5.7 Completion of 7-Acetylsinumaximol B 
Completion of 7-acetylsinumaximol B was envisioned to occur analogously to the synthesis 
of 7-epi-pukalide. Thus, the acetate product 438 was subjected to the same three step 
sequence: deprotection, macrolactonisation and RCM. Treatment of acetate 438 with TBAF 
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effected cleavage of both silyl ethers and the trimethyl silyl ethyl ester to afford hydroxy acid 
444 which was used directly in the macrolactonisation reaction. In this case, both 
diastereoisomers underwent Yamaguchi macrolactonisation, but the macrolactone 445 was 
obtained in relatively low yield and attempts to optimise the sequence were unsuccessful 
(Scheme 131). Corey-Nicolaou, Shiina and Mukaiyama macrolactonisation conditions, along 
with the Yonemitsu variation of the Yamaguchi reaction, were all tested, but in all cases the 
product was not observed.  
 
 
 
 
 
Scheme 131 Formation of the 7-acetylsinumaximol B macrocyclic intermediate 445 
As was previously observed for 7-epi-pukalide, the transannular ring-closing metathesis 
reaction to effect butenolide formation was not successful when either the Grubbs 2nd 
generation catalyst or the Hoveyda-Grubbs 2nd generation catalyst was used. Only one 
diastereoisomer of the triene 445 underwent RCM to produce the butenolide when treated 
with the anthracene modified catalyst 442 and virtually all of the unreacted triene was 
recovered (Scheme 132). Analysis of the 1H and 13C NMR data confirmed that the 
diastereoisomer that underwent cyclisation was the one required for preparation of the 
natural product 16. NMR data for the final compound were identical to those reported for 7-
acetylsinumaximol B that had been isolated from natural sources. 
 
 
 
 
 
Scheme 132 Completion of the synthesis of 7-acetylsinumaximol B 
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2.6 Conclusions and Future Work 
In conclusion, convergent total syntheses of both 7-epi-pukalide and 7-acetylsinumaximol B 
have been completed with longest linear sequences of 16 steps from (R)-perillyl alcohol 
(Scheme 133). In addition, a new synthesis of the starting material (R)-perillyl alcohol has 
also been devised. The routes represent the first total syntheses of both 7-epi-pukalide and 
7-acetylsinumaximol B and demonstrate an effective strategy for the introduction of oxygen 
substituents at C7 and C8. The key THT-promoted reaction allowed the rapid and 
convergent assembly of the complete furan-containing skeleton and permitted completion of 
the syntheses by a parallel macrolactonisation and ring-closing metathesis sequence. 
 
 
 
 
 
 
 
 
 
 
Scheme 133 Summary of the synthesis of 7-epi-pukalide and 7-acetylsinumaximol B 
In future, the above strategy may be adapted for the synthesis of other, more complex, 
furanocembrane natural products and their epimers. For example, biologically active 
lophotoxin and its analogue lophodiol B possess an epoxide and diol, respectively, at the 
C7-C8 position; motifs which may be accessed directly through the one-pot Knoevenagel 
condensation furan formation strategy. 
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Scheme 134 Proposed future targets  
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3. Experimental Section 
3.1 General Experimental Information 
Air and/or moisture sensitive reactions were performed under an atmosphere of argon in 
flame dried apparatus. Tetrahydrofuran, toluene, dichloromethane, acetonitrile and diethyl 
ether were purified using a Pure-SolvTM 500 Solvent Purification System. Other dry organic 
solvents and starting materials were obtained from commercial sources and used as 
received unless otherwise specified. Triethylamine, diisopropylamine, diisopropylethylamine, 
titanium tetrachloride, titanium isopropoxide, acetaldehyde and methyl acetate were distilled 
and stored under argon prior to use. nButyllithium and methyllithium solutions were titrated 
against diphenylacetic acid to obtain accurate molarity. 4 Å molecular sieves were oven-
dried prior to use.  
Reactions were monitored by thin layer chromatography (TLC) using Merck silica gel 60 
covered alumina plates F254. Visualisation of TLC plates was carried out under UV light and 
stained using either potassium permanganate solution or acidic ethanolic anisaldehyde 
solution. Flash column chromatography was performed using silica gel – Fluorochem 35-70 
μm, 60A. Petroleum ether used for column chromatography was the 40–60 ºC fraction. 
IR spectra were recorded at rt using a Shimadzu FTIR-8400S spectrometer by ATR and 
selected frequencies (vmax) are reported. All 
1H spectra were recorded on Bruker 400 MHz or 
500 MHz spectrometers at rt. 1H NMR data are reported as follows: chemical shifts in ppm 
relative to CDCl3 (7.26) or C6D6 (7.16) on the δ scale, integration, multiplicity (s = singlet, d = 
doublet, t = triplet, q = quartet, m = multiplet, br = broad, app. = apparent or a combination of 
thereof), coupling constant(s) J (Hz) and assignment. All 13C NMR spectra were recorded on 
a Bruker 400 MHz and Bruker 500 MHz spectrometers at 101 MHz and 126 MHz 
respectively. Data are reported as follows; chemical shifts in ppm relative to CHCl3 (77.16) or 
C6D6 (128.06) on the δ scale and assignment.HSQC and COSY data were utilised for 
structural assignments.  Mass spectra were recorded by the University of Glasgow mass 
spectometry service using positive chemical ionization (CI+), positive ion impact (EI+) and 
positive ion electrospray (ESI+) techniques on a Jeol MStation JMS-700 instrument. The 
intensity of each peak is quoted as a percentage of the largest where this information was 
available. Optical rotations were recorded on an Autopol V polarimeter. Ozonolysis was 
carried out using a Degremont Technologies Triogen ozone generator. 
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3.2 Experimental Procedures 
(R)-Perillyl alcohol (R)-32 
 
To a solution of allylic alcohol 304 (25.9 g, 171 mmol) in CH2Cl2 (700 mL) at 0 °C was added 
triethylamine (59.6 mL, 427 mmol) followed by methanesulfonyl chloride (14.1 mL, 188 
mmol). The mixture was stirred for 1 h before the addition of H2O (200 mL) and saturated aq. 
NaHCO3 (200 mL), then stirred at rt for 5.5 h. The resulting mixture biphasic mixture was 
separated and the organic phase was washed with brine (300 mL) then dried over MgSO4 
and filtered. The solvent was removed under vacuum and the residue was purified by silica 
gel column chromatography (pet. ether:Et2O, 7:3) to afford (R)-perillyl alcohol ((R)-32) as a 
colourless oil (11.3 g, 44%)a.     
   +86 (c = 1.51, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 5.73–
5.68 (1H, m, CH-C3), 4.81–4.63 (2H, m, CH2-C16), 4.08–3.94 (2H, m, CH2-C21), 2.22–2.03 
(4H, m, CH2-C2, CH2-C13), 2.03–1.91 (1H, m, CH2-C14), 1.90–1.83 (1H, m, CH-C1), 1.74 
(3H, s, CH3-C17), 1.54–1.43 (1H, m, CH2-C14); 
13C NMR (126 MHz, CDCl3) δ 149.8 (C-
C15), 137.3 (C-C12), 122.5 (CH-C3), 108.7 (CH2-C16), 67.3 (CH2-C21), 41.1 (CH-C1), 30.4 
(CH2-C2), 27.5 (CH2-C13), 26.1 (CH2-C14), 20.8 (CH3-C17); LRMS m/z (EI+) [M+H]
+ 152.21 
(20%), 134.20 (32%), 121.19 (53%), 93.14 (82%), 79.12 (100%), 68.13 (85%), 67.12 (76%), 
55.15 (33%). 
aReaction on 0.66 mmol scale delivered a higher yield (61%). 
(E/Z)-Ethyl 2-acetyl-6-hydroxy-6-methylhept-2-en-4-ynoate 297 
 
 
 
To a solution of ynenone 383 (520 mg, 1.54 mmol) in MeOH (9 mL) at 0 °C was added (+)-
CSA (17.9 mg, 0.08 mmol). The reaction was stirred for 45 min before removal of the solvent 
under vacuum. The resulting residue was purified by silica gel column chromatography (pet. 
ether: Et2O, 30:70  50:50) to afford the title compound 297 as an orange oil (306 mg, 89%) 
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as a 1:1 mix of E and Z isomers. E isomer: 1H NMR (400 MHz, CDCl3) 6.80 (1H, s, CH-C6), 
4.27 (2H, q, J = 7.1 Hz, CH2-C9), 2.45 (3H, s, CH3-C12), 2.03 (1H, s, OH-C1), 1.56 (6H, s, 
CH3-C2, CH3-C3), 1.31 (3H, t, J = 7.1 Hz, CH3-C10); 
13C NMR (126 MHz, CDCl3) δ 194.6 (C-
C11), 163.8 (C-C8), 142.3 (C-C7), 122.7 (CH-C6), 110.9 (C-C4),  77.8 (C-C5) , 65.8 (C-C1), 
61.9 (CH2-C9), 31.0 (2C, CH3-C2, CH3-C3), 24.3 (CH3-C12), 14.2 (CH3-C10); Z isomer: 
1H 
NMR (400 MHz, CDCl3) 6.78 (1H, s, CH-C6), 4.35 (2H, q, J = 7.1 Hz, CH2-C9), 2.36 (3H, s, 
CH3-C12), 2.05 (1H, s, OH-C1), 1.57 (6H, s, CH3-C2, CH3-C3), 1.38 (3H, t, J = 7.1 Hz, CH3-
C10); 13C NMR (126 MHz, CDCl3) δ, 194.0 (C-C11), 165.4 (C-C8), 142.3 (C-C7), 124.1 (CH-
C6), 109.4 (C-C4), 78.1 (C-C5), 65.9 (C-C1), 61.8 (CH2-C9), 31.0 (2C, CH3-C2, CH3-C3), 
27.7 (CH3-C12), 14.3 (CH3-C10); Isomeric mixture: HRMS (ESI
+) calcd. for C12H16O4Na 
[M+Na]+ 247.0941, found 247.0931; IR νmax 3447, 2983, 2937, 1712, 1697, 1599, 1585, 
1371, 1136 cm-1. 
 
Ethyl 5-(3,3-dimethyloxiran-2-yl)-2-methylfuran-3-carboxylate 298  
 
To a sealed tube under argon was added a solution of enyne 297 (100 mg, 0.45 mmol) in 
CH2Cl2 (1 mL). THT (7 μl, 0.09 mmol) was added and the solution heated to 45 °C for 40.5 
h. The solvent was removed under vacuum and the resulting residue purified by silica gel 
column chromatography (pet ether: Et2O, 7:3) to afford the title compound 298 as a 
colourless oil (57.1 mg, 57%) along with recovered (Z)-297 as a pale yellow oil (32.9 mg, 
33%). 1H NMR (400 MHz, CDCl3) δ 6.51 (1H, s, CH-C4), 4.27 (2H, q, J = 7.0 Hz, CH2-C11), 
3.67 (1H, s, CH-C6), 2.56 (3H, s, CH3-C1), 1.44 (3H, s, CH3-C8), 1.35 (3H, s, CH3-C9), 1.33 
(1H, t, J = 7.0Hz, CH3-C12); 
13C NMR (101 MHz, CDCl3) δ 163.9 (C-C10), 159.1 (C-C3), 
148.5 (CH-C4), 114.4 (C-C2), 109.3 (C-C5), 61.4 (C-C7), 60.2 (CH-C6), 58.3 (CH2-C11), 
24.2 (CH3-C8), 18.8 (CH3-C9), 14.3 (CH3-C1), 13.8 (CH3-C12). HRMS (ESI
+) calcd. for 
C12H16O4Na [M+Na]
+ 247.0941, found 247.0931; IR νmax 1714, 1617, 1420 cm
-1 
(4R)-4-(Prop-1-en-2-yl)-1-((triisopropylsilyloxy)methyl)cyclohex-1-ene 311 
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To a solution of (R)-perillyl alcohol ((R)-32) (11.0 g, 72.3 mmol) in CH2Cl2 (400 ml) was 
added imidazole (6.40 g, 94.0 mmol) and DMAP (0.88 g, 7.2 mmol) followed by 
chlorotriisopropylsilane (17.1 mL, 79.6 mmol). The mixture was stirred at rt for 4 h and brine 
(400 mL) was added. The biphasic mixture separated and the aqueous phase was extracted 
with CH2Cl2 (2 × 100 mL). The combined organic extracts washed with saturated aq. NH4Cl 
(300 mL), dried over MgSO4 and then filtered. The solvent was removed under vacuum and 
the residue was purified by silica gel column chromatography (pet. ether:EtOAc, 9:1) to 
afford the silyl ether 311 as a pale yellow oil (22.3 g, quant.).     
   +50 (c = 0.71, CHCl3); 
1H 
NMR (500 MHz, CDCl3) δ 5.70 (1H, dd, J = 3.0, 1.5 Hz, CH-C3), 4.71 (2H, s, CH2-C21), 
4.19–4.00 (2H, m, CH2-C16), 2.20–2.09 (2H, m, CH2-C2, CH2-C13), 2.09–2.01 (2H, m, CH2-
C2, CH2-C13), 2.01–1.90 (1H, m, CH2-C14), 1.87–1.80 (1H, m, CH-C1), 1.74 (3H, s, CH3-
C17), 1.53–1.42 (1H, m, CH2-C14), 1.22–0.97 (21H, m, CH(CH3)2); 
13C NMR (126 MHz, 
CDCl3) δ 150.3 (C-C15), 137.2 (C-C12), 120.4 (CH-C3), 108.6 (CH2-C16), 67.3 (CH2-C21), 
41.6 (CH-C1), 30.5 (CH2-C2), 27.7 (CH2-C13), 26.1 (CH2-C14), 21.0 (CH3-C17), 18.2 
(CH(CH3)2), 12.2 (CH(CH3)2); HRMS (ESI
+) calcd for C19H36OSiNa [M+Na]
+ 331.2428, found 
331.2412; IR νmax 2941, 2866, 1645, 1464 cm
–1  
7-Hydroxy-5-(prop-1-en-2-yl)-1-(triisopropylsilyloxy)heptan-3-one 313 
 
A solution of silyl ether 311 (5.0 g, 16 mmol), pyridine (1.3 mL, 16 mmol) and isoprene (16.2 
mL, 162 mmol) in a mixture (1:4) of CH2Cl2 and MeOH (225 mL) at −78 °C was subjected to 
ozonolysis and monitored by TLC. After 1 h the mixture was flushed with O2 and the reaction 
was quenched with dimethyl sulfide (50 mL) before being warmed to rt and stirred overnight. 
This reaction was repeated on three further batches and the solutions were combined. The 
solvent was removed under vacuum and the residue was dissolved in Et2O (1 L). The 
solution was washed with H2O (2 × 400 mL) and brine (400 mL), then dried over MgSO4 and 
filtered. The solvent was removed under vacuum and the residue was passed through a 
short pad of silica gel (pet ether:Et2O, 85:15) to afford the crude product 312 as a yellow oil.  
To a solution of crude aldehyde 312 in toluene (400 mL) was added NaB(OAc)3H (7.88 g, 
37.2 mmol) and the reaction mixture stirred at rt for 4.5 days. The reaction was quenched by 
addition of saturated aq. NaHCO3 (400 mL) and the biphasic mixture separated. The 
aqueous phase was extracted with EtOAc (3 × 200 mL) and the combined organic extracts 
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were dried over MgSO4 and filtered. The solvent was removed under vacuum and the 
residue was purified by silica gel column chromatography (pet. ether:Et2O, 7:3 → 1:1) to 
afford the alcohol 313 as a colourless oil (8.64 g, 38% over 2 steps).     
   −1.4 (c = 1.16, 
CHCl3); 
1H NMR (400 MHz, CDCl3) δ 4.79 (1H, dq, J = 2.6, 1.4Hz, CH2-C16), 4.75–4.73 (1H, 
m, CH2-C16), 4.20 (2H, s, CH2-C21), 3.68–3.55 (2H, m, CH2-C3), 2.53 (2H, dd, J = 7.9, 
7.1Hz, CH2-C13), 2.27–2.19 (1H, m, CH-C1), 1.80–1.53 (4H, m, CH2-C2, CH2-C14), 1.61 
(3H, dd, J = 1.4, 0.8Hz, CH3-C17), 1.23–0.97 (21H, m, CH(CH3)2); 
13C NMR (126 MHz, 
CDCl3) δ 212.0 (C-C12), 146.8 (C-C15), 113.0 (CH2-C16), 69.9 (CH2-C21), 61.5 (CH2-C3), 
43.9 (CH-C1), 36.4 (CH2-C13), 36.3 (CH2-C2), 26.1 (CH2-C14), 18.0 (CH3-C17), 17.7 
(CH(CH3)2), 12.0 (CH(CH3)2)3); HRMS (ESI
+) calcd for C19H38O3SiNa [M+Na]+ 365.2482, 
found 365.2467; IR νmax 3402, 2941, 2866, 1719, 1643, 1464, 1369 cm
–1  
 
(3R)-3-(Prop-1-en-2-yl)-6-((triisopropylsilyloxy)methyl)hept-6-en-1-ol 314 
 
To a solution of methyl triphenylphosphonium bromide (13.8 g, 38.7 mmol) in THF (80 mL) 
at 0 °C was added nBuLi (17.6 mL of a 2.2 M solution in hexane, 39 mmol) and the solution 
stirred for 45 min. A solution of the alcohol 313 (5.3 g, 15 mmol) in THF (20 mL) was then 
added and the solution stirred at rt for 18 h. The reaction was quenched with H2O (100 mL) 
and the biphasic mixture was separated. The aqueous phase was extracted with Et2O (3 × 
100 mL) and the combined organic extracts were washed with brine (200 mL), dried over 
MgSO4 and filtered. The solvent was removed under vacuum and the residue was purified 
by silica gel column chromatography (pet. ether:EtOAc, 9:1) to afford the diene 314 as a 
colourless oil (4.51 g, 86%).     
   −3.5 (c = 0.67, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 5.09–
5.06 (1H, m, CH2-C
A), 4.83–4.78 (2H, m, CH2-C
A, CH2-C16), 4.77–4.75 (1H, m, CH2-C16), 
4.13 (2H, s, CH2-C21), 3.71–3.48 (2H, m, CH2-C3), 2.27–2.19 (1H, m, CH-C1), 2.02–1.84 
(2H, m, CH2-C13), 1.66–1.60 (5H, m, CH2-C2, CH3-C17), 1.54–1.47 (2H, m, CH2-C14), 
1.24–0.89 (21H, m, CH(CH3)2); 
13C NMR (126 MHz, CDCl3) δ 148.8 (C-C12), 147.4 (C-C15), 
112.6 (CH2-C
A), 108.1 (CH2-C16), 66.2 (CH2-C21), 61.8 (CH2-C3), 44.4 (CH-C1), 36.3 (CH2-
C2), 31.6 (CH2-C13), 30.5 (CH2-C14), 18.2 (CH3-C17), 17.8 (CH(CH3)2), 12.2 (CH(CH3)2); 
HRMS (ESI+) calcd for C20H40O2SiNa [M+Na]+ 363.2690, found 363.2673; IR νmax 3329, 
2941, 2866, 1645, 1462 cm–1  
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(R)-3-(Prop-1-en-2-yl)-6-(((triisopropylsilyl)oxy)methyl)hept-6-enal 315 
 
To a solution of alcohol 314 (50.0 mg, 0.15 mmol) in CH2Cl2 (4 mL) was added Dess-Martin 
periodinane (97.0 mg, 0.18 mmol) and the resulting solution was stirred at rt for 5 h. 
Saturated aq. Na2S2O3 (3 mL) was added and the phases separated. The organic phase 
was washed with saturated aq. NaHCO3 (2 × 2 mL), dried over MgSO4, filtered and the 
solvent removed under vacuum to afford crude title compound. Purification of the residue by 
silica gel column chromatography (pet. ether:EtOAc, 9:1) afforded the title compound 315 
(48.6 mg, quant.) as a colourless oil.     
   −1.2 (c = 0.250, CHCl3); 
1H NMR (500 MHz, 
CDCl3) δ 9.67 (1H, t, J = 2.4Hz, CHO-C3), 5.15–5.05 (1H, m, CH2-C
A), 4.84–4.80 (2H, m, 
CH2-C16), 4.80–4.76 (1H, m, CH2-C
A), 4.13 (2H, s, CH2-C21), 2.69 (1H, app p, J = 7.3 Hz, 
CH-C1), 2.52–2.38 (2H, m, CH2-C2), 2.08–1.87 (2H, m, CH2-C13), 1.59–1.55 (2H, m, CH2-
C14), 1.54 (3H, s, CH3-C17) 1.18–0.96 (21H, m, CH(CH3)2); 
13C NMR (101 MHz, CDCl3) δ 
202.2 (CHO-C3), 148.2 (C-C15), 145.6 (C-C12), 112.8 (CH2-C16), 108.4 (CH2-C
A), 66.1 
(CH2-C21), 47.5 (CH2-C2), 41.3 (CH-C1), 31.1 (CH2-C14), 30.0 (CH2-C13), 18.7 (CH3-C17), 
18.0 (CH(CH3)2), 12.0 (CH(CH3)2); IR νmax 3075, 2942, 2891, 2866, 2716, 1726, 1647, 1462 
cm-1 
Methyl (R)-3-oxo-5-(prop-1-en-2-yl)-8-(triisopropylsilyloxy)methyl)non-8-enoate 316 
 
Methylglycine hydrochloride (300 mg, 2.39 mmol) and NaNO2 (198 mg, 2.87 mmol) were 
dissolved in a ≈3:1 mixture of CH2Cl2 (0.8 mL) and H2O (0.3 mL) and the resulting mixture 
was stirred for 1.5 h. Saturated aq. NaHCO3 (2 mL) and CH2Cl2 (2 mL) were added and the 
biphasic mixture separated. The organic phase was dried over MgSO4 and filtered to give a 
solution of methyl diazoacetate which was used directly in the reaction.  
To tin(II) chloride (12.2 mg, 0.064 mmol) was added the solution of methyl diazoacetate (4.0 
mL, ~0.6 M in CH2Cl2, ~2.4 mmol) and aldehyde 315 (210 mg, 0.62 mmol) in CH2Cl2 (5 mL). 
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The resulting solution was stirred at rt for 19 h before removal of solvent under vacuum. 
Purification of the residue by silica gel column chromatography (pet. ether:Et2O, 95:5  
90:10) afforded recovered aldehyde starting material 315 (59.3 mg, 28%) followed by the 
title compound 316 (tautomeric mixture by NMR) as a colourless oil (144 mg, 57%).     
   
−0.7 (c = 1.0, CHCl3); 
1H NMR (400 MHz, CDCl3) δ 11.98 (0.2H, s, OH-C3, enol), 5.10-5.06 
(1H, m, CH2-C
A), 4.96 (0.2H, s, CH-C4, enol), 4.84-4.77 (2H, m, CH2-C16), 4.76-4.72 (1H, 
m, CH2-C
A), 4.13 (2H, s, CH2-C21), 3.73 (2.4H, s, CH3-C19), 3.72 (0.6H, s, CH3-C19, enol) 
3.44 (0.8H, d, J = 15.5 Hz, CH2-C4), 3.40 (0.8H, d, J = 15.5 Hz, CH2-C4),  2.69–2.53 (2.6H, 
m, CH-C1, CH2-C2), 2.24 (0.4H, d, J = 7.5 Hz, CH2-C2, enol), 2.03–1.81 (2H, m, CH2-C13), 
1.65 (2.4H, dd, J = 1.5, 0.8 Hz, CH3-C17), 1.63 (0.6H, dd, J = 1.4, 0.8 Hz, CH3-C17, enol), 
1.59–1.43 (2H, m, CH2-C14), 1.21–0.95 (21H, m, CH(CH3)2); 
13C NMR (101 MHz, CDCl3) δ 
201.5 (C-C3), 177.3 (C-C3 enol), 167.5 (C-C18), 148.4 (C-C15 enol), 148.3 (C-C15), 145.9 
(C-C12), 145.6 (C-C12 enol), 112.7 (CH2-C16 enol), 112.5 (CH2-C16), 108.2 (CH2-C
A), 
108.2 (CH2-C
A enol), 89.9 (CH-C4 enol), 66.1 (CH2-C21), 52.3 (CH3-C19), 51.0 (CH3-C19 
enol), 49.3 (CH2-C4), 47.5 (CH2-C2), 44.2 (CH2-C2 enol), 42.1 (CH-C1), 39.8 (CH-C1 enol), 
31.1 (CH2-C14), 30.7 (CH2-C14 enol), 30.2 (CH2-C13 enol), 30.1 (CH2-C13), 18.9 (CH3-
C17), 18.3 (CH3-C17 enol), 18.0 (CH(CH3)2), 12.0 (CH(CH3)2); HRMS (ESI
+) calcd. for 
C23H43O4Si [M+H]
+ 411.2931 found 411.2930; IR νmax 3075, 2943, 2866, 1751, 1719, 1647, 
1630, 1449, 1437 cm-1. 
 
Methyl (R)-8-(hydroxymethyl)-3-oxo-5-(prop-1-en-2-yl)non-8-enoate 317 
 
To a solution of silyl ether 316 (130 mg, 0.32 mmol) in THF (3.5 mL) at rt was added TBAF 
(0.35 mL, 1 M in THF, 0.35 mmol) dropwise. The resulting solution was stirred for 2 h before 
a second addition of TBAF (0.35 mL, 1 M in THF, 0.35 mmol) and stirring for a further 3 h. 
H2O (10 mL) and Et2O (10 mL) were added and the biphasic mixture was separated. The 
aqueous phase was extracted with Et2O (3 × 10 mL) and the combined organic extracts 
dried over Na2SO4, filtered and the solvent removed under vacuum to afford the crude 
product. Purification of the residue by silica gel column chromatography (pet. ether:EtOAc, 
6:4) afforded the title compound 317 (tautomeric mixture by NMR) as a colourless oil (78.0 
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mg, 97%).     
   −5.0 (c = 0.66, CHCl3); 
1H NMR (400 MHz, CDCl3) δ 11.99 (0.15H, s, OH-
C3, enol), 5.06–5.00 (1H, m, CH2-C
A), 4.96 (0.15H, s, CH-C4, enol), 4.88–4.86 (1H, m, CH2-
C16), 4.82–4.80 (1H, m, CH2-C16), 4.78–4.73 (1H, m, CH2-C
A), 4.07 (2H, d, J = 5.8 Hz, 
CH2-C21), 3.73 (2.55H, s, CH3-C19), 3.72 (0.45H, s, CH3-C19, enol), 3.45 (0.85H, d, J = 
15.4 Hz, CH2-C4), 3.43 (0.85H, d, J = 15.4 Hz, CH2-C4), 2.71–2.55 (3H, m, CH-C1, CH2-
C2), 2.09–1.91 (2H, m, CH2-C13), 1.66 (2.55H, dd, J = 1.5, 0.9 Hz, CH3-C17), 1.64 (0.45H, 
dd, J = 1.5, 0.8 Hz, CH3-C17, enol), 1.62–1.45 (2H, m, CH2-C14); 
13C NMR (101 MHz, 
CDCl3) δ 201.8 (C-C3), 167.7 (C-C18), 148.6 (C-C15), 145.9 (C-C12), 113.0 (CH2-C16 
enol), 112.7 (CH2-C16), 109.8 (CH2-C
A), 109.5 (CH2-C
A enol), 90.1 (CH-C4 enol), 66.1 (CH2-
C21), 52.5 (CH3-C19), 49.4 (CH2-C4), 47.6 (CH2-C2), 44.2 (CH2-C2 enol), 41.9 (CH-C1), 
39.9 (CH-C1 enol), 30.9 (CH2-C14), 30.7 (CH2-C14 enol), 30.5 (CH2-C13 enol), 30.5 (CH2-
C13), 19.1 (CH3-C17), 18.4 (CH3-C17 enol); IR νmax 3430, 3075, 2926, 2859, 1743, 1713, 
1645, 1632, 1437, 1406 cm-1. 
Methyl (R)-8-formyl-3-oxo-5-(prop-1-en-2-yl)non-8-enoate 318 
 
 
 
 
To a solution of alcohol 317 (20 mg, 0.08 mmol) in CH2Cl2 (1 mL) was added Dess-Martin 
periodinane (40 mg, 0.09 mmol) and the resulting solution stirred at rt for 6 h. The solution 
was filtered through a silica gel plug and the solvent removed under vacuum to afford the 
title compound 318 (tautomeric mixture by NMR) as a colourless oil without purification (19.8 
mg, quant.).     
   −6.1 (c = 0.21, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 11.97 (0.1H, s, OH-
C3, enol), 9.51 (1H, s, CHO-C21), 6.27 (0.9H, app s, CH2-C
A), 6.25-6.23 (0.1H, m, CH2-C
A, 
enol), 5.99 (0.9H, app s, CH2-C
A), 5.99 (0.1H, app s, CH2-C
A, enol), 4.94 (0.1H, s, CH-C4 
enol), 4.86-4.84 (0.1H, m, CH2-C16 enol), 4.81 (0.9H, dq, J = 1.6, 1.5 Hz, CH2-C16), 4.75 
(1H, br s, CH2-C16), 3.72 (2.7H, s, CH3-C19), 3.71 (0.3H, s, CH3-C19, enol), 3.44 (0.9H, d, J 
= 15.8 Hz, CH2-C4), 3.40 (0.9H, d, J = 15.8Hz, CH2-C4), 2.69–2.53 (3H, m, CH-C1, CH2-
C2), 2.26–2.16 (1H, m, CH2-C13), 2.14–2.06 (1H, m, CH2-C13), 1.66 (3H, br s, CH3-C17), 
1.55–1.45 (2H, m, CH2-C14); 
13C NMR (126 MHz, CDCl3) δ 201.6 (C-C3), 194.7 (CHO-C21), 
167.6 (C-C18), 149.9 (C-C15), 145.6 (C-C12), 145.3 (C-C12 enol), 134.4 (CH2-C
A), 113.3 
(CH2-C16 enol) 112.9 (CH2-C16), 90.1 (CH2-C4 enol), 52.5 (CH3-C19), 49.5 (CH2-C4), 47.4 
(CH2-C2), 44.2 (CH2-C2 enol), 42.0 (CH-C1), 39.8 (CH-C1 enol), 30.9 (CH2-C14), 29.8 (CH2-
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C14 enol), 25.9 (CH2-C13 enol), 25.7 (CH2-C13), 19.0 (CH3-C17), 18.3 (CH3-C17 enol);  
HRMS (ESI+) calcd. for C14H20O4Na [M+Na]
+ 275.1254 found 275.1249; IR νmax 2953, 2928, 
2856, 1748, 1717, 1686, 1645, 1628, 1437, 1406 cm-1 
(R)-Triisopropyl(5-2-4-methoxybenzyloxyethyl)-6-methyl-2-methylenehept-6-en-1-
yloxy)silane 319 
 
 
 
To a solution of alcohol 314 (440 mg, 1.29 mmol) in THF (10 mL) at rt was added NaH (62.0 
mg of a 60% dispersion in mineral oil, 1.55 mmol) and the reaction stirred for 30 min. TBAI 
(48 mg, 0.13 mmol) and PMBCl (0.2 mL, 1.42 mmol) were added and the reaction stirred for 
17 h. DMF (1 mL) was added and the reaction was heated to 45 °C for 17 h. After cooling to 
rt, saturated aq. NH4Cl (10 mL) and Et2O (10 mL) were added and the biphasic mixture 
separated. The aqueous phase was extracted with Et2O (2 × 10 mL) and the combined 
organic extracts dried over MgSO4, filtered and the solvent removed under vacuum to afford 
the crude product. Purification of the residue by silica gel column chromatography (pet. 
ether:EtOAc, 95:5) afforded the title compound 319 (590 mg, 99%) as a colourless oil.     
   
−4.7 (c = 0.64, CHCl3); 
1H NMR (400 MHz, CDCl3) δ 7.27–7.23 (2H, m, Ar-PMB), 6.91–6.82 
(2H, m, Ar-PMB), 5.07 (1H, d, J = 1.8 Hz, CH2-C
A), 4.80 (1H, d, J = 1.8 Hz, CH2-C
A), 4.75 
(1H, dq, J = 2.6, 1.4 Hz, CH2-C16), 4.69 (1H, dq, J = 2.6, 0.7 Hz, CH2-C16), 4.40 (2H, s, 
CH2-PMB), 4.12 (2H, s, CH2-C21), 3.80 (3H, s, CH3-PMB), 3.45–3.32 (2H, m, CH2-C3), 2.21 
(1H, tt, J = 9.6, 5.4 Hz, CH-C1), 2.02–1.83 (2H, m, CH2-C13), 1.75–1.61 (2H, m, CH2-C2), 
1.59 (3H, dd, J = 1.4, 0.7 Hz, CH3-C17), 1.54–1.41 (2H, m, CH2-C14), 1.19–0.95 (21H, m, 
CH(CH3)2; 
13C NMR (101 MHz, CDCl3) δ 159.6 (Ar-PMB), 149.3 (C-C12), 147.1 (C-C15), 
131.3 (Ar-PMB), 129.7 (Ar-PMB), 114.2 (Ar-PMB), 112.7 (CH2-C
A), 108.2 (CH2-C16), 73.1 
(CH2-PMB), 68.9 (CH2-C3), 66.6 (CH2-C21), 55.8 (CH3-PMB), 44.4 (CH-C1), 33.8 (CH2-C2), 
32.0 (CH2-C13), 30.9 (CH2-C14), 18.5 (CH3-C17), 18.3 (CH(CH3)2), 12.5 (CH(CH3)2); HRMS 
(EI+) calcd for C28H48O3Si 460.3373, found 460.3376; IR νmax 2970, 2891, 2864, 1612, 1512, 
1464 cm-1. 
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(R)-5-(2-4-Methoxybenzyloxyethyl)-6-methyl-2-methylenehept-6-en-1-ol 320 
 
 
 
To a solution of silyl ether 319 (500 mg, 1.09 mmol) in THF (20 mL) at rt was added TBAF 
(2.17 mL, 1 M in THF, 2.17 mmol). The resulting mixture was stirred for 14.5 h before H2O 
(10 mL) and Et2O (15 mL) were added and the biphasic mixture separated. The aqueous 
phase was extracted with Et2O (2 × 15 mL) and the combined organic extracts dried over 
MgSO4, filtered and the solvent removed under vacuum to afford the crude title compound. 
Purification of the residue by silica gel column chromatography (pet. ether:EtOAc, 4:1) 
afforded title compound 320 (290 mg, 88%) as a colourless oil.     
   −8.8 (c = 0.500, 
CHCl3); 
1H NMR (500 MHz, CDCl3) δ 7.27–7.23 (2H, m, Ar-PMB), 6.89–6.85 (2H, m, CH Ar-
PMB), 5.02–4.99 (1H, m, CH2-C
A), 4.85 (1H, d, J = 1.3 Hz, CH2-C
A), 4.77 (1H, dq, J = 2.9, 
1.0 Hz, CH2-C16), 4.71–4.68 (1H, m, CH2-C16), 4.40 (2H, s, CH2-PMB), 4.05 (2H, d, J = 6.2 
Hz, CH2-C21), 3.80 (3H, s, CH3-PMB), 3.44–3.33 (2H, m, CH2-C3). 2.23 (1H, tt, J = 9.4, 5.5 
Hz, CH-C1), 2.03–1.88 (1H, m, CH2-C13), 1.73–1.60 (2H, m, CH2-C2), 1.60 (3H, q, J = 1.0 
Hz, CH3-C17), 1.52–1.45 (2H, m, CH2-C14), 1.37 (1H, t, J = 6.2 Hz, OH-C21); 
13C NMR (126 
MHz, CDCl3) δ 159.5 (Ar-PMB), 149.6 (C-C12), 146.9 (C-C15), 131.2 (Ar-PMB), 129.7 (Ar-
PMB), 114.2 (Ar-PMB), 112.7 (CH2-C
A), 109.5 (CH2-C16), 73.1 (CH2-PMB), 68.8 (CH2-C3), 
66.5 (CH2-C21), 55.7 (CH3-PMB), 44.2 (CH-C1), 33.7 (CH2-C2), 31.8 (CH2-C13), 31.1 (CH2-
C14), 18.2 (CH3-C17); HRMS (EI
+) calcd for C19H28O3 304.2038, found 304.2035; IR νmax 
3424, 2934, 2859, 2837, 1613, 1512 cm-1. 
(R)-5-(2-4-Methoxybenzyloxyethyl)-6-methyl-2-methylenehept-6-enoic acid 321 
 
 
 
To a solution of alcohol 320 (240 mg, 0.79 mmol) in CH2Cl2 (6 mL) at rt was added Dess-
Martin periodinane and the resulting mixture stirred for 3 h. The reaction was filtered through 
a silica plug, washed with CH2Cl2 (20 mL) and the solvent removed under vacuum to afford 
the crude aldehyde (251 mg) which was used directly in the next reaction without further 
purification. 
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To a solution of crude (R)-5-(2-4-methoxybenzyloxyethyl)-6-methyl-2-methylenehept-6-enal 
(~0.79 mmol) and 2-methyl-2-butene (0.67 mL, 6.3 mmol) in tBuOH (4.75 mL) was added a 
solution of NaH2PO4·2H2O (800 mg, 5.14 mmol) and NaClO2 (239 mg, 4.74 mmol) in H2O 
(9.5 mL). The resulting mixture was stirred at rt for 7 h before addition of CH2Cl2 (30 mL). 
The biphasic mixture was separated and the aqueous phase was extracted with CH2Cl2 (2 × 
30 mL). The combined organic extracts were dried over Na2SO4, filtered and the solvent 
removed under vacuum to afford the crude product. Purification of the residue by silica gel 
column chromatography (pet. ether:EtOAc, 4:1  3:2) afforded the title compound 321 (251 
mg, quant. over 2 steps) as a yellow oil.     
   −6.6 (c = 0.875, CHCl3); 
1H NMR (500 MHz, 
CDCl3) δ 7.29–7.21 (2H, m, Ar-PMB, CH- Ar-PMB), 6.91–6.81 (2H, m, Ar-PMB), 6.26 (1H, d, 
J = 1.4 Hz, CH2-C
A), 5.68–5.59 (1H, m, CH2-C
A), 4.81–4.74 (1H, m, CH2-C16), 4.74–4.67 
(1H, m, CH2-C16), 4.40 (2H, s, CH2-PMB), 3.80 (3H, s, CH3-PMB), 3.47–3.31 (2H, m, CH2-
C3), 2.32–2.20 (2H, m, CH2-C13), 2.20–2.11 (1H, m, CH-C1), 1.75–1.58 (2H, m, CH2-C2), 
1.61 (3H, s, CH3-C17), 1.57–1.41 (2H, m, CH2-C14); 
13C NMR (126 MHz, CDCl3) δ 172.6 
(COOH-C21), 159.5 (Ar-PMB), 146.7 (C-C12), 140.6 (C-C15), 131.1 (Ar-PMB), 129.7 (Ar-
PMB), 127.3 (CH2-C
A), 114.1 (CH2-C16), 112.9 (Ar-PMB), 73.0 (CH2-PMB), 68.7 (CH2-C3), 
55.7 (CH3-PMB), 44.2 (CH-C1), 33.6 (CH2-C2), 32.4 (CH2-C13), 30.0 (CH2-C14), 18.1 (CH3-
C17); HRMS (ESI+) calcd. for C19H26O4Na [M+Na]
+ 341.1723 found 341.1709; IR νmax 2926, 
2854, 1694, 1512 cm-1. 
 
(E)-5-Hydroxy-1-(triisopropylsilyl)undec-6-en-1-yn-3-one 327 
 
Racemic: To a solution of triethylamine (0.50 mL, 3.6 mmol) in Et2O (10 mL) at 0 °C was 
added chlorodicyclohexylborane (3.35 mL, 1.0 M in hexane, 3.35 mmol) followed by ketone 
325 (502 mg, 2.23 mmol). The solution was stirred for 2 h before being cooled to −78 °C and 
addition of trans-2-heptenal (0.58 mL, 4.5 mmol). After 4 h stirring at −78 °C The reaction 
was quenched with H2O (10 mL) and the phases separated. The aq. phase was extracted 
with Et2O (20 mL) and the combined organic extracts washed with saturated aq. NH4Cl (20 
mL) before being dried over MgSO4, filtered and the solvent removed under vacuum to yield 
the crude product. Purification of the residue by silica gel column chromatography (pet ether: 
Et2O, 9:1) afforded the title compound 327 as a pale yellow oil (498 mg, 66%). 
Enantiopure: To a solution of silyl ether 396 (1.01 g, 2.24 mmol) in MeOH (10 mL) and 
CH2Cl2 (10 mL) at 0 °C was added (+)-CSA (52 mg, 0.22 mmol). The resulting mixture was 
stirred for 2 h before removal of the solvent under vacuum to afford the crude product. 
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Purification of the residue by silica gel column chromatography (pet. ether:EtOAc, 90:10  
85:15) afforded the title compound 327 (692 mg, 92%) as a yellow oil.     
   −9.1 (c = 1.25, 
CHCl3); 
1H NMR (400 MHz, CDCl3) δ 5.66 (1H, dtd, J = 15.3, 6.7, 1.0 Hz, CH-C
B), 5.41 (1H, 
ddt, J = 15.3, 6.7, 1.4 Hz, CH-C11), 4.64–4.46 (1H, m, CH-C10), 2.90–2.75 (2H, m, CH2-
C9), 2.46 (1H, d, J = 3.9 Hz, OH-C10), 1.96 (2H, app. q, J = 6.7 Hz, CH2-C
C), 1.39–1.16 (4H, 
m, CH2-C
D, CH2-C
E), 1.16–0.91 (21H, m, CH(CH3)2), 0.82 (3H, t, J = 7.1 Hz, CH3-C
F); 13C 
NMR (126 MHz, CDCl3) δ 186.2 (C-C8), 133.0 (CH-C
B), 130.3 (CH-C11), 104.2 (C-C7), 97.0 
(C-C6), 68.6 (CH-C10), 52.6 (CH2-C9), 31.8 (CH2-C
C), 31.2 (CH2-C
D), 22.2 (CH2-C
E), 18.5 
(CH(CH3)2), 13.9 (CH3-C
F), 11.0 (CH(CH3)2); HRMS (ESI
+) calcd. for C20H36O2SiNa [M+Na] 
359.2377 found 359.2378; IR νmax 3414, 2943, 2866, 2149, 1672, 1464, 1385 cm
-1 
 
(E)-3-Methyl-1-(triisopropylsilyl)undec-6-en-1-yne-3,5-diol 328 
 
Racemic: To a stirred solution of ZnBr2 (99.3 mg, 0.44 mmol) in CH2Cl2 (1 mL) at rt was 
added a solution of β-hydroxy ketone 327 (75.8 mg, 0.22 mmol) in CH2Cl2 (1 mL). The 
resulting mixture was stirred at rt for 1 h before cooing to 0 °C and addition of MeLi (0.55 mL 
of a 1.6 M solution in Et2O, 0.88 mmol). The reaction was warmed to rt and stirred for 2 h 
before quenching with 1 M HCl (2 mL). The phases were separated and the aq. phase 
extracted with Et2O (3 × 3 mL). Combined organic extracts were washed with brine (5 mL), 
dried over MgSO4, filtered and the solvent removed under vacuum to yield the crude product 
as pale yellow oil. Purification of the residue by silica gel column chromatography (pet. 
ether:Et2O, 8:2) afforded the anti title compound anti-328 (34.7 mg, 45%) followed by the 
syn title compound syn-328 (14.4 mg, 19%). 
Enantiopure: To a solution of Ti(OiPr)4 (4.5 mL, 15 mmol) in Et2O (22.5 mL) at 0 °C was 
added TiCl4 (0.5 mL, 5 mmol). The resulting solution was warmed to rt for 30 min and then 
cooled to 0 °C. MeLi (12.5 mL of a 1.6 M solution in Et2O, 20 mmol) was added and the 
mixture was stirred for 1 h. A portion of the solution (15.9 mL) was added to a solution of β-
hydroxy ketone 327 (180 mg, 7.97 mmol) in Et2O (5 mL) at −78 °C. The solution was stirred 
for 15 minutes, warmed to 0 °C and then stirred for 30 min. 2 M HCl (15 mL) was added 
dropwise and the biphasic mixture was warmed to rt. The phases were separated and the 
aqueous phase was extracted with Et2O (2 × 15 mL). The combined organic extracts were 
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washed with brine (30 mL), dried over Na2SO4 and filtered. The solvent was removed under 
vacuum and the residue was purified by silica gel column chromatography (pet. ether:Et2O, 
8:2) to deliver the anti 1,3-diol anti-328 (40 mg, 20%) as a colourless oil (less polar isomer) 
followed by the diastereomeric syn 1,3-diol syn-328 (155 mg, 78%) as a colourless oil (more 
polar isomer). Anti-328     
   +17 (c = 1.25, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 5.67 (1H, 
dtd, J = 15.2, 6.9, 0.8 Hz, CH-CB), 5.51 (1H, ddt, J = 15.2, 6.9, 1.3 Hz, 1H, CH-C11), 4.87–
4.78 (1H, CH-C10), 4.07 (1H, s, OH-C8), 2.33 (1H, d, J = 2.7 Hz, OH-C10), 2.03 (2H, dd, J = 
13.8, 6.9 Hz, CH2-C9), 1.79–1.72 (2H, m, CH2-C
C), 1.55 (3H, s, CH3-C20), 1.40–1.23 (4H, 
m, CH2-C
D, CH2-C
E), 1.16–0.93 (21H, m, CH(CH3)2), 0.90 (3H, t, J = 7.1 Hz, CH3-C
F);13C 
NMR (126 MHz, CDCl3) δ 132.2 (CH-C
B), 132.1 (CH-C11) 111.1 (C-C7), 83.8 (C-C6), 72.4 
(C-C8), 68.6 (CH-C10), 48.6 (CH2-C9), 31.8 (CH2-C
C), 31.3 (CH2-C
D), 31.2 (CH3-C20), 22.2 
(CH2-C
E), 18.6 (CH(CH3)2), 13.9 (CH(CH3)2), 11.2 (CH3-C
F); HRMS (ESI+) calcd. for 
C21H40O2Si [M+Na]
+ 375.2690 found 375.2669; IR νmax 3329, 2928, 2866, 2361, 2342, 1462 
cm-1. Syn-328     
   +6.3 (c = 0.71, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 5.83–5.67 (1H, m, 
CH-CB), 5.53 (1H, ddt, J = 15.3, 7.1, 1.3 Hz, CH-C11), 4.62–4.48 (1H, m, CH-C10), 2.72 
(1H, d, J = 2.3 Hz, OH-C10), 2.67 (1H, s, OH-C8), 2.08–1.99 (3H, m, CH2-C
C, CH2-C9), 1.86 
(1H, dd, J = 14.5, 3.6 Hz, CH2-C9), 1.55 (3H, s, CH3-C20), 1.42–1.18 (4H, m, CH2-C
D, CH2-
CE), 1.15–0.94 (21H, m, CH(CH3)2), 0.89 (3H, t, J = 7.1 Hz, CH3-C
F); 13C NMR (126 MHz, 
CDCl3) δ 132.7 (CH-C
B), 132.3 (CH-C11), 111.8 (C-C7), 84.5 (C-C6), 70.3 (C-C8), 67.4 (CH-
C10), 49.3 (CH2-C9), 31.9 (CH2-C
C), 31.2 (CH2-C
D), 30.1 (CH3-C20), 22.2 (CH2-C
E), 18.6 
(CH(CH3)2), 13.9 (CH(CH3)2), 11.1 (CH3-C
F); HRMS (ESI+) calcd. for C21H40O2Si [M+Na]
+ 
375.2690 found 375.2672; IR νmax  3356, 2928, 2866, 2361, 2342, 1462 cm
-1 
 
(±)-(4R,6R)-6-((E)-Hex-1-en-1-yl)-4-methyl-4-((triisopropylsilyl)ethynyl)-1,3-dioxan-2-
one 329 
 
To a solution of racemic 1,3-diol anti-328 (32.0 mg, 0.085 mmol) in CH2Cl2 (1 mL) was 
added pyridine (70 μL, 0.90 mmol) and the solution cooled to −78 °C. Triphosgene (53.4 mg, 
0.18 mmol) was added and the reaction stirred for 40 min before being warmed to rt and 
stirred for a further 35 min. The reaction was quenched by addition of saturated aq. NH4Cl (3 
mL). The biphasic mixture was separated and the aq. phase washed with CH2Cl2 (2 × 3 mL). 
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The combined organic extracts were washed with brine (5 mL), dried over Na2SO4, filtered 
and the solvent removed under vacuum to to afford the title compound 329 as pale yellow oil 
(36.5 mg). 1H NMR (400 MHz, CDCl3) δ 5.90–5.79 (1H, m, CH-C
B), 5.48 (1H, ddt, J = 15.3, 
7.2, 1.3 Hz, CH-C11), 5.31–5.16 (1H, m, CH-C10), 2.18 (1H, dd, J = 14.1, 3.2 Hz, CH2-C9), 
2.07 (2H, app q, J = 13.5, 6.7 Hz, CH2-C
C), 1.98–1.86 (1H, m, CH2-C9), 1.70 (3H, s, CH3-
C20), 1.44–1.22 (4H, m, CH2-C
D, CH2-C
E), 1.18–0.96 (21H, m, CH(CH3)2), 0.89 (3H, t, J = 
7.1 Hz, CH3-C
F); 13C NMR (101 MHz, CDCl3) δ 148.2 (OC(O)O), 136.8 (CH-C
B), 125.9 (CH-
C11), 104.9 (C-C7), 89.1 (C-C6), 78.3 (C-C8), 75.2 (CH-C10), 40.2 (CH2-C9), 31.8 (CH2-C
C), 
30.8 (CH3-C20), 28.9 (CH2-CH
D), 22.2 (CH2-C
E), 18.5 (CH(CH3)2), 13.9 (CH(CH3)2), 11.0 
(CH3-C
F); HRMS (ESI+) calcd for C22H38O3Si [M+Na]
+ 401.2482 found 41.2450; IR νmax 
2941, 2866, 1761, 1464 cm-1. 
 
(±)-(4S,6R)-6-((E)-Hex-1-en-1-yl)-4-methyl-4-((triisopropylsilyl)ethynyl)-1,3-dioxan-2-
one 330 
 
To a solution of racemic 1,3-diol syn-328 (14.0 mg, 0.043 mmol) in CH2Cl2 (1 mL) was 
added pyridine (30 μL, 0.40 mmol) and the solution cooled to −78 °C. Triphosgene (23.7 mg, 
0.08 mmol) was added and the reaction stirred for 40 min before being warmed to rt and 
stirred for a further 35 min. The reaction was quenched by addition of saturated aq. NH4Cl (2 
mL). The biphasic mixture was separated and the aqueous phase washed with CH2Cl2 (2 × 
3 mL). Combined organic extracts were washed with brine (5 mL), dried over Na2SO4, 
filtered and the solvent removed under vacuum to yield the title compound 330 as pale 
yellow oil (15.7 mg). 1H NMR (400 MHz, CDCl3) δ 5.85 (1H, dtd, J = 15.3, 6.7, 0.5 Hz, CH-
CB), 5.63 (1H, ddt, J = 15.3, 7.4, 1.4 Hz, CH-C11), 4.92–4.80 (1H, m, CH-C10), 2.34–2.20 
(2H, m, CH2-C9), 2.03–2.11 (2H, m, CH2-C
C), 1.76 (3H, s, CH3-C20), 1.47–1.21 (4H, m, CH-
2-C
D, CH2-C
E), 1.21–0.97 (21H, m, CH(CH3)2), 0.89 (3H, t, J = 7.1 Hz, CH3-C
F); 13C NMR 
(126 MHz, CDCl3) δ 148.4 (OC(O)O), 137.2 (CH-C
B), 125.9 (CH-C11), 106.0 (C-C7), 88.1 
(C-C6), 76.6 (C-C8), 75.0 (CH-C10), 39.4 (CH2-C9), 31.8 (CH2-C
C), 30.8 (CH3-C20), 28.3 
(CH2-C
D), 22.2 (CH2-C
E), 18.5 (CH(CH3)2), 13.9 (CH(CH3)2), 11.0 (CH3-C
F); HRMS (ESI+) 
calcd for C22H38O3Si [M+Na]
+ 401.2482 found 41.2470; IR νmax  2942, 2866, 1753, 1464, 
1381, 1234 cm-1. 
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(E)-3-Methylundec-6-en-1-yne-3,5-diol 331 
 
 
 
To a solution of 1,3-diol syn-328 (2.03 g, 5.75 mmol) in THF (100 mL) was added TBAF 
(6.33 mL of a   1 M solution in THF, 6.33 mmol) and the resulting solution stirred at rt for 2 h. 
Saturated aq. NH4Cl (70 mL) and Et2O (70 mL) were added and the biphasic mixture 
separated. The aqueous phase was extracted with Et2O (2 × 70 mL) and the combined 
organic extracts dried over Na2SO4, filtered and the solvent removed under vacuum to afford 
the crude product. Purification of the residue by silica gel column chromatography (pet. 
ether:Et2O, 3:2) afforded title compound 331 (1.10 g, 97%) as a yellow oil.     
   −10.7 (c = 
0.600, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 5.73 (1H, dtd, J = 15.4, 6.7, 1.0 Hz, CH-C
B), 
5.54 (1H, ddt, J = 15.4, 7.0, 1.5 Hz, CH-C11), 4.52 (1H, dddd, J = 9.4, 7.0, 3.3, 2.8 Hz, CH-
C10), 3.11 (1H, s, OH-C8), 2.51 (1H, s, CH-C6), 2.42 (1H, d, J = 2.8 Hz, OH-C10), 2.08 (1H, 
dd, J = 14.5, 9.4 Hz, CH2-C9), 2.07–2.00 (2H, m, CH2-C
C), 1.87 (1H, dd, J = 14.5, 3.3 Hz, 
CH2-C9), 1.60 (3H, s, CH3-C20), 1.42–1.25 (4H, m, CH2-C
D, CH2-C
E), 0.89 (3H, t, J = 7.1 Hz, 
CH3-C
F); 13C NMR (101 MHz, CDCl3) δ 132.8 (CH-C
B), 132.2 (CH-C11), 88.0 (C-C7), 71.5 
(C-C6), 70.3 (CH-C10), 67.1 (C-C8), 48.6 (CH2-C9), 31.8 (CH2-C
C), 31.2 (CH2-C
D), 29.5 
(CH3-C20), 22.2 (CH2-C
E), 13.9 (CH3-C
F); HRMS (ESI+) calcd. for C12H20O2Na [M+Na]
+ 
219.1356, found 219.1345; IR νmax 3402, 3309, 3300, 2957, 2926, 2860, 1420 cm
-1. 
(E)-3,3,9,9-Tetraethyl-5-ethynyl-7-(hex-1-en-1-yl)-5-methyl-4,8-dioxa-3,9-disilaundecane 
332 
 
 
 
To a solution of 1,3-diol 331 (1.10 g, 5.60 mmol) in CH2Cl2 (50 mL) at −78 °C was added 
lutidine (4.24 mL, 36.4 mmol) followed by TESOTf (4.05 mL, 17.9 mmol). The resulting 
solution was stirred for 1 h before addition of aq. NaHCO3 (50 mL). The biphasic mixture 
was separated and the aqueous phase extracted with CH2Cl2 (2 × 50 mL). The combined 
organic extracts dried over Na2SO4, filtered and the solvent removed under vacuum to afford 
the crude product. Purification of the residue by silica gel column chromatography (pet. 
ether:Et2O, 100:0  95:5) afforded title compound 332 (2.38 g, quant.) as a colourless oil. 
    
   +4.1 (c = 0.945, CHCl3); 
1H NMR (400 MHz, CDCl3) δ 5.62–5.43 (2H, m, CH-C
B, CH-
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C11), 4.43 (1H, ddd, J = 6.2, 6.2, 6.0 Hz, CH-C10), 2.43 (1H, s, CH-C6), 2.03–1.96 (2H, m, 
CH2-C
C), 1.91 (1H, dd, J = 13.8, 6.2 Hz, CH2-C9), 1.87 (1H, dd, J = 13.8, 6.0 Hz, CH2-C9), 
1.50 (3H, s, CH3-C20), 1.42–1.23 (4H, m, CH2-C
D, CH2-C
E), 0.96 (9H, t, J = 7.9 Hz, 
Si(CH2CH3)3), 0.94 (9H, t, J = 7.9 Hz, Si(CH2CH3)3), 0.89 (3H, t, J = 7.1 Hz, CH3-C
F), 0.72–
0.61 (6H, m, Si(CH2CH3)3), 0.65–0.54 (6H, m, Si(CH2CH3)3); 
13C NMR (101 MHz, CDCl3) δ 
134.3 (CH-CB), 130.1 (CH-C11), 88.3 (C-C7), 72.2 (CH-C6), 71.2 (CH-C10), 68.4 (C-C8), 
53.4 (CH2-C9), 31.8 (CH2-C
C), 31.7 (CH3-C20), 31.3 (CH2-C
D), 22.3 (CH2-C
E), 13.9 (CH3-C
F), 
7.0 (Si(CH2CH3)3), 6.9 (Si(CH2CH3)3), 6.2 (Si(CH2CH3)3), 5.2 (Si(CH2CH3)3); HRMS (ESI
+) 
calcd. for C24H48O2Si2Na [M+Na]
+ 447.3085, found 447.3053; IR νmax  3310, 2954, 2936, 
2914, 2876, 1458, 1414 cm-1. 
(E)-4-Methyl-4,6-bis(triethylsilyloxy)dodec-7-en-2-ynal 333 
 
 
 
To a solution of alkyne 332 (2.37 g, 5.58 mmol) in THF (100 mL) at −78 °C under argon was 
added nBuLi (2.70 mL of a 2.28 M solution in hexane, 6.16 mmol). The resulting solution 
was stirred for 30 min before warming to 0 °C and addition of DMF (0.87 mL, 11.2 mmol). 
After 30 min stirring at 0 °C the reaction was warmed to rt and stirred for 1 h. 5% aq. KH2PO4 
(100 mL) and Et2O (100 mL) were added and the biphasic mixture separated. The aqueous 
phase was extracted with Et2O (2 × 100 mL) and the combined organic extracts were 
washed with 5% aq. KH2PO4 (100 mL) before being dried over Na2SO4, filtered and the 
solvent removed under vacuum to afford the title compound 333 (2.48 g, quant.) as a 
colourless oil which was used directly in the next reaction.     
   +8.5 (c = 0.770, CHCl3); 
1H 
NMR (500 MHz, CDCl3) δ 9.24 (1H, s, CHO-C5), 5.56 (1H, dt, J = 15.4, 6.5 Hz, CH-C
B), 5.46 
(1H, ddt, J = 15.4, 7.3, 1.4 Hz, CH-C11), 4.38 (1H, app td, J = 7.3, 5.2 Hz, CH-C10), 2.04–
1.96 (3H, m, CH2-C9, CH2-C
C), 1.89 (1H, dd, J = 13.9, 5.2 Hz, CH2-C9), 1.57 (3H, s, CH3-
C20), 1.42–1.21 (4H, m, CH2-C
D, CH2-C
E), 0.97 (9H, t, J = 7.9 Hz, Si(CH2CH3)3), 0.93 (9H, t, 
J = 7.9 Hz, Si(CH2CH3)3), 0.90 (3H, t, J = 7.1 Hz, CH3-C
F), 0.74–0.62 (6H, m, Si(CH2CH3)3), 
0.58 (6H, q, J = 7.9 Hz, Si(CH2CH3)3); 
13C NMR (126 MHz, CDCl3) δ 176.5 (CHO-C5), 133.8 
(CH-CB), 131.2 (CH-C11), 101.0 (C-C7), 83.8 (C-C6), 71.1 (CH-C10), 68.6 (C-C8), 53.0 
(CH2-C9), 32.0 (CH2-C
C), 31.3 (CH2-C
D), 31.2 (CH3-C20), 22.5 (CH2-C
E), 14.1 (CH3-C
F), 7.1 
(Si(CH2CH3)3), 7.0 (Si(CH2CH3)3), 6.3 (Si(CH2CH3)3), 5.3 (Si(CH2CH3)3); IR νmax 2955, 2936, 
2915, 2876, 2209, 1458, 1414 cm-1. 
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2‐[(2E,3R,5S)‐5‐[(1E)‐hex‐1‐en‐1‐yl]‐3‐Hydroxy‐3‐methyloxolan‐2‐ylidene]acetaldehyde 
336 
 
 
 
To a solution of aldehyde 333 (180 mg, 0.40 mmol) in THF (4 mL) was added a solution of 
TBAF (0.83 mL of a 1 M solution in THF, 0.83 mmol) and the resulting mixture stirred at rt for 
1 h.  H2O (10 mL) and Et2O (10 mL) were added and the biphasic mixture separated. The 
organic phase was dried over Na2SO4, filtered and the solvent removed under vacuum. 
Purification of the residue by silica gel column chromatography (pet. ether:Et2O, 1:4) 
afforded title compound 336 (69 mg, 58%) as a yellow oil.     
   +6.3 (c = 0.07, CHCl3)
a; 1H 
NMR (400 MHz, CDCl3) δ 9.84 (1H, d, J = 8.5 Hz, CHO-C5), 5.85 (1H, dtd, J = 15.3, 6.8, 0.9 
Hz, CH-CB), 5.45 (1H, ddt, J = 15.3, 7.9, 1.5 Hz, CH-C11), 5.17 (1H, d, J = 8.5 Hz, CH-C6), 
5.14–5.07 (1H, m, CH-C10), 3.89 (1H, br s, OH-C8) 2.32 (1H, dd, J = 13.2, 5.4 Hz, CH2-C9), 
2.10–2.03 (2H, m, CH2-C
C), 1.75 (1H, dd, J = 13.2, 9.7 Hz, CH2-C9), 1.50 (3H, s, CH3-C20) 
1.42–1.26 (4H, m, CH2-C
D, CH2-C
E), 0.88 (3H, t, J = 7.2 Hz, CH3-C
F); 13C NMR (101 MHz, 
CDCl3) δ 191.2 (CHO-C5), 180.8 (C-C7), 137.3 (CH-C
B), 126.9 (CH-C11), 98.6 (CH-C6), 
85.1 (CH-C10), 78.7 (C-C8), 44.8 (CH2-C9), 32.0 (CH2-C
C), 30.9 (CH2-C
D), 24.9 (CH3-C20), 
22.3 (CH2-C
E), 14.0 (CH3-C
F); HRMS (ESI+) calcd. for C13H20O3Na [M+Na]
+ 247.1305, found 
247.1296; IR νmax 3407, 2958, 2926, 2852, 1648, 1637, 1619, 1457 cm
-1. 
aOptical rotation data were obtained from enantiopure material; although only the racemic 
procedure is reported 
(E)-4-Methyl-4,6-bis(triethylsilyloxy)dodec-7-en-2-yn-1-ol 337 
 
 
 
 
To a solution of aldehyde 333 (~1.65 mmol) in MeOH (30 mL) at 0 °C was added NaBH4 (95 
mg, 2.48 mmol) and the resulting solution stirred for 1.5 h. Saturated aq. NH4Cl (20 mL) was 
added and the resulting solution extracted with CH2Cl2 (3 × 50 mL). The combined organic 
extracts were dried over Na2SO4, filtered and the solvent removed under vacuum to afford 
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the crude product. Purification of the residue by silica gel column chromatography (pet. 
ether:Et2O, 85:15) afforded title compound 337 (660 mg, 88%) as a yellow oil.     
   +5.6 (c = 
0.590, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 5.59–5.46 (2H, m, CH-C
B, CH-C11), 4.39 (1H, 
ddd, J = 6.1, 6.1, 6.0 Hz, CH-C10), 4.29 (2H, d, J = 6.3 Hz, CH2-C5), 2.00 (2H, dt, J = 6.7, 
6.4 Hz, CH2-C
C), 1.91 (1H, dd, J = 13.7, 6.1 Hz, CH2-C9), 1.87 (1H, dd, J = 13.7, 6.0 Hz, 
CH2-C9), 1.49 (3H, s, CH3-C20), 1.37 (1H, t, J = 6.3 Hz, OH-C5), 1.36–1.28 (4H, m, CH2-C
D, 
CH2-C
E), 0.96 (9H, t, J = 7.9 Hz, Si(CH2CH3)3), 0.95 (9H, t, J = 7.9 Hz, Si(CH2CH3)3), 0.89 
(3H, t, J = 7.1 Hz, CH3-C
F), 0.70–0.62 (6H, m, Si(CH2CH3)3), 0.59 (6H, q, J = 7.9 Hz, 
Si(CH2CH3)3); 
13C NMR (101 MHz, CDCl3) δ 134.4 (CH-C
B), 130.3 (CH-C11), 90.7 (C-C7), 
82.0 (C-C6), 71.4 (CH-C10), 68.7 (C-C8), 53.5 (CH2-C9), 51.5 (CH2-C5), 32.0 (CH2-C
C), 
31.8 (CH2-C
D), 31.4 (CH3-C20), 22.5 (CH2-C
E), 14.1 (CH3-C
F), 7.2 (Si(CH2CH3)3), 7.0 
(Si(CH2CH3)3), 6.4 (Si(CH2CH3)3), 5.3 (Si(CH2CH3)3); HRMS (ESI
+) calcd. for C25H50O3Si2Na 
[M+Na]+ 477.3191, found 477.3164; IR νmax 3375, 2955, 2928, 2876, 1458, 1413 cm
-1. 
aOptical rotation data were obtained from enantiopure material; although only the racemic 
synthesis is reported in this document 
(S,E)-1-((R)-4-Benzyl-2-thioxothiazolidin-3-yl)-3-hydroxynon-4-en-1-one 341-major and 
(R,E)-1-((R)-4-Benzyl-2-thioxothiazolidin-3-yl)-3-hydroxynon-4-en-1-one 341-minor  
 
 
 
 
 
 
To a solution of thiazolidine-2-thione 343 (1.31 g, 5.21 mmol) in CH2Cl2 (50 mL) at 0 °C was 
added TiCl4 (0.57 mL, 5.42 mmol) followed by DIPEA (0.99 mL, 5.68 mmol) and the resulting 
solution cooled to −78 °C. The mixture was stirred for 30 min and trans-2-heptenal (0.67 mL, 
5.16 mmol) was added. The solution was stirred for a further 1 h before warming to 0 °C and 
the addition of saturated aq. NH4Cl (40 mL). After further warming to rt the biphasic mixture 
was separated and the aqueous phase washed with CH2Cl2 (2 × 40 mL). The combined 
organic extracts were dried over Na2SO4, filtered and the solvent removed under vacuum to 
afford the crude product. Purification of the residue by silica gel column chromatography 
(pet. ether:Et2O, 75:25  60:40) afforded 341-minor (195 mg, 10%) as a yellow oil followed 
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by 341-major (1.00 g, 54%) as a yellow oil. Minor:     
   −124 (c = 0.87, CHCl3); 
1H NMR 
(500 MHz, CDCl3) δ 7.38–7.33 (2H, m, Ph), 7.31–7.27 (3H, m, Ph), 5.74 (1H, dtd, J = 15.1, 
7.0, 1.2 Hz, CH-CB), 5.54 (1H, ddt, J = 15.1, 6.4, 1.5 Hz, CH-C11), 5.40 (1H, ddd, J = 10.6, 
7.1, 3.8 Hz, CH-Aux), 4.60–4.53 (1H, m, CH-C10), 3.61 (1H, dd, J = 17.4, 9.0 Hz, CH2-C9), 
3.42–3.37 (2H, m, CH2-C9, CH2Ph), 3.23 (1H, dd, J = 13.3, 3.8 Hz, CH2-Aux), 3.05 (1H, dd, 
J = 13.3, 10.6 Hz, CH2-Aux), 3.01 (1H, d, J = 3.6 Hz, OH-C10), 2.91 (1H, d, J = 11.5 Hz, 
CH2Ph), 2.05 (2H, dt, J = 7.0, 6.9 Hz, CH2-C
C), 1.42–1.27 (4H, m, CH2-C
D, CH2-C
E), 0.89 
(3H, t, J = 7.1 Hz, CH3-C
F); 13C NMR (101 MHz, CDCl3) δ 201.5 (C=S), 173.2 (C-C8), 136.5 
(Ph), 133.0 (CH-CB), 130.7 (CH-C11), 129.6 (Ph), 129.1 (Ph), 127.4 (Ph), 69.4 (CH-C10), 
68.4 (CH-Aux), 45.8 (CH2-C9), 37.0 (CH2-Aux), 32.2 (CH2-Bn), 32.0 (CH2-C
C), 31.3 (CH2-
CD), 22.4 (CH2-C
E), 14.1 (CH3-C
F); HRMS (ESI+) calcd. for C19H25NO2S2Na [M+Na]
+ 
330.0593, found 330.0588; IR νmax 3565, 2953, 2924, 2855, 1694, 1674, 1497, 1437 cm
-1. 
Major:     
   −167 (c = 1.16, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 7.37–7.33 (2H, m, Ph), 
7.31–7.27 (3H, m, Ph), 5.76 (1H, dtd, J = 15.1, 6.9, 1.2 Hz, CH-CB), 5.55 (1H, ddt, J = 15.1, 
6.5, 1.5 Hz, CH-C11), 5.39 (1H, ddd, J = 10.6, 7.1, 3.9 Hz, CH-Aux), 4.68–4.62 (1H, m, CH-
C10), 3.61 (1H, dd, J = 17.6, 2.9 Hz, CH2-C9), 3.40 (1H, ddd, J = 11.5, 7.1, 0.8 Hz, CH2Ph), 
3.32 (1H, dd, J = 17.6, 9.0 Hz, CH2-C9), 3.23 (1H, dd, J = 13.2, 3.9 Hz, CH2-Aux), 3.05 (1H, 
dd, J = 13.2, 10.6 Hz, CH2-Aux), 2.90 (1H, d, J = 11.5 Hz, CH2Ph ), 2.65 (1H, br s, OH-C10), 
2.05 (2H, dt, J = 6.9, 6.8 Hz, CH2-C
C), 1.42–1.25 (4H, m, CH2-C
D, CH2-C
E), 0.90 (3H, t, J = 
7.2 Hz, CH3-C
F); 13C NMR (126 MHz, CDCl3) δ 201.5 (C=S), 172.8 (C-C8), 136.6 (Ph), 132.9 
(CH-CB), 130.5 (CH-C11), 129.6 (Ph), 129.1 (Ph), 127.4 (Ph), 68.9 (CH-C10), 68.5 (CH-
Aux), 46.0 (CH2-C9), 37.0 (CH2-Aux), 32.3 (CH2-Bn), 32.0 (CH2-C
C), 31.4 (CH2-C
D), 22.4 
(CH2-C
E), 14.1 (CH3-C
F); HRMS (ESI+) calcd. for C19H25NO2S2Na [M+Na]
+ 330.0593, found 
330.0592;  IR νmax 3439, 2955, 2924, 2856, 2690, 1497, 1437 cm
-1. 
(S,E)-3-Hydroxy-1-((R)-4-mesityl-2-thioxooxazolidin-3-yl)non-4-en-1-one 342 
 
 
 
To a solution of oxazolidinethione 344 (1.01 g, 3.80 mmol) in CH2Cl2 (20 mL) at −40 °C was 
added TiCl4 (0.84 mL, 7.6 mmol). After 5 minutes, DIPEA (1.33 mL, 7.60 mmol) was added 
and the resulting solution stirred for 2 h. The solution was cooled to −78 °C, trans-2-heptenal 
(0.60 mL, 4.6 mmol) added and the mixture stirred for a further 5 h. Half-saturated aq. NH4Cl 
(30 mL) was added and the mixture was warmed to rt. The biphasic mixture was separated 
and the aqueous phase extracted with CH2Cl2 (3 × 30 mL). The combined organic extracts 
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were dried over Na2SO4, filtered and the solvent removed under vacuum to afford the crude 
product. Purification of the residue by silica gel column chromatography (pet. ether:Et2O, 7:3 
 5:5) afforded title compound 342 (1.21 g, 85%) as a yellow oil.     
   +44 (c = +0.51, 
CHCl3); 
1H NMR (500 MHz, CDCl3) δ 6.87 (1H, s, CH-Mes), 6.85 (1H, s, CH-Mes), 6.11 (1H, 
dd, J = 11.0, 7.2 Hz, CH-Aux), 5.68 (1H, dtd, J = 15.1, 6.7, 1.2 Hz, CH-CB), 5.49 (1H, ddt, J = 
15.1, 6.2, 1.5 Hz, CH-C11), 4.87 (1H, dd, J = 11.0, 9.3 Hz, CH2-Aux), 4.52–4.46 (1H, m, CH-
C10), 4.40 (1H, dd, J = 9.3, 7.2 Hz, CH2-Aux), 3.66 (1H, dd, J = 17.8, 9.1 Hz, CH2-C9), 3.39 
(1H, dd, J = 17.8, 2.9 Hz, CH2-C9), 2.45 (3H, s, CH3-Mes), 2.25 (6H, s, CH3-Mes), 2.01 (2H, 
dt, J = 7.0, 6.7 Hz, CH2-C
C), 1.38–1.25 (4H, m, CH2-C
D, CH2-C
E), 0.88 (3H t, J = 7.2 Hz, 
CH3-C
F); 13C NMR (126 MHz, CDCl3) δ 186.1 (C=S), 173.1 (C-C8), 138.5 (Ar), 135.0 (Ar) 
133.0 (CH-CB), 132.0 (Ar), 130.5 (Ar), 130.4 (CH-C11), 130.0 (Ar), 72.0 (CH2-Aux), 68.8 
(CH-C10), 58.4 (CH-Aux), 45.3 (CH2-C9), 32.0 (CH2-C
C), 31.3 (CH2-C
D), 22.4 (CH2-C
E), 20.9 
(CH3-Mes), 20.8 (CH3-Mes), 14.1 (CH3-C
F); HRMS (EI+) calcd for C21H29NO3S 375.1868, 
found 375.1864; IR νmax 3451, 2959, 2926, 2859, 1705, 1613, 1483 cm
-1. 
(S,E)-3-Hydroxy-N-methoxy-N-methylnon-4-enamide 345 
 
 
 
To a solution of aldol adduct 342 (1.15 g, 3.06 mmol) in CH2Cl2 (60 mL) was added N,O-
dimethylhydroxylamine hydrochloride (1.78 g, 18.4 mmol) and imidazole (2.11 g, 30.6 mmol) 
and the resulting solution stirred for 21 h at rt. Saturated aq. NH4Cl (50 mL) was added and 
the biphasic mixture separated. The aqueous phase was extracted with CH2Cl2 (3 × 50 mL) 
and the combined organic extracts dried over Na2SO4, filtered and the solvent removed 
under vacuum to afford the crude product. Purification of the residue by silica gel column 
chromatography (pet. ether:EtOAc, 8:2  1:1) afforded recovered oxazolidinethione 
auxiliary (657 mg, 99%) followed by the title compound 345 (599 mg, 91%) as a yellow oil. 
    
   −32 (c = 0.74, CHCl3); 
1H NMR (400 MHz, CDCl3) δ 5.74 (1H, dtd, J = 15.4, 6.6, 1.2 
Hz, CH-CB), 5.51 (1H, ddt, J = 15.4, 6.6, 1.4 Hz, CH-C11), 4.56–4.47 (1H, m, CH-C10), 3.78 
(1H, d, J = 3.2 Hz, OH-C10), 3.69 (3H, s, NCH3), 3.19 (3H, s, OCH3), 2.74–2.53 (2H, m, 
CH2-C9), 2.04 (2H, dt, J = 6.7, 6.6 Hz, CH2-C
C), 1.45–1.23 (4H, m, CH2-C
D, CH2-C
E), 0.89 
(3H, t, J = 7.1 Hz, CH3-C
F); 13C NMR (101 MHz, CDCl3) δ 173.6 (C-C8), 132.4 (CH-C11), 
131.0 (CH-CB), 69.0 (CH-C10), 61.4 (NCH3), 38.7 (CH2-C9), 32.0 (CH2-C
C, OCH3), 31.4 
(CH2-C
D), 22.4 (CH2-C
E), 14.1 (CH3-C
F); HRMS (EI+) calcd. for C11H21NO3 215.1521, found 
215.1519; IR νmax 3435, 2957, 2926, 2872, 2859, 1640, 1464, 1437 cm
-1. 
127 
 
(S,E)-N-Methoxy-N-methyl-3-(triethylsilyloxy)non-4-enamide 346 
 
 
 
To a solution of allylic alcohol 345 (50.4 mg, 0.23 mmol) in CH2Cl2 (1 mL) at −78 °C under 
argon was added 2,6-lutidine (0.07 mL, 0.6 mmol) followed by TESOTf (0.06 mL, 0.3 mmol). 
The resulting solution was stirred for 1 h before addition of saturated aq. NaHCO3 (2 mL) 
and warming to rt. The biphasic mixture was separated and the aqueous phase extracted 
with CH2Cl2 (3 × 3 mL). The combined organic extracts were dried over Na2SO4, filtered and 
the solvent removed under vacuum to afford the crude title compound. Purification of the 
residue by silica gel column chromatography (pet. ether:EtOAc, 9:1) afforded the title 
compound 346 (67.4 mg, 89%) as a yellow oil.  α  
   −17 (c = 0.65, CHCl3); 
1H NMR (400 
MHz, CDCl3) δ 5.64 (1H, dtd, J = 15.3, 6.7, 1.0 Hz, CH-C
B), 5.47 (1H, ddt, J = 15.3, 6.7, 1.4 
Hz, CH-C11), 4.63 (1H, ddd, J = 7.4, 6.7, 5.6 Hz, CH-C10), 3.69 (3H, s, NCH3), 3.17 (3H, s, 
OCH3), 2.80 (1H dd, J = 14.2, 7.4 Hz, CH2-C9), 2.43 (1H, dd, J = 14.2, 5.6 Hz, CH2-C9), 2.00 
(2H, dt, J = 6.7, 6.6 Hz, CH2-C
C), 1.42–1.22 (4H, m, CH2-C
D, CH2-C
E), 0.93 (9H, t, J = 7.9 
Hz, Si(CH2CH3)3), 0.88 (3H, t, J = 7.0 Hz, CH3-C
F), 0.58 (6H, q, J = 7.9 Hz, Si(CH2CH3)3); 
13C 
NMR (101 MHz, CDCl3) δ 167.6 (C-C8), 132.6 (CH-C11), 131.3 (CH-C
B), 70.7 (CH-C10), 
61.5 (NCH3), 40.9 (CH2-C9), 31.9 (CH2-C
C, OCH3), 31.4 (CH2-C
D), 22.4 (CH2-C
E), 14.1 (CH3-
CF), 6.9 (Si(CH2CH3)3), 5.0 (Si(CH2CH3)3); HRMS (EI
+) calcd. for C17H35NO3Si 330.2464, 
found 330.2463; IR νmax 2955, 2934, 2916, 2876, 1665, 1460, 1441 cm
-1 
(S,E)-3,3-Diethyl-5-(hex-1-en-1-yl)-13,13-dimethyl-12,12-diphenyl-4,11-dioxa-3,12-
disilatetradec-8-yn-7-one 349 
 
 
 
 
To a solution of protected propargylic alcohol 347 (187 mg, 0.64 mmol) in THF (3 mL) at rt 
was added nBuLi (0.30 mL, 2.1 M in hexane, 0.64 mmol) and the resulting solution stirred for 
30 min. A solution of amide 346 (140 mg, 0.43 mmol) in THF (2 mL) was added and the 
solution stirred for 10 min before warming to rt and stirring for 1 h. Saturated aq. NH4Cl (5 
mL) was added and the biphasic mixture separated. The aqueous phase was extracted with 
Et2O (2 × 10 mL) and the combined organic extracts dried over Na2SO4, filtered and the 
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solvent removed under vacuum to afford the crude product. Filtration through silica (pet. 
ether:Et2O, 100:0  95:5) afforded an inseparable mixture (347 mg) of alkynone 348 and 
excess protected propargylic aldehyde 347 which was carried forward directly to the next 
reaction. 
To a solution of crude alkynone 348 (~6.56 mmol) in MeOH (46 mL) and THF (15 mL) at 0 
°C was added PPTS (164 mg, 0.65 mmol). The resulting mixture was stirred for 6 h before 
addition of saturated aq. NaHCO3 (40 mL) and warming to rt. EtOAc (40 mL) was added and 
the biphasic mixture separated. The aqueous phase was extracted with EtOAc (3 × 60 mL) 
and the combined organic extracts dried over Na2SO4, filtered and the solvent removed 
under vacuum to afford the crude product. Purification of the residue by silica gel column 
chromatography (pet. ether:EtOAc, 90:10  85:15) afforded title compound 349 (2.27 g, 
77% over 2 steps) as a yellow oil.     
   −8.8 (c = 0.50, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 
7.71–7.67 (4H, m, Ph), 7.48–7.39 (6H, m, Ph), 5.70 (1H, dtd, J = 15.2, 6.9, 1.2 Hz, CH-CB), 
5.45 (1H, ddt, J = 15.2, 6.6, 1.4 Hz, CH-C11), 4.60–4.52 (1H, m, CH-C10), 4.47 (2H, s, CH2-
C5), 2.74–2.62 (2H, m, CH2-C9), 2.40 (1H, d, J = 4.0 Hz, OH-C10), 2.04 (2H, dt, J = 6.9, 6.7 
Hz, CH2-C
C), 1.44–1.28 (4H, m, CH2-C
D, CH2-C
E), 1.07 (9H, s, C(CH3)3), 0.90 (3H, t, J = 7.1 
Hz, CH3-C
F); 13C NMR (126 MHz, CDCl3) δ 186.4 (C-C8), 135.7 (Ph), 133.1 (CH-C11), 132.6 
(Ph), 130.4 (CH-CB), 130.2 (Ph), 128.0 (Ph), 91.4 (C-C6), 84.2 (C-C7), 68.6 (CH-C10), 52.6 
(CH2-C5), 52.2 (CH2-C9), 32.0 (CH2-C
C), 31.3 (CH2-C
D), 26.8 (C(CH3)3), 22.3 (CH2-C
E), 19.3 
(C(CH3)3), 14.1 (CH3-C
F); HRMS (ESI+) calcd. for C28H36O3SiNa [M+Na]
+ 471.2304, found 
471.2326; IR νmax 3437, 2957, 2930, 2859, 2214, 1709, 1676, 1464 cm
-1. 
 
(4R,6S,E)-1-(tert-Butyldiphenylsilyloxy)-4-methyldodec-7-en-2-yne-4,6-diol 350-syn 
and (4S,6S,E)-1-(tert-Butyldiphenylsilyloxy)-4-methyldodec-7-en-2-yne-4,6-diol 350-
anti  
 
 
 
 
 
 
To a solution of Ti(OiPr)4 (0.9 mL, 3 mmol) in Et2O (4.5 mL) at 0 °C was added TiCl4 (0.1 mL, 
0.9 mmol). The resulting solution was warmed to rt for 30 min before cooling to 0 °C and 
addition of MeLi (2.5 mL of a 1.6 M in Et2O, 4.0 mmol). After stirring for 1 h a portion of the 
solution (6.42 mL) was added to a solution of ynone 349 (96 mg, 0.21 mmol) in Et2O (4 mL) 
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at −78 °C. The solution was stirred for 15 minutes before warming to 0 °C and stirring for 30 
min. 2 M HCl (5 mL) was added dropwise before warming to rt and separation of the 
biphasic mixture. The aqueous phase was extracted with Et2O (2 × 10 mL) and the 
combined organic extracts washed with brine (10 mL) before being dried over Na2SO4, 
filtered and the solvent removed under vacuum to afford the crude product. Purification of 
the residue by silica gel column chromatography (pet. ether:Et2O, 6:4) afforded 350-anti 
(18.9 mg, 19%) as a colourless oil followed by 350-syn (70.2 mg, 72%) as a colourless oil. 
Anti:     
   +6.6 (c = 0.42, CHCl3); 
1H NMR (400 MHz, CDCl3) δ 7.76–7.68 (4H, m, Ph), 
7.48–7.34 (6H, m, Ph), 5.62 (1H, dtd, J = 15.4, 6.7, 1.0 Hz, CH-CB), 5.44 (1H, ddt, J = 15.4, 
6.7, 1.4 Hz, CH-C11), 4.67–4.55 (1H, m, CH-C10), 4.43 (1H, d, J = 16.0 Hz, CH2-C5),  4.41 
(1H, d, J = 16.0 Hz, CH2-C5),  4.18 (1H, s, OH-C8), 2.28 (1H, dd, J = 2.9, 1.0 Hz, OH-C10), 
2.02 (2H, dt, J = 6.7, 6.6 Hz, CH2-C
C), 1.75 (1H, dd, J = 14.4, 10.7 Hz, CH2-C9), 1.63 (1H, 
ddd, J = 14.4, 2.3, 1.0, CH2-C9), 1.40 (3H, s, CH3-C20), 1.38–1.27 (4H, m, CH2-C
D, CH2-C
E), 
1.06 (9H, s, C(CH3)3), 0.90 (3H, t, J = 7.0 Hz, CH3-C
F); 13C NMR (101 MHz, CDCl3) δ 135.8 
(Ph), 133.4 (Ph), 132.2 (CH-C11), 132.1 (CH-CB), 129.9 (Ph), 127.8 (Ph), 88.3 (C-C7), 82.2 
(C-C6), 72.2 (CH-C10), 68.3 (C-C8), 52.9 (CH2-C5), 48.1 (CH2-C9), 31.9 (CH-C
C), 31.4 
(CH2-C
D), 30.9 (CH3-C20), 26.8 (C(CH3)3), 22.3 (CH2-C
E), 19.3 (C(CH3)3), 14.1 (CH3-C
F); 
HRMS (ESI+) calcd. for C29H40O3Na [M+Na]
+ 487.2639, found 487.2616; IR νmax 3343, 3073, 
3048, 2955, 2930, 2859, 1474, 1462, 1427 cm-1. Syn:     
   +2.7 (c = 0.11, CHCl3); 
1H NMR 
(400 MHz, CDCl3) δ 7.75–7.68 (4H, m, Ph), 7.48–7.36 (6H, m, Ph), 5.69 (1H, dtd, J = 15.4, 
6.8, 1.1 Hz, CH-CB), 5.48 (1H, ddt, J = 15.4, 7.1, 1.3 Hz, CH-C11), 4.46–4.38 (1H, m, CH-
C10), 4.36 (2H, s, CH2-C5), 2.61 (1H, s, OH-C8), 2.57 (1H, d, J = 2.5 Hz, OH-C10), 2.02 
(2H, dt, J = 7.0, 6.8 Hz, CH2-C
C), 1.92 (1H, dd, J = 14.5, 9.3 Hz, CH2-C9), 1.72 (1H, dd, J = 
14.5, 3.5 Hz, CH2-C9), 1.45 (3H, s, CH3-C20), 1.41–1.24 (4H, m, CH2-C
D, CH2-C
E), 1.05 (9H, 
s, C(CH3)3), 0.89 (3H, t, J = 7.1 Hz, CH3-C
F); 13C NMR (101 MHz, CDCl3) δ 135.8 (Ph), 133.4 
(Ph), 132.6 (CH-C11), 132.4 (CH-CB), 129.9 (Ph), 127.8 (Ph), 89.1 (C-C7), 82.2 (C-C6), 70.2 
(CH-C10), 67.4 (C-C8), 52.8 (CH2-C5), 48.7 (CH2-C9), 32.0 (CH2-C
C), 31.4 (CH2-C
D), 29.3 
(CH3-C20), 26.9 (C(CH3)3), 22.4 (CH2-C
E), 19.3 (C(CH3)3), 14.1 (CH3-C
F); HRMS (ESI+) 
calcd. for C29H40O3Na [M+Na]
+ 487.2639, found 487.2616; IR νmax 3358, 3073, 3048, 2957, 
2859, 1472, 1464, 1427 cm-1. 
 
 
 
 
130 
 
(4R,6S,E)-1-(tert-Butyldiphenylsilyloxy)-4-hydroxy-4-methyldodec-7-en-2-yn-6-yl (R)-5-
(2-(4-methoxybenzyloxyethyl)-6-methyl-2-methylenehept-6-enoate 351 
 
 
 
 
 
 
To a solution of Et3N (0.42 mL, 1.9 mmol), DMAP (77 mg, 0.63 mmol) and MNBA (227 mg, 
0.66 mmol) in CH2Cl2 (4 mL) was added a solution of carboxylic acid 321 (201 mg, 0.63 
mmol) in CH2Cl2 (4 mL). The resulting solution was stirred at rt for 30 min before addition of 
a solution of diol 350-syn (293 mg, 0.63 mmol) in CH2Cl2 (4 mL). The resulting solution was 
stirred for 18 h before addition of saturated aq. NaHCO3 (10 mL). The biphasic mixture was 
separated and the aqueous phase extracted with CH2Cl2 (2 × 10 mL). The combined organic 
extracts were dried over Na2SO4, filtered and solvent removed under vacuum to afford the 
crude product. Purification of the residue by silica gel column chromatography (pet. 
ether:EtOAc, 8:2) afforded recovered diol 350-syn (57 mg, 31%) followed by the title 
compound 351 (328 mg, 68%) as a yellow oil.     
   −5.4 (c = 1.12, CHCl3); 
1H NMR (500 
MHz, CDCl3) δ 7.73–7.66 (4H, m, Ph), 7.46–7.35 (6H, m, Ph), 7.26–7.21 (2H, m, Ar-PMB), 
6.90–6.84 (2H, m, Ar-PMB), 6.06 (1H, d, J = 1.5 Hz, CH2-C
A), 5.76 (1H, dtd, J = 15.3, 6.8, 
0.9 Hz, CH-CB), 5.59 (1H, ddd, J = 7.9, 7.7, 4.6 Hz, 1H, CH-C10), 5.46 (1H, ddt, J = 15.3, 
7.7, 1.5 Hz, CH-C11), 5.42 (1H, d, J = 1.5 Hz, CH2-C
A), 4.75 (1H, dq, J = 2.6, 1.3 Hz, CH2-
C16), 4.68 (1H, d, J = 2.6 Hz, CH2-C16), 4.40 (1H, d, J = 11.7 Hz, CH2-PMB), 4.37 (1H, d, J 
= 11.7 Hz, CH2-PMB), 4.27 (1H, d, J = 15.7 Hz, CH2-C5), 4.25 (1H, d, J = 15.7 Hz, CH2-C5), 
3.80 (3H, s, CH3-PMB), 3.42–3.30 (2H, m, CH2-C3), 2.25–2.14 (2H, m, CH2-C13), 2.12–1.97 
(4H, m, CH-C1, CH2-C9, CH2-C
C), 1.85 (1H, dd, J = 14.3, 4.6 Hz, CH2-C9), 1.70–1.54 (2H, 
m, CH2-C2), 1.58 (3H, d, J = 1.3 Hz, CH3-C17), 1.48–1.39 (2H, m, CH2-C14), 1.38 (3H, s, 
CH3-C20), 1.36–1.26 (4H, m, CH2-C
D, CH2-C
E), 1.04 (9H, s, C(CH3)3), 0.87 (3H, t, J = 7.2 
Hz, CH3-C
F); 13C NMR (126 MHz, CDCl3) δ 167.1 (C-C21), 159.2 (Ar-PMB), 146.4 (C-C12), 
141.2 (C-C15), 135.8 (Ph), 135.0 (CH-CB), 133.4 (Ph), 130.9 (Ar-PMB), 129.9 (Ph), 129.4 
(Ar-PMB), 128.5 (CH-C11), 127.8 (Ph), 124.9 (CH2-C
A), 113.9 (Ar-PMB), 112.7 (CH2-C16), 
88.3 (C-C7), 82.0 (C-C6), 72.8 (CH2-PMB), 72.2 (CH-C10), 68.5 (CH2-C3), 65.7 (C-C8), 55.4 
(CH3-PMB), 52.8 (CH2-C5), 47.7 (CH2-C9), 44.0 (CH-C1), 33.3 (CH2-C2), 32.4 (CH2-C14), 
32.0 (CH2-C
C), 31.2 (CH3-C20), 30.7 (CH2-C
D), 30.0 (CH2-C13), 26.9 (C(CH3)3), 22.3 (CH2-
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CE), 19.3 (C(CH3)3), 17.9 (CH3-C17), 14.1 (CH3-C
F); HRMS (ESI+) calcd. for C48H64O6SiNa 
[M+Na]+ 787.4364 found 787.4318; IR νmax 3453, 3071, 2955, 2857, 1715, 1612, 1587, 
1512, 1464, 1443, 1429 cm-1. 
(4R,6S,E)-1-(tert-Butyldiphenylsilyloxy)-4-methyl-4-(triethylsilyloxy)dodec-7-en-2-yn-6-
yl (R)-5-(2-4-methoxybenzyloxyethyl)-6-methyl-2-methylenehept-6-enoate 353 
 
 
 
 
 
 
To a solution of ester 351 (300 mg, 0.39 mmol) in CH2Cl2 (12 mL) at −78 °C was added 2,6-
lutidine (0.12 mL, 1.0 mmol) followed by TESOTf (0.11 mL, 0.51 mmol). The resulting 
solution was stirred for 1.5 h before addition of saturated aq. NaHCO3 (10 mL). The phases 
were separated and the aqueous phase extracted with CH2Cl2 (3 × 15 mL). The combined 
organic extracts were dried over Na2SO4, filtered and the solvent removed under vacuum to 
afford the crude product. Purification of the residue by silica gel column chromatography 
(pet. ether:EtOAc, 9:1) afforded the title compound (306 mg, 89%) as a colourless oil.     
   
−10.2 (c = 0.21, CHCl3); 
1H NMR (400 MHz, CDCl3) δ 7.73–7.67 (4H, m, Ph), 7.47–7.35 (6H, 
m, Ph), 7.28–7.23 (2H, m, Ar-PMB), 6.90–6.85 (2H, m, Ar-PMB), 6.07 (1H, d, J = 1.5 Hz, 
CH2-C
A), 5.71–5.61 (1H, m, CH-CB), 5.55 (1H, ddd, J = 7.5, 7.4, 3.9 Hz, CH-C10), 5.48–5.40 
(2H, m, CH-C11, CH2-C
A), 4.76 (1H, dq, J = 2.6, 1.3 Hz, CH2-C16), 4.69 (1H, d, J = 2.6 Hz, 
CH2-C16), 4.39 (2H, s, CH2-PMB), 4.28 (2H, s, CH2-C5), 3.80 (3H, s, CH3-PMB), 3.43–3.31 
(2H, m, CH2-C3), 2.28–2.03 (4H, m, CH2-C9, CH2-C13, CH-C1), 1.99 (2H, dt, J = 6.7, 6.6 
Hz, CH2-C
C), 1.92 (1H, dd, J = 14.3, 3.9 Hz, CH2-C9), 1.73–1.54 (2H, m, CH2-C2) 1.59 (3H, 
d, J = 1.3 Hz, CH3-C17), 1.50–1.42 (2H, m, CH2-C14), 1.42 (3H, s, CH3-C20), 1.37–1.22 
(4H, m, CH2-C
D, CH2-C
E), 1.05 (9H, s, C(CH3)3), 0.94 (9H, t, J = 7.9 Hz, Si(CH2CH3)3), 0.86 
(3H, t, J = 7.1 Hz, CH3-C
F), 0.67 (6H, app qd, J = 7.9, 2.2 Hz, Si(CH2CH3)3); 
13C NMR (101 
MHz, CDCl3) δ 166.2 (C-C21), 159.2 (Ar-PMB), 146.5 (C-C12), 141.6 (C-C15), 135.7 (Ph), 
133.3 (Ph), 133.2 (CH-CB), 130.9 (Ar-PMB), 129.9 (Ph), 129.4 (Ar-PMB), 129.2 (CH-C11), 
127.9 (Ph), 124.1 (CH2-C
A), 113.9 (Ar-PMB), 112.5 (CH2-C16), 88.6 (C-C7), 82.6 (C-C6), 
72.8 (CH2-PMB), 72.1 (CH-C10), 68.6 (CH2-C3), 67.7 (C-C8), 55.4 (CH3-PMB), 52.8 (CH2-
C5), 49.7 (CH2-C9), 44.0 (CH-C1), 33.3 (CH2-C2), 32.4 (CH2-C14), 32.0 (CH2-C
C), 31.7 
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(CH3-C20), 31.2 (CH2-C
D), 30.1 (CH2-13), 26.8 (C(CH3)3), 22.3 (CH2-C
E), 19.3 (C(CH3)3), 
17.9 (CH3-C17), 14.1 (CH3-C
F), 7.2 (Si(CH2CH3)3), 6.2 (Si(CH2CH3)3); HRMS (ESI
+) calcd. 
for C54H78O6Si2Na [M+Na]
+ 901.5234 found 901.5208; IR νmax 3071, 2955, 2930, 2874, 2859, 
1717, 1643, 1630, 1613, 1514, 1464 cm-1. 
(4R,6S,E)-1-(tert-Butyldiphenylsilyloxy)-4-methyl-4-(triethylsilyloxy)dodec-7-en-2-yn-6-
yl (R)-5-(2-hydroxyethyl)-6-methyl-2-methylenehept-6-enoate 353 
 
 
 
 
 
 
To a solution of (4R,6S,E)-1-(tert-butyldiphenylsilyloxy)-4-methyl-4-(triethylsilyloxy)dodec-7-
en-2-yn-6-yl (R)-5-(2-4-methoxybenzyloxyethyl)-6-methyl-2-methylenehept-6-enoate (295 
mg, 0.34 mmol) in a 9:1 mixture of CH2Cl2 (9 mL) and aqueous pH7 buffer (1 mL) was added 
DDQ (84 mg, 0.37 mmol) and the resulting solution stirred at rt for 1.5 h. Saturated aq. 
NaHCO3 (5 mL) and CH2Cl2 (5 mL) were added and the biphasic mixture separated. The 
aqueous phase was washed with CH2Cl2 (2 × 10 mL) and the combined organic extracts 
dried over Na2SO4, filtered and the solvent removed under vacuum to afford the crude 
product. Purification of the residue by silica gel column chromatography (pet. ether:EtOAc, 
9:1  8:2) afforded the title compound 353 (240 mg, 93%) as a yellow oil.     
   −5.15 (c = 
0.68, CHCl3);  
1H NMR (500 MHz, CDCl3) δ 7.73–7.66 (4H, m, Ph), 7.47–7.35 (6H, m, Ph), 
6.08 (1H, d, J = 1.4 Hz, CH2-C
A), 5.66 (1H, dtd, J = 15.3, 6.7, 1.0 Hz, CH-CB), 5.55 (1H, ddd, 
J = 7.7, 7.4, 3.7 Hz, CH-C10), 5.48–5.39 (2H, m, CH-C11, CH2-C
A), 4.78 (1H, dq, J = 2.4, 
1.2 Hz, CH2-C16), 4.75 (1H, d, J = 2.4 Hz, CH2-C16), 4.26 (1H, d, J = 15.8 Hz, CH2-C5),  
4.29 (1H, d, J = 15.8 Hz, CH2-C5),  3.65–3.51 (2H, m, CH2-C3), 2.26–2.15 (2H, m, CH-C1, 
CH2-C13), 2.18–2.09 (1H, m, CH2-C13), 2.08 (1H, dd, J = 14.3, 7.7 Hz, CH2-C9), 1.99 (2H, 
dt, J = 6.7, 6.6 Hz, CH2-C
C), 1.92 (1H, dd, J = 14.3, 3.7 Hz, CH2-C9), 1.62 (3H, d, J = 1.2 Hz, 
CH3-C17), 1.61–1.56 (2H, m, CH2-C2), 1.47 (2H, dt, J = 7.8, 7.6 Hz, CH2-C14), 1.42 (3H, s, 
CH3-C20), 1.36–1.24 (4H, m, CH2-C
D, CH2-C
E), 1.04 (9H, s, C(CH3)3), 0.94 (9H, t, J = 7.9 
Hz, Si(CH2CH3)3), 0.86 (3H, t, J = 7.1 Hz, CH3-C
F), 0.66 (6H, app qd, J = 7.9, 3.4 Hz, 
Si(CH2CH3)3); 
13C NMR (126 MHz, CDCl3) δ 166.1 (C-C21), 147.2 (C-C12), 141.4 (C-C15), 
135.7 (Ph), 133.3 (Ph), 133.2 (CH-CB), 129.9 (Ph), 129.1 (CH-C11), 127.9 (Ph), 124.3 (CH2-
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CA), 112.7 (CH2-C16), 88.6 (C-C7), 82.6 (C-C6), 72.1 (CH-C10), 67.7 (C-C8), 61.7 (CH2-C3), 
52.8 (CH2-C5), 49.6 (CH2-C9), 44.3 (CH-C1), 36.2 (CH2-C2), 32.4 (CH2-C14), 32.0 (CH2-C
C), 
31.7 (CH3-C20), 31.2 (CH2-C
D), 30.1 (CH2-C13), 26.8 (C(CH3)3), 22.3 (CH2-C
E), 19.3 
(C(CH3)3), 17.8 (CH3-C17), 14.1 (CH3-C
F), 7.2 (Si(CH2CH3)3), 6.2 (Si(CH2CH3)3); HRMS 
(ESI+) calcd. for C46H70O5Si2Na [M+Na]
+ 781.4654 found 781.4597; IR νmax 3412, 3072, 
2955, 2932, 2874, 2859, 1717, 1643, 1630, 1462, 1429 cm-1. 
(4R,6S,E)-1-(tert-Butyldiphenylsilyloxy)-4-methyl-4-(triethylsilyloxy)dodec-7-en-2-yn-6-
yl (R)-6-methyl-2-methylene-5-(2-oxoethyl)hept-6-enoate 354 
 
 
 
 
 
 
To a solution of alcohol 353 (220 mg, 0.29 mmol) in CH2Cl2 (10 mL) was added Dess-Martin 
periodinane (148 mg, 0.35 mmol) and the resulting solution stirred at rt for 4 h. The solvent 
was removed under vacuum and the residue purified by silica gel column chromatography 
(pet. ether:EtOAc, 9:1) to afford the title compound 354 (219 mg, quant.) as a yellow oil. 
    
   −1.65 (c = 0.61, CHCl3); 
1H NMR (400 MHz, CDCl3) δ 9.65 (1H, dd, J = 2.8, 2.0 Hz, 
CHO-C3), 7.76–7.66 (4H, m, Ph), 7.49–7.35 (6H, m, Ph), 6.11 (1H, d, J = 1.5 Hz, CH2-C
A), 
5.67 (1H, ddd, J = 15.3, 6.9, 6.1 Hz, CH-CB), 5.56 (1H, ddd, J = 7.7, 7.4, 3.8 Hz, CH-C10), 
5.50–5.39 (2H, m, CH-C11, CH2-C
A), 4.82 (1H, dq, J = 1.6, 1.5 Hz, CH2-C16), 4.78 (1H, dq, 
J = 1.6, 0.8 Hz, CH2-C16), 4.28 (2H, s, CH2-C5), 2.68 (1H, app p, J = 7.2 Hz, CH-C1), 2.51–
2.33 (2H, m, CH2-C2), 2.30–2.13 (2H, m, CH2-C13), 2.09 (1H, dd, J = 14.3, 7.7 Hz, CH2-C9), 
2.00 (2H, dt, J = 6.9, 6.7 Hz, CH2-C
C), 1.93 (1H, dd, J = 14.3, 3.8 Hz, CH2-C9), 1.66 (3H, dd, 
J = 1.5, 0.8 Hz, CH3-C17), 1.56–1.49 (2H, m, CH2-C14), 1.43 (3H, s, CH3-C20), 1.38–1.22 
(4H, m, CH2-C
D, CH2-C
E), 1.06 (9H, s, C(CH3)3), 0.95 (9H, t, J = 7.9 Hz, Si(CH2CH3)3), 0.87 
(3H, t, J = 7.0 Hz, CH3-C
F), 0.67 (6H, app qd, J = 7.9, 2.2 Hz, Si(CH2CH3)3); 
13C NMR (126 
MHz, CDCl3) δ 202.3 (CHO-C3), 166.0 (C-C21), 145.5 (C-C12), 140.9 (C-C15), 135.7 (Ph), 
133.4 (Ph), 133.2 (CH-CB), 129.9 (Ph), 129.1 (CH-C11), 127.9 (Ph), 124.6 (CH2-C
A), 113.1 
(CH2-C16), 88.6 (C-C7), 82.6 (C-C6), 72.2 (CH-C10), 67.7 (C-C8), 52.8 (CH2-C5), 49.6 
(CH2-C9), 47.4 (CH2-C2), 41.5 (CH-C1), 32.1 (CH2-C14), 32.0 (CH2-C
C), 31.7 (CH3-C20), 
31.2 (CH2-C
D), 29.8 (CH2-C13), 26.8 (C(CH3)3), 22.3 (CH2-C
E), 19.3 (C(CH3)3), 18.8 (CH3-
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C17), 14.1 (CH3-C
F), 7.2 (Si(CH2CH3)3), 6.2 (Si(CH2CH3)3); HRMS (ESI
+) calcd. for 
C46H68O5Si2Na [M+Na]
+ 779.4497 found 779.4441; IR νmax 3072, 2955, 2930, 2874, 2859, 
2716, 1721, 1643, 1630, 1462, 1429 cm-1. 
1-((4R,6S,E)-1-(tert-Butyldiphenylsilyloxy)-4-methyl-4-(triethylsilyloxy)dodec-7-en-2-
yn-6-yl) 9-methyl (5R)-7-hydroxy-2-methylene-5-(prop-1-en-2-yl)nonanedioate 355 
 
To a solution of diisopropylamine (0.08 mL, 0.6 mmol) in THF (3 mL) at −78 °C was added 
nBuLi (0.35 mL, 1.68 M in hexane, 0.59 mmol). After 30 min stirring, methyl acetate (0.05 
mL, 0.64 mmol) was added dropwise and the resulting solution stirred for a further 30 min. A 
solution of aldehyde 354 (180 mg, 0.24 mmol) in THF (2 mL) was added and the reaction 
stirred for 3 h before addition of saturated aq. NH4Cl (5 mL) and warming to rt. The biphasic 
mixture was separated and the aqueous phase extracted with Et2O (3 × 6 mL). The 
combined organic extracts were dried over Na2SO4, filtered and the solvent removed under 
vacuum to afford the crude title compound. Purification of the residue by silica gel column 
chromatography (pet. ether:EtOAc, 9:1) afforded the title compound 355 (1:1 mixture of 
diastereoisomers, 185 mg, 93%) as a yellow oil. 1H NMR (500 MHz, CDCl3) δ 7.74–7.66 
(4H, m, Pha,b), 7.47–7.35 (6H, m, Pha,b), 6.08 (1H, dd, J = 4.0, 1.6 Hz, CH2-C
Aa,b), 5.71–5.62 
(1H, m, CH-CBa,b), 5.55 (1H, ddd, J = 7.7, 3.8, 3.6 Hz, CH-C10a,b), 5.48–5.39 (2H, m, CH-
C11, CH2-C
Aa,b), 4.84–4.82 (0.5H, m, CH2-C16
a), 4.81–4.76 (1H, m, CH2-C16
a,b), 4.75 (0.5H, 
d, J = 2.1 Hz, CH2-C16
b), 4.28 (2H, s, CH2-C5
a,b), 4.04–3.90 (1H, m, CH-C3a,b), 3.70 (1.5H, 
s, CH3-C19
a), 3.70 (1.5H, s, CH3-C19
b), 2.94 (0.5H, d, J = 3.8 Hz, OH-C3a), 2.70 (0.5H, d, J 
= 4.2 Hz, OH-C3b), 2.51 (0.5H, dd, J = 16.2, 3.2 Hz, CH2-C4
a), 2.43 (1H, d, J = 6.1 Hz, CH2-
C4b), 2.38–2.30 (0.5H, m, CH-C1a), 2.37 (0.5H, dd, J = 16.2, 9.0 Hz, CH2-C4
a), 2.25–2.10 
(2.5H, m, CH2-C13
a,b, CH-C1b), 2.08 (1H, ddd, J = 14.3, 7.7, 1.7 Hz, CH2-C9
a,b), 1.99 (2H, dt, 
J = 6.6, 6.5 Hz, CH2-C
Ca,b), 1.92 (1H, ddd, J = 14.3, 3.8, 1.7 Hz, CH2-C9
a,b), 1.71–1.64 (1H, 
m, CH2-C2
a), 1.64 (1.5H, s, CH3-C17
a), 1.60 (1.5H, s, CH3-C17
b), 1.52–1.43 (3H, m, CH2-
C2b, CH2-C14
a,b), 1.43 (1.5H, s, CH3-C20
a), 1.42 (1.5H, s, CH3-C20
b), 1.36–1.24 (4H, m, 
CH2-C
Da,b, CH2-C
Ea,b), 1.05 (9H, s, C(CH3)3
a,b), 0.94 (9H, t, J = 7.9 Hz, Si(CH2CH3)3
a,b), 0.86 
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(3H, t, J = 7.1 Hz, CH3-C
Fa,b), 0.67 (6H, app qd, J = 7.9, 3.3 Hz, Si(CH2CH3)3
a,b); 13C NMR 
(126 MHz, CDCl3) δ 173.3 (C-C18), 173.3 (C-C18), 166.1 (C-C21), 166.1 (C-C21), 147.2 (C-
C12), 146.2 (C-C12), 141.4 (C-C15), 141.3 (C-C15), 135.7 (Ph), 133.3 (CH-CB), 133.3 (CH-
CB), 133.2 (Ph), 129.9 (Ph), 129.2 (CH-C11), 129.1 (CH-C11), 127.9 (Ph), 124.3 (CH2-C
A), 
124.2 (CH2-C
A), 113.4 (CH2-C16), 112.9 (CH2-C16), 88.5 (C-C7), 82.6 (C-C6), 72.2 (CH-
C10), 72.1 (CH-C10), 67.7 (C-C8), 67.7 (C-C8), 67.0 (CH-C3), 65.9 (CH-C3), 52.8 (CH2-C5), 
51.9 (CH3-C19), 51.8 (CH3-C19), 49.6 (CH2-C9), 44.3 (CH-C1), 43.4 (CH-C1), 41.9 (CH2-
C4), 40.9 (CH2-C4), 40.2 (CH2-C2), 40.1 (CH2-C2), 32.8 (CH2-C14), 32.1 (CH2-C14), 32.0 
(CH2-C
C), 31.7 (CH2-C
C), 31.2 (CH3-C20), 30.5 (CH3-C20), 30.2 (CH2-C
D), 29.9 (CH2-C
D), 
29.8 (CH2-C13), 26.8 (C(CH3)3),  22.3 (CH2-C
E),  19.3 (C(CH3)3), 17.8 (CH3-C17), 17.7 (CH3-
C17), 14.1 (CH3-C
F), 7.2 (Si(CH2CH3)3), 6.2 (Si(CH2CH3)3); HRMS (ESI
+) calcd. for 
C49H74O7Si2Na [M+Na]
+ 853.4865 found 853.4826; IR νmax 3508, 3071, 2955, 2930, 2874, 
2859, 1717, 1643, 1630, 1458, 1429 cm-1 
1-((4R,6S,E)-1,4-Dihydroxy-4-methyldodec-7-en-2-yn-6-yl) 9-methyl (5R)-7-hydroxy-2-
methylene-5-(prop-1-en-2-yl)nonanedioate 356 
 
 
 
 
 
 
To a solution of silyl ether 355 (175 mg, 0.21 mmol) in THF (8 mL) was added AcOH (35 μL, 
0.63 mmol) followed by TBAF (0.74 mL, 1 M in THF, 0.74 mmol). The resulting solution was 
stirred for 120 h at rt before addition of saturated aq. NH4Cl (10 mL) and Et2O (10 mL). The 
biphasic mixture was separated and the aqueous phase extracted with Et2O (3 × 10 mL). 
The combined organic extracts were dried over Na2SO4, filtered and the solvent removed 
under vacuum to afford the crude product. Purification of the residue by silica gel column 
chromatography (pet. ether:EtOAc, 2:3) afforded the title compound 356 (105 mg, 98%) as a 
yellow oil. 1H NMR (500 MHz, CDCl3) δ 6.17 (1H, dd, J = 2.6, 1.5 Hz, CH2-C
Aa,b), 5.78 (1H, 
dtd, J = 15.3, 7.2, 1.7 Hz, CH-CBa,b), 5.70 (1H, app tt, J = 8.5, 4.3 Hz, CH-C10a,b), 5.56 (1H, 
dd, J = 1.5, 1.4 Hz, CH2-C
Aa,b), 5.50 (1H, app ddq, J = 15.3, 7.3, 1.6 Hz, CH-C11a,b), 4.85 
(0.5H, dq, J = 2.9, 1.5 Hz, CH2-C16
a), 4.82–4.79 (1H, m, CH2-C16
a,b), 4.77 (0.5H, d, J = 2.1 
Hz, CH2-C16
b), 4.17 (1H, s, CH2-C5
a), 4.17 (1H, s, CH2-C5
b), 4.06–3.99 (0.5H, m, CH-C3a), 
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4.01–3.92 (1H, m, CH-C3b), 3.70 (1.5H, s, CH3-C19
a), 3.69 (1.5H, s, CH3-C19
b), 3.30 (0.5H, 
s, OH-C8a), 3.26 (0.5H, s, OH-C8b), 3.06 (0.5H, br s, OH-C3a), 2.89 (0.5H, br s, OH-C3b), 
2.51 (0.5H, dd, J = 16.3, 3.3 Hz, CH2-C4
a), 2.44 (1H, d, J = 6.3 Hz, CH2-C4
b), 2.39 (0.5H, dd, 
J = 16.3, 8.9 Hz, CH2-C4
a), 2.33–2.13 (3H, m, CH-C1a,b, CH2-C13
a,b), 2.11 (1H, app ddd, J = 
14.5, 8.5, 2.2 Hz, CH2-C9
a,b), 2.03 (2H, ddd, J = 7.9, 7.4, 7.2 Hz, CH2-C
Ca,b), 1.94 (1H, app 
ddd, J = 14.5, 5.7, 4.3 Hz, CH2-C9
a,b), 1.66 (1.5H, br s, CH3-C17
a), 1.61 (1.5H, br s, CH3-
C17b), 1.59–1.42 (4H, m, CH2-C2
a,b, CH2-C14
a,b), 1.49 (3H, s, CH3-C20
a,b) 1.39–1.23 (4H, m, 
CH2-C
Da,b, CH2-C
Ea,b), 0.88 (3H, t, J = 7.1 Hz, CH3-C
Fa,b); 13C NMR (126 MHz, CDCl3) δ 173.4 
(C-C18), 173.3 (C-C18), 167.5 (C-C21), 167.4 (C-C21), 147.2 (C-C12), 146.1 (C-C12), 
141.2 (C-C15) 141.2 (C-C15), 135.0 (CH-CB), 134.9 (CH-CB), 128.3 (CH-C11), 128.3 (CH-
C11), 125.5 (CH2-C
A), 125.4 (CH2-C
A), 113.6 (CH2-C16), 112.8 (CH2-C16), 88.9 (C-C7), 88.8 
(C-C7), 82.1 (C-C6), 72.4 (CH-C10), 72.3 (CH-C10), 66.7 (C-C8), 66.0 (C-C8), 65.8 (CH-
C3), 65.7 (CH-C3), 51.9 (CH3-C19), 51.9 (CH3-C19), 51.1 (CH2-C5), 51.1 (CH2-C5), 48.0 
(CH2-C9), 44.0 (CH-C1), 43.4 (CH-C1), 41.9 (CH2-C4), 41.0 (CH2-C4), 40.3 (CH2-C2), 40.1 
(CH2-C2), 32.7 (CH2-C14), 32.0 (CH2-C
C), 31.8 (CH2-C14), 31.2 (CH2-C
D), 31.1 (CH3-C20), 
30.0 (CH2-C13), 29.9 (CH2-C13), 22.3 (CH2-C
E), 18.0 (CH3-C17), 17.8 (CH3-C17), 14.0 
(CH3-C
F); HRMS (ESI+) calcd. for C27H42O7Na [M+Na]
+ 501.2823 found 501.2799; IR νmax 
3428, 3071, 2955, 2928, 2858, 1714, 1643, 1630, 1439 cm-1. 
1‐(4R,6S,7E)‐4‐Hydroxy‐4‐methyl‐1‐oxododec‐7‐en‐2‐yn‐6‐yl 9‐methyl(5R)‐2‐ 
methylidene ‐7‐oxo‐5‐(prop‐1‐en‐2‐yl)nonanedioate 357  
 
 
 
 
 
 
To a solution of alcohol 356 (15 mg, 0.03 mmol) in CH2Cl2 (1 mL) was added Dess-Martin 
periodinane (33 mg, 0.08 mmol) and the resulting mixture stirred at rt for 6 h. Aq. NH4Cl (2 
mL) and CH2Cl2 (2 mL) were added and the phases were separated. The aqueous phase 
was extracted with CH2Cl2 (3 × 3 mL) and the combined organic extracts dried over Na2SO4, 
filtered and the solvent removed under vacuum. Purification of the residue by silica gel 
column chromatography (pet. ether:EtOAc, 7:3  1:1) afforded the title compound 357 (10.4 
mg, 71%) as a colourless oil.     
   −7.8 (c = 0.51, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 9.09 
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(1H, s, CHO-C5), 6.19 (1H, s, CH2-C
A), 5.84–5.76 (1H, m, CH-CB), 5.65 (1H, ddd, J = 10.1, 
7.2, 3.4 Hz, CH-C10), 5.58 (1H, d, J = 1.4 Hz, CH2-C
A), 5.50 (1H, ddt, J = 15.4, 7.2, 1.6 Hz, 
CH-C11), 4.93 (2H, s, CH2-C4), 4.82–4.80 (1H, m, CH2-C16), 4.76 (1H, s, CH2-C16), 3.85 
(3H, s, CH3-C19), 2.77–2.62 (3H, m, CH-C1, CH2-C2), 2.28–2.09 (3H, m, CH2-C9, CH2-
C13), 2.05 (2H, app q, J = 6.7 Hz, CH2-C
C), 1.98 (1H, dd, J = 14.7, 3.4 Hz, CH2-C9), 1.66 
(3H, s, CH3-C17), 1.57 (3H, s, CH3-C20), 1.54–1.47 (2H, m, CH2-C14), 1.38–1.26 (4H, m, 
CH2-C
D, CH2-C
E), 0.89 (3H, t, J = 7.1 Hz, CH3-C
F); 13C NMR (126 MHz, CDCl3) δ 202.1 (C-
C3), 176.5 (CHO-C5), 169.6 (C-C18), 168.0 (C-C21), 145.5 (C-C12), 140.5 (C-C15), 135.5 
(CH-CB), 127.5 (CH-C11), 126.4 (CH2-C
A), 112.9 (CH2-C16), 99.3 (C-C7), 92.7 (CH2-C4), 
82.6 (C-C6), 71.7 (CH-C10), 65.2 (C-C8), 54.0 (CH3-C19), 47.9 (CH2-C9), 41.4 (CH-C1), 
40.2 (CH2-C2), 32.0 (CH2-C
C), 31.6 (CH2-C14), 31.1 (CH2-C
D), 30.4 (CH3-C20), 29.6 (CH2-
C13), 22.3 (CH2-C
E), 19.1 (CH3-C17), 14.0 (CH3-C
F); HRMS (ESI+) calcd. for C27H38O7Na 
[M+Na]+ 497.2510 found 497.2503. 
Methyl (6R,8S,9E)‐6‐methyl‐2‐[(3R)‐3‐(prop‐1‐en‐2‐yl)‐6‐({[tris(propan‐2‐yl)silyl]oxy} 
methyl)hept‐6‐enoyl]‐6,8‐bis[(triethylsilyl)oxy]tetradeca‐2,9‐dien‐4‐ynoate 362 
 
 
 
 
 
 
Aldehyde 333 (14 mg, 0.03 mmol) and β-keto ester 316 (15 mg, 0.03 mmol) were dissolved 
in a stock solution of toluene (0.1 mL) containing AcOH (0.02 mmol) and piperidine (3 μmol) 
in the presence of MgSO4. The resulting mixture was stirred at rt for 2 h before the solvent 
was removed under vacuum. Purification of the residue by silica gel column chromatography 
(pet. ether:Et2O, 95:5) afforded title compound 362 (1:1.5 mixture of E:Z isomers, 25 mg, 
88%) as a yellow oil. 1H NMR (500 MHz, CDCl3) δ 6.82 (0.4H, s, CH-C5E), 6.77 (0.6H, s, 
CH-C5Z), 5.58 (0.4H, app t, J = 6.6 Hz, CH-C
B
E), 5.55 (0.6H, app t, J = 6.6 Hz, CH-C
B
Z), 
5.51–5.43 (1H, m, CH-C11E,Z), 5.11–5.05 (1H, m, CH2-C
A
E,Z), 4.83–4.79 (1H, m, CH2-C
A
E,Z), 
4.79–4.76 (1H, m, CH2-C16E,Z), 4.76–4.74 (0.4H, m, CH2-C16E), 4.73–4.69 (0.6H, m, CH2-
C16Z), 4.39–4.32 (1H, m, CH-C10E,Z), 4.12 (2H, s, CH2-C21E,Z), 3.84 (1.8H, s, CH3-C19Z), 
3.78 (1.2H, s, CH3-C19E), 2.89–2.76 (1H, m, CH2-C2E,Z), 2.76–2.69 (1.4H, CH2-C2E,Z, CH-
C1E), 2.69–2.61 (0.6H, m, CH-C1Z), 2.02–1.83 (6H, CH2-C
C
E,Z, CH2-C9E,Z, CH2-C13E,Z), 
1.66–1.65 (1.2H, m, CH3-C17E), 1.64 (1.8H, dd, J = 1.2, 0.7 Hz, CH3-C17Z), 1.56–1.46 (2H, 
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m, CH2-C14E,Z), 1.53 (1.8H, s, CH3-C20Z), 1.50 (1.2H, s, CH3-C20E), 1.36–1.28 (4H, m, CH2-
CDE,Z, CH2-C
E
E,Z), 1.16–1.08 (3H, m, CH(CH3)2 E,Z), 1.07 (10.8H, s, CH(CH3)2 Z), 1.05 (7.2H, 
s, CH(CH3)2  E), 0.97–0.91 (18H, m, Si(CH2CH3)3 E,Z), 0.89 (3H, t, J = 7.1 Hz, CH3-C
F
E,Z), 
0.66–0.60 (6H, m, Si(CH2CH3)3 E,Z), 0.57 (6H, q, J = 7.8 Hz, Si(CH2CH3)3 E,Z); 
13C NMR (126 
MHz, CDCl3) δ 199.6 (C-C3E), 195.5 (C-C3Z), 165.8 (C-C18Z), 164.6 (C-C18E), 148.5 (C-
C12E), 148.5 (C-C12Z), 146.1 (C-C15E), 146.1 (C-C15Z), 142.5 (CH-C
B
E), 141.6 (CH-C
B
Z), 
134.1 (CH-C11E,Z), 130.9 (C-C4E), 130.8 (C-C4Z), 124.2 (CH-C5Z), 122.8 (CH-C5E), 112.5 
(CH2-C16Z), 112.5 (CH2-C16E), 111.5 (C-C7Z), 110.4 (C-C7E), 108.2 (CH2-C
A
Z), 108.0 (CH2-
CAE), 80.0 (C-C6Z), 79.3 (C-C6E), 71.2 (CH-C10Z), 71.1 (CH-C10E), 69.2 (C-C8Z), 69.2 (C-
C8E), 66.2 (CH2-C21E,Z), 53.4 (CH3-C19Z), 53.3 (CH3-C19E), 52.6 (CH2-C9E), 52.4 (CH2-C9Z), 
47.6 (CH2-C2E), 44.6 (CH2-C2Z), 42.6 (CH-C1Z), 41.8 (CH-C1E), 32.0 (CH2-C
C
E,Z), 31.4 (CH2-
CDE), 31.4 (CH2-C
D
Z), 31.3 (CH2-C14E), 31.2 (CH2-C14Z), 31.0 (CH2-C13E), 30.5 (CH2-C13Z), 
30.3 (CH2-C
E
Z), 30.2 (CH2-C
E
E), 22.5 (CH3-C20E), 22.5 (CH3-C20Z), 19.2 (CH3-C17E), 19.1 
(CH3-C17Z), 18.2 (CH(CH3)2 E,Z), 14.1 (CH3-C
F
E,Z), 12.2 (CH(CH3)2 E,Z), 7.1 (Si(CH2CH3)3 E), 
7.1 (Si(CH2CH3)3 Z), 7.1 (Si(CH2CH3)3 E), 7.0 (Si(CH2CH3)3 Z), 6.3 (Si(CH2CH3)3 E), 6.2 
(Si(CH2CH3)3 Z), 5.3 (Si(CH2CH3)3 E), 5.3 (Si(CH2CH3)3 Z); HRMS (ESI
+) calcd. for 
C48H88O6Si3Na [M+Na]
+ 867.5781 found 867.5774; IR νmax 2953, 2938, 2874, 1722, 1695, 
1584, 1460, 1437 cm-1. 
Methyl (2S,4R)‐2‐[(1E)‐hex‐1‐en‐1‐yl]‐4‐hydroxy‐4‐methyl‐7‐[(2R)‐2‐(prop‐1‐en‐2‐yl)‐5‐ 
({[tris(propan‐2‐yl)silyl]oxy}methyl)hex‐5‐en‐1‐yl]‐1,6‐dioxaspiro[4.5]deca‐7,9‐diene‐8‐c
arboxylate 364 
 
 
 
 
 
 
To a solution of ynenone 362 (143 mg, 0.17 mmol) in MeOH (2 mL) at 0 °C was added (+)-
CSA (2.2 mg, 8.7 μmol). The resulting mixture was stirred for 1.5 h before removal of the 
solvent under vacuum. Purification of the residue by silica gel column chromatography (pet. 
ether:Et2O, 1:1) afforded the title compound 364 (73 mg, 68%) as a pale yellow oil. 
1H NMR 
(400 MHz, C6D6) δ 7.00 (1H, d, J = 10.2 Hz, CH-C5), 5.66 (1H, d, J = 10.2 Hz, CH-C6), 
5.63–5.53 (2H, m, CH-C11, CH-CB), 5.32–5.27 (1H, m, CH2-C
A), 4.99–4.97 (1H, m, CH2-C
A), 
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4.92–4.91 (1H, m, CH2-C16), 4.82–4.77 (1H, m, CH2-C16), 4.71 (1H, dt, J = 9.8, 6.5 Hz, CH-
C10), 4.18 (2H, s, CH2-C21), 3.42 (3H, s, CH3-C19), 3.41–3.34 (1H, m, CH2-C2), 2.89–2.73 
(2H, m, CH-C1, CH2-C2), 2.18 (1H, ddd, J = 15.2, 10.0, 5.3 Hz, CH2-C13), 2.13–2.01 (2H, 
m, CH2-C9, CH2-C13), 2.01–1.91 (3H, m, CH2-C9, CH2-C
C), 1.77–1.64 (2H, m, CH2-C14), 
1.72 (3H, s, CH3-C17), 1.34–1.22 (4H, m, CH2-C
D, CH2-C
E), 1.20 (3H, s, CH3-C20), 1.14–
1.10 (21H, m, CH(CH3)2), 0.84 (3H, t, J = 7.1 Hz, CH3-C
F);13C NMR (101 MHz, C6D6) δ 166.2 
(C-C18), 166.1 (C-C3), 148.8 (C-C12), 146.7 (C-C15), 133.3 (CH-C11), 132.3 (CH-CB), 
126.6 (CH-C5), 113.0 (CH2-C16), 110.2 (C-C7), 109.6 (CH-C6), 108.7 (CH2-C
A), 104.3 (C-
C4), 82.0 (C-C8), 79.8 (CH-C10), 66.6 (CH2-C21), 50.9 (CH3-C19), 46.3 (CH-C1), 44.5 (CH2-
C9), 37.9 (CH2-C2), 32.3 (CH2-C
C), 31.6 (CH2-C
D), 31.5 (CH2-C14), 30.8 (CH2-C13), 22.6 
(CH2-C
E), 22.0 (CH3-C20), 18.6 (CH3-C17), 18.3 (CH(CH3)2), 14.1 (CH3-C
F), 12.4 
(CH(CH3)2); HRMS (ESI
+) calcd. for C36H60O6SiNa [M+Na]
+ 639.4051 found 
639.4008; IR νmax 3473, 2941, 2928, 2866, 1713, 1645, 1578, 1462, 1437 cm
-1. 
  
(±)-Ethyl (9E)‐2‐acetyl‐6‐methyl‐6,8‐bis[(triethylsilyl)oxy]tetradeca‐2,9‐dien‐4‐ynoate 
365 
 
 
 
 
 
 
 
To a solution of racemic aldehyde 333 (300 mg, 0.66 mmol) in toluene (2 mL) was added 
ethyl acetoacetate (0.1 mL, 0.7 mmol), piperidine (7 μL, 0.1 mmol), AcOH (0.02 mL, 0.4 
mmol) and MgSO4 (16 mg, 0.13 mmol). The resulting mixture was stirred at rt for 3 h before 
the solvent was removed under vacuum. Purification of the residue by silica gel column 
chromatography (pet. ether:Et2O, 9:1) afforded the title compound 365 (1:1 mixture of E:Z 
isomers, 266 mg, 71%) as a pale yellow oil. 1H NMR (500 MHz, CDCl3) δ 6.78 (0.5H, s, CH-
C3), 6.78 (0.5H, s, CH-C3), 5.60–5.51 (1H, m, CH-C12), 5.49–5.42 (1H, m, CH-C11), 4.38–
4.28 (2H, m, CH-C10, CH2-C18), 4.25 (1H, q, J = 7.1 Hz, CH2-C18), 2.42 (1.5H, s, CH3-C7), 
2.34 (1.5H, CH3-C7), 2.02–1.91 (3H, CH2-C9, CH2-C13), 1.88 (0.5H, app t, J = 5.7 Hz, CH2-
C9), 1.85 (0.5H, app t, J = 5.8 Hz, CH2-C9), 1.51 (1.5H, s, CH3-C17), 1.51 (1.5H, s, CH3-
C17), 1.36–1.27 (7H, m, CH2-C14, CH2-C15, CH3-C19), 0.96–0.89 (18H, m, (Si(CH2CH3)3), 
0.87 (3H, t, J = 7.0 Hz, CH2-C16), 0.65–0.52 (12H, m, (Si(CH2CH3)3); 
13C NMR (126 MHz, 
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CDCl3) δ 198.3 (C-C5), 193.9 (C-C5), 165.2 (C-C6), 163.9 (C-C6), 143.0 (CH-C12), 141.8 
(CH-C12), 134.1 (CH-C11), 134.0 (CH-C11), 130.8 (C-C4), 130.8 (C-C4), 124.0 (CH-C3), 
122.5 (CH-C3), 111.7 (C-C1), 110.3 (C-C1), 79.8 (C-C2), 79.4 (C-C2), 71.2 (CH-C10), 71.1 
(CH-C10), 69.2 (C-C8), 69.2 (C-C8), 61.8 (CH2-C18), 61.6 (CH2-C18), 53.3 (CH2-C9), 53.3 
(CH2-C9), 31.9 (CH2-C13), 31.3 (CH2-C14), 31.3 (CH3-C17), 31.2 (CH3-C17), 30.5 (CH3-C7), 
27.7 (CH3-C7), 22.4 (CH2-C15), 14.3 (CH3-C19), 14.2 (CH3-C19), 14.0 (CH3-C16), 7.1 
(Si(CH2CH3)3), 7.0 (Si(CH2CH3)3), 6.2 (Si(CH2CH3)3),  5.2 (Si(CH2CH3)3). HRMS (ESI
+) calcd. 
for C31H56O5Si2Na [M+Na]
+ 587.3558 found 587.3530; IR νmax 2955, 2936, 2914, 2876, 2209, 
1717, 1699, 1587, 1458, 1413 cm-1. 
 
Ethyl (2E)-2-acetyl-4-[(2E)-5-[(1E)-hex-1-en-1-yl]-3-hydroxy-3-methyloxolan-2-ylidene] 
but-2-enoate 366 and ethyl 2-[(1E)-hex-1-en-1-yl]-4-hydroxy-4,7-dimethyl-1,6-
dioxaspiro[4.5]deca-7,9-diene-8-carboxylate 367 
 
 
 
 
 
 
 
To a solution of ynenone 365 (266 mg, 0.47 mmol) in MeOH (5 mL) was added (+)-CSA 
(5 mg, 0.02 mmol) and the resulting mixture stirred at rt for 1 hr. Saturated aq. NaHCO3 (10 
mL) and CH2Cl2 (10 mL) were added and the biphasic mixture separated. The organic phase 
was dried over Na2SO4, filtered and the solvent removed under vacuum. Purification of the 
residue by silica gel column chromatography (pet. ether:Et2O, 1:1) afforded spirocycle 367 
(54 mg, 34%) as a pale yellow oil followed by diene 366 (20.4 mg, 13%) as a yellow oil. 
Spirocycle 367: 1H NMR (500 MHz, CDCl3) δ 6.84 (1H, d, J = 10.1 Hz, CH-C3), 5.62 (1H, 
dt, J = 15.2, 6.8 Hz, CH-C12), 5.57 (1H, d, J = 10.1 Hz, CH-C2), 5.39 (1H, ddt, J = 15.2, 8.1, 
1.4 Hz, CH-C11), 4.68–4.62 (1H, m, CH-C10), 4.22–4.15 (2H, m, CH2-C18), 2.36 (3H, s, 
CH3-C7), 2.20 (1H, dd, J = 13.1, 6.7 Hz, CH2-C9), 2.15 (1H, dd, J = 13.1, 9.4 Hz, CH2-C9), 
2.05–1.96 (2H, m, CH2-C13), 1.40–1.23 (10H, m, CH2-C14, CH2-C15, CH3-C17, CH3-C19), 
0.87 (3H, J = 7.1 Hz, CH3-C16); 
13C NMR (126 MHz, CDCl3) δ 166.2 (C-C6), 163.8 (C-C5), 
134.3 (CH-C2), 131.2 (CH-C11), 126.8 (CH-C3), 109.0 (CH-C12), 108.7 (C-C4), 104.1 (C-
C1), 82.0 (C-C8), 79.8 (CH-C10), 60.2 (CH2-C18), 44.0 (CH2-C9), 31.9 (CH2-C13), 31.2 
(CH2-C14) , 22.3 (CH3-C17), 21.7 (CH2-C15), 20.5 (CH3-C7), 14.5 (CH3-C19), 14.0 (CH3-
C16); HRMS (ESI+) calcd. for C19H28O5Na [M+Na]
+ 359.1829 found 359.1810.  
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Diene 366: 1H NMR (500 MHz, CDCl3) δ 7.79 (1H, d, J = 12.1 Hz, CH-C3), 5.85 (1H, dt, J = 
15.3, 6.7 Hz, CH-C12), 5.80 (1H, d, J = 12.1 Hz, CH-C2), 5.45 (1H, ddt, J = 15.3, 7.9, 1.6 
Hz, CH-C11), 5.06–4.99 (1H, m, CH-C10), 4.36–4.23 (3H, m, CH2-C18, OH-C8) 2.35 (3H, s, 
CH3-C7), 2.30 (1H, dd, J = 13.1, 5.2 Hz, CH2-C9), 2.12–1.99 (2H, m, CH2-C13), 1.76 (1H, 
dd, J = 13.1, 10.0 Hz, CH2-C9), 1.42 (3H, s, CH3-C17), 1.41–1.27 (7H, CH2-C14, CH2-C15, 
CH3-C19), 0.90 (3H, t, J = 7.2 Hz, CH3-C16); 
13C NMR (126 MHz, CDCl3) δ 196.2 (C-C5), 
173.5 (C-C6), 167.2 (C-C1), 141.1 (CH-C3), 137.1 (CH-C12), 128.2 (C-C4), 127.2 (CH-C11), 
92.6 (CH-C2), 83.8 (CH-C10), 78.1 (C-C8) 61.0 (CH2-C18), 45.7 (CH2-C9), 32.0 (CH2-C13), 
31.0 (CH2-C14), 28.0 (CH3-C17), 25.0 (CH3-C7) 22.4 (CH2-C15), 14.4 (CH3-C19), 14.0 (CH3-
C16); HRMS (ESI+) calcd. for C19H28O5Na [M+Na]
+ 359.1829 found 359.1805. 
(4R,6S,7E)‐1‐[(tert‐Butyldiphenylsilyl)oxy]‐4‐hydroxy‐4‐methyldodec‐7‐en‐2‐yn‐6‐yl 
2,2‐dimethylpropanoate 371 
 
 
 
 
 
 
 
To a solution of diol 350 (51 mg, 0.11 mmol) in CH2Cl2 (1 mL) was added Et3N (20 μL, 0.13 
mmol) and pivaloyl chloride (10 μL, 0.11 mmol). The resulting mixture was stirred at rt for 3 
h. Saturated aq. NH4Cl (1 mL) and the phases were separated. The organic phase was 
washed with brine (2 mL) before being dried over Na2SO4, filtered and the solvent removed 
under vacuum. Purification of the residue by silica gel column chromatography (pet. 
ether:Et2O, 7:3) afforded the title compound 371 (67 mg, quant) as a pale yellow oil.     
   
−48 (c = 0.30, CHCl3); 
1H NMR (400 MHz, CDCl3) δ 7.79–7.68 (4H, m, Ph), 7.49–7.33 (6H, 
m, Ph), 5.76 (1H, dt, J = 13.7, 6.8 Hz, CH-CB), 5.53–5.39 (2H, m, CH-C11, CH-C10), 4.35 
(2H, s, CH2-C5), 2.64 (1H, s, OH-C8), 2.08–1.97 (3H, m, CH2-C
C, CH2-C9), 1.88 (1H, dd, J = 
14.3, 5.1 Hz, CH2-C9), 1.40 (3H, s, CH3-C20), 1.37–1.29 (4H, m, CH2-C
D, CH2-C
E), 1.17 (9H, 
s, Piv-C(CH3)3), 1.06 (9H, s, SiC(CH3)3), 0.88 (3H, t, J = 7.1 Hz, CH3-C
F); 13C NMR (101 
MHz, CDCl3) δ 177.9 (C=O), 135.8 (Ph),  134.9 (Ph), 133.4 (CH-C
B), 129.9 (CH-C11), 128.8 
(Ph), 127.8 (Ph), 88.5 (C-C7), 82.1 (C-C6), 72.1 (CH-C10), 66.2 (C-C8), 52.8 (CH2-C5), 47.5 
(CH2-C9), 38.8 (Piv-C(CH3)3), 31.9 (CH2-C
C), 31.1 (CH2-C
D), 30.5 (CH3-C20), 27.2 
(SiC(CH3)3), 26.8 (SiC(CH3)3), 22.2 (CH2-C
E), 19.3 (SiC(CH3)3), 14.0 (CH3-C
F); HRMS (ESI+) 
calcd. for C34H48O4SiNa [M+Na]
+ 571.3214 found 571.3187; IR νmax 3451, 2958, 2930, 2858, 
1428 cm-1. 
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(4R,6S,7E)‐1,4‐Dihydroxy‐4‐methyldodec‐7‐en‐2‐yn‐6‐yl 2,2‐dimethylpropanoate 372 
 
 
 
 
 
To a solution of silyl ether 371 (60.5 mg, 0.11 mmol) in THF (2 mL) was added TBAF (0.13 
mL, 1 M in THF, 0.13 mmol) and the resulting mixture stirred at rt for 16 h. Saturated aq. 
NH4Cl (5 mL) and Et2O (5 mL) were added and the biphasic mixture separated. The organic 
extract was washed with brine (5 mL) before being dried over Na2SO4, filtered and the 
solvent removed under vacuum. Purification of the residue by silica gel column 
chromatography (pet. ether:Et2O, 25:75) afforded the title compound 372 (37.2 mg, quant) 
as a colourless oil.     
   −29 (c = 0.05, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 5.77 (1H, dt, J 
= 14.7, 6.8 Hz, CH-CB), 5.61–5.52 (1H, m, CH-C10), 5.46 (1H, ddt, J = 14.7, 7.2, 1.3 Hz, 
CH-C11), 4.25 (2H, s, CH2-C5), 2.07 (1H, dd, J = 14.3, 7.5 Hz, CH2-C9), 2.05–1.99 (2H, m, 
CH2-C
C), 1.96 (1H, dd, J = 14.3, 5.3 Hz, CH2-C9), 1.49 (3H, s, CH3-C20), 1.37–1.23 (4H, m, 
CH2-C
D, CH2-C
E), 1.18 (9H, s, C(CH3)3), 0.87 (3H, t, J = 7.1 Hz, CH3-C
F); 13C NMR (126 
MHz, CDCl3) δ 178.4 (C=O), 135.0 (CH-C
B), 128.7 (CH-C11), 88.8 (C-C7), 82.4 (C-C6), 72.4 
(CH-C10), 66.4 (C-C8), 51.0 (CH2-C5), 47.8 (CH2-C9), 38.9 (C(CH3)3), 31.9 (CH2-C
C), 31.1 
(CH2-C
D), 30.8 (CH3-C20), 27.2 (C(CH3)3), 22.2 (CH2-C
E), 14.0 (CH3-C
F); HRMS (ESI+) 
calcd. for C18H30O4Na [M+Na]
+ 333.2036 found 333.2020; IR νmax 3392, 2958, 2929, 2872, 
1727, 1708, 1480, 1459 cm-1. 
(4R,6S,7E)‐4‐Hydroxy‐4‐methyl‐1‐oxododec‐7‐en‐2‐yn‐6‐yl 2,2‐dimethylpropanoate 373 
 
 
 
 
To a solution of primary alcohol 372 (32 mg, 0.10 mmol) in CH2Cl2 (1 mL) was added Dess-
Martin periodinane (66 mg, 0.15 mmol) and the resulting mixture stirred at rt for 3 h. 
Saturated aq. Na2S2O3 (2 mL) was added and the phases were separated. The organic 
phase was washed with brine (2 mL) before being dried over Na2SO4, filtered and the 
solvent removed under vacuum. Purification of the residue by silica gel column 
chromatography (pet. ether:Et2O, 3:7) afforded the title compound 373 (30 mg, 97%) as a 
colourless oil.     
   −9.4 (c = 0.21, CHCl3);
 1H NMR (500 MHz, CDCl3) δ 9.21 (1H, s, CHO-
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C5), 5.78 (1H, dt, J = 13.8, 6.8 Hz, C-CB), 5.51–5.43 (2H, m, CH-C10, CH-C11), 3.67 (1H, s, 
OH-C8), 2.18 (1H, dd, J = 14.6, 8.3 Hz, CH2-C9), 2.06–1.97 (3H, m, CH2-C9, CH2-C
C), 1.57 
(3H, s, CH3-C20), 1.38–1.21 (4H, CH2-C
D, CH2-C
E), 1.18 (9H, s, C(CH3)3), 0.88 (3H, t, J = 
7.2 Hz, CH3-C
F); 13C NMR (126 MHz, CDCl3) δ 178.9 (C=O), 176.6 (CHO-C5), 135.5 (CH-
CB), 128.0 (CH-C11), 99.3 (C-C7), 82.6 (C-C6), 71.8 (CH-C10), 65.8 (C-C8), 47.3 (CH2-C9), 
39.0 (C(CH3)3), 31.9 (CH2-C
C), 31.1 (CH2-C
D), 30.3 (CH3-C20), 27.1 (C(CH3)3), 22.2 (CH2-
CE), 14.0 (CH3-C
F); HRMS (ESI+) calcd. for C18H28O4Na [M+Na]
+ 331.1880 found 331.1799; 
IR νmax 3447, 2959, 2928, 2872, 2857, 2214, 1728, 1707, 1670, 1460 cm
-1. 
(4R,6S,7E)‐4‐Methyl‐1‐oxo‐4‐[(triethylsilyl)oxy]dodec‐7‐en‐2‐yn‐6‐yl 2,2‐dimethyl-
propanoate 374 
 
 
 
 
To a solution of aldehyde 373 (27 mg, 0.09 mmol) in CH2Cl2 (1 mL) at −78 °C was added 
2,6-lutidine (30 μL, 0.23 mmol) and triethylsilyl triflate (20 μL, 0.11 mmol) and the resulting 
mixture stirred for 2 h. The reaction was quenched with saturated aq. NH4Cl (1 mL) and 
warmed gradually to rt. The phases were separated and the organic phase was washed with 
brine (2 mL) before being dried over Na2SO4, filtered and the solvent removed under 
vacuum. Purification of the residue by silica gel column chromatography (pet. ether:Et2O, 
95:5) afforded the title compound 374 (34 mg, 90%) as a colourless oil.     
   −29.8 (C = 
0.05, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 9.22 (1H, s, CHO-C5), 5.73–5.63 (1H, m, CH-
CB), 5.47 (1H, td, J = 7.5, 4.0 Hz, CH-C10), 5.39 (1H, ddt, J = 15.3, 7.3, 1.4 Hz, CH-C11), 
2.13 (1H, dd, J = 14.4, 7.5 Hz, CH2-C9), 2.04–1.95 (3H, m, CH2-C9, CH2-C
C), 1.54 (3H, s, 
CH3-C20), 1.37–1.24 (4H, m, CH2-C
D, CH2-C
E), 1.17 (9H, s, C(CH3)3), 0.96 (9H, t, J = 8.0 Hz, 
Si(CH2CH3)3), 0.87 (3H, t, J = 7.1 Hz, CH3-C
F), 0.68 (6H, app qd, J = 8.0, 2.2 Hz, 
Si(CH2CH3)3); 
13C NMR (126 MHz, CDCl3) δ 177.3 (C=O), 176.4 (CHO-C5), 134.0 (CH-C
B), 
128.8 (CH-C11), 99.9 (C-C7), 83.7 (C-C6), 71.1 (CH-C10), 67.8 (C-C8), 49.2 (CH2-C9), 38.8 
(C(CH3)3), 31.9 (CH2-C
C), 31.3 (CH2-C
D), 31.1 (CH3-C20), 27.2 (C(CH3)3), 22.2 (CH2-C
E), 
14.0 (CH3-C
F), 7.0 (Si(CH2CH3)3), 6.2 (Si(CH2CH3)3); HRMS (ESI
+) calcd. for C24H42O4Na 
[M+Na]+ 445.2744 found 445.2664; IR νmax 2957, 2931, 2876, 2209, 1729, 1673, 1458 cm
-1. 
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Methyl (6R,8S,9E)‐8‐[(2,2‐dimethylpropanoyl)oxy]‐6‐methyl‐2‐[(3R)‐3‐(prop‐1‐en‐2‐yl)‐6‐ 
({[tris(propan‐2‐yl)silyl]oxy}methyl)hept‐6‐enoyl]‐6‐[(triethylsilyl)oxy]tetradeca‐2,9‐dien
‐4‐ynoate 375  
 
 
 
 
 
 
 
Aldehyde 374 (33 mg, 0.08 mmol) and β-keto ester 316 (32 mg, 0.08 mmol) were dissolved 
in a stock solution of toluene (0.25 mL) containing AcOH (0.05 mmol) and piperidine (8 
μmol) in the presence of MgSO4. The resulting mixture was stirred at rt for 2 h before the 
solvent was removed under vacuum. Purification of the residue by silica gel column 
chromatography (pet. ether:Et2O, 95:5  90:10) afforded title compound 375 (1:1.2 mixture 
of E:Z isomers, 25 mg, 88%) as a colourless oil. 1H NMR (400 MHz, CDCl3) δ 6.78 (0.55H, s, 
CH-C5Z), 6.75 (0.45H, s, CH-C5E), 5.72–5.61 (1H, m, CH-C
B 
E,Z), 5.49–5.35 (2H, m, CH-
C11E,Z, CH-C10E,Z), 5.12–5.03 (1H, m, CH2-C
A E,Z), 4.84–4.69 (3H, m, CH2-C
A 
E,Z, CH2-
C16E,Z), 4.12 (2H, s, CH2-C21E,Z), 3.87 (1.35H, s, CH3-C19E), 3.78 (1.65H, s, CH3-C19Z), 
2.90–2.60 (3H, m, CH2-C2E,Z, CH-C1E,Z), 2.16–1.84 (6H, m, CH2-C
C
E,Z, CH2-C9E,Z, CH2-
C13E,Z), 1.65 (1.65H, s, CH3-C17Z), 1.64 (1.35H, s, CH3-C17E), 1.62–1.51 (2H, m, CH2-
C14E,Z), 1.49 (1.35H, s, CH3-C20E), 1.47 (1.65H, s, CH3-C20Z), 1.38–1.25 (4H, m, CH2-C
D
E,Z, 
CH2-C
E
E,Z), 1.16 (4.05H, s, C(CH3)3 E), 1.15 (4.95H, s, C(CH3)3 Z), 1.13–1.03 (21H, m, 
CH(CH3)2 E,Z) 0.97–0.92 (9H, m, Si(CH2CH3)3 E,Z), 0.87 (3H, t, J = 7.0 Hz, CH3-C
F
E,Z), 0.68–
0.59 (6H, m, Si(CH2CH3)3 E,Z); 
13C NMR (101 MHz, CDCl3) δ 199.5 (C-C3), 195.4 (C-C3), 
177.3 (Piv-C=O), 177.2 (Piv-C=O), 165.7 (C-C18), 164.4 (C-C18), 148.6 (C-C12), 148.5 (C-
C12), 146.2 (C-C15), 146.1 (C-C15), 142.7 (CH-CB), 141.7 (CH-CB), 133.7 (CH-C11), 133.5 
(CH-C11), 129.1 (C-C4), 129.1 (C-C4), 123.9 (CH-C5), 122.7 (CH-C5), 112.5 (CH2-C16), 
112.4 (CH2-C16), 110.5 (CH2-C7), 109.4 (CH2-C7), 108.2 (CH2-C
A), 108.0 (CH2-C
A), 80.3 (C-
C6), 79.6 (C-C6), 71.4 (CH-C10), 71.3 (CH-C10), 68.7 (C-C8), 68.4 (C-C8), 66.2 (CH2-C21), 
52.6 (CH3-C19), 52.5 (CH3-C19), 49.7 (CH2-C9), 49.5 (CH2-C9), 47.5 (CH2-C2), 44.6 (CH2-
C2), 42.5 (CH-C1), 41.8 (CH-C1), 38.8 (C(CH3)3), 32.0 (CH2-C
C), 32.0 (CH2-C
C), 31.4 (CH2-
CD), 31.2 (CH2-C14), 31.1 (CH2-C13), 30.5 (CH2-C13), 30.3 (CH2-C
E), 30.2 (CH2-C
E), 27.3 
(C(CH3)3), 27.2 (C(CH3)3), 22.2 (CH3-C20), 19.2 (CH3-C17), 19.1 (CH3-C17), 18.2 
(CH(CH3)2), 14.0 (CH3-C
F), 12.2 (CH(CH3)2), 7.1 (Si(CH2CH3)3), 6.2 (Si(CH2CH3)3), 6.1 
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(Si(CH2CH3)3); HRMS (ESI
+) calcd. for C47H82O7Si2Na [M+Na]
+ 837.5491 found 837.5495; IR 
νmax 2957, 2932, 2866, 2211, 1728, 1586, 1460, 1437 cm
-1. 
 
Methyl 
5‐[(2S,3R)‐3‐[(2S,3E)‐2‐[(2,2‐dimethylpropanoyl)oxy]oct‐3‐en‐1‐yl]‐3‐methyl‐oxiran‐2‐yl]
‐2‐[(2R)‐2‐(prop‐1‐en‐2‐yl)‐5‐({[tris(propan‐2‐yl)silyl]oxy}methyl)hex‐5‐en‐1‐yl]furan‐3‐c
arboxylate 377, methyl 
(2Z,6R,8S,9E)‐8‐[(2,2‐dimethylpropanoyl)oxy]‐6‐hydroxy‐6‐methyl‐2‐[(3R)‐3‐(prop‐1‐en‐
2‐yl)‐6‐({[tris(propan‐2‐yl)silyl]oxy}methyl)hept‐6‐enoyl]tetradeca‐2,9‐dien‐4‐ynoate 
(Z)-375 and methyl 
5‐[(2R,4S)‐6‐butyl‐4‐[(2,2‐dimethyl‐propanoyl)oxy]‐2‐hydroxy‐2‐methylbicyclo[31.0]hex
an‐1‐yl]‐2‐[(2R)‐2‐(prop‐1‐en‐2‐yl)‐5‐({[tris(propan‐2‐yl)silyl]oxy}methyl)hex‐5‐en1‐yl]fur
an‐3‐carboxylate 378 
 
To a solution of ynenone 375 (33 mg, 0.04 mmol) in MeOH (0.5 mL) at 0 °C was added (+)-
CSA and the resulting mixture stirred for 5.5 h. The solvent was removed under vacuum and 
the residue was passed through a short pad of silica gel (pet ether:Et2O, 7:3  5:5) to afford 
a crude mixture of ynenone and cyclopropylfuran products as a yellow oil (11.7 mg).  
To a sealed tube under argon was added a solution of crude ynenones (11.7 mg) and THT 
(1 μl, 0.01 mmol) in CH2Cl2 (0.1 mL). The resulting solution was heated to 45 °C for 16 h. 
The solvent was removed under vacuum and the residue was purified by silica gel column 
chromatography (pet ether: Et2O, 8:2  5:5) to afford epoxyfuran 377 (1.6 mg, 6% 2 steps) 
followed by Z-enynone (Z)-375 (2.1 mg, 8% 2 steps) and cyclopropyl furan 378 (1.3 mg, 5% 
2 steps). Epoxyfuran 377: 1H NMR (400 MHz, CDCl3) δ 6.50 (1H, s, CH-C5), 5.64 (1H, dt, J 
= 15.7, 6.8 Hz, CH-CB), 5.40–5.30 (1H, m, CH-C10), 5.17–5.09 (1H, m, CH-C11), 5.07 (1H, 
d, J = 1.9 Hz, CH2-C
A), 4.79 (1H, d, J = 1.9 Hz, CH2-C
A), 4.69 (1H, q, J = 1.4 Hz, CH2-C16), 
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4.62 (1H, s, CH2-C16), 4.11 (2H, s, CH2-C21), 3.81 (3H, s, CH3-C19), 3.59 (1H, s, CH-C7), 
3.12 (1H, dd, J = 14.3, 6.8 Hz, CH2-C2), 2.99 (1H, dd, J = 14.3, 8.6 Hz, CH2-C2), 2.64–2.52 
(1H, m, CH-C1), 2.08–1.81 (6H, m, CH2-C9, CH2-C13, CH2-C
C), 1.64–1.56 (2H, m, CH2-
C14), 1.43 (3H, d, J = 1.4 Hz, CH3-C17), 1.37–1.23 (7H, m, CH2-C
D, CH2-C
E, CH3-C20), 1.20 
(9H, s, C(CH3)3), 1.15–1.01 (21H, m, CH(CH3)2), 0.87 (3H, t, J = 7.0 Hz, CH3-C
F); HRMS 
(ESI+) calcd. for C41H68O7SiNa [M+Na]
+ 723.4627 found 723.4578; IR νmax 3467, 2957, 2929, 
2866, 1725, 1581, 1480, 1462, 1438 cm-1. Ynenone (Z)-375: 1H NMR (400 MHz, CDCl3) δ 
6.74 (1H, s, CH-C5), 5.87–5.76 (CH-CB), 5.55–5.42 (2H, m, CH-C10, CH-C11), 5.08 (1H, d, 
J = 1.8 Hz, CH2-C
A), 4.80 (1H, d, J = 1.8 Hz, CH2-C
A), 4.78–4.75 (1H, m, CH2-C16), 4.72–
4.69 (1H, m, CH2-C16), 4.12 (2H, s, CH2-C21), 3.87 (3H, s, CH3-C19), 2.74 (2H, dd, J = 7.0, 
4.9 Hz, CH2-C2), 2.71–2.59 (1H, m, CH-C1), 2.27 (1H, s, OH-C8), 2.15 (1H, dd, J = 14.4, 7.4 
Hz, CH2-C9), 2.08–1.83 (5H, m, CH2-C9, CH2-C13, CH2-C
C), 1.64–1.63 (3H, m, CH3-C17), 
1.55–1.47 (5H, m, CH2-C14, CH3-C20), 1.38–1.23 (4H, m, CH2-C
D, CH2-C
E), 1.17 (9H, s, 
C(CH3)3), 1.15–1.03 (21H, m, CH(CH3)2), 0.88 (3H, t, J = 7.1 Hz, CH3-C
F); HRMS (ESI+) 
calcd. for C41H68O7SiNa [M+Na]
+ 723.4627 found 723.4587; IR νmax 3467, 2957, 2929, 2866, 
1725, 1581, 1480, 1462, 1438 cm-1. Cyclopropylfuran 378: 1H NMR (400 MHz, CDCl3) δ 
6.32 (1H, s, CH-C5), 5.18 (1H, td, J = 8.2, 4.3 Hz, CH-C10), 5.08 (1H, d, J = 2.0 Hz, CH2-
CA), 4.79 (1H, d, J = 2.0 Hz, CH2-C
A), 4.66 (1H, q, J = 1.2 Hz, CH2-C16), 4.60 (1H, s, CH2-
C16), 4.11 (2H, s, CH2-C21), 3.80 (3H, s, CH3-C19), 3.12 (1H, dd, J = 14.6, 9.4 Hz, CH2-C2), 
2.99 (1H, dd, J = 14.6, 6.1 Hz, CH2-C2), 2.64–2.55 (1H, m, CH-C1), 2.13 (1H, dd, J = 13.4, 
8.2 Hz, CH-C9), 2.08–1.93 (2H, m, CH2-C9, CH-C
B) 1.88 (1H, app t, J = 4.3 Hz, CH-C11), 
1.65 (3H, d, J = 1.2 Hz, CH3-C17), 1.40–1.22 (13H, m, CH2-C13, CH2-C14, CH3-C20, CH2-
CC CH2-C
D, CH2-C
E), 1.20 (9H, s, C(CH3)3), 1.11–1.03 (21H, m, CH(CH3)2), 0.83 (3H, t, J = 
7.0 Hz, CH3-C
F); HRMS (ESI+) calcd. for C41H68O7SiNa [M+Na]
+ 723.4627 found 723.4586. 
 
(E/Z)-Ethyl 2-acetyl-6-methyl-6-((triethylsilyl)oxy)hept-2-en-4-ynoate 383 
 
 
 
 
To a solution of triethyl((2-methylbut-3-yn-2-yl)oxy)silane (1.09 g, 5.49 mmol) in Et2O (10 
mL) at −78 °C was added nBuLi (2.5 M in hexane, 2.19 mL, 6.0 mmol) dropwise and the 
solution stirred for 15 min before dropwise addition of DMF (0.85 mL, 11 mmol) and further 
stirring for 30 min. The solution was warmed to 0 °C and stirred for 15 min before the 
reaction was quenched by addition to 10% aq. KH2PO4 (20 mL). Following vigorous stirring 
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for 30 min the biphasic mixture was separated and the organic phase was washed with 10% 
aq. KH2PO4 (2 × 10mL). The combined organic extracts were dried over MgSO4, filtered and 
the solvent removed under vacuum to yield the aldehyde 382 as yellow oil (1.12 g) which 
was used in the next step without further purification. 
Anhydrous MgSO4 (53.0 mg, 0.44 mmol), acetic acid (8 μL, 1.32 mmol) and piperidine (20 
μL, 0.22 mmol) were added sequentially to a stirred solution of aldehyde 4-methyl-4-
(triethylsilyloxy)pent-2-ynal 382 (500 mg, 2.21 mmol) and ethylacetoacetate (0.28 mL, 2.23 
mmol) in toluene (8mL) at rt. The reaction was stirred for 1 h before quenching with H2O (10 
mL). The phases were separated and the aqueous phase was extracted with EtOAc (3 × 10 
mL). The combined organic extracts were dried over MgSO4, filtered and the solvent was 
removed under vacuum to yield the crude product. Purification of the residue by silica gel 
column chromatography (pet ether:Et2O, 10:1) afforded the title compound 383 as a 1:1 mix 
of E and Z isomers (560 mg, 75%). Isomeric mixture: 1H NMR (400 MHz, CDCl3) δ 6.79 
(0.5H, s, CH-C6), δ 6.79 (0.5H, s, CH-C6), 4.33 (1H, q, J = 7.1 Hz, CH2-C9), 4.26 (1H, q, J = 
7.1 Hz, CH2-C9), 2.44 (1.5H, s, CH3-C12), 2.36 (1.5H, s, CH3-C12),  1.51 (3H, s, CH3-C2, 
CH3-C3), 1.50 (3H, s, CH3-C2, CH3-C3),  1.36 (1.5H, t, J = 7.1 Hz, CH3-C10),1.30 (1.5H, t, J 
= 7.1 Hz, CH3-C10),  0.94 (4.5H, t, J = 7.8 Hz, Si(CH2CH3)3), 0.94 (4.5H, t, J = 7.9 Hz, 
Si(CH2CH3)3), 0.63 (3H, q, J = 7.8 Hz, Si(CH2CH3)3), 0.63 (3H, q, J = 7.9 Hz, Si(CH2CH3)3); 
13C NMR (101 MHz, CDCl3) δ 193.9 (C-C11), 165.3 (C-C8), 163.8 (C-C8), 143.0 (CH-C6), 
141.9 (CH-C6), 123.9 (C-C7), 122.4 (C-C7), 112.0 (C-C4), 110.8 (C-C4), 78.3 (C-C5), 77.9 
(C-C5), 66.8 (C-C1), 66.8 (C-C1), 61.7 (CH2-C9), 61.6 (CH2-C9), 32.5 (2C, CH3-C2, CH3-
C3), 32.5 (2C, CH3-C2, CH3-C3), 30.4 (CH3-C12), 27.5 (CH3-C12), 14.2 (CH3-C10), 14.1 
(CH3-C10), 6.9 (Si(CH2CH3)3), 5.97 (Si(CH2CH3)3); HRMS (ESI
+) calcd. for C18H30O4SiNa 
[M+Na]+ 361.1806, found 361.1793; IR νmax 2955, 2876, 1727, 1697, 1600, 1585, 1459, 
1360, 1225 cm-1  
 
5‐Phenylpent‐1‐en‐3‐yl 2‐methylprop‐2‐enoate 386  
 
To a solution of allylic alcohol 385 (510 mg, 3.14 mmol), methacrylic acid (0.27 mL, 3.14 
mmol) and DMAP (38 mg, 0.31 mmol) in CH2Cl2 (15 mL) was added DCC (712 mg, 3.45 
mmol) and the resulting mixture stirred at rt for 24 h. The resulting suspension was filtered 
and the solvent removed under vacuum. Purification of the residue by silica gel column 
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chromatography (pet. ether:Et2O, 4:1) afforded the title compound 386 as a colourless oil 
(575 mg, 80%). 1H NMR (500 MHz, CDCl3) δ 7.37–7.30 (2H, m, CH-C3, CH-C1), 7.27–7.20 
(3H, m, CH-C2, CH-C4, CH-C6), 6.22–6.17 (1H, m, CH2-C14), 5.91 (1H, ddd, J = 17.1, 10.6, 
6.2 Hz, CH-C10), 5.63 (1H, dq, J = 1.6, 1.6 Hz, CH2-C14), 5.42–5.37 (1H, m, CH-C9), 5.34 
(1H, dt, J = 17.1, 1.4 Hz, CH2-C11), 5.27 (1H, dt, J = 10.6, 1.4 Hz, CH2-C11), 2.80–2.66 (2H, 
m, CH2-C7), 2.16–1.97 (5H, m, CH2-C8, CH3-C15); 
13C NMR (126 MHz, CDCl3) δ 166.8 (C-
C12), 141.5 (C-C5), 136.7 (CH-C10), 136.4 (C-C13), 128.6 (CH-C1, CH-C3), 128.5 (CH-C4, 
CH-C6), 126.1 (CH-C2), 125.6 (CH2-C14), 117.0 (CH2-C11), 74.6 (CH-C9), 36.0 (CH2-C8), 
31.5 (CH2-C7), 18.5 (CH3-C15); HRMS (ESI
+) Calcd. for C15H18O2Na [M+Na]
+ 253.1199, 
found 253.1194; IR νmax 3028, 2953, 2928, 1717, 1638, 1497, 1454 cm
-1. 
 
3‐Methyl‐5‐(2‐phenylethyl)‐2,5‐dihydrofuran‐2‐one 387 
 
 
To a solution of ester 386 (100 mg, 0.43 mmol) and epoxyfuran 298 (97 mg, 0.43 mmol) in 
CH2Cl2 (11 mL) was added Grubbs II (34 mg, 0.04 mmol) and the resulting mixture heated to 
45 °C for 18 h. The solvent was removed under vacuum and the resulting residue was 
purified by silica gel column chromatography (pet. ether: Et2O, 4:1  3:2) to afford the title 
compound 387 as a colourless oil (84 mg, 97%). 1H NMR (500 MHz, CDCl3) δ 7.30 (2H, dd, 
J = 8.1, 6.9 Hz, CH-C1, CH-C3), 7.24–7.18 (3H, m, CH-C2, CH-C4, CH-C6), 6.99–6.97 (1H, 
m, CH-C10), 4.90–4.84 (1H, m, CH-C9), 2.87–2.73 (2H, m, CH2-C7), 2.03 (1H, dddd, J = 
13.9, 9.2, 7.3, 4.6 Hz, CH2-C8), 1.95–1.85 (5H, m, CH2-C8, CH3-C13); 
13C NMR (126 MHz, 
CDCl3) δ 174.4 (C-C12), 148.7 (CH-C10), 140.7 (C-C5), 130.2 (C-C11), 128.7 (CH-C1, CH-
C3), 128.7 (CH-C4, CH-C6), 126.4 (CH-C2), 80.3 (CH-C9), 35.4 (CH2-C7), 31.6 (CH2-C8), 
10.8 (CH3-C13); HRMS (ESI
+) calcd. for C13H14O2Na [M+Na]
+ 225.0886, found 225.0882; IR 
νmax 3063, 2924, 1751, 1658, 1497, 1451 cm
-1. 
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(7R)‐14‐Methyl‐7‐(prop‐1‐en‐2‐yl)‐13,13‐bis(propan‐2‐yl)‐2,4,12‐trioxa‐13‐silapentadeca
n‐10‐one 391 
 
To a solution of alcohol 313 (200 mg, 0.58 mmol) in CH2Cl2 (5 mL) was added DIPEA (0.2 
mL, 1.2 mmol) and DMAP (24 mg, 1.2 mmol), followed by MOMCl (0.09 mL, 1.2 mmol) and 
the resulting mixture stirred at rt for 3 h. Aq. 1 M NaOH (2.5 mL) was added and the mixture 
stirred for 1 h. The biphasic mixture was separated and the organic extract washed with 
brine (5 mL), dried over MgSO4, filtered and the solvent removed under vacuum. Purification 
of the residue by silica gel column chromatography (pet. ether:Et2O, 9:1) afforded the title 
compound 391 as a colourless oil (155 mg, 69%).     
   −7.9 (c = 0.18, CHCl3); 
1H NMR (500 
MHz, CDCl3) δ 4.78 (1H, dq, J = 2.9, 1.8 Hz, CH2-C16), 4.70 (1H, d, J = 1.8 Hz, CH2-C16), 
4.60 (1H, d, J = 6.5 Hz, MOM-CH2), 4.58 (1H, d, J = 6.5 Hz, MOM-CH2), 4.20 (2H, s, CH2-
C21), 3.49–3.42 (2H, m, CH2-C3), 3.34 (3H, s, MOM-CH3), 2.58–2.45 (2H, m, CH2-C13), 
2.21 (1H, tt, J = 10.1, 5.0 Hz, CH-C1), 1.75–1.55 (7H, m, CH2-C2, CH2-C14, CH3-C17), 
1.16–1.00 (21H, m, CH(CH3)2); 
13C NMR (126 MHz, CDCl3) δ 211.9 (C-C12), 146.0 (C-C15), 
113.1 (CH2-C16), 96.6 (MOM-CH2), 69.9 (CH2-C21), 66.1 (CH2-C3), 55.3 (MOM-CH3), 43.8 
(CH-C1), 36.5 (CH2-C13), 33.4 (CH2-C2), 26.3 (CH2-C14), 18.0 (CH(CH3)2), 17.7 (CH3-C17),  
12.0 (CH(CH3)2); HRMS (ESI
+) calcd. for C21H42O4SiNa [M+Na]
+ 409.2745, found 409.2724; 
IR νmax 2942, 2867, 1734, 1721, 1644, 1464 cm
-1. 
(7R)‐14‐Methyl‐10‐methylidene‐7‐(prop‐1‐en‐2‐yl)‐13,13‐bis(propan‐2‐yl)‐2,4,12‐trioxa‐1
3‐silapentadecane 
 
To a solution of methyltriphenylphosphonium bromide (296 mg, 0.83 mmol) in THF (4 mL) at 
0 °C was added nBuLi (0.08 mL of a 11 M solution in hexane, 0.83 mmol). After 1 h at 0 °C a 
solution of ketone 391 (144 mg, 0.41 mmol) in THF (4 mL) was added and the resulting 
mixture warmed to rt and stirred for 18 h. The reaction was quenched with H2O (10 mL) and 
Et2O (10 mL) added. The biphasic mixture was separated and the organic extract was 
washed with brine (15 mL), dried over MgSO4, filtered and the solvent removed under 
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vacuum. Purification of the residue by silica gel column chromatography (pet. ether:Et2O, 
95:5  90:10) afforded the title compound as a colourless oil (148 mg, quant.).     
   −2.7 (c 
= 0.33, CHCl3); 
1H NMR (400 MHz, CDCl3) δ 5.08 (1H, d, J = 1.7 Hz, CH2-C
A), 4.81 (1H, dq, 
J = 2.1, 1.4 Hz, CH2-C16), 4.78 (1H, dq, J = 2.9, 1.4 Hz, CH2-C16), 4.72–4.69 (1H, m, CH2-
CA), 4.60 (1H, d, J = 6.6 Hz, MOM-CH2), 4.58 (1H, d, J = 6.6 Hz, MOM-CH2), 4.13 (2H, s, 
CH2-C21), 3.54–3.39 (m, 2H, CH2-C3), 3.35 (3H, s, MOM-CH3), 2.22 (1H, tt, J = 9.3, 5.5 Hz, 
CH-C1), 2.02–1.82 (2H, m, CH2-C13), 1.73–1.58 (5H, m, CH2-C2, CH3-C17), 1.55–1.45 (2H, 
m, CH2-C14), 1.19–1.00 (21H, m, CH(CH3)2); 
13C NMR (126 MHz, CDCl3) δ 148.9 (C-C12), 
146.6 (C-C15), 112.6 (CH2-C
A), 108.0 (CH2-C16), 96.7 (MOM-CH2), 66.3 (CH2-C21), 66.2 
(CH2-C3), 55.3 (MOM-CH3), 44.1 (CH-C1), 33.4 (CH2-C2), 31.7 (CH2-C13), 30.6 (CH2-C14), 
18.2 (CH(CH3)2), 17.8 (CH3-C17), 12.2 (CH(CH3)2); HRMS (ESI
+) calcd. for C22H44O3SiNa 
[M+Na]+ 407.2952, found 407.2936; IR νmax 2940, 2866, 1644, 1463, 1441 cm
-1. 
(5R)‐5‐[2‐(Methoxymethoxy)ethyl]‐6‐methyl‐2‐methylidenehept‐6‐en‐1‐ol 392 
 
To a solution of 
(7R)‐14‐Methyl‐10‐methylidene‐7‐(prop‐1‐en‐2‐yl)‐13,13‐bis(propan‐2‐yl)‐2,4,12‐trioxa‐13‐sil
apentadecane (135 mg, 0.39 mmol) in THF (3 mL) was added TBAF (0.43 mL of a 1 M 
solution in THF, 0.43 mmol) and the resulting mixture stirred at rt for 2 h. The reaction was 
quenched with saturated aq. NH4Cl (5 mL) and Et2O (5 mL) added. The phases were 
separated and the aqueous phase was extracted with Et2O (5 mL). The combined organic 
extracts were dried over MgSO4, filtered and the solvent removed under vacuum. The 
residue was purified by silica gel column chromatography (pet. ether:Et2O, 1:1) to afford the 
allylic alcohol 392 as a pale yellow oil (85 mg, quant.);     
   −13.6 (c = 0.06, CHCl3); 
1H 
NMR (500 MHz, CDCl3) δ 4.97 (1H, d, J = 1.8 Hz, CH2-C
A), 4.81 (1H, d, J = 1.4 Hz, CH2-
C16), 4.75 (1H, dq, J = 2.8, 1.4 Hz, CH2-C16), 4.69–4.67 (1H, m, CH2-C
A), 4.56 (1H, d, J = 
6.6 Hz, MOM-CH2), 4.54 (1H, d, J = 6.6 Hz, MOM-CH2), 4.00 (2H, s, CH2-C21), 3.47–3.37 
(2H, m, CH2-C3), 3.31 (3H, s, MOM-CH3), 2.24–2.15 (1H, m, CH-C1), 2.01–1.85 (2H, m, 
CH2-C13), 1.69–1.54 (5H, m, CH2-C2, CH3-C17), 1.51–1.42 (2H, m, CH2-C14); 
13C NMR 
(126 MHz, CDCl3) δ 149.2 (C-C12), 146.3 (C-C15), 112.7 (CH2-C
A), 109.0 (CH2-C16), 96.5 
(MOM-CH2), 66.1 (CH2-C21), 65.8 (CH2-C3), 55.2 (MOM-CH3), 43.8 (CH-C1), 33.2 (CH2-
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C2), 31.4 (CH2-C13), 30.7 (CH2-C14), 17.7 (CH3-C17); HRMS (ESI
+) calcd. for C13H24O3Na 
[M+Na]+ 251.1617, found 251.1598; IR νmax 3408, 2929, 2882, 1645, 1442 cm
-1. 
(3R)-3-(Prop-1-en-2-yl)-6-((trisisopropylsilyloxy)methyl)hept-6-en-1-yl acetate 
 
To a solution of alcohol 314 (4.50 g, 13.2 mmol) and DMAP (161 mg, 1.32 mmol) in CH2Cl2 
(100 mL) at rt was added triethylamine (5.50 mL, 39.7 mmol) followed by acetic anhydride 
(1.50 mL, 15.9 mmol) and the solution stirred for 15 h. The reaction was quenched with 
saturated aq. NH4Cl (100 mL) and the phases were separated. The organic phase was 
washed with brine (50 mL), dried over MgSO4 and filtered. The solvent was removed under 
vacuum and the residue was purified by silica gel column chromatography (pet. ether:Et2O, 
19:1) to deliver the title acetate as a colourless oil (4.74 g, 94%).     
   −6.1 (c = 0.28, 
CHCl3); 
1H NMR (400 MHz, CDCl3) δ 5.09–5.07 (1H, d, J = 1.7 Hz, CH2-C
A), 4.82–4.78 (2H, 
m, CH2-C
A, CH2-C16), 4.72–4.70 (1H, m, CH2-C16), 4.13 (2H, s, CH2-C21), 4.07–3.92 (2H, 
m, CH2-C3), 2.22–2.14 (1H, m, CH-C1), 2.03 (3H, s, OAc-CH3), 2.01–1.83 (2H, m, CH2-
C13), 1.77–1.63 (2H, m, CH2-C2), 1.61 (3H, dd, J = 1.3, 0.8 Hz, CH3-C17), 1.55–1.47 (2H, 
m, CH2-C14), 1.17–1.03 (21H, m, CH(CH3)2); 
13C NMR (101 MHz, CDCl3) δ 171.3 (Ac-C(O)), 
148.7 (C-C12), 146.0 (C-C15), 113.0 (CH2-C
A), 108.1 (CH2-C16), 66.2 (CH2-C21), 63.2 
(CH2-C3), 44.0 (CH-C1), 32.1 (CH2-C2), 31.5 (CH2-C13), 30.5 (CH2-C14), 21.1 (Ac-CH3), 
18.2 (CH(CH3)2), 17.8 (CH3-C17), 12.2 (CH(CH3)2); HRMS (ESI
+) calcd for C22H42O3SiNa 
[M+Na]+ 405.2796, found 405.2777; IR νmax 2941, 2893, 2866, 1744, 1645, 1464 cm
–1. 
(3R)-3-(Prop-1-en-2-yl)-6-(hydroxymethyl)hept-6-en-1-yl acetate 393 
 
To a solution of (3R)-3-(Prop-1-en-2-yl)-6-((trisisopropylsilyloxy)methyl)hept-6-en-1-yl 
acetate (6.30 g, 16.5 mmol) in THF (80 mL) was added TBAF (16.5 mL of a 1 M solution in 
THF, 16.5 mmol) and the resulting mixture stirred at rt for 18 h. The reaction was quenched 
with saturated aq. NH4Cl (100 mL) and Et2O (100 mL) added. The phases were separated 
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and the aqueous phase was extracted with Et2O (100 mL). The combined organic extracts 
were dried over MgSO4, filtered and the solvent removed under vacuum. The residue was 
purified by silica gel column chromatography (pet. ether:EtOAc, 1:1) to afford the allylic 
alcohol 393 as a yellow oil (3.72 g, quant.).  α  
   −12 (c = 0.22, CHCl3); 
1H NMR (500 MHz, 
CDCl3) δ 4.96–4.94 (1H, m, CH2-C
A), 4.80–4.77 (1H, m, CH2-C16), 4.75–4.73 (1H, m, CH2-
C16), 4.67–4.64 (1H, m, CH2-C
A), 4.01–3.95 (3H, m, CH2-C21, CH2-C3), 3.89 (1H, ddd, J = 
11.0, 7.4, 7.3 Hz, CH2-C3), 2.40 (1H, br s, OH-C21), 2.16–2.09 (1H, m, CH-C1), 1.97 (3H, s, 
Ac-CH3), 1.96–1.84 (2H, m, CH2-C13), 1.69–1.58 (2H, m, CH2-C2), 1.56 (3H, dd, J = 1.2, 0.7 
Hz, CH3-C17), 1.48–1.42 (2H, m, CH2-C14); 
13C NMR (126 MHz, CDCl3) δ 171.3 (Ac-C(O)), 
148.9 (C-C12), 145.7 (C-C15), 112.9 (CH2-C
A), 109.0 (CH2-C16), 65.7 (CH2-C21), 63.0 
(CH2-C3), 43.7 (CH-C1), 31.9 (CH2-C2), 31.2 (CH2-C13), 30.5 (CH2-C14), 21.0 (Ac-CH3), 
17.6 (CH3-C17); HRMS (ESI
+) calcd for C13H22O3Na [M+Na]+ 249.1461, found 249.1456; 
IR νmax 3431, 3072, 2934, 2901, 2862, 1739, 1720, 1645, 1447 cm
–1. 
(5R)‐5‐[2‐(Methoxymethoxy)ethyl]‐6‐methyl‐2‐methylidenehept‐6‐enoic acid 394  
 
 
 
 
To a solution of the allylic alcohol 392 (80 mg, 0.35 mmol) in CH2Cl2 (3.5 mL) was added 
Dess-Martin periodinane (163 mg, 0.39 mmol) and the resulting mixture was stirred at rt for 
2.5 h. The reaction was quenched with saturated aq. Na2S2O3 (5 mL) and the phases were 
separated. The organic phase was washed with saturated aq. Na2S2O3 (2 × 5 mL), dried 
over MgSO4 and filtered. The solvent was removed under vacuum to afford the crude 
product, which was used directly in the next step. 
To a solution of crude aldehyde in tBuOH (5.35 mL) was added 2-methyl-2-butene (0.76 mL, 
7.12 mmol). A solution of NaH2PO4 (896 mg, 5.78 mmol) and NaClO2 (483 g, 5.34 mmol) in 
H2O (10.7 mL) was then added and the biphasic mixture stirred at rt for 16 h. CH2Cl2 (20 mL) 
was added and the phases separated. The aqueous phase was washed with CH2Cl2 (2 × 20 
mL) and the combined organic extracts were dried over Na2SO4 and filtered. The solvent 
was removed under vacuum to afford the carboxylic acid 394 as a colourless oil (85 mg, 
quant.).     
   −14 (c = 0.05, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 6.24 (1H, d, J = 1.4 Hz, 
CH2-C
A), 5.61 (1H, d, J = 1.4 Hz, CH2-C
A), 4.78 (1H, dq, J = 2.5, 1.4 Hz, CH2-C16), 4.71 (1H, 
d, J = 2.5 Hz, CH2-C16), 4.59 (1H, d, J = 6.6 Hz, MOM-CH2), 4.57 (1H, d, J = 6.6 Hz, MOM-
CH2), 3.49–3.39 (2H, m, CH2-C3), 3.33 (3H, s, MOM-CH3), 2.29–2.19 (2H, m, CH2-C13), 
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2.19–2.10 (1H, m, CH-C1), 1.71–1.58 (5H, m, CH2-C2, CH3-C17), 1.55–1.47 (2H, m, CH2-
C14); 13C NMR (126 MHz, CDCl3) δ 172.5 (C-C21), 146.1 (C-C15), 140.3 (C-C12), 127.0 
(CH2-C
A), 112.9 (CH2-C16), 96.5 (MOM-CH2), 66.2 (CH2-C3), 55.2 (MOM-CH3), 43.9 (CH-
C1), 33.2 (CH2-C2), 32.1 (CH2-C13), 29.7 (CH2-C14), 17.7 (CH3-C17); HRMS (ESI
+) calcd. 
for C13H22O4Na [M+Na]
+ 265.1410, found 265.1412; IR νmax 3071, 2930, 2882, 1719, 1694, 
1645, 1628, 1441 cm-1. 
 
(5R)-5-(2-Acetoxyethyl)-6-methyl-2-methylidenehept-6-enoic acid 395 
 
To a solution of the allylic alcohol 393 (3.7 g, 16 mmol) in CH2Cl2 (80 mL) was added Dess-
Martin periodinane (7.2 g, 17 mmol) and the resulting mixture was stirred at rt for 2.5 h. The 
reaction was quenched with saturated aq. Na2S2O3 (100 mL) and the phases were 
separated. The organic phase was washed with saturated aq. Na2S2O3 (2 × 100 mL), dried 
over MgSO4 and filtered. The solvent was removed under vacuum to afford the crude 
product, which was used directly in the next step. 
To a solution of crude aldehyde in tBuOH (120 mL) was added 2-methyl-2-butene (13.1 mL, 
123 mmol). A solution of NaH2PO4 (15.5 g, 100 mmol) and NaClO2 (8.35 g, 92.3 mmol) in 
H2O (240 mL) was then added and the biphasic mixture stirred at rt for 17 h. CH2Cl2 (200 
mL) was added and the phases separated. The aqueous phase was washed with CH2Cl2 (2 
× 200 mL) and the combined organic extracts were dried over Na2SO4 and filtered. The 
solvent was removed under vacuum to afford the carboxylic acid 395 as a colourless oil 
(3.91 g, quant.).     
   −11 (c = 0.16, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 10.56 (1H, br, 
CO2H), 6.23 (1H, d, J = 0.9 Hz, CH2-C
A), 5.60–5.58 (1H, m, CH2-C
A), 4.78–4.75 (1H, m, 
CH2-C16), 4.68 (1H, d, J = 1.8 Hz, CH2-C16), 3.99 (1H, ddd, J = 11.0, 7.3, 5.7 Hz, CH2-C3), 
3.92 (1H, ddd, J = 11.0, 7.3, 7.3 Hz, CH2-C3), 2.27–2.08 (3H, m, CH2-C13, CH-C1), 1.99 
(3H, s, Ac-CH3), 1.71–1.59 (2H, m, CH2-C2), 1.58 (3H, d, J = 1.3 Hz, CH3-C17), 1.53–1.46 
(2H, m, CH2-C14); 
13C NMR (126 MHz, CDCl3) δ 172.4 (C-C21), 171.4 (Ac-C(O)), 145.5 (C-
C15), 140.1 (C-C12), 127.1 (CH2-C
A), 113.2 (CH2-C16), 63.0 (CH2-C3), 43.8 (CH-C1), 32.0 
(CH2-C2), 31.8 (CH2-C13), 29.5 (CH2-C14), 21.0 (Ac-CH3), 17.5 (CH3-C17); HRMS (ESI
+) 
calcd for C13H20O4Na [M+Na]+ 263.1254, found 263.1254; IR νmax 3171, 3072, 2936, 1738, 
1724, 1693, 1645, 1628, 1440 cm–1 
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(5R)‐5‐(2‐Hydroxyethyl)‐6‐methyl‐2‐methylidenehept‐6‐enoic acid 388  
 
To a solution of acid 395 (214 mg, 0.89 mmol) in THF (2 mL) was added a solution of LiOH 
(85 mg, 3.56 mmol) in H2O (1 mL) and the resulting mixture stirred at rt for 3 h. The reaction 
was quenched with 1M HCl which was added until pH 2 was reached. CH2Cl2 (10 mL) was 
added and the biphasic mixture separated. The aqueous phase was washed with CH2Cl2 (3 
× 10 mL). The combined organic extracts were washed with brine, dried over MgSO4, filtered 
and the solvent removed under vacuum to afford the alcohol 388 as a colourless oil (168 mg, 
95%).     
   −27 (c = 0.09, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 6.27 (1H, d, J = 1.4 Hz, 
CH2-C
A), 5.65 (1H, d, J = 1.4 Hz, CH2-C
A), 4.82 (1H, dq, J = 2.6, 1.5 Hz, CH2-C16), 4.78 (1H, 
d, J = 2.6 Hz, CH2-C16), 3.67–3.56 (2H, m, CH2-C3), 2.33–2.23 (2H, m, CH2-C13), 2.22–
2.13 (1H, m, CH-C1), 1.67–1.60 (5H, CH2-C2, CH3-C17), 1.58–1.51 (2H, m, CH2-C14); 
13C 
NMR (101 MHz, CDCl3) δ 171.4 (C-C21), 147.0 (C-C15), 140.1 (C-C12), 127.2 (CH2-C
A), 
112.9 (CH2-C16), 61.6 (CH2-C3), 44.2 (CH-C1), 36.2 (CH2-C2), 32.3 (CH2-C13), 29.8 (CH2-
C14), 17.8 (CH3-C17); HRMS (ESI
+) calcd for C11H18O3Na [M+Na]
+ 221.1148, found 
221.1145; IR νmax 3284, 3071, 2938, 2879, 1690, 1627, 1443 cm
–1. 
(5R)‐9‐Methoxy‐2‐methylidene‐7,9‐dioxo‐5‐(prop‐1‐en‐2‐yl)nonanoic acid 301 
 
To a solution of alcohol 388 (73 mg, 0.37 mmol) in CH2Cl2 (2 mL) was added Dess-Martin 
periodinane (2.54 g, 5.99 mmol). The resulting mixture was stirred at rt for 3 h and the 
reaction was then quenched with saturated aq. Na2S2O3 (2 mL). The phases were separated 
and the organic phase washed with saturated aq. Na2S2O3 (2 × 2 mL), then dried over 
Na2SO4 and filtered to afford the crude aldehyde which was used without further purification. 
To a solution of glycine methyl ester hydrochloride (694 mg, 5.55 mmol) in CH2Cl2 (1.8 mL) 
was added a solution of NaNO2 (459 mg, 6.66 mmol) in H2O (0.6 mL). The biphasic mixture 
was stirred for 1.5 h at rt and then saturated aq. NaHCO3 (0.5 mL) was added. The phases 
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were separated and the organic phase was dried over MgSO4 and filtered. The solution of  
methyl diazoacetate was then used directly. 
To a solution of the crude aldehyde and SnCl2 (148 mg, 0.74 mmol) in CH2Cl2 (2.5 mL) was 
added the freshly prepared solution of methyl diazoacetate (1.5 mL, 5.55 mmol). The 
resulting mixture was stirred at rt for 16 h and the excess diazo ester was destroyed by 
dropwise addition of glacial acetic acid (0.2 mL). The solvent was removed under vacuum 
and the residue was purified by silica gel column chromatography (pet. ether:EtOAc, 1:1  
2:8) to afford the title compound 301 as a colourless oil (45.2 mg, 46%). 1H NMR (400 MHz, 
CDCl3) δ 6.28 (1H, s, CH2-C
A), 5.66 (1H, s, CH2-C
A), 4.81 (1H, q, J = 1.3 Hz, CH2-C16), 4.76 
(1H, s, CH2-C16), 3.72 (3H, s, CH2-C19), 3.43 (2H, s, CH2-C4), 2.73–2.52 (3H, m, CH2-C13, 
CH-C1), 2.33–2.20 (1H, m, CH2-C2), 2.23–2.08 (1H, m, CH2-C2), 1.67 (3H, d, J = 1.3 Hz, 
CH3-C17), 1.60–1.49 (2H, m, CH2-C14); 
13C NMR (101 MHz, CDCl3) δ 201.7 (C-C3), 172.5 
(C-C21), 167.7 (C-C18), 145.7 (C-C15), 139.8 (C-C12), 127.5 (CH2-C
A), 112.9 (CH2-C16), 
52.5 (CH3-C19), 49.4 (CH2-C4), 47.5 (CH2-C2), 42.0 (CH-C1), 31.7 (CH2-C13), 29.3 (CH2-
C14), 18.9 (CH3-C17); HRMS (ESI
+) calcd for C14H20O5Na [M+Na]
+ 291.1203, found 
291.1196; IR νmax 3070, 2930, 1742, 1718, 1694, 1628, 1438 cm
–1. 
(5S,6E)‐5‐[(Triethylsilyl)oxy]‐1‐[tris(propan‐2‐yl)silyl]undec‐6‐en‐1‐yn‐3‐one 396 
 
To a solution of triisopropylsilylacetylene (1.23 mL, 5.47 mmol) in THF (9 mL) at 0 °C was 
added nBuLi (2.18 mL of a 2.5 M solution in hexanes, 5.47 mmol) and the resulting solution 
was stirred at 0 °C for 30 mins. A solution of the amide 346 (1.20 g, 3.65 mmol) in THF (6 
mL) was added and the mixture stirred at 0 °C for 10 min then warmed to rt and stirred for 1 
h. The reaction was quenched with saturated aq. NH4Cl (20 mL) and Et2O (20 mL) added. 
The phases were separated and the organic phase was dried over Na2SO4 and filtered. The 
solvent was removed under vacuum and the residue was purified by silica gel column 
chromatography (pet. ether:Et2O, 98:2) to afford the propargylic ketone 396 as a colourless 
oil (1.55 g, 94%).     
   −4.8 (c = 0.56, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 5.67–5.58 (1H, 
m, CH-CB), 5.43 (1H, ddt, J = 15.3, 7.0, 1.4 Hz, CH-C11), 4.74–4.67 (1H, m, CH-C10), 2.84 
(1H, dd, J = 14.5, 7.5 Hz, CH2-C9), 2.65 (1H, dd, J = 14.5, 5.8 Hz, CH2-C9), 2.00 (1H, app q, 
J = 6.8 Hz, CH2-C
C), 1.38–1.24 (4H, m, CH2-C
D, CH2-C
E), 1.18–1.05 (21H, m, CH(CH3)2), 
0.93 (9H, t, J = 7.8 Hz, Si(CH2CH3)2), 0.88 (3H, t, J = 7.1 Hz, CH3-C
F), 0.58 (6H, q, J = 7.8 
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Hz, Si(CH2CH3)3); 
13C NMR (101 MHz, CDCl3) δ 185.2 (C-C8), 132.0 (CH-C
B), 131.9 (CH-
C11), 104.9 (C-C7), 95.8 (C-C6), 70.3 (CH-C10), 54.8 (CH2-C9), 31.9 (CH2-C
C), 31.3 (CH2-
CD), 22.3 (CH2-C
E), 18.6 (CH(CH3)2), 14.1 (CH3-C
F), 11.2 (CH(CH3)2), 6.9 (Si(CH2CH3)3), 5.0 
(Si(CH2CH3)3); HRMS (ESI
+) calcd for C26H50O2Si2Na [M+Na]
+ 473.3242, found 473.3208; IR 
νmax 2955, 2947, 2868, 2147, 1678, 1628, 1462, 1414 cm
–1. 
(3R,5S,6E)‐5‐[(tert‐Butyldimethylsilyl)oxy]‐3‐methylundec‐6‐en‐1‐yn‐3‐ol 399 
 
To a solution of NaH (46 mg of 60% dispersion in mineral oil, 1.16 mmol) in THF (1 mL) at 0 
°C was added a solution of 1,3-diol 397 (228 mg, 1.16 mmol) in THF (1.5 mL). The resulting 
mixture was gradually warmed to rt and stirred for 20 min. A solution of tert-butyldimethylsilyl 
chloride (175 mg, 1.16 mmol) in THF (1.5 mL) was then added and the mixture was stirred at 
rt for 17.5 h. Brine (10 mL) and Et2O (10 mL) were added and the phases separated. The 
organic phase was dried over Na2SO4 and filtered. The solvent was removed under vacuum 
and the residue was purified by silica gel column chromatography (pet. ether:Et2O, 8:2) to 
afford the alkyne 399 as a yellow oil (341 mg, 95%).     
   −24 (c = 0.165, CHCl3); 
1H NMR 
(400 MHz, CDCl3) δ 5.68–5.52 (2H, m, CH-C11, CH-C
B), 4.53 (1H, td, J = 7.4, 5.1 Hz, CH-
C10), 4.25 (1H, s, OH-C8), 2.44 (1H, s, CH-C6), 2.09 (1H, dd, J = 14.4, 7.4 Hz, CH2-C9), 
2.06–1.99 (2H, m, CH2-C
C), 1.86 (1H, dd, J = 14.4, 5.1 Hz, CH2-C9), 1.54 (3H, s, CH3-C20), 
1.42–1.28 (4H, m, CH2-C
D, CH2-C
E), 0.93–0.86 (12H, m, CH3-C
F, Si(CH3)2C(CH3)3), 0.10 
(3H, s, Si(CH3)2C(CH3)3), 0.06 (3H, s, Si(CH3)2C(CH3)3); 
13C NMR (101 MHz, CDCl3) δ 133.2 
(CH-CB), 132.7 (CH-C11), 88.5 (C-C7), 73.3 (CH-C6), 71.0 (CH-C10), 67.1 (C-C8), 49.1 
(CH2-C9), 31.9 (CH2-C
C), 31.2 (CH2-C
D), 30.0 (CH3-C20), 26.0 (Si(CH3)2C(CH3)3), 22.4 (CH2-
CE), 18.1(Si(CH3)2C(CH3)3), 14.1 (CH3-C
F), −3.4 (Si(CH3)2C(CH3)3), −4.6 (Si(CH3)2C(CH3)3); 
HRMS (ESI+) calcd for C18H34O2SiNa [M+Na]
+ 333.2220, found 333.2210; IR νmax 3470, 
3312, 2957, 2930, 2857, 1668, 1472, 1464 cm–1  
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(3R,5S,6E)‐3‐Methyl‐5‐{[tris(propan‐2‐yl)silyl]oxy}undec‐6‐en‐1‐yn‐3‐ol 400 
 
To a solution of NaH (19 mg of 60% dispersion in mineral oil, 0.48 mmol) in THF (1 mL) at 0 
°C was added a solution of 1,3-diol 397 (94 mg, 0.48 mmol) in THF (1 mL). The resulting 
mixture was gradually warmed to rt and stirred for 20 min. Triisopropylsilyl chloride (0.11 mL, 
0.50 mmol) was then added and the mixture was stirred at rt for 14 h. Brine (5 mL) and Et2O 
(5 mL) were added and the phases separated. The organic phase was dried over Na2SO4 
and filtered. The solvent was removed under vacuum and the residue was purified by silica 
gel column chromatography (pet. ether:Et2O, 8:2) to afford the alkyne 400 as a colourless oil 
(166 mg, 98%).     
   −12 (c = 0.07, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 5.76–5.63 (2H, m, 
CH-C11, CH-CB), 4.66 (1H, td, J = 6.9, 5.4 Hz, CH-C10), 4.09 (1H, s, OH-C8), 2.46 (1H, s, 
CH-C6), 2.11–2.00 (3H, m, CH2-C9, CH2-C
C), 1.94 (1H, dd, J = 14.2, 6.9 Hz, CH2-C9), 1.52 
(3H, s, CH3-C20), 1.41–1.28 (4H, m, CH2-C
D, CH2-C
E), 1.14–1.00 (21H, m, CH(CH3)2), 0.89 
(3H, t, J = 7.1 Hz, CH3-C
F); 13C NMR (126 MHz, CDCl3) δ 133.8 (CH-C
B), 132.8 (CH-C11), 
88.4 (C-C7), 73.5 (CH-C6), 71.5 (CH-C10), 66.8 (C-C8), 49.8 (CH2-C9), 31.9 (CH2-C
C), 31.2 
(CH2-C
D), 30.9 (CH3-C20), 22.5 (CH2-C
E), 18.3 (CH(CH3)2), 18.2 (CH(CH3)2), 14.0 (CH3-C
F), 
12.6 (CH(CH3)2); HRMS (ESI
+) calcd for C21H40O2SiNa [M+Na]+ 375.2690, found 375.2673; 
IR νmax 3466, 3312, 2943, 2930, 2866, 1464 cm
–1 
(4R,6S,7E)‐6‐[(tert‐Butyldimethylsilyl)oxy]‐4‐hydroxy‐4‐methyldodec‐7‐en‐2‐ynal 401 
 
To a solution of alkyne 399 (170 mg, 0.55 mmol) in THF (15 mL) at −78 °C was added nBuLi 
(0.54 mL of a 2.15 M solution in hexane, 1.15 mmol). The resulting solution was stirred for 5 
mins and then warmed to 0 °C. DMF (0.11 mL, 1.37 mmol) was added and the mixture was 
stirred for 1 h. The reaction was quenched with 5% aq. KH2PO4 (20 mL) and Et2O (20 mL) 
was added. The phases were separated and the organic phase washed wth brine (20 mL), 
dried over Na2SO4 and filtered. The solvent was removed under vacuum and the residue 
was purified by silica gel column chromatography (pet. ether:Et2O, 7:3) to deliver the 
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propargylic aldehyde 401 as a colourless oil (186 mg, quant.).     
   −7.5 (c = 0.10, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 9.24 (1H, s, CHO-C5), 5.70–5.53 (2H, m, CH-C11, CH-C
B), 
4.79 (1H, s, OH-C8), 4.54 (1H, td, J = 7.0, 4.5 Hz, CH-C10), 2.12 (1H, dd, J = 14.5, 7.0 Hz, 
CH2-C9), 2.06–1.99 (2H, m, CH2-C
C), 1.94 (1H, dd, J = 14.5, 4.5 Hz, CH2-C9), 1.58 (3H, s, 
CH2-C20), 1.43–1.27 (4H, m, CH2-C
D, CH2-C
E), 0.98–0.85 (12H, m, CH3-C
F, 
Si(CH3)2C(CH3)3), 0.10 (3H, s, Si(CH3)2C(CH3)3), 0.07 (3H, s, Si(CH3)2C(CH3)3); 
13C NMR 
(126 MHz, CDCl3) δ 176.9 (CHO-C5), 133.0 (CH-C
B), 132.2 (CH-C11), 100.5 (C-C7), 82.9 
(C-C6), 73.3 (CH-C10), 67.5 (C-C8), 47.9 (CH2-C9), 31.9 (CH2-C
C), 31.2 (CH2-C
D), 29.6 
(CH3-C20), 25.9 (Si(CH3)2C(CH3)3), 22.4 (CH2-C
E), 18.1 (Si(CH3)2C(CH3)3), 14.1 (CH3-C
F), 
−3.5 (Si(CH3)2C(CH3)3), −4.7 (Si(CH3)2C(CH3)3); HRMS (ESI
+) calcd for C19H34O3SiNa 
[M+Na]+ 361.2169, found 361.2122; IR νmax 3451, 2957, 2930, 2859, 2210, 1672, 1472, 1646 
cm–1. 
 
(4R,6S,7E)‐4‐Hydroxy‐4‐methyl‐6‐{[tris(propan‐2‐yl)silyl]oxy}dodec‐7‐en‐2‐ynal 402 
 
To a solution of alkyne 400 (122 mg, 0.35 mmol) in THF (2.5 mL) at −78 °C was added 
nBuLi (0.33 mL of a 2.2 M solution in hexane, 0.73 mmol). The resulting solution was stirred 
for 5 mins and then warmed to 0 °C. DMF (0.07 mL, 0.86 mmol) was added and the mixture 
was stirred for 1 h. The reaction was quenched with 5% aq. KH2PO4 (5 mL) and Et2O (5 mL) 
was added. The phases were separated and the organic phase washed wth brine (5 mL), 
dried over Na2SO4 and filtered. The solvent was removed under vacuum and the residue 
was purified by silica gel column chromatography (pet. ether:Et2O, 8:2) to deliver the 
propargylic aldehyde 402 as a colourless oil (133 mg, quant.).     
   −20 (c = 0.03, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 9.24 (1H, s, CHO-C5), 5.78–5.63 (2H, m, CH-C11, CH-C
B), 
4.82 (1H, s, OH-C8), 4.66 (1H, dt, J = 7.3, 5.3 Hz, CH-C10), 2.08 (2H, dd, J = 5.3, 3.7 Hz, 
CH2-C9), 2.06–2.00 (2H, m, CH2-C
C), 1.57 (3H, s, CH3-C20), 1.39–1.29 (4H, m, CH2-C
D, 
CH2-C
E), 1.13–1.04 (21H, m, CH(CH3)2), 0.89 (3H, t, J = 7.0 Hz, CH3-C
F); 13C NMR (126 
MHz, CDCl3) δ 176.7 (CHO-C5), 132.9 (CH-C
B), 132.5 (CH-C11), 100.7 (C-C7), 83.5 (C-C6), 
73.7 (CH-C10), 67.3 (C-C8), 48.6 (CH2-C9), 31.9 (CH2-C
C), 31.1 (CH2-C
D), 30.5 (CH3-C20), 
22.5 (CH2-C
E), 18.2 (CH(CH3)2), 18.1 (CH(CH3)2), 14.0 (CH3-C
F), 12.5 (CH(CH3)2); HRMS 
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(ESI+) calcd. for C22H40O3SiNa [M+Na]
+ 403.2639, found 403.2614; IR νmax 3441, 2943, 2932, 
2866, 2209, 1672, 1464 cm–1. 
Methyl (5R)‐5‐(2‐hydroxyethyl)‐6‐methyl‐2‐methylidenehept‐6‐enoate 404 
 
To a solution of carboxylic acid 395 (200 mg, 0.83 mmol) and DMAP (10 mg, 0.08 mmol) in 
CH2Cl2 (4 mL) and MeOH (0.2 mL) at 0 °C was added DCC (190 mg, 0.92 mmol). The 
resulting mixture was warmed to rt and stirred for 17 h. K2CO3 (23 mg, 0.17 mmol) and 
MeOH (4 mL) were added and the reaction stirred at rt for a further 6 hours. The reaction 
was quenched with saturated aq. NH4Cl (5 mL) and AcOH (2 drops) and CH2Cl2 (5 mL) 
added. The phases were separated and the organic phase dried over Na2SO4 and filtered. 
The solvent was removed under vacuum and the residue was purified by silica gel column 
chromatography (pet. ether:EtOAc, 7:3) afforded the methyl ester 404 as a colourless oil 
(176 mg, quant.).     
   +4.0 (c = 0.05, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 6.11 (1H, d, J = 
1.4 Hz, CH2-C
A), 5.52 (1H, d, J = 1.4 Hz, CH2-C
A), 4.80 (1H, dq, J = 2.6, 1.4 Hz, CH2-C16), 
4.76 (1H, dq, J = 2.6, 0.7 Hz, CH2-C16), 3.74 (3H, s, OCH3), 3.65–3.54 (2H, m, CH2-C3), 
2.31–2.21 (2H, m, CH2-C13), 2.15 (1H, dddd, J = 14.6, 9.0, 6.6, 1.2 Hz, CH-C1), 1.64 (3H, 
dd, J = 1.4, 0.7 Hz, CH3-C17), 1.64–1.59 (2H, m, CH2-C2), 1.54–1.47 (2H, m, CH2-C14); 
13C 
NMR (126 MHz, CDCl3) δ 167.8 (C-C21), 147.0 (C-C15), 140.8 (C-C12), 124.9 (CH2-C
A), 
112.7 (CH2-C16), 61.5 (CH2-C3), 51.9 (OCH3), 44.1 (CH-C1), 36.2 (CH2-C2), 32.3 (CH2-
C13), 30.1 (CH2-C14), 17.7 (CH3-C17); HRMS (ESI
+) calcd for C12H20O3Na [M+Na]
+ 
235.1305, found 235.1299; IR νmax 3392, 3076, 2935, 2860, 1721, 1644, 1628, 1440 cm
–1 
1,9‐Dimethyl (5R)‐2‐methylidene‐7‐oxo‐5‐(prop‐1‐en‐2‐yl)nonanedioate 406 
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To a solution of alcohol 404 (176 mg, 0.83 mmol) in CH2Cl2 (8 mL) was added Dess-Martin 
periodinane (422 mg, 0.99 mmol). The resulting mixture was stirred at rt for 2.5 h and the 
reaction was then quenched with saturated aq. Na2S2O3 (10 mL). The phases were 
separated and the organic phase washed with saturated aq. Na2S2O3 (2 × 10 mL), then dried 
over Na2SO4 and filtered to afford the crude aldehyde 405 which was used without further 
purification. 
To a solution of glycine methyl ester hydrochloride (627 mg, 4.98 mmol) in CH2Cl2 (1.7 mL) 
was added a solution of NaNO2 (414 mg, 5.98 mmol) in H2O (0.6 mL). The biphasic mixture 
was stirred for 1.5 h at rt and then saturated aq. NaHCO3 (0.5 mL) was added. The phases 
were separated and the organic phase was dried over MgSO4 and filtered. The solution of  
methyl diazoacetate was then used directly. 
To a solution of the crude aldehyde 405 and SnCl2 (166 mg, 0.83 mmol) in CH2Cl2 (12.5 mL) 
was added the freshly prepared solution of methyl diazoacetate (1.7 mL, 4.98 mmol). The 
resulting mixture was stirred at rt for 15 h and the excess diazo ester was destroyed by 
dropwise addition of glacial acetic acid (0.1 mL). The solvent was removed under vacuum 
and the residue was purified by silica gel column chromatography (pet. ether:EtOAc, 8:2) to 
afford the title compound 406 (tautomeric mixture by NMR) as a colourless oil (98 mg, 40%). 
 α  
   +28 (c = 0.007, CHCl3);  
1H NMR (500 MHz, CDCl3) δ 11.98 (0.1H, s, OH-C3 enol), 
6.13 (1H, d, J = 1.4 Hz, CH2-C
A), 5.54 (0.9H, d, J = 1.4 Hz, CH2-C
A), 5.53 (0.1H, d, J = 1.7 
Hz, CH2-C
A enol), 4.95 (0.1H, s, CH-C4 enol), 4.83–4.81 (1H, m CH2-C16), 4.76 (1H, s, CH2-
C16), 3.74 (3H, s, OCH3), 3.73 (2.7H, s, CH3-C19), 3.72 (0.3H, s, CH3-C19 enol), 3.43 (1.8H, 
d, J = 1.3 Hz, CH2-C4), 2.70–2.56 (3H, m, CH-C1, CH2-C2), 2.30–2.23 (1H, m, CH2-C13), 
2.20–2.12 (1H, m, CH2-C13), 1.68–1.66 (2.7H, m, CH3-C17), 1.66–1.65  (0.3H, s, CH3-C17 
enol), 1.59–1.50 (2H, m, CH2-C14); 
13C NMR (126 MHz, CDCl3) δ 201.7 (C-C3), 167.7 (C-
C21), 167.7 (C-C18), 145.8 (C-C15), 140.3 (C-C12), 125.2 (CH2-C
A), 112.9 (CH2-C16), 52.5 
(CH3-C19), 51.9 (OCH3), 49.5 (CH2-C4), 47.5 (CH2-C2), 42.1 (CH-C1), 31.8 (CH2-C13), 29.8 
(CH2-C14), 18.9 (CH3-C17); HRMS (ESI
+) calcd for C15H22O5Na [M+Na]
+ 305.1359, found 
305.1350; IR νmax 2953, 2926, 2857, 2361, 2336, 1749, 1719, 1645, 1630, 1437 cm
–1. 
Methyl 4‐[(3R)‐2,2‐dimethyloxolan‐3‐yl]‐2‐methylidenebutanoate 408 
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To a solution of acetate 407 (50 mg, 0.21 mmol) in MeOH (3.5 mL) was added HCl (1.5 mL 
of a 5 M aqueoous solution, 7.5 mmol) and the resultant stirred at rt for 72 h. Et2O (10 mL) 
was added and the phases separated. The organic phase was dried over Na2SO4, filtered 
and the solvent removed under vacuum. Purification of the residue by silica gel column 
chromatography (pet. ether:EtOAc, 8:2) afforded methyl ester 408 as a yellow oil (28 mg, 
63%).  α  
   −14 (c = 0.055, CHCl3); 
1H NMR (400 MHz, CDCl3) δ 6.16–6.13 (1H, m, CH2-
CA), 5.55 (1H, d, J = 1.4 Hz, CH2-C
A), 3.83 (1H, td, J = 8.7, 3.2 Hz, CH2-C3), 3.78–3.71 (4H, 
m, OCH3, CH2-C3), 2.44–2.34 (1H, m, CH2-C13), 2.32–2.22 (1H, m, CH2-C13), 2.13 (1H, 
dtd, J = 11.9, 7.4, 3.2 Hz, CH2-C2), 1.80–1.69 (1H, m, CH-C1), 1.68–1.50 (2H, m, CH2-C2, 
CH2-C14), 1.38–1.26 (1H, m, CH2-C14), 1.23 (3H, s, CH3-C16), 0.99 (3H, s, CH3-C17); 
13C 
NMR (101 MHz, CDCl3) δ 167.7 (C-C21), 140.6 (C-C12), 124.9 (CH2-C
A), 81.7 (C-C15), 64.9 
(CH2-C3), 51.9 (OCH3), 48.4 (CH-C1), 32.1 (CH2-C2), 31.5 (CH2-C13), 29.5 (CH2-C14), 27.7 
(CH3-C16), 22.1 (CH3-C17); HRMS (ESI
+) calcd. for C12H20O3Na [M+Na]
+ 235.1305, found 
235.1302; IR νmax 2969, 2934, 2873, 1721, 1631, 1438 cm
–1. 
Methyl 2‐[(2R)‐6‐methoxy‐5‐methylidene‐6‐oxo‐2‐(prop‐1‐en‐2‐yl)hexyl]‐5‐[(3R)‐3‐ 
methyl‐3‐[(2S,3E)‐2‐{[tris(propan‐2‐yl)silyl]oxy}oct‐3‐en‐1‐yl]oxiran‐2‐yl]furan‐3‐carbox
ylate 412 and Methyl 
5‐[(2R,4S,5E)‐1‐(acetyloxy)‐2‐hydroxy‐2‐methyl‐4‐{[tris(propan‐2‐yl)silyl]oxy}dec‐5‐en-
1‐yl]‐2‐[(2R)‐6‐methoxy‐5‐methylidene‐6‐oxo‐2‐(prop‐1‐en‐2‐yl)hexyl]furan‐3‐carboxylat
e 413 
 
 
 
 
 
 
 
 
β-keto ester 406 (18 mg, 0.06 mmol) and propargylic aldehyde 402 (26 mg, 0.08 mmol) were 
dissolved in a solution of piperidine in CH2Cl2 (0.2 mL, 0.03 M, 0.006 mmol) in the presence 
of 4 Å molecular seives and THT (1 μL, 0.013 mmol) and AcOH (2 μL, 0.038 mmol) were 
added. The resulting mixture was heated to 35 °C and stirred at this temperature for 15 h. 
The solvent was removed under vacuum and the residue purified by silica gel column 
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chromatography (pet. ether:Et2O, 80:20  75:25) to afford the epoxyfuran 412 (1:1 mixture 
of diastereoisomers) as a colourless oil (1.1 mg, 3%) followed by the acetate 413 (~3:2 
mixture of diastereoisomers) as a colourless oil (7.2 mg, 17%). Epoxyfuran 412: 1H NMR 
(400 MHz, CDCl3) δ 6.82 (0.5H, s, CH-C5), 6.81 (0.5H, s, CH-C5), 6.26 (0.5H, d, J = 1.6 Hz, 
CH2-C
A), 6.25 (0.5H, d, J = 1.6 Hz, CH2-C
A), 5.72–5.54 (1.5H, m, CH-C11, CH-CB), 5.49–
5.42 (0.5H, m, CH-C11), 5.40 (0.5H, d, J = 1.6 Hz, CH2-C
A), 5.37 (0.5H, d, J = 1.6 Hz, CH2-
CA), 4.92–4.89 (1H, m, CH2-C16), 4.87–4.84 (1H, m, CH2-C16), 4.53–4.42 (1H, m, CH-C10), 
3.82 (0.5H, s, CH-C7), 3.59 (0.5H, s, CH-C7), 3.53 (1.5H, s, CH3-C19), 3.53 (1.5H, s, CH3-
C19), 3.46 (1.5H, s, OCH3), 3.46 (1.5H, s, OCH3), 3.43–3.31 (1H, m, CH2-C2), 3.23 (0.5H, 
dd, J = 14.3, 8.5 Hz, CH2-C2), 3.11 (0.5H, dd, J = 14.3, 6.5 Hz, CH2-C2), 2.96–2.83 (1H, m, 
CH-C1), 2.41 (0.5H, dd, J = 13.5, 4.8 Hz, CH2-C13), 2.35–2.24 (1.5H, m, CH2-C13), 2.18–
2.01 (3H, m, CH2-C9, CH2-C
C), 1.83 (1.5H, s, CH3-C17), 1.80 (1.5H, s, CH3-C17), 1.79–1.63 
(3H, m, CH2-C9, CH2-C14), 1.48 (3H, s, CH3-C20), 1.45–1.36 (4H, m, CH2-C
D, CH2-C
E), 
1.31–1.17 (21H, m, CH(CH3)2), 0.99 (3H, t, J = 7.0 Hz, CH3-C
F); HRMS (ESI+) calcd for 
C37H60O7SiNa [M+Na]
+ 667.4000, found 667.3889; IR νmax 2950, 2926, 2866, 1719, 1645, 
1630, 1617, 1579, 1462, 1439 cm–1. Acetate 413: 1H NMR (500 MHz, C6D6) δ 6.90 (0.4H, s, 
CH-C5), 6.86 (0.6H, s, CH-C5), 6.17 (0.4H, d, J = 1.6 Hz, CH2-C
A), 6.16 (0.6H, d, J = 1.6 Hz, 
CH2-C
A), 6.11 (0.4H, s, CH-C7),  6.09 (0.6H, s, CH-C7), 5.62–5.48 (2H, m, CH-C11, CH-CB), 
5.30 (0.4H, d, J = 1.6 Hz, CH2-C
A), 5.29 (0.6H, d, J = 1.6 Hz, CH2-C
A), 4.78–4.70 (3H, m, 
CH2-C16, CH-C10), 4.25 (0.6H, s, OH-C8), 4.10 (0.4H, s, OH-C8), 3.41 (1.8H, s, CH3-C19), 
3.41 (1.2H, s, CH3-C19), 3.37 (1.2H, s, OCH3), 3.36 (1.8H, s, OCH3), 3.16–3.05 (2H, m, 
CH2-C2), 2.75 (1H, dtd, J = 14.8, 9.2, 5.7 Hz, CH-C1), 2.43–2.30 (2H, m, CH2-C9, CH2-C13), 
2.24–2.10 (2H, m, CH2-C9, CH2-C13), 1.96–1.85 (3H, m, CH2-C14, CH2-C
C), 1.72 (4.8H, s, 
CH3-C17, CH3-C20), 1.69 (1.2H, s, CH3-C17), 1.64–1.53 (2.2H, m, CH2-C14, Ac-CH3), 1.46 
(1.8H, s, Ac-CH3), 1.34–1.19 (4H, m, CH2-C
D, CH2-C
E), 1.18–1.07  (21H, m, CH(CH3)2), 
0.90–0.83 (3H, m, CH3-C
F); 13C NMR (126 MHz, C6D6) δ 169.4 (Ac-C=O), 169.3 (Ac-C=O), 
167.2 (C-C21), 164.0 (C-C18), 161.7 (C-C3), 161.7 (C-C3), 150.2 (C-C6), 150.2 (C-C6), 
146.4 (C-C15), 146.3 (C-C15), 141.2 (C-C12), 141.1 (C-C12), 133.9 (CH-CB), 133.8 (CH-CB), 
132.4 (CH-C11), 132.3 (CH-C11), 124.5 (CH2-C
A), 124.5 (CH2-C
A), 115.0 (C-C4), 114.9 (C-
C4), 113.1 (CH2-C16), 113.0 (CH2-C16), 110.8 (CH-C5), 110.7 (CH-C5), 75.3 (CH-C7), 75.2 
(CH-C7), 73.9 (CH-C10), 73.7 (C-C8), 73.5 (C-C8), 51.3 (OCH3), 50.8 (CH3-C19), 47.0 (CH-
C1), 32.2 (CH2-C2), 32.2 (CH2-C2), 32.1 (CH2-C
C), 32.0 (CH2-C14), 32.0 (CH2-C14), 31.3 
(CH2-C
D), 31.3 (CH2-C
D), 30.5 (CH2-C13), 30.4 (CH2-C9), 24.0 (Ac-CH3), 23.5 (Ac-CH3), 22.7 
(CH2-C
E), 22.7 (CH2-C
E), 20.5 (CH3-C20), 18.5 (CH(CH3)2), 18.4 (CH(CH3)2), 18.1 (CH3-C17), 
18.0 (CH3-C17), 14.1 (CH3-C
F), 14.1 (CH3-C
F), 13.2 (CH(CH3)2); IR νmax 3486, 2950, 2929, 
2867, 1747, 1722, 1646, 1629, 1612, 1576, 1458, 1438 cm–1 
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2-(Trimethylsilyl)ethyl (5R)-5-(2-acetoxyethyl)-6-methyl-2-methylidenehept-6-enoate 
414 
 
To a solution of carboxylic acid 395 (50 mg, 0.21 mmol), 2-(trimethylsilyl)ethanol (0.06 mL, 
0.4 mmol) and DMAP (2.6 mg, 0.021 mmol) in CH2Cl2 (1 mL) at 0 °C was added DCC (48 
mg, 0.23 mmol). The resulting mixture was warmed to rt and stirred for 17 h. The mixture 
was filtered and the solid washed with Et2O (5 mL). The filtrate was collected and the solvent 
removed under vacuum to yield the crude product. Purification of the residue by silica gel 
column chromatography (pet. ether:Et2O, 93:7 → 9:1) afforded the ester 414 as a colourless 
oil (62.5 mg, 87%).     
   −3.4 (c = 1.46, CHCl3); 
1H NMR (400 MHz, CDCl3) δ 6.10 (1H, d, J 
= 1.4 Hz, CH2-C
A), 5.50 (1H, d, J = 1.4 Hz, CH2-C
A), 4.83–4.80 (1H, m, CH2-C16), 4.74–4.72 
(1H, m, CH2-C16), 4.27–4.21 (2H, m, (CH3)3SiCH2CH2O), 4.08–3.92 (2H, m, CH2-C3), 2.31–
2.10 (3H, m, CH-C1, CH2-C2), 2.03 (3H, s, Ac-CH3), 1.76–1.64 (2H, m, CH2-C13), 1.64 (3H, 
dd, J = 1.4, 0.8 Hz, CH3-C17), 1.56–1.48 (2H, m, CH2-C14), 1.07–0.99 (2H, m, 
(CH3)3SiCH2CH2O), 0.05 (9H, s, (CH3)3SiCH2CH2O); 
13C NMR (101 MHz, CDCl3) δ 171.3 
(Ac-C(O)), 167.5 (C-C21), 145.7 (C-C15), 141.2 (C-C12), 124.5 (CH2-C
A), 113.2 (CH2-C16), 
63.1 ((CH3)3SiCH2CH2O), 63.0 (CH2-C3), 44.0 (CH-C1), 32.3 (CH2-C2), 32.0 (CH2-C13), 
30.1 (CH2-C14), 21.1 (Ac-CH3), 17.8 (CH3-C17), 17.5 ((CH3)3SiCH2CH2O), −1.3 
((CH3)3SiCH2CH2O); HRMS (ESI
+) calcd for C18H32O4SiNa [M+Na]+ 363.1962, found 
363.1946; IR νmax 2953, 2899, 2350, 2310, 1742, 1713, 1645, 1630, 1452, 1440 cm
–1 
 
2-(Trimethylsilyl)ethyl (5R)-6-methyl-5-(2-oxoethyl)-2-methylidenehept-6-enoate 415 
 
To a solution of the acetate 414 (1.70 g, 4.99 mmol) in MeOH (43 mL) was added K2CO3 
(138 mg, 0.998 mmol) and the resulting mixture was stirred at rt for 3 h. Saturated aq. NH4Cl 
(50 mL) and CH2Cl2 (100 mL) were added and the phases were separated. The organic 
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phase was dried over Na2SO4 and filtered. Removal of the solvent under vacuum afforded 
the crude alcohol which was used directly in the next step. 
The crude alcohol was dissolved in CH2Cl2 (25 mL) and Dess-Martin periodinane (2.54 g, 
5.99 mmol) added. The resulting mixture was stirred at rt for 3 h and the reaction was then 
quenched with saturated aq. Na2S2O3 (25 mL). The phases were separated and the organic 
phase washed with saturated aq. Na2S2O3 (2 × 25 mL), then dried over Na2SO4 and filtered. 
The solvent was removed under vacuum and the residue was purificed by silica gel column 
chromatography (pet. ether:EtOAc, 9:1) to deliver the aldehyde 415 as a colourless oil (1.24 
g, 84%).     
   −3.2 (c = 0.29, CHCl3); 
1H NMR (400 MHz, CDCl3) δ 9.68 (1H, t, J = 2.2 Hz, 
CHO-C3), 6.12 (1H, s, CH2-C
A), 5.52 (1H, s, CH2-C
A), 4.84 (1H, s, CH2-C16), 4.80 (1H, s, 
CH2-C16), 4.24 (2H, dd, J = 9.3, 7.8 Hz, (CH3)3SiCH2CH2O), 2.75–2.67 (1H, m, CH-C1), 
2.53–2.37 (2H, m, CH2-C2), 2.35–2.14 (2H, m, CH2-C13), 1.68 (3H, s, CH3-C17), 1.62–1.54 
(2H, m, CH2-C14), 1.03 (2H, dd, J = 9.3, 7.8 Hz, (CH3)3SiCH2CH2O), 0.05 (9H, s, 
(CH3)3SiCH2CH2O); 
13C NMR (126 MHz, CDCl3) δ 202.3 (CHO-C3), 167.4 (C-C21), 145.5 
(C-C15), 140.8 (C-C12), 124.8 (CH2-C
A), 113.2 (CH2-C16), 63.1 ((CH3)3SiCH2CH2O), 47.5 
(CH-C1), 41.4 (CH2-C2), 32.0 (CH2-C13), 29.8 (CH2-C14), 18.7 (CH3-C17), 17.5 
((CH3)3SiCH2CH2O), −1.3 ((CH3)3SiCH2CH2O); HRMS (ESI
+) calcd for C16H28O3SiNa 
[M+Na]+ 319.1700, found 319.1690; IR νmax 2953, 2918, 2723, 1714, 1646, 1630, 1440, 1406 
cm–1 
 
1-Methyl 9-(trimethylsilyl)ethyl 8-methylidene-3-oxo-5-(prop-1-en-2-yl)nonanedioate 
416 
 
To a solution of glycine methyl ester hydrochloride (10.5 g, 83.8 mmol) in CH2Cl2 (28 mL) 
was added a solution of NaNO2 (6.94 g, 101 mmol) in H2O (11 mL). The biphasic mixture 
was stirred for 1.5 h at rt and then saturated aq. NaHCO3 (2 mL) was added. The phases 
were separated and the organic phase was dried over MgSO4 and filtered. The solution of  
methyl diazoacetate was then used directly. 
To a solution of the aldehyde 415 (1.24 g, 4.19 mmol) and SnCl2 (945 mg, 4.98 mmol) in 
CH2Cl2 (40 mL) was added the freshly prepared solution of methyl diazoacetate (14 mL, 42 
165 
 
mmol). The resulting mixture was stirred at rt for 16 h and the excess diazo ester was 
destroyed by dropwise addition of glacial acetic acid (1 mL). The solvent was removed under 
vacuum and the residue was purified by silica gel column chromatography (pet. ether:EtOAc, 
9:1) to afford the title compound 416 (tautomeric mixture by NMR) as a yellow oil (1.03 g, 
67%).     
   +2.2 (c = 0.51, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 11.98 (0.1H, s, (OH-C3 
enol), 6.11 (1H, d, J = 1.4 Hz, CH2-C
A), 5.52 (0.9H, app q, J = 1.4 Hz, CH2-C
A), 5.50 (0.1H, 
app q, J = 1.4 Hz, CH2-C
A enol), 4.95 (0.1H, s, CH-C4 enol), 4.81 (1H, dq, J = 1.5, 1.4 Hz, 
CH2-C16), 4.77–4.75 (1H, m, CH2-C16), 4.28–4.19 (2H, m, (CH3)3SiCH2CH2O), 3.73 (2.7H, 
s, CH3-C19), 3.71 (0.3H, s, CH3-C19 enol), 3.42 (1.8H, app d, J = 1.3 Hz, CH2-C4), 2.71–
2.55 (3H, m, CH-C1, CH2-C2), 2.31–2.22 (1H, m, CH2-C13), 2.19–2.10 (1H, m, CH2-C13), 
1.68–1.67 (2.7H, m, CH3-C17), 1.66–1.64 (0.3H, m, CH3-C17 enol), 1.57–1.49 (2H, m, CH2-
C14), 1.06–1.00 (2H, m, (CH3)3SiCH2CH2O), 0.05 (9H, s, (CH3)3SiCH2CH2O); 
13C NMR (126 
MHz, CDCl3) δ 201.7 (C-C3), 167.7 (C-C21), 167.4 (C-C18), 145.8 (C-C15), 140.8 (C-C12), 
124.7 (CH2-C
A), 112.8 (CH2-C16), 63.0 ((CH3)3SiCH2CH2O), 52.5 (CH3-C19), 49.5 (CH2-C4), 
47.5 (CH2-C2), 42.1 (CH-C1), 31.9 (CH2-C13), 29.8 (CH2-C14), 19.0 (CH3-C17), 17.4 
((CH3)3SiCH2CH2O), −1.3 ((CH3)3SiCH2CH2O); HRMS (ESI
+) calcd for C19H32O5SiNa 
[M+Na]+ 391.1911, found 391.1911; IR νmax 2954, 2925, 2899, 2861, 1750, 1714, 1646, 
1630, 1449, 1437, 1406 cm–1 
Methyl 5‐[(3R)‐3‐methyl‐3‐[(2S,3E)‐2‐{[tris(propan‐2‐yl)silyl]oxy}oct‐3‐en‐1‐yl] 
oxiran‐2‐yl]‐2‐[(2R)‐5‐methylidene‐6‐oxo‐2‐(prop‐1‐en‐2‐yl)‐6‐[2‐(trimethylsilyl)ethoxy]h
exyl]furan‐3‐carboxylate 417 and Methyl 5‐[(2R,4S,5E)‐1‐(acetyloxy)‐2‐hydroxy 
‐2‐methyl‐4‐{[tris(propan‐2‐yl)silyl]oxy}dec‐5‐en‐1‐yl]‐2‐[(2R)‐5‐methylidene‐6‐oxo‐2‐(pr
op‐1‐en‐2‐yl)‐6‐[2‐(trimethylsilyl)ethoxy]hexyl]furan‐3‐carboxylate 418 
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β-keto ester 416 (53 mg, 0.145 mmol) and propargylic aldehyde 402 (49 mg, 0.145 mmol) 
were dissolved in a solution of piperidine and AcOH in THT (0.028 M, 0.5 mL, 0.014 mmol) 
in the presence of 4 Å molecular seives. The resulting mixture was heated to 43 °C and 
stirred at this temperature for 15 h. The solvent was removed under vacuum and the residue 
purified by silica gel column chromatography (pet. ether:Et2O, 9:1  8:2) to afford the 
epoxyfuran 417 (1:1 mixture of diastereoisomers) as a colourless oil (25 mg, 24%) followed 
by the acetate 418 (3:2 mixture of diastereoisomers) as a colourless oil (25.5 mg, 22%). 
Epoxyfuran 417: 1H NMR (400 MHz, C6D6) δ 6.71 (0.5H, s, CH-C5), 6.70 (0.5H, s, CH-C5), 
6.26 (0.5H, d, J = 1.7 Hz, CH2-C
A), 6.25 (0.5H, d, J = 1.7 Hz, CH2-C
A), 5.62–5.44 (2H, m, 
CH-C11, CH-CB), 5.36 (0.5H, d, J = 1.7 Hz, CH2-C
A), 5.33 (0.5H, d, J = 1.7 Hz, CH2-C
A), 
4.84–4.82 (1H, m, CH2-C16), 4.80–4.78 (0.5H, m, CH2-C16), 4.76 (0.5H, dq, J = 2.9, 1.4 Hz, 
CH2-C16), 4.42–4.32 (1H, m, CH-C10), 4.25–4.19 (2H, m, (CH3)3SiCH2CH2O), 3.72 (0.5H, s, 
CH-C7), 3.50 (0.5H, s, CH-C7), 3.44 (1.5H, s, CH3-C19), 3.43 (1.5H, s, CH3-C19), 3.33–3.24 
(1H, m, CH2-C2), 3.14 (0.5H, dd, J = 14.3, 8.4 Hz, CH2-C2), 3.03 (0.5H, dd, J = 14.3, 6.6 Hz, 
CH2-C2), 2.88–2.75 (1H, m, CH-C1), 2.57–2.42 (1.5H, m, CH2-C13), 2.36–2.23 (2H, m, CH2-
CC), 2.17 (0.5H, dd, J = 13.7, 5.2 Hz, CH2-C13), 2.06–1.91 (3H, m, CH2-C9, CH2-C14), 1.75 
(1.5H, s, CH3-C17), 1.74–1.64 (2.5H, s, CH3-C17, CH2-C14),  1.39 (1.5H, s, CH3-C20), 1.38 
(1.5H, s, CH3-C20), 1.36–1.26 (4H, m, CH2-C
D, CH2-C
E), 1.17–1.06 (21H, m, CH(CH3)2), 
0.92–0.86 (5H, s, CH3-C
F, (CH3)3SiCH2CH2O), −0.08 (9H, s, (CH3)3SiCH2CH2O); 
13C NMR 
(126 MHz, C6D6) δ 166.9 (C-C21), 166.9 (C-C21), 163.9 (C-C18), 163.9 (C-C18), 161.9 (C-
C3), 161.9 (C-C3), 149.8 (C-C6), 149.8 (C-C6), 146.4 (C-C15), 146.3 (C-C15), 141.7 (C-
C12), 133.5 (CH-CB), 131.7 (CH-C11), 131.5 (CH-C11), 124.2 (CH2-C
A), 124.1 (CH2-C
A), 
115.2 (C-C4), 115.1 (C-C4), 113.1 (CH2-C16), 112.9 (CH2-C16), 109.6 (CH-C5), 72.9 (CH-
C10), 72.2 (CH-C10), 62.7 ((CH3)3SiCH2CH2O), 62.2 (C-C8), 61.4 (C-C8), 58.6 (CH-C7), 
58.1 (CH-C7), 50.9 (CH3-C19), 46.9 (CH-C1), 46.8 (CH-C1), 41.4 (CH2-C9), 32.5 (CH2-C2), 
32.4 (CH2-C2), 32.3 (CH2-C
C), 32.2 (CH2-C
C), 32.1 (CH2-C14), 31.9 (CH2-C14), 31.7 (CH2-
CD), 30.5 (CH2-C13), 30.4 (CH2-C13), 23.2 (CH2-C
E) 22.8 (CH3-C20), 22.7 (CH3-C20), 18.5 
(CH(CH3)2) 18.4 (CH(CH3)2), 17.5 ((CH3)3SiCH2CH2O), 14.2 (CH3-C
F), 12.8 (CH(CH3)2), −1.6 
((CH3)3SiCH2CH2O); HRMS (ESI
+) calcd for C41H70O7Si2Na [M+Na]
+ 753.4552, found 
753.4517; IR νmax 2953, 2924, 2866, 1719, 1645, 1631, 1580, 1462, 1438 cm
–1. Acetate 
418: 1H NMR (500 MHz, C6D6) δ 6.89 (0.4H, s, CH-C5), 6.85 (0.6H, s, CH-C5), 6.27 (0.4H, d, 
J = 1.8 Hz, CH2-C
A), 6.25 (0.6H, d, J = 1.7 Hz, CH2-C
A), 6.11 (0.4H, s, CH-C7), 6.08 (0.6H, s, 
CH-C7), 5.61–5.48 (2H, m, CH-C11, CH-CB), 5.37–5.34 (1H, m, CH2-C
A), 4.80–4.70 (3H, m, 
CH2-C16, CH-C10), 4.27–4.19 (2H, m, (CH3)3SiCH2CH2O), 3.42 (1.8H, s, CH3-C19), 3.42 
(1.2H, s, CH3-C19), 3.17–3.08 (1.6H, m, CH2-C2), 3.02 (0.4H, dd, J = 14.2, 5.8 Hz, CH2-C2), 
2.83–2.74 (1H, m, CH-C1), 2.51–2.43 (1H, m, CH2-C9), 2.34 (0.6H, dd, J = 14.5, 9.1 Hz, 
CH2-C13), 2.31–2.23 (2H, m, CH2-C9, CH2-C13), 2.13 (0.4H, dd, J = 14.3, 8.9 Hz, CH2-C13), 
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1.96–1.89 (2H, m, CH2-C
C), 1.78–1.59 (8H, m, CH2-C14, CH3-C17, CH3-C20), 1.55 (1.2H, s, 
Ac-CH3), 1.46 (1.8H, s, Ac-CH3), 1.34–1.21 (4H, m, CH2-C
D, CH2-C
E), 1.19–1.05 (21H, m, 
CH(CH3)2), 0.93–0.80 (5H, m, CH3-C
F, (CH3)3SiCH2CH2O), −0.08 (3.6H, s, 
(CH3)3SiCH2CH2O), −0.08 (5.4H, s, (CH3)3SiCH2CH2O); 
13C NMR (126 MHz, C6D6) δ 169.4 
(Ac-C=O), 169.3 (Ac-C=O), 166.9 (C-C21), 164.0 (C-C18), 161.8 (C-C3), 161.7 (C-C3), 
150.2 (C-C6), 150.1 (C-C6), 146.4 (C-C15), 146.3 (C-C15), 141.7 (C-C12), 133.9 (CH-CB), 
133.9 (CH-CB), 132.4 (CH-C11), 132.3 (CH-C11), 124.1 (CH2-C
A), 114.9 (C-C4), 113.1 (CH2-
C16), 110.9 (CH-C5), 110.8 (CH-C5), 75.3 (CH-C7), 75.2 (CH-C7), 73.9 (CH-C10), 73.7 (C-
C8), 73.5 (C-C8), 62.7 ((CH3)3SiCH2CH2O), 50.8 (CH3-C19), 47.0 (CH-C1), 32.2 (CH2-C2), 
32.2 (CH2-C2), 32.1 (CH2-C
C), 32.1 (CH2-C14), 31.3 (CH2-C
D), 31.3 (CH2-C
D), 30.5 (CH2-
C13), 30.5 (CH2-C9), 24.1 (OAc-CH3), 22.7 (CH2-C
E), 22.7 (CH2-C
E), 20.6 (CH3-C20), 18.5 
(CH(CH3)2), 18.4 (CH(CH3)2), 18.1 (CH3-C17), 17.5 ((CH3)3SiCH2CH2O), 14.1 (CH3-C
F), 13.2 
(CH(CH3)2), −1.5 ((CH3)3SiCH2CH2O); HRMS (ESI
+) calcd for C43H74O9Si2Na [M+Na]
+ 
813.4764, found 813.4727; IR νmax 3489, 2952, 2925, 2867, 1745, 1716, 1644, 1630, 1613, 
1573, 1462, 1439 cm–1. 
 
Methyl (4R,6R,12R)‐6‐[(1E)‐hex‐1‐en‐1‐yl]‐4‐methyl‐9‐methylidene‐8‐oxo‐12‐(prop‐1‐en‐ 
2‐yl)‐3,7,17‐trioxatricyclo[12.2.1.02,4]heptadeca‐1(16),14‐diene‐15‐carboxylate 420  
 
 
To a solution of the epoxyfuran 417 (30 mg, 0.04 mmol) in THF (0.2 mL) at 10 °C was added 
TBAF (0.09 mL of a 1 M solution in THF, 0.09 mmol) and the resulting mixture was stirred for 
3 h. H2O (0.5 mL) and Et2O (2 mL) were added and the phases were separated. The 
aqueous phase was washed with Et2O (2 × 2 mL) and the combined organic extracts were 
dried over Na2SO4 and filtered. The solvent was removed under vacuum to yield crude seco-
acid 419, which was used directly in the next step. 
To a solution of the crude seco-acid 419 in benzene (4 mL) at rt was added DIPEA (0.10 mL, 
0.60 mmol) followed by trichlorobenzoyl chloride (0.06 mL, 0.40 mmol) and the resulting 
mixture was stirred for 4.5 h. A solution of DMAP (195 mg, 1.60 mmol) in benzene (16 mL) 
was added and the mixture stirred for a further 11.5 h. H2O (30 mL) and Et2O (20 mL) were 
added and the phases separated. The organic phase was washed with brine (30 mL), dried 
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over Na2SO4 and filtered. The solvent was removed under vacuum and the residue was 
purified by silica gel column chromatography (pet. ether:EtOAc, 93:7) to deliver the 
macrolactone 420 as a single isomer and colourless oil (4.7 mg, 25%).     
   −17.8 (c = 0.45, 
CHCl3); 
1H NMR (500 MHz, C6D6) δ 6.70 (1H, s, CH-C5), 6.28 (1H, d, J = 1.8 Hz, CH2-C
A), 
5.69–5.62 (2H, m, CH-C10, CH-CB), 5.29 (1H, ddt, J = 15.4, 7.7, 1.5 Hz, CH-C11), 5.12 (1H, 
d, J = 1.8 Hz, CH2-C
A), 4.78 (1H, dq, J = 1.7 Hz, CH2-C16), 4.75 (1H, d, J = 1.7 Hz, CH2-
C16), 3.45 (3H, s, CH3-C19), 3.37 (1H, s, CH-C7), 3.33 (1H, dd, J = 15.3, 12.2 Hz, CH2-C2), 
3.00 (1H, dd, J = 15.3, 3.6 Hz, CH2-C2), 2.74 (1H, ddt, J = 12.2, 8.2, 3.6 Hz, CH-C1), 2.33–
2.25 (2H, m, CH2-C9, CH2-C13), 2.18–2.11 (2H, m, CH2-C9, CH2-C13), 1.87–1.81 (2H, m, 
CH2-C
C), 1.78–1.70 (1H, m, CH2-C14), 1.58–1.56 (3H, m, CH3-C17), 1.56–1.47 (1H, m, CH2-
C14), 1.21–1.16 (4H, m, CH2-C
D, CH2-C
E), 1.13 (3H, s, CH3-C20), 0.82 (3H, t, J = 7.0 Hz, 
CH3-C
F); 13C NMR (126 MHz, C6D6) δ 166.1 (C-C21), 163.7 (C-C18), 161.7 (C-C3), 148.9 
(C-C6), 146.8 (C-C15), 141.0 (C-C12), 134.7 (CH-CB), 128.6 (CH-C11), 126.2 (CH2-C
A), 
115.7 (C-C4), 111.8 (CH2-C16), 111.1 (CH-C5), 73.3 (CH-C10), 61.9 (C-C8), 58.8 (CH-C7), 
51.0 (CH3-C19), 43.9 (CH-C1), 37.6 (CH2-C9), 32.4 (CH2-C2), 32.1 (CH2-C
C), 31.3 (CH2-C
D), 
30.2 (CH2-C13), 30.0 (CH2-C14), 23.5 (CH3-C20), 22.5 (CH2-C
E), 19.8 (CH3-C17), 14.0 
(CH3-C
F); HRMS (ESI+) calcd for C27H36O6Na [M+Na]
+ 479.2404, found 479.2386; IR νmax 
2952, 2925, 2860, 1719, 1644, 1630, 1610, 1577, 1440 cm–1. 
 
(3S)-N-Methoxy-N-methyl-3-(triethylsilyloxy)pent-4-enamide 425 
 
To a solution of (3S)-3-hydroxy-N-methoxy-N-methylpent-4-enamide 424 (400 mg, 2.51 
mmol) in CH2Cl2 (25 mL) was added chlorotriethylsilane (0.51 mL, 3.01 mmol) and the 
resulting solution was stirred at rt for 14 h. Saturated aq. NH4Cl (30 mL) was added and the 
phases were separated. The organic phase was dried over Na2SO4 and filtered. The solvent 
was removed under vacuum and the residue was purified by silica gel column 
chromatography (pet. ether:EtOAc, 9:1 → 7:3) to give the silyl ether 425 as a colourless oil 
(650 mg, 95%).     
   −16 (c = 0.60, CHCl3); 
1H NMR (400 MHz, CDCl3) δ 5.83 (1H, ddd, J = 
17.1, 10.4, 5.9 Hz, CH-C11), 5.19 (1H, ddd, J = 17.1, 1.5, 1.5 Hz, CH2-C
B), 5.00 (1H, ddd, J 
= 10.4, 1.5, 1.5 Hz, CH2-C
B), 4.66–4.60 (1H, m, CH-C10), 3.62 (3H, s, NCH3), 3.11 (3H, s, 
OCH3), 2.75 (1H, dd, J = 14.7, 7.8 Hz, CH2-C9), 2.38 (1H, dd, J = 14.7, 5.5 Hz, CH2-C9), 
0.87 (9H, t, J = 7.9 Hz, Si(CH2CH3)3), 0.53 (6H, q, J = 7.9 Hz, Si(CH2CH3)3); 
13C NMR (101 
MHz, CDCl3) δ 171.8 (C-C8), 141.0 (CH-C11), 114.3 (CH2-C
B), 70.7 (CH-C10), 61.5 (OCH3) 
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40.8 (NCH3), 32.1 (CH2-C9), 6.9 (Si(CH2CH3)3), 4.9 (Si(CH2CH3)3); HRMS (ESI
+) calcd for 
C13H27NO3SiNa [M+Na]
+ 296.1652, found 296.1648; IR νmax 3078, 2955, 2941, 2913, 2878, 
2822, 1663, 1460, 1414 cm–1 
 
(5S)-5-(Triethylsilyloxy)-1-(trisisopropylsilyl)hept-6-en-1-yn-3-one 426 
 
 
 
To a solution of triisopropylsilylacetylene (1.97 mL, 8.78 mmol) in THF (20 mL) at 0 °C was 
added nBuLi (3.66 mL of a 2.4 M solution in hexanes, 8.78 mmol) and the resulting solution 
was stirred at 0 °C for 30 mins. A solution of the amide 425 (1.60 g, 5.85 mmol) in THF (15 
mL) was added and the mixture stirred at 0 °C for 10 min then warmed to rt and stirred for 1 
h. The reaction was quenched with saturated aq. NH4Cl (40 mL) and Et2O (20 mL) added. 
The phases were separated and the organic phase was dried over Na2SO4 and filtered. The 
solvent was removed under vacuum and the residue was purified by silica gel column 
chromatography (pet. ether:Et2O, 100:0 → 95:5) to afford the propargylic ketone 426 as a 
colourless oil (2.10 g, 91%).     
   +2.8 (c = 0.36, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 5.85 
(1H, ddd, J = 17.1, 10.3, 6.2 Hz, CH-C11), 5.24 (1H, ddd, J = 17.1, 1.4, 1.4 Hz, CH2-C
B), 
5.08 (1H, ddd, J = 10.3, 1.4, 1.4 Hz, CH2-C
B), 4.78–4.72 (1H, m, CH-C10), 2.85 (1H, dd, J = 
14.8, 7.6 Hz, CH2-C9), 2.68 (1H, dd, J = 14.8, 5.6 Hz, CH2-C9), 1.16–1.08 (21H, m, 
CH(CH3)2), 0.94 (9H, t, J = 7.9 Hz, Si(CH2CH3)3), 0.60 (6H, q, J = 7.9 Hz, Si(CH2CH3)3); 
13C 
NMR (126 MHz, CDCl3) δ 185.0 (C-C8), 140.2 (CH-C11), 114.9 (CH2-C
B), 104.8 (C-C6), 
96.2 (C-C7), 70.3 (CH-C10), 54.4 (CH2-C9), 18.6 (CH(CH3)2), 11.2 (CH(CH3)2), 6.9 
(Si(CH2CH3)3), 5.0 (Si(CH2CH3)3); HRMS (ESI
+) calcd for C22H42O2Si2Na [M+Na]
+ 417.2616, 
found 417.2616; IR νmax 2947, 2868, 2147, 1678, 1462, 1416 cm
–1 
 
(5S)-5-(Hydroxy)-1-(trisisopropylsilyl)hept-6-en-1-yn-3-one 427 
 
 
 
To a solution of propargylic ketone 426 (2.00 g, 5.05 mmol) in a mixture (3:1) of THF and 
MeOH (50 mL) at 0 °C was added PPTS (127 mg, 0.505 mmol) and the resulting solution 
was stirred for 4.5 h. The reaction was quenched with saturated aq. NaHCO3 (40 mL) and 
EtOAc (50 mL) was then added. The phases were separated and the organic phase dried 
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over Na2SO4 and filtered. The solvent was removed under vacuum ansd the residue was 
purified by silica gel column chromatography (pet. ether:Et2O, 85:15 → 3:1) to deliver the β-
hydroxy ketone 427 as a colourless oil (1.42 g, quant.).  α  
   −5.8 (c = 0.12, CHCl3); 
1H NMR 
(500 MHz, CDCl3) δ 5.88 (1H, ddd, J = 17.2, 10.5, 5.7 Hz, CH-C11), 5.33 (1H, ddd, J = 17.2, 
1.4, 1.4 Hz, CH2-C
B), 5.17 (1H, ddd, J = 10.5, 1.4, 1.4 Hz, CH2-C
B), 4.71–4.65 (1H, m, CH-
C10), 2.85 (2H, d, J = 6.1 Hz, CH2-C9), 2.57 (1H, d, J = 4.2 Hz, OH-C10), 1.19–1.07 (21H, 
m, CH(CH3)2); 
13C NMR (126 MHz, CDCl3) δ 186.1 (C-C8), 138.7 (CH-C11), 115.7 (CH2-C
B), 
104.2 (C-C6), 97.5 (C-C7), 68.7 (CH-C10), 52.3 (CH2-C9), 18.6 (CH(CH3)2), 11.1 
(CH(CH3)2); HRMS (ESI
+) calcd for C16H28O2SiNa [M+Na]+ 303.1751, found 303.1751; IR 
νmax 3443, 2945, 2893, 2866, 2147, 1672, 1464, 1424 cm
–1 
 
(3S,5R)-5-Methyl-7-(trisisopropylsilyl)hept-1-en-6-yne-3,5-diol syn-428 and (3S,5S)-5-
Methyl-7-(trisisopropylsilyl)hept-1-en-6-yne-3,5-diol anti-428 
 
 
 
 
To a solution of Ti(OiPr)4 (27 mL, 91 mmol) in Et2O (135 mL) at 0 °C was added TiCl4 (3.0 
mL, 27 mmol). The resulting solution was warmed to rt for 30 min and then cooled to 0 °C. 
MeLi (75 mL of a 1.6 M solution in Et2O, 120 mmol) was added and the mixture was stirred 
for 1 h. A portion of the solution (150 mL) was added to a solution of β-hydroxy ketone 427 
(1.20 g, 4.30 mmol) in Et2O (95 mL) at −78 °C. The solution was stirred for 15 minutes, 
warmed to 0 °C and then stirred for 30 min. 2 M HCl (150 mL) was added dropwise and the 
biphasic mixture was warmed to rt. The phases were separated and the aqueous phase was 
extracted with Et2O (2 × 150 mL). The combined organic extracts were washed with brine 
(300 mL), dried over Na2SO4 and filtered. The solvent was removed under vacuum and the 
residue was purified by silica gel column chromatography (pet. ether:Et2O, 6:4) to deliver the 
1,3-diol anti-428 (172 mg, 9%) as a colourless oil (less polar isomer) followed by the 
diastereomeric 1,3-diol syn-428 (1.44 g, 88%) as a colourless oil (more polar isomer). syn-
428:     
   +7.0 (c = 0.22, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 5.92 (1H, ddd, J = 17.2, 10.4, 
6.0 Hz, CH-C11), 5.31 (1H, ddd, J = 17.2, 1.4, 1.4 Hz, CH2-C
B), 5.13 (1H, ddd, J = 10.4, 1.4, 
1.4 Hz, CH2-C
B), 4.61–4.55 (1H, m, CH-C10), 2.98 (1H, d, J = 2.5 Hz, OH-C10), 2.55 (1H, s, 
OH-C8), 2.03 (1H, dd, J = 14.5, 9.3 Hz, CH2-C9), 1.90 (1H, dd, J = 14.5, 3.1 Hz, CH2-C9), 
1.60 (3H, s, CH3-C20), 1.12–0.97 (21H, m, CH(CH3)2); 
13C NMR (126 MHz, CDCl3) δ 140.7 
(CH-C11), 114.9, (CH2-C
B), 111.8 (C-C6), 85.0 (C-C7), 70.3 (CH-C10), 67.6 (C-C8), 49.1 
(CH2-C9), 30.4 (CH3-C20), 18.7 (CH(CH3)2), 11.2 (CH(CH3)2); HRMS (ESI
+) calcd for 
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C17H32O2SiNa [M+Na]+ 319.2064, found 319.2056; IR νmax 3352, 2943, 2893, 2866, 2166, 
1464 cm–1. anti-428:     
   +8.2 (c = 0.11, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 5.93 (1H, 
ddd, J = 17.2, 10.4, 6.0 Hz, CH-C11), 5.29 (1H, ddd, J = 17.2, 1.4, 1.4 Hz, CH2-C
B), 5.15 
(1H, ddd, J = 10.4, 1.4, 1.4 Hz, CH2-C
B), 4.92–4.86 (1H, m, CH-C10), 3.88 (1H, s, OH-C8), 
2.57 (1H, d, J = 2.8Hz, OH-C10), 1.95–1.73 (2H, m, CH2-C9), 1.56 (3H, s, CH3-C20), 1.12–
1.08 (21H, m, CH(CH3)2); 
13C NMR (126 MHz, CDCl3) δ 140.4 (CH-C11), 114.6 (CH2-C
B), 
111.7 (C-C6), 72.4 (C-C7), 69.8 (CH-C10), 68.7 (C-C8), 48.2 (CH2-C9), 31.3 (CH3-C20), 
18.6 (CH(CH3)2), 11.2 (CH(CH3)2); HRMS (ESI
+) calcd for C17H32O2SiNa [M+Na]+ 319.2064, 
found 319.2055; IR νmax 3345, 2943, 2893, 2866, 2166, 1464, 1422 cm
–1 
 
(3S,5R)-5-Methylhept-1-en-6-yne-3,5-diol syn-429 
 
To a solution of the1,3-diol syn-428  (1.40 g, 4.7 mmol) in THF (50 mL) was added TBAF 
(5.2 mL of a 1 M solution in THF, 5.2 mmol) and the resulting solution was stirred at rt for 1 
h. Saturated aq. NH4Cl (50 mL) and Et2O (50 mL) were added and the phases were 
separated. The organic phase was washed with brine (50 mL), dried over Na2SO4 and 
filtered. The solvent was removed under vacuum and the residue was purified by silica gel 
column chromatography (pet. ether:Et2O, 1:1 → 55:45) to give the 1,3-diol syn-429 as a 
yellow oil (585 mg, 89%).     
   +4.6 (c = 0.24, CHCl3); 
1H NMR (400 MHz, CDCl3) δ 5.92 
(1H, ddd, J = 17.1, 10.4, 6.0 Hz, CH-C11), 5.31 (1H, ddd, J = 17.1, 1.4, 1.4 Hz, CH2-C
B), 
5.15 (1H, ddd, J = 10.4, 1.4, 1.4 Hz, CH2-C
B), 4.61–4.54 (1H, m, CH-C10), 2.94 (1H, s, OH-
C8), 2.67 (1H, d, J = 2.6 Hz, OH-C10), 2.53 (1H, s, CH-C6), 2.07 (1H, dd, J = 14.6, 9.5 Hz, 
CH2-C9), 1.90 (1H, dd, J = 14.6, 3.1 Hz, CH2-C9), 1.61 (3H, s, CH3-C20); 
13C NMR (101 
MHz, CDCl3) δ 140.5 (CH-C11), 115.2 (CH2-C
B), 87.9 (C-C7), 72.0 (CH-C6), 70.3 (CH-C10), 
67.3 (C-C8), 48.4 (CH2-C9), 29.7 (CH3-C20); HRMS (ESI
+) calcd for C8H12O2Na [M+Na]+ 
163.0730, found 163.0722; IR νmax 3356, 3300, 3082, 2983, 2922, 2876, 2110, 1645, 1450, 
1419, 1406 cm–1 
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(3S,5R)-5-Methyl-3-(trisisopropylsilyloxy)hept-1-en-6-yn-5-ol 430 
 
To a solution of NaH (71.6 mg of 60% dispersion in mineral oil, 1.79 mmol) in THF (2 mL) at 
0 °C was added a solution of 1,3-diol syn-429 (250 mg, 1.79 mmol) in THF (4 mL). The 
resulting mixture was gradually warmed to rt and stirred for 20 min. Chlorotriisopropylsilane 
(0.38 mL, 1.8 mmol) was then added and the mixture was stirred at rt for 17 h. Brine (10 mL) 
and Et2O (10 mL) were added and the phases separated. The organic phase was dried over 
Na2SO4 and filtered. The solvent was removed under vacuum and the residue was purified 
by silica gel column chromatography (pet. ether:Et2O, 7:3) to afford the alkyne 430 as a 
yellow oil (520 mg, 98%).     
   −7.2 (c = 0.20, CHCl3); 
1H NMR (400 MHz, CDCl3) δ 6.15 
(1H, ddd, J = 17.2, 10.3, 7.9 Hz, CH-C11), 5.27 (1H, ddd, J = 17.2, 1.2, 1.1 Hz, CH2-C
B), 
5.15 (1H, ddd, J = 10.3, 1.1, 1.0 Hz, CH2-C
B), 4.72–4.66 (1H, m, CH-C10), 4.04 (1H, s, OH-
C8), 2.48 (1H, s, CH-C6), 2.09 (1H, dd, J = 14.3, 5.2 Hz, CH2-C9), 1.99 (1H, dd, J = 14.3, 
6.7 Hz, CH2-C9), 1.53 (3H, s, CH3-C20), 1.13–1.03 (21H, m, CH(CH3)2); 
13C NMR (101 MHz, 
CDCl3) δ 142.0 (CH-C11), 115.9 (CH2-C
B), 88.2 (C-C7), 74.0 (CH-C10), 71.9 (CH-C6), 66.8 
(C-C8), 49.4 (CH2-C9), 31.1 (CH3-C20), 18.2 (CH(CH3)2), 18.2 (CH(CH3)2), 12.5 (CH(CH3)2); 
HRMS (ESI+) calcd for C17H32O2SiNa [M+Na]+ 319.2064, found 319.2052; IR νmax 3456, 
3312, 2943, 2893, 2866, 1464, 1419 cm–1 
(3S,5R)-3,5-Bis(trisisopropylsilyloxy)-5-methylhept-1-en-6-yne 431 
 
To a solution of 1,3-diol syn-429 (39 mg, 0.28 mmol) in CH2Cl2 (4 mL) at −78 °C was added 
2,6-lutidine (0.14 mL, 1.2 mmol) followed by triisopropylsilyl trifluoromethanesulfonate (0.16 
mL, 0.59 mmol). The resulting solution was gradually warmed to rt and then stirred for 24 h. 
Saturated aq. NaHCO3 (5 mL) and Et2O (5 mL) were added and the phases separated. The 
organic phase was dried over Na2SO4 and filtered. The solvent was removed under vacuum 
and the residue was purified by silica gel column chromatography (pet. ether) to give the bis-
silyl ether 431 as a yellow oil (122 mg, 97%).     
   +25 (c = 0.04, CHCl3); 
1H NMR (400 
MHz, CDCl3) δ 6.00 (1H, ddd, J = 17.2, 10.3, 6.9 Hz, CH-C11), 5.20 (1H, ddd, J = 17.2, 1.7, 
1.1 Hz, CH2-C
B), 5.01 (1H, ddd, J = 10.3, 1.7, 0.8 Hz, CH2-C
B), 4.62–4.55 (1H, m, CH-C10), 
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2.43 (1H, s, CH-C6), 2.07 (1H, dd, J = 13.7, 5.5 Hz, CH2-C9), 1.97 (1H, dd, J = 13.7, 6.7 Hz, 
CH2-C9), 1.57 (3H, s, CH3-C20), 1.26–0.98 (42H, m, CH(CH3)2); 
13C NMR (101 MHz, CDCl3) 
δ 142.7 (CH-C11), 113.7 (CH2-C
B), 88.6 (C-C7), 72.5 (CH-C10), 72.2 (CH-C6), 68.5 (C-C8), 
54.0 (CH2-C9), 31.8 (CH3-C20), 18.6 (CH(CH3)2), 18.5 (CH(CH3)2), 18.4 (CH(CH3)2), 18.3 
(CH(CH3)2), 13.3 (CH(CH3)2), 12.8 (CH(CH3)2); HRMS (ESI
+) calcd for C26H52O2Si2Na 
[M+Na]+ 475.3398, found 475.3380; IR νmax 3310, 2960, 2943, 2926, 2866, 2892, 2866, 
1464, 1419 cm–1 
(4R,6S)-4-Hydroxy-4-methyl-6-(trisisopropylsilyloxy)oct-7-en-2-ynal 432 
 
To a solution of alkyne 430 (100 mg, 0.337 mmol) in THF (9 mL) at −78 °C was added nBuLi 
(0.3 mL of a 2.3 M solution in hexane, 0.70 mmol). The resulting solution was stirred for 5 
mins and then warmed to 0 °C. DMF (0.06 mL, 0.84 mmol) was added and the mixture was 
stirred for 1 h. The reaction was quenched with 5% aq. KH2PO4 (10 mL) and Et2O (10 mL) 
was added. The phases were separated and the organic phase washed with brine (10 mL), 
dried over Na2SO4 and filtered. The solvent was removed under vacuum and the residue 
was purified by silica gel column chromatography (pet. ether:Et2O, 7:3) to deliver the 
propargylic aldehyde 432 as a colourless oil (99 mg, 90%).     
   +8.6 (c = 0.04, CHCl3); 
1H 
NMR (400 MHz, CDCl3) δ 9.24 (1H, s, CHO-C5), 6.14 (1H, ddd, J = 17.3, 10.3, 7.3 Hz, CH-
C11), 5.28 (1H, ddd, J = 17.3, 1.2, 1.2 Hz, CH2-C
B), 5.18 (1H, ddd, J = 10.3, 1.2, 1.2 Hz, 
CH2-C
B), 4.73 (1H, s, OH-C8), 4.72–4.67 (1H, m, CH-C10), 2.12 (2H, d, J = 5.2 Hz, CH2-C9), 
1.58 (3H, s, CH3-C20), 1.11–1.04 (21H, m, CH(CH3)2); 
13C NMR (101 MHz, CDCl3) δ 176.8 
(CHO-C5), 140.6 (CH-C11), 116.1 (CH2-C
B), 100.3 (C-C7), 83.4 (C-C6), 74.0 (CH-C10), 
67.1 (C-C8), 47.9 (CH2-C9), 30.6 (CH3-C20), 18.1 (CH(CH3)2), 18.0 (CH(CH3)2), 12.3 
(CH(CH3)2); HRMS (ESI
+) calcd for C18H32O3SiNa [M+Na]+ 347.2013, found 347.1903; IR 
νmax 3446, 2943, 2893, 2866, 2206, 1670, 1464, 1419 cm
–1 
 
(4R,6S)-4,6-Bis(trisisopropylsilyloxy)-4-methyloct-7-en-2-ynal 433 
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To a solution of alkyne 431 (91 mg, 0.20 mmol) in THF (1.5 mL) at −78 °C was added nBuLi 
(0.10 mL of a 2.3 M solution in hexane, 0.24 mmol). The resulting solution was stirred for 5 
mins and then warmed to 0 °C. DMF (0.03 mL, 0.40 mmol) was added and the mixture was 
stirred for 1 h. The reaction was quenched with 5% aq. KH2PO4 (2 mL) and Et2O (2 mL) was 
added. The phases were separated and the organic phase washed with brine (5 mL), dried 
over Na2SO4 and filtered. The solvent was removed under vacuum and the residue was 
purified by silica gel column chromatography (pet. ether:Et2O, 95:5) to give the propargylic 
aldehyde 433 as a colourless oil (91 mg, 97%).     
   −21 (c = 0.28, CHCl3); 
1H NMR (500 
MHz, CDCl3) δ 9.22 (1H, s, CHO-C5), 5.95 (1H, ddd, J = 17.3, 10.2, 7.3 Hz, CH-C11), 5.20 
(1H, ddd, J = 17.3, 1.5, 1.2 Hz, CH2-C
B), 5.05 (1H, ddd, J = 10.2, 1.5, 0.8 Hz, CH2-C
B), 4.56–
4.49 (1H, m, CH-C10), 2.13 (1H, dd, J = 13.8, 5.6 Hz, CH2-C9), 2.04 (1H, dd, J = 13.8, 6.6 
Hz, CH2-C9), 1.64 (3H, s, CH3-C20), 1.20–1.02 (42H, m, CH(CH3)2); 
13C NMR (126 MHz, 
CDCl3) δ 176.4 (CHO-C5), 142.1 (CH-C11), 114.7 (CH2-C
B), 100.8 (C-C7), 83.9 (C-C6), 72.0 
(CH-C10), 68.5 (C-C8), 53.4 (CH2-C9), 31.0 (CH3-C20), 18.5 (CH(CH3)2), 18.4 (CH(CH3)2), 
18.3 (CH(CH3)2), 18.3 (CH(CH3)2), 13.3 (CH(CH3)2), 12.8 (CH(CH3)2); IR νmax 2945, 2893, 
2868, 2210, 1674, 1464, 1421 cm–1 
 
(3S,5S)-5-Methylhept-1-en-6-yne-3,5-diol anti-429 
 
To a solution of the anti 1,3-diol anti-428 (100 mg, 0.34 mmol) in THF (2 mL) was added 
TBAF (0.37 mL of a 1M solution in THF, 0.37 mmol) and the resulting solution was stirred at 
rt for 2 h. Saturated aq. NH4Cl (5 mL) and Et2O (5 mL) were added and the phases were 
separated. The organic phase was washed with brine (5 mL), dried over Na2SO4 and filtered. 
The solvent was removed under vacuum and the residue was purified by silica gel column 
chromatography (pet. ether:Et2O, 1:1) to give the corresponding anti 1,3-diol anti-429 as a 
colourless oil (37 mg, 78%).     
   +16 (c = 0.12, CHCl3);  
1H NMR (400 MHz, CDCl3) δ 5.87 
(1H, ddd, J = 17.2, 10.4, 5.8 Hz, CH-C11), 5.27 (1H, ddd, J = 17.2, 1.4, 1.4 Hz, CH2-C
B), 
5.11 (1H, ddd, J = 10.4, 1.4, 1.3 Hz, CH2-C
B), 4.84–4.77 (1H, m, CH-C10), 4.73 (1H, s, OH-
C8), 3.19 (1H, d, J = 2.9 Hz, OH-C10), 2.50 (1H, s, CH-C6), 1.84–1.73 (2H, m, CH2-C9), 
1.50 (3H, s, CH3-C20); 
13C NMR (101 MHz, CDCl3) δ 140.3 (CH-C11), 114.9 (CH2-C
B), 87.0 
(C-C7), 72.1 (CH-C6), 72.1  (CH-C10), 68.3 (C-C8), 47.5 (CH2-C9), 31.0 (CH2-C20); HRMS 
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(ESI+) calcd for C8H12O2Na [M+Na]
+ 163.0730, found 163.0736; IR νmax 3358, 3294, 3078, 
2983, 2915, 2874, 2110, 1653, 1423, 1419 cm–1 
(4R,6S)-4-Ethynyl-4-methyl-6-vinyl-1,3-dioxan-2-one 434 
 
To a solution of diol syn-429 (27 mg, 0.19 mmol) in CH2Cl2 (1 mL) was added pyridine (0.16 
mL, 1.9 mmol) and the resultant cooled to −78 °C. A solution of triphosgene (114 mg, 0.39 
mmol) in CH2Cl2 (1 mL) was added and the reaction stirred for 45 min before being warmed 
to rt and stirred for a further 40 min. Saturated aq. NH4Cl (5 mL) was added and the mixture 
stirred vigorously for 10 min. The biphasic mixture was separated and the aq. phase washed 
with CH2Cl2 (5 mL). Combined organic extracts were washed with brine (10 mL), dried over 
Na2SO4, filtered and the solvent removed under vacuum to yield the cyclic carbonate 434 as 
a pale yellow oil (31.5 mg, 98%).     
   +40 (c = 0.20, CHCl3); 
1H NMR (400 MHz, CDCl3) δ 
5.94 (1H, ddd, J = 17.2, 10.6, 6.1 Hz, CH-C11), 5.44 (1H, ddd, J = 17.2, 1.4, 0.7 Hz, CH2-
CB), 5.36–5.32 (1H, m, CH2-C
B), 4.96–4.89 (1H, m, CH-C10), 2.69 (1H, s, CH-C6), 2.35– 
2.24 (2H, m, CH2-C9), 1.77 (3H, s, CH3-C20); 
13C NMR (101 MHz, CDCl3) δ 147.8 
(OC(O)O), 133.8 (CH-C11), 119.1 (CH2-C
B), 82.7 (C-C7), 75.9 (CH-C6), 75.1 (C-C8), 74.8 
(CH-C10), 38.7 (CH2-C9), 28.0 (CH3-C20); HRMS (ESI
+) calcd for C9H10O3Na [M+Na]
+ 
189.0522, found 189.0523; IR νmax 3287, 2994, 2916, 2847, 1751, 1736, 1651, 1543, 1435  
cm–1 
 
(4S,6S)-4-Ethynyl-4-methyl-6-vinyl-1,3-dioxan-2-one 435 
 
To a solution of diol anti-429 (37 mg, 0.26 mmol) in CH2Cl2 (1.3 mL) was added pyridine 
(0.21 mL, 2.6 mmol) and the resultant cooled to −78 °C. A solution of triphosgene (157 mg, 
0.53 mmol) in CH2Cl2 (1.3 mL) was added and the reaction stirred for 45 min before being 
warmed to rt and stirred for a further 40 min. Saturated aq. NH4Cl (6 mL) was added and the 
mixture stirred vigorously for 10 min. The biphasic mixture was separated and the aq. phase 
washed with CH2Cl2 (5 mL). Combined organic extracts were washed with brine (10 mL), 
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dried over Na2SO4, filtered and the solvent removed under vacuum to yield the cyclic 
carbonate 435 as a pale yellow oil (43.3 mg, 99%).    
   +25 (c = 0.12, CHCl3); 
1H NMR (400 
MHz, CDCl3) δ 5.85 (1H, ddd, J = 17.2, 10.5, 6.0 Hz, CH-C11), 5.44 (1H, ddd, J = 17.2, 1.4, 
0.8 Hz, CH2-C
B), 5.34–5.30 (1H, m, CH2-C
B), 5.28–5.21 (1H, m, CH-C10), 2.73 (1H, s ,CH-
C6), 2.25 (1H, dd, J = 14.2, 3.2 Hz, CH2-C9), 1.91 (1H, dd, J = 14.2, 12.0 Hz, CH2-C9), 1.70 
(3H, s, CH3-C20); 
13C NMR (101 MHz, CDCl3) δ 147.7 (OC(O)O), 133.9 (CH-C11), 118.8 
(CH2-C
B), 81.6 (C-C7), 77.5 (CH-C6), 75.9 (C-C8), 74.8 (CH-C10), 39.3 (CH2-C9), 28.8 
(CH3-C20); HRMS (ESI
+) calcd for C9H10O3Na [M+Na]
+ 189.0522, found 189.0529; IR νmax 
3256, 2994, 2916, 2847, 2121, 1751, 1736, 1651, 1535, 1427  cm–1 
Methyl 5‐[(3R)‐3‐methyl‐3‐[(2S)‐2‐{[tris(propan‐2‐yl)silyl]oxy}but‐3‐en‐1‐yl]oxiran‐2‐yl] 
‐2‐[(2R)‐5‐methylidene‐6‐oxo‐2‐(prop‐1‐en‐2‐yl)‐6‐[2‐(trimethylsilyl)ethoxy]hexyl]furan‐
3‐carboxylate 436 
 
Pivalic acid (12 mg, 0.12 mmol), the β-keto ester 416 (75 mg, 0.20 mmol) and the 
propargylic aldehyde 432 (162 mg, 0.499 mmol) were dissolved in a solution of piperidine in 
THT (0.027 M, 0.75 mL, 0.02 mmol) in the presence of 4 Å molecular seives. The resulting 
mixture was heated to 35 °C and stirred at this temperature for 16 h. The solvent was 
removed under vacuum and the residue purified by silica gel column chromatography (pet. 
ether:Et2O, 9:1) to afford the epoxyfuran 436 (1:1 mixture of diastereoisomers) as a 
colourless oil (84 mg, 62%). 1H NMR (400 MHz, C6D6) δ 6.69 (1H, s, CH-C5), 6.26 (0.5H, d, 
J = 1.7 Hz, CH2-C
A), 6.24 (0.5H, d, J = 1.7 Hz, CH2-C
A), 5.88–5.67 (1H, m, CH-C11), 5.35 
(0.5H, d, J = 1.7 Hz, CH2-C
A), 5.32 (0.5H, d, J = 1.7 Hz, CH2-C
A), 5.15 (0.5H, d, J = 17.3 Hz, 
CH2-C
B), 5.10 (0.5H, d, J = 17.3 Hz, CH2-C
B), 5.01 (0.5H, d, J = 10.0 Hz, CH2-C
B), 4.94 
(0.5H, d, J = 10.0 Hz, CH2-C
B), 4.81 (1H, s, CH2-C16), 4.75 (0.5H, s, CH2-C16), 4.74 (0.5H, 
s, CH2-C16), 4.41–4.28 (1H, m, CH-C10), 4.24–4.18 (2H, m, (CH3)3SiCH2CH2O), 3.70 (0.5H, 
s, CH-C7), 3.49 (0.5H, s, CH-C7), 3.43 (1.5H, s, CH3-C19), 3.42 (1.5H, s, CH3-C19), 3.26–
3.16 (1.5H, m, CH2-C2), 3.08 (0.5H, dd, J = 14.3, 6.4 Hz, CH2-C2), 2.87–2.73 (1H, m, CH-
C1), 2.54–2.41 (1H, m, CH2-C13), 2.34–2.22 (1.5H, m, CH2-C13, CH2-C9), 2.12 (0.5H, dd, J 
= 13.8, 5.1 Hz, CH2-C9), 1.96 (0.5H, dd, J = 13.8, 8.3 Hz, CH2-C9), 1.74 (1.5H, s, CH3-C17), 
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1.70 (1.5H, s, CH3-C17), 1.69–1.60 (2.5H, m, CH2-C9, CH2-C14), 1.34 (1.5H, s, CH3-C20), 
1.28 (1.5H, s, CH3-C20), 1.12–1.05 (21H, m, CH(CH3)2), 0.91–0.85 (2H, m, 
(CH3)3SiCH2CH2O), −0.09 (9H, s, (CH3)3SiCH2CH2O); 
13C NMR (101 MHz, C6D6) δ 166.9 (C-
C21), 166.9 (C-C21), 163.9 (C-C18), 163.9 (C-C18), 161.9 (C-C3), 149.7 (C-C6), 149.6 (C-
C6), 146.4 (C-C15), 146.3 (C-C15), 141.7 (CH-C11), 141.4 (CH-C11), 124.3 (CH2-C
A), 124.2 
(CH2-C
A), 115.1 (C-C4), 115.0 (C-C4), 114.9 (CH2-C
B), 114.7 (CH2-C
B), 113.1 (CH2-C16), 
112.9 (CH2-C16), 109.5 (CH-C5), 109.4 (CH-C5), 73.0 (CH-C10), 72.4 (CH-C10), 62.7 
((CH3)3SiCH2CH2O), 62.0 (C-C8), 61.2 (C-C8), 58.6 (CH-C7), 58.0 (CH-C7), 50.9 (CH3-C19), 
47.6 (CH2-C9), 46.9 (CH-C1), 46.9 (CH-C1), 41.0 (CH2-C9), 32.4 (CH2-C2), 32.0 (CH2-C14), 
32.0 (CH2-C14), 30.5 (CH2-C13), 30.5 (CH2-C13), 23.1 (CH3-C20), 18.4 (CH(CH3)2), 18.4 
(CH(CH3)2), 18.2 (CH3-C17), 18.2 (CH3-C17), 17.5 ((CH3)3SiCH2CH2O), 12.7 (CH(CH3)2), 
−1.6 ((CH3)3SiCH2CH2O); HRMS (ESI
+) calcd for C37H62O7Si2Na [M+Na]
+ 697.3926, found 
697.3898; IR νmax 2947, 2928, 2894, 2866, 1717, 1645, 1630, 1617, 1579, 1439 cm
–1 
 
Methyl 5‐[(2R,4S)‐1‐(acetyloxy)‐2‐hydroxy‐2‐methyl‐4‐{[tris(propan‐2‐yl)silyl]oxy}hex‐ 
5‐en‐1‐yl]‐2‐[5‐methylidene‐6‐oxo‐2‐(prop‐1‐en‐2‐yl)‐6‐[2‐(trimethylsilyl)ethoxy]hexyl]fu
ran‐3‐carboxylate 437 
 
The β-Keto ester 416 (69 mg, 0.187 mmol) and the propargylic aldehyde 432 (82 mg, 0.253 
mmol) were dissolved in a solution of acetic acid (2 μL, 0.035 mmol) and piperidine (3 μL, 
0.029 mmol) in THT (1 mL) in the presence of 4 Å molecular seives. The resulting mixture 
was heated to 40 °C and stirred at this temperature for 16 h. The solvent was removed 
under vacuum and the residue purified by silica gel column chromatography (pet. 
ether:EtOAc, 9:1  7:3) to afford the epoxyfuran 436 (1:1 mixture of diastereoisomers) as a 
colourless oil (38.3 mg, 30%) followed by the acetate 437 (~3:2 mixture of diastereoisomers) 
as a colourless oil (44.6 mg, 32%). Acetate: 1H NMR (400 MHz, C6D6) δ 6.86 (0.4H, s, CH-
C5), 6.82 (0.6H, s, CH-C5), 6.26 (0.4H, d, J = 1.7 Hz, CH2-C
A), 6.24 (0.6H, d, J = 1.7 Hz, 
CH2-C
A), 6.05 (0.4H, s CH-C7), 6.02 (0.6H, s, CH-C7), 5.91–5.78 (1H, m, CH-C11), 5.35 
(0.4H, d, J = 1.7 Hz, CH2-C
A), 5.34 (0.6H, d, J = 1.7 Hz, CH2-C
A), 5.05 (0.6H, d, J = 6.0 Hz, 
CH2-C
B), 5.01 (0.4H, d, J = 6.0 Hz, CH2-C
B), 4.89 (0.6H, dd, J = 4.2, 1.3 Hz, CH2-C
B), 4.86 
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(0.4H, dd, J = 4.2, 1.3 Hz, CH2-C
B), 4.74 (2H, m, CH2-C16), 4.72–4.63 (1H, m, CH-C10), 
4.25–4.18 (2H, m, (CH3)3SiCH2CH2O), 4.01 (0.6H, s, OH-C8), 3.89 (0.4H, s, OH-C8), 3.42 
(3H, s, CH3-C19), 3.28–2.98 (2H, m, CH2-C2), 2.82–2.71 (1H, m, CH-C1), 2.50–2.41 (1H, m, 
CH2-C13), 2.32–2.21 (1.4H, m, CH2-C9, CH2-C13), 2.07 (0.4H, dd, J = 14.5, 8.6 Hz, CH2-C9), 
1.83 (0.6H, dd, J = 14.4, 3.9 Hz, CH2-C9), 1.71 (1.2H, s, Ac-CH3), 1.71 (1.8H, s, Ac-CH3), 
1.70 (1.2H, s, CH3-C17), 1.70 (1.8H, s, CH3-C17), 1.68–1.57 (2.6H, CH2-C14, CH2-C9), 1.40 
(1.2H, s, CH3-C20), 1.38 (1.8H, s, CH3-C20), 1.18–1.05 (21H, m, CH(CH3)2), 0.91– 0.85 (2H, 
m, (CH3)3SiCH2CH2O), −0.09 (9H, s, (CH3)3SiCH2CH2O); 
13C NMR (101 MHz, C6D6) δ 169.4 
(Ac-C=O), 169.3 (Ac-C=O), 166.9 (C-C21), 164.0 (C-C18), 161.8 (C-C3), 161.7 (C-C3), 
150.1 (C-C6), 150.0 (C-C6), 146.4 (C-C15), 146.3 (C-C15), 142.1 (C-C12), 142.0 (C-C12), 
141.7 (CH-C11), 124.2 (CH2-C
A), 115.4 (CH2-C
B), 115.3 (CH2-C
B), 114.9 (C-C4), 114.8 (C-
C4), 113.1 (CH2-C16), 113.0 (CH2-C16), 110.8 (CH-C5), 110.7 (CH-C5), 75.3 (CH-C7), 75.2 
(CH-C7), 73.9 (CH-C10), 73.9 (CH-C10), 73.7 (C-C8), 62.7 ((CH3)3SiCH2CH2O), 50.8 (CH3-
C19), 47.0 (CH-C1), 45.2 (CH2-C9), 44.3 (CH2-C9), 32.3 (CH2-C2) , 32.2 (CH2-C2), 32.1 
(CH2-C14), 32.0 (CH2-C14), 30.5 (CH2-C13), 30.4 (CH2-C13), 24.2 (CH3-C20), 24.1 (CH3-
C20), 20.5 (Ac-CH3), 18.4 (CH(CH3)2), 18.4 (CH(CH3)2), 18.1 (CH3-C17), 18.1 (CH3-C17), 
17.5 ((CH3)3SiCH2CH2O), 13.1 (CH(CH3)2), −1.5 ((CH3)3SiCH2CH2O); HRMS (ESI
+) calcd for 
C39H66O9Si2Na [M+Na]
+ 757.4138, found 757.4108; IR νmax  3485, 3074, 2948, 2894, 2867, 
1748, 1718, 1645, 1630, 1613, 1573, 1456, 1439 cm–1 
 
Methyl 5‐[(2R,4S)‐1‐(acetyloxy)‐2‐methyl‐2,4‐bis({[tris(propan‐2‐yl)silyl]oxy})hex‐5‐en‐1 
‐yl]‐2‐[5‐methylidene‐6‐oxo‐2‐(prop‐1‐en‐2‐yl)‐6‐[2‐(trimethylsilyl)ethoxy]hexyl]furan‐3‐
carboxylate 438 
 
The β-Keto ester 416 (53 mg, 0.14 mmol) and the propargylic aldehyde 433 (134 mg, 0.279 
mmol) were dissolved in a solution of acetic acid (10 μL, 0.17 mmol) and piperidine (3 μL, 
0.029 mmol) in THT (0.5 mL) in the presence of 4 Å molecular seives. The resulting mixture 
was heated to 35 °C and stirred at this temperature for 18 h. The solvent was removed 
under vacuum and the residue purified by silica gel column chromatography (pet. 
ether:EtOAc, 7:3) to afford the furan 438 (~3:2 mixture of diastereoisomers) as a colourless 
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oil (110 mg, 85%). 1H NMR (500 MHz, C6D6) δ 6.92 (0.6H, s, CH-C5), 6.92 (0.4H, s, CH-C5), 
6.30–6.26 (1H, m, CH2-C
A), 6.19 (0.6H, s, CH-C7), 6.11 (0.4H, s, CH-C7), 6.04 (0.6H, 
ddd, J = 17.3, 10.2, 7.9 Hz, CH-C11), 5.94 (0.4H, ddd, J = 17.3, 10.1, 8.2 Hz, CH-C11), 
5.39–5.37 (1H, m, CH2-C
A), 5.27 (0.6H, dd, J = 17.3, 1.5 Hz, CH2-C
B), 5.16 (0.4H, dd, J = 
17.3, 1.4 Hz, CH2-C
B), 5.08 (0.6H, dd, J = 10.2, 1.5 Hz, CH2-C
B), 4.98 (0.4H, dd, J = 10.1, 
1.4 Hz, CH2-C
B), 4.85 (0.6H, d, J = 2.2 Hz, CH2-C16), 4.83 (0.4H, d, J = 2.2 Hz, CH2-C16), 
4.83–4.79 (0.6H, m, CH2-C16), 4.81–4.76 (0.4H, m, CH2-C16), 4.64 (0.6H, ddd, J = 7.9, 7.5, 
5.7 Hz, CH-C10), 4.60–4.52 (0.4H, m, CH-C10), 4.27–4.17 (2H, m, (CH3)3SiCH2CH2O), 3.46 
(1.2H, s, CH3-C19), 3.43 (1.8H, s, CH3-C19), 3.33 (0.6H, dd, J = 14.3, 9.1 Hz, CH2-C2), 3.24 
(0.4H, dd, J = 14.3, 6.4 Hz, CH2-C2), 3.15 (0.4H, dd, J = 14.3, 8.8 Hz, CH2-C2), 3.05 (0.6H, 
dd, J = 14.3, 6.2 Hz, CH2-C2), 2.88–2.80 (1H, m, CH-C1), 2.55–2.47 (1H, m, CH2-C13), 2.37 
(0.6H, dd, J = 14.3, 5.7 Hz, CH2-C9), 2.34–2.25 (1.4H, m, CH2-C9, CH2-C13), 2.25–2.16 (1H, 
m, CH2-C9), 1.78 (1.2H, s, Ac-CH3), 1.77 (1.8H, s, Ac-CH3), 1.75 (3H, s, CH3-C17), 1.74–
1.59 (2H, m, CH2-C14), 1.55 (1.2H, s, CH3-C20), 1.53 (1.8H, s, CH3-C20), 1.25–1.07 (42H, s, 
CH(CH3)2), 0.93–0.86 (2H, m, (CH3)3SiCH2CH2O), −0.08 (5.4H, s, (CH3)3SiCH2CH2O), −0.08 
(3.6H, s, (CH3)3SiCH2CH2O); 
13C NMR (126 MHz, C6D6) δ 169.2 (Ac-C=O), 166.9 (C-C21), 
164.0 (C-C18), 164.0 (C-C18), 161.4 (C-C3), 161.4 (C-C3), 150.4 (C-C6), 150.3 (C-C6), 
146.2 (C-C15), 146.2 (C-C15), 142.7 (C-C12), 142.5 (C-C12), 141.8 (CH-C11), 124.2 (CH2-
CA), 115.6 (CH2-C
B), 115.2 (CH2-C
B), 115.0 (C-C4), (CH-C7), 115.0 (C-C4), 113.2 (CH2-C16), 
113.2 (CH2-C16), 111.1 (CH-C5), 110.8 (CH-C5), 76.6 (CH-C7), 76.4 (CH-C7), 74.8 (CH-
C10), 74.2 (CH-C10), 72.9 (C-C8), 72.7 (C-C8), 62.7 ((CH3)3SiCH2CH2O), 62.7 
((CH3)3SiCH2CH2O), 50.9 (CH3-C19), 49.6 (CH-C1) 49.5 (CH-C1), 47.2 (CH2-C9), 47.0 (CH2-
C9), 32.4 (CH2-C2), 32.4 (CH2-C2), 32.2 (CH2-C14), 32.2 (CH2-C14), 30.5 (CH2-C13), 26.2 
(CH3-C20), 26.0 (CH3-C20), 20.6 (Ac-CH3), 20.6 (Ac-CH3), 18.7 (CH(CH3)2), 18.7 (CH(CH3)2), 
18.6 (CH(CH3)2), 18.6 (CH(CH3)2), 18.6 (CH(CH3)2), 18.6 (CH(CH3)2), 18.5 (CH(CH3)2), 18.5 
(CH(CH3)2), 18.2 (CH3-C17), 18.1 (CH3-C17), 17.5 ((CH3)3SiCH2CH2O), 17.5 
((CH3)3SiCH2CH2O), 14.1 (CH(CH3)2), 14.0 (CH(CH3)2), 13.2 (CH(CH3)2), 13.1 (CH(CH3)2), 
−1.6 ((CH3)3SiCH2CH2O); HRMS (ESI
+) calcd for C48H86O9Si3Na [M+Na]
+ 913.5467, found 
913.5427; IR νmax  2945, 2893, 2866, 1749, 1720, 1645, 1631, 1612, 1574, 1464, 1441 cm
–1 
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Methyl 5‐[(3R,5S)‐5‐ethenyl‐3‐hydroxy‐3‐methyloxolan‐2‐yl]‐2‐[(2R)‐5‐methylidene‐6‐ 
oxo‐2‐(prop‐1‐en‐2‐yl)‐6‐[2‐(trimethylsilyl)ethoxy]hexyl]furan‐3‐carboxylate 440 
 
1H NMR (400 MHz, C6D6) δ 6.63 (1H, s, CH-C5), 6.26 (1H, s, CH2-C
A), 5.99 (1H, ddd, J = 
17.0, 10.4, 6.5 Hz, CH-C11), 5.34 (1H, s, CH2-C
A), 5.29 (1H, dd, J = 17.0, 1.6 Hz, CH2-C
B), 
5.05 (1H, dd, J = 10.4, 1.6 Hz, CH2-C
B), 4.82–4.70 (4H, m, CH2-C16, CH-C7, CH-C10), 
4.28–4.19 (2H, m, (CH3)3SiCH2CH2O), 3.45 (3H, s, CH3-C19), 3.19–3.05 (2H, m, CH2-C2), 
2.81–2.69 (1H, m, CH-C1), 2.54–2.43 (1H, m, CH2-C13), 2.34–2.24 (1H, CH2-C13), 1.81–
1.60 (7H, m, CH2-C9, CH2-C14, CH3-C17), 1.38 (3H, s, CH3-C20), 0.96–0.86 (2H, m, 
(CH3)3SiCH2CH2O), −0.09 (9H, s, (CH3)3SiCH2CH2O); 
13C NMR (101 MHz, C6D6) δ 167.0 
(C-C21), 164.1 (C-C18), 161.7 (C-C3), 153.0 (C-C6), 146.3 (C-C15), 141.7 (C-C12), 139.2 
(CH-C11), 124.3 (CH2-C
A), 115.7 (CH2-C
B), 114.7 (C-C4), 113.1 (CH2-C16), 108.6 (CH-C5), 
85.2 (CH-C7), 81.3 (C-C8), 79.8 (CH-C10), 62.8 ((CH3)3SiCH2CH2O), 50.9 (CH3-C19), 47.1 
(CH-C1), 46.3 (CH2-C9), 32.3 (CH2-C2), 32.2 (CH2-C14), 30.5 (CH3-C20), 30.2 (CH2-C13), 
18.2 (CH3-C17), 17.5 ((CH3)3SiCH2CH2O), −1.6 ((CH3)3SiCH2CH2O); HRMS (ESI
+) calcd for 
C28H42O7SiNa [M+Na]
+ 541.2592, found 541.2574; IR νmax  3481, 3078, 2949, 2926, 2856, 
1719, 1647, 1629, 1613, 1577, 1457, 1437 cm–1 
 
 
 
 
181 
 
Methyl 5‐[(3R)‐3‐[(2S)‐2‐hydroxybut‐3‐en‐1‐yl]‐3‐methyloxiran‐2‐yl]‐2‐[(2R)‐5‐ 
methylidene‐6‐oxo‐2‐(prop‐1‐en‐2‐yl)‐6‐[2‐(trimethylsilyl)ethoxy]hexyl]furan‐3‐carboxyl
ate 441 
 
 
1H NMR (500 MHz,C6D6) δ 6.70 (0.5H, s, CH-C5), 6.69 (0.5H, s, CH-C5), 6.25 (0.5H, d, J = 
1.8 Hz, CH2-C
A), 6.24 (0.5H, d, J = 1.7 Hz, CH2-C
A), 5.71–5.62 (1H, m, CH-C11), 5.34–5.32 
(1H, m , CH2-C
A), 5.19 (0.5H, dt, J = 17.2, 1.6 Hz, CH2-C
B), 5.18 (0.5H, dt, J = 17.2, 1.6 Hz, 
CH2-C
B), 4.96 (0.5H, dt, J = 10.4, 1.5 Hz, CH2-C
B), 4.93 (0.5H, dt, J = 10.4, 1.5 Hz, CH2-C
B), 
4.80–4.74 (3H, CH2-C16, CH-C10) 4.24–4.18 (2H, m, (CH3)3SiCH2CH2O), 3.66 (0.5H, s, CH-
C7), 3.47 (0.5H, s, CH-C7), 3.44 (1.5H, s, CH3-C19), 3.40 (1.5H, s, CH3-C19), 3.29–3.18 
(1H, m, CH2-C2), 3.16–3.03 (1H, m, CH2-C2), 2.86–2.73 (1H, m, CH-C1), 2.52–2.40 (1H, m, 
CH2-C13), 2.34–2.24 (1H, m, CH2-C13), 1.86 (0.5H, dd, J = 14.2, 9.0 Hz, CH2-C9), 1.75–
1.60 (6H, m, CH2-C9, CH2-C14, CH3-C17), 1.53 (0.5H, dd, J = 14.2, 4.3 Hz, CH2-9), 1.25 
(1.5H, s, CH3-C20), 1.19 (1.5H, s, CH3-C20), 0.92–0.84 (2H, m, (CH3)3SiCH2CH2O), −0.09 
(9H, s, (CH3)3SiCH2CH2O); 
13C NMR (126 MHz, C6D6) δ 167.0 (C-C21), 166.9 (C-C21), 
163.9 (C-C18), 163.8 (C-C18), 162.1 (C-C3), 162.0 (C-C3), 149.3 (C-C6), 149.1 (C-C6), 
146.4 (C-C15), 146.4 (C-C15), 141.7 (C-C12), 141.7 (C-C12), 141.3 (CH-C11), 141.2 (CH-
C11), 124.4 (CH2-C
A), 124.2 (CH2-C
A), 115.2 (C-C4), 115.1 (C-C4), 114.1 (CH2-C
B), 114.1 
(CH2-C
B), 112.9 (CH2-C16), 112.9 (CH2-C16), 109.8 (CH-C5), 109.7 (CH-C5), 70.6 (CH-
C10), 70.0 (CH-C10), 63.1 ((CH3)3SiCH2CH2O), 62.8 ((CH3)3SiCH2CH2O), 62.8 (C-C8), 62.4 
(C-C8), 57.9 (CH-C7), 57.4 (CH-C7), 50.9 (CH3-C19), 46.8 (CH2-C9), 44.6 (CH-C1), 39.4 
(CH2-C9), 32.4 ((CH2-C2), 32.0 (CH2-C14), 31.9 (CH2-C14), 30.5 (CH2-C13), 30.5 (CH2-
C13), 22.4 (CH3-C20), 18.3 (CH3-C17), 18.2 (CH3-C17), 17.5 ((CH3)3SiCH2CH2O), −1.56 
((CH3)3SiCH2CH2O); HRMS (ESI
+) calcd for C28H42O7SiNa [M+Na]
+ 541.2592, found 
541.2575; IR νmax 3493, 2953, 2928, 2857, 1717, 1645, 1631, 1614, 1578, 1441 cm
–1 
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Methyl (2R,4R,6S,12R)‐6‐ethenyl‐4‐methyl‐9‐methylidene‐8‐oxo‐12‐(prop‐1‐en‐2‐yl) 
‐3,7,17‐trioxatricyclo[12.2.1.02,4]heptadeca‐1(16),14‐diene‐15‐carboxylate 421 
 
Macrolactonisation under Yamaguchi conditions 
To a solution of the epoxyfuran 438 (35 mg, 50 µmol) in THF (0.25 mL) at 10 °C was added 
TBAF (0.11 mL of a 1 M solution in THF, 0.11 mmol) and the resulting mixture was stirred for 
3.5 h. H2O (0.5 mL) and Et2O (2 mL) were added and the phases were separated. The 
aqueous phase was washed with Et2O (2 × 2 mL) and the combined organic extracts were 
dried over Na2SO4 and filtered. The solvent was removed under vacuum to yield crude seco-
acid 439, which was used directly in the next step. 
To a solution of the crude seco-acid 439 in benzene (6.5 mL) at rt was added DIPEA (0.13 
mL, 0.75 mmol) followed by trichlorobenzoyl chloride (0.08 mL, 0.5 mmol) and the resulting 
mixture was stirred for 4 h. A solution of DMAP (244 mg, 2.00 mmol) in benzene (18.5 mL) 
was added and the mixture stirred for a further 15.5 h. H2O (30 mL) and EtOAc (20 mL) were 
added and the phases separated. The organic phase was washed with brine (30 mL), dried 
over Na2SO4 and filtered. The solvent was removed under vacuum and the residue was 
purified by silica gel column chromatography (pet. ether:EtOAc, 85:15 → 75:25) to deliver 
the macrolactone 421 as a single isomer and colourless oil (7.8 mg, 39%). 
Macrolactonisation under Corey-Nicolaou conditions 
To a solution of epoxy-furan 438 (16.5 mg, 24 µmol) in THF (0.1 mL) at 10 °C was added 
TBAF (0.05 mL of a 1 M solution in THF, 50 µmol) and the resulting solution was stirred for 3 
h. H2O (0.2 mL) and Et2O (2 mL) were added and the phases separated. The aqueous 
phase was washed with Et2O (2 × 1 mL) and the combined organic extracts dried over 
Na2SO4, filtered and the solvent removed under vacuum to yield the crude seco-acid 439, 
which was used directly in the next step. 
To a solution of crude seco-acid 439 in toluene (1 mL) at rt was added 2,2′-dipyridyl disulfide 
(7.3 mg, 33 µmol) and triphenylphosphine (8.7 mg, 33 µmol) and the resulting mixture stirred 
for 7 h. Toluene (26 mL) was added and the solution was heated to reflux for 14 h. The 
solution was cooled to rt and the solvent removed under vacuum and the residue was 
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purified by silica gel column chromatography (pet. ether:EtOAc, 85:15 → 80:20) to give the 
macrolactone 421 as a single isomer and colourless oil (4.5 mg, 46%).     
   −15 (c = 0.36, 
CHCl3); 
1H NMR (500 MHz, C6D6) δ 6.65 (1H, s, CH-C5), 6.25 (1H, d, J = 1.9 Hz, CH2-C
A), 
5.68–5.62 (1H, m, CH-C10), 5.56 (1H, ddd, J = 17.1, 10.4, 6.3 Hz, CH-C11), 5.12 (1H, ddd, 
J = 17.1, 1.3, 1.3 Hz, CH2-C
B)  5.13–5.11 (1H, m, CH2-C
A), 4.92 (1H, ddd, J = 10.4, 1.3, 1.3 
Hz, CH2-C
B), 4.79 (1H, dq, J = 1.8, 1.5 Hz, CH2-C16), 4.77–4.75 (1H, m, CH2-C16), 3.44 (3H, 
s, CH3-C19), 3.33 (1H, s, CH-C7), 3.20 (1H, dd, J = 15.1, 11.9 Hz, CH2-C2), 3.06 (1H, dd, J 
= 15.1, 3.7 Hz, CH2-C2), 2.71 (1H, dddd, J = 11.9, 8.2, 4.2, 3.7 Hz, CH-C1), 2.32–2.24 (1H, 
m, CH2-C13), 2.17–2.07 (2H, m, CH2-C9, CH2-C13), 1.98 (1H, dd, J = 14.9, 5.0 Hz, CH2-C9), 
1.71–1.68 (1H, m, CH2-C14), 1.58 (3H, s, CH3-C17), 1.57–1.49 (1H, m, CH2-C14), 1.07 (3H, 
s, CH3-C20); 
13C NMR (101 MHz, C6D6) δ 166.0 (C-C21), 163.7 (C-C18), 161.8 (C-C3), 
148.7 (C-C6), 147.1 (C-C15), 140.8 (C-C12), 137.0 (CH-C11), 126.3 (CH2-C
A), 116.4 (CH2-
CB), 115.5 (C-C4), 111.6 (CH2-C16), 110.9 (CH-C5), 72.6 (CH-C10), 61.8 (C-C8), 58.7 (CH-
C7), 51.0 (CH3-C19), 43.6 (CH-C1), 37.0 (CH2-C9), 32.3 (CH2-C2), 30.2 (CH2-C14), 29.6 
(CH2-C13), 23.6 (CH3-C20), 20.0 (CH3-C17); HRMS (ESI
+) calcd for C23H28O6Na [M+Na]
+ 
423.1778, found 423.1766; IR νmax 2953, 2924, 2852, 1720, 1643, 1631, 1609, 1578, 1441 
cm–1 
 
7-epi-Pukalide 443 
 
The macrolactone 421 (5.0 mg, 12 µmol) and the ruthenium catalyst 442 (1.0 mg, 1.2 µmol) 
were dissolved in degassed CH2Cl2 (1.3 mL) and heated at 40 °C for 17 h. The solvent was 
removed under vacuum and the residue was purified by silica gel column chromatography 
(pet. ether: EtOAc, 8:2 → 7:3) to give 7-epi-pukalide (443) as a colourless wax (4.6 mg, 
90%).     
   +31 (c = 0.13, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 6.88 (1H, s, CH-C5), 6.42 
(1H, d, J = 1.8 Hz, CH-C11), 5.00 (1H, br d, J = 12.2 Hz, CH-C10), 4.86 (1H, q, J = 1.6 Hz, 
CH2-C16), 4.79 (1H, s, CH2-C16), 3.85 (3H, s, CH3-C19), 3.72 (1H, s, CH-C7), 3.47 (1H, dd, 
J = 14.8, 12.6 Hz, CH2-C2), 2.87 (1H, dd, J = 12.6, 3.4 Hz, CH2-C9), 2.69 (1H, dd, J = 14.8, 
3.5 Hz, CH2-C2), 2.37 (1H, ddd, J = 15.5, 13.2, 3.4 Hz, CH2-C13), 2.17–2.04 (2H, m, CH-C1, 
CH2-C13), 2.01 (1H, app t, J = 12.6 Hz, CH2-C9), 1.79–1.74 (1H, m, CH2-C14), 1.74 (3H, s, 
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CH3-C17), 1.58 (3H, s, CH2-C20), 1.30–1.22 (1H, m, CH2-C14); 
13C NMR (126 MHz, CDCl3) 
δ 173.5 (C-C21), 163.8 (C-C18), 162.8 (C-C3), 149.0 (CH-C11), 146.9 (C-C6), 145.3 (C-
C15), 133.9 (C-C12), 116.3 (C-C4), 114.6 (CH-C5), 113.2 (CH2-C16), 77.9 (CH-C10), 60.9 
(C-C8), 57.8 (CH-C7), 51.8 (CH3-C19), 43.7 (CH-C1), 40.5 (CH2-C9), 31.7 (CH2-C2), 30.0 
(CH2-C14), 23.3 (CH3-C20), 20.6 (CH2-C13), 19.3 (CH3-C17); HRMS (ESI
+) calcd for 
C21H24O6Na [M+Na]
+
 395.1465, found 395.1448; IR νmax 2953, 2924, 1757, 1718, 1647, 
1612, 1578, 1443 cm
–1 
Methyl (3R,5S,11R)‐2‐(acetyloxy)‐5‐ethenyl‐3‐hydroxy‐3‐methyl‐8‐methylidene‐7‐oxo 
‐11‐(prop‐1‐en‐2‐yl)‐6,16‐dioxabicyclo[11.2.1]hexadeca‐1(15),13‐diene‐14‐carboxylate 
445 
 
 
 
 
 
 
To a solution of furan 438 (20.1 mg, 22.6 µmol) in THF (0.2 mL) at 10 °C was added TBAF 
(0.1 mL of a 1 M solution in THF, 0.1 mmol) and the resultant mixture was stirred at 10 °C for 
7 h. Three drops of half saturated aq. NH4Cl were added and the mixture stirred for 10 min. 
The solution was diluted with Et2O (10 mL), dried over Na2SO4 and filtered. The solvent was 
removed under vacuum to afford the crude seco-acid 444 which was used directly in the 
next step. 
To a solution of the crude seco-acid 444 in benzene (2.2 mL) at rt was added DIPEA (0.06 
mL, 0.3 mmol) followed by trichlorobenzoyl chloride (0.04 mL, 0.3 mmol) and the resulting 
mixture was stirred for 5 h at rt. A solution of DMAP (108 mg, 0.884 mmol) in benzene (6.6 
mL) was added and the mixture stirred for a further 16 h. Half saturated brine (10 mL) and 
EtOAc (10 mL) were added and the phases separated. The organic phase was washed with 
brine (2 × 10 mL), dried over Na2SO4 and filtered. The solvent was removed under vacuum 
and the residue was purified by silica gel column chromatography (pet. ether:EtOAc, 7:3) to 
afford the title compound 445 (~2:1 mixture of diastereomers) as a colourless oil (2.6 mg, 
25%). 1H NMR (500 MHz, C6D6) δ 6.77 (0.35H, s, CH-C5), 6.74 (0.65H, s, CH-C5), 6.27 
(0.35H, d, J = 2.1 Hz, CH2-C
A), 6.19 (0.65H, d, J = 1.9 Hz, CH2-C
A), 6.06 (0.65H, s, CH-C7), 
5.99–5.93 (1H, m, CH-C10), 5.82 (0.65H, ddd, J = 17.1, 10.5, 6.0 Hz, CH-C11), 5.73–5.65 
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(0.7H, m, CH-C7, CH-C11), 5.21 (0.65H, dt, J = 17.1, 1.4 Hz, CH2-C
B), 5.17 (0.35H, dt, J = 
17.1, 1.4 Hz, CH2-C
B), 5.18–5.16 (0.35H, m, CH2-C
A), 5.14–5.12 (0.65H, m, CH2-C
A), 4.98–
4.92 (1H, m, CH2-C
B), 4.78–4.76 (1H, m, CH2-C16), 4.70–4.68 (0.65H, m, CH2-C16), 4.68–
4.66 (0.35H, m, CH2-C16), 3.42 (1.95H, s, CH3-C19), 3.42 (1.05H, s, CH3-C19), 3.16 (1H, dd, 
J = 15.1, 11.5 Hz, CH2-C2), 3.04 (1H, dd, J = 15.1, 3.6 Hz, CH2-C2), 2.68–2.61 (1.65H, m, 
CH-C1, OH-C8), 2.58 (0.35H, s, OH-C8), 2.31–2.22 (1H, m, CH2-C13), 2.19 (1H, dd, J = 
15.7, 6.2 Hz, CH2-C9), 2.12–1.98 (1H, m, CH2-C13), 1.86 (1H, dd, J = 15.7, 3.4 Hz, CH2-C9), 
1.73–1.69 (0.65H, m, CH2-C14) 1.67 (1.05H, s, OAc-CH3), 1.66–1.63 (0.35H, m, CH2-C14), 
1.56–1.55 (5.95H, m, CH2-C14, CH3-C17, OAc-CH3), 1.20 (1.95H, s, CH3-C20), 1.09 (1.05H, 
s, CH3-C20); 
13C NMR (126 MHz, C6D6) δ 169.7 (Ac-C=O), 169.0 (Ac-C=O), 167.0 (C-C21), 
166.5 (C-C21), 163.7 (C-C18), 163.7 (C-C18), 162.1 (C-C3), 161.8 (C-C3), 150.1 (C-C6), 
149.2 (C-C6), 146.4 (C-C15), 146.0 (C-C15), 140.6 (C-C12), 140.3 (C-C12), 138.0 (CH-C11), 
137.8 (CH-C11), 127.4 (CH2-C
A), 126.6 (CH2-C
A), 115.6 (CH2-C
B), 115.4 (CH2-C
B), 115.3 (C-
C4), 113.2 (CH-C5), 112.6 (CH2-C16), 112.1 (CH2-C16), 110.5 (CH-C5), 74.8 (CH-C7), 73.3 
(C-C8), 73.2 (C-C8), 73.1 (CH-C7), 71.5 (CH-C10), 71.1 (CH-C10), 51.0 (CH3-C19), 50.9 
(CH3-C19), 44.0 (CH-C1), 43.8 (CH-C1), 42.5 (CH2-C9), 42.3 (CH2-C9), 32.4 (CH2-C2), 32.2 
(CH2-C2), 30.5 (CH2-C13), 30.2 (CH2-C13), 29.6 (CH2-C14), 29.3 (CH2-C14), 25.6 (CH3-
C20), 24.9 (CH3-C20), 20.3 (Ac-CH3), 20.2 (Ac-CH3), 19.6 (CH3-C17), 19.5 (CH3-C17); 
HRMS (ESI+) calcd for C25H32O8Na [M+Na]
+ 483.1989, found 483.1979; IR νmax  3487, 2953, 
2924, 2855, 2365, 2343, 2328, 1725, 1719, 1647, 1611, 1570, 1439 cm–1 
 
7-Acetylsinumaximol B 16 
 
 
 
 
 
 
 
To a solution of macrolactone 445 (4.5 mg, 9.8 µmol) in degassed CH2Cl2 (0.5 mL) was 
added a solution of the ruthenium catalyst 442 (0.8 mg, 1.0 µmol) in degassed CH2Cl2 (0.6 
mL). The resulting solution was heated to 40 °C for 16 h. The solvent was removed under 
vacuum and residual material was purified by silica gel column chromatography (pet. 
ether:EtOAc, 8:2 → 1:1) to afford recovered starting material 445 (3.3 mg, 73%) followed by 
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7-acetylsinumaximol B (16) as a white solid (1.1 mg, 25%).     
   −38 (c = 0.080, CHCl3) {lit. 
    
   −56.0 (c = 0.6, CHCl3)}
[1]; 1H NMR (500 MHz, CDCl3) δ 6.65 (1H, s, CH-C5), 5.80 (1H, 
br s, CH-C11), 5.58 (1H, s, CH-C7), 4.94 (1H, br d, J = 11.4 Hz, CH-C10), 4.85–4.82 (1H, m, 
CH2-C16), 4.80 (1H, s, CH2-C16), 3.85 (3H, s, CH3-C19), 3.41 (1H, dd, J = 14.7, 12.3 Hz, 
CH2-C2), 2.73 (1H, dd, J = 14.7, 2.5 Hz, CH2-C2), 2.60 (1H, dd, J = 14.9, 4.0 Hz, CH2-C9), 
2.37–2.29 (1H, m, CH2-C13), 2.24–2.17 (1H, m, CH-C1), 2.17–2.06 (4H, m, CH2-C13, Ac-
CH3), 1.95 (1H, dd, J = 14.9, 11.4 Hz, CH2-C9), 1.86–1.79 (1H, m, CH2-C14), 1.77 (3H, s, 
CH3-C17), 1.52–1.49 (1H, m, CH2-C14), 1.48 (3H, s, CH3-C20); 
13C NMR (126 MHz, CDCl3) 
δ 173.3 (Ac-C=O), 169.6 (C-C21), 163.8 (C-C18), 161.3 (C-C3), 149.5 (C-C6), 148.3 (CH-
C11), 146.2 (C-C15), 133.9 (C-C12), 116.4 (C-C4), 112.8 (CH2-C16), 109.7 (CH-C5), 78.5 
(CH-C10), 76.1 (CH-C7), 72.9 (C-C8), 51.8 (CH3-C19), 44.2 (CH-C1), 43.3 (CH2-C9), 32.1 
(CH2-C2), 28.3 (CH2-C14), 21.8 (CH2-C13), 21.2 (Ac-CH3), 21.2 (CH3-C20), 19.2 (CH3-C17); 
HRMS (ESI+) calcd for C23H28O8Na [M+Na]
+ 455.1676, found 455.1664; IR νmax 3464, 2924, 
1755, 1722, 1610, 1572, 1443 cm–1 
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